<SEC-DOCUMENT>0001824293-22-000034.txt : 20220509
<SEC-HEADER>0001824293-22-000034.hdr.sgml : 20220509
<ACCEPTANCE-DATETIME>20220509161204
ACCESSION NUMBER:		0001824293-22-000034
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		54
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220509
DATE AS OF CHANGE:		20220509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vallon Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001824293
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				824369909
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40034
		FILM NUMBER:		22905059

	BUSINESS ADDRESS:	
		STREET 1:		TWO LOGAN SQUARE
		STREET 2:		100 N. 18TH STREET, SUITE 300
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
		BUSINESS PHONE:		(267) 207-3606

	MAIL ADDRESS:	
		STREET 1:		TWO LOGAN SQUARE
		STREET 2:		100 N. 18TH STREET, SUITE 300
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ck0001824293-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:817af30f-ec0d-4f27-a9e3-e41325810995,g:c8a142b5-1941-49b7-ac1b-a5b54ada4279,d:59843287b8de4d67b8e56c082207e5cd--><html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ck0001824293="http://www.vallon-pharma.com/20220331" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ck0001824293-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80L2ZyYWc6M2FlZmQ5YmI1NmMxNGI2NzhiNzE0Yzg0MDE4NGI0YmMvdGFibGU6MzBkMzA3YzhmZDkzNDk1Nzk0YTdlMzYxYWUxMGFiYmMvdGFibGVyYW5nZTozMGQzMDdjOGZkOTM0OTU3OTRhN2UzNjFhZTEwYWJiY18yOS0xLTEtMS0zNzAzOQ_e63eee76-064a-4cad-b209-ebadd78a33a6">0001824293</ix:nonNumeric><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80L2ZyYWc6M2FlZmQ5YmI1NmMxNGI2NzhiNzE0Yzg0MDE4NGI0YmMvdGFibGU6MzBkMzA3YzhmZDkzNDk1Nzk0YTdlMzYxYWUxMGFiYmMvdGFibGVyYW5nZTozMGQzMDdjOGZkOTM0OTU3OTRhN2UzNjFhZTEwYWJiY18zMC0xLTEtMS0zNzAzOQ_e05f4f2b-295c-4b69-9816-e4888bd9e7b2">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80L2ZyYWc6M2FlZmQ5YmI1NmMxNGI2NzhiNzE0Yzg0MDE4NGI0YmMvdGFibGU6MzBkMzA3YzhmZDkzNDk1Nzk0YTdlMzYxYWUxMGFiYmMvdGFibGVyYW5nZTozMGQzMDdjOGZkOTM0OTU3OTRhN2UzNjFhZTEwYWJiY18zMS0xLTEtMS0zNzAzOQ_f40ac4cc-6ac8-4be5-83ee-191b0139378c">2022</ix:nonNumeric><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80L2ZyYWc6M2FlZmQ5YmI1NmMxNGI2NzhiNzE0Yzg0MDE4NGI0YmMvdGFibGU6MzBkMzA3YzhmZDkzNDk1Nzk0YTdlMzYxYWUxMGFiYmMvdGFibGVyYW5nZTozMGQzMDdjOGZkOTM0OTU3OTRhN2UzNjFhZTEwYWJiY18zMi0xLTEtMS0zNzAzOQ_44a65ee2-572b-4bd8-9281-7ab7940a73e3">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80L2ZyYWc6M2FlZmQ5YmI1NmMxNGI2NzhiNzE0Yzg0MDE4NGI0YmMvdGFibGU6MzBkMzA3YzhmZDkzNDk1Nzk0YTdlMzYxYWUxMGFiYmMvdGFibGVyYW5nZTozMGQzMDdjOGZkOTM0OTU3OTRhN2UzNjFhZTEwYWJiY18zMy0xLTEtMS0zNzAzOQ_2436b887-4206-4264-9fd3-f79dbd0b6a73">FALSE</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i49ad1f772a4248b5984122466ba426db_D20210212-20210212" decimals="3" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80My9mcmFnOmFlNGVjN2Q4NWMyOTRjMGU5M2U4MzZjYzM0OWJmN2NjL3RhYmxlOjE0NWUwMjJlYTZmYTQxODU5NWNmODFmMDc1MjgwY2MwL3RhYmxlcmFuZ2U6MTQ1ZTAyMmVhNmZhNDE4NTk1Y2Y4MWYwNzUyODBjYzBfMS0xLTEtMS0zNzAzOQ_8d10f7e1-1cb0-435c-a507-7f90e884a66e">0.025</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ck0001824293-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19484616c8c8480b9d94b951bcae0361_I20220506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="if3397d410ba3402b845134ba54257a68_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i55dd8e26998945bf948e411d61ec483e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7614adf727b407d9dcfe9c7866dadec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cf4793645e7478396bfebc5d1280046_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b89c603f01d4777a2dedbf1801d5be1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb04f7e476724b32ac14d93d1aecd6cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ed8cb8b770442c18891f8011fdd7380_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i112cbf6fe6d94f7e95aa68e4b3b82566_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i696ce2800db940be9f493ce1a41cc843_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fb11e86e5bf43d385426e1375734dd6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52bc59ea9a964dd2878f917948cf15f6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c36969402654f268647e2010c59c641_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibca337c014ca4895aaf539d38c0f5424_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c71d40ad8c8445783218c6cc8c9fd95_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e72d21b8d324c0ca3c1f71d2e152b0e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47d3c892e0334a90bfe742b8fc3fb929_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d5ea48dd69c4c3fb4e49bd12780ad99_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff52b3f4d3964f18b58baec76585133c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i470300e9f67349a4a8f5ed6f67792df9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0cec8f00f4844c59bf6b4e46fa04203_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4e4d371903843b8a67b3c95775d3069_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e4a9d93e6d448e682d05b667992ba82_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaec88160062a4e4ebb51935d4831bccf_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="participant"><xbrli:measure>ck0001824293:participant</xbrli:measure></xbrli:unit><xbrli:context id="iac76cfecf8b945eda2c37283b0d1bafa_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i459e0d6af0f74d42a0f684f536cfd55c_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49ad1f772a4248b5984122466ba426db_D20210212-20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="if636725079b740db9f7e05e222c86d29_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5006cf101226413bb3ec2ab87613cd4e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic295d867cba3424dbf9d11196a15a2b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6895b671b37a41a2983fb05af80a2952_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c4b8521c9f140c7a9592f7f41d732a6_I20210212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i908364284b2449eaa88060f3a0a6fa84_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieace1ee3e7294bcc9238b92ee0af49d2_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f0dc3494c1646ab80c715e4bcf2f8e2_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7820e87649a24600869cfef32d0d6f5b_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ae8348a777d4256870275ec7f5b29c4_D20211101-20211101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ab34f687d26476ca4c37cdeaec3802c_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63431f71e5c74bdbb2b0f31ac2cafe55_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfbaf3deac01401e89ec75e6ea05ae13_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d2639da3a56431abd41a0af1356176b_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1911bf6daa244c328b316073998944ff_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c74df4f8925487f845fee1c71e9e072_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fc7bd8d7fea4e7eba01520925d56116_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id978ce266ef042feb765030a9e74ad19_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0c5dc3daa51452a98594f5d3f6b538f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i009ef9a9802043c7a795e51fb1ac96b0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e848c92cf53437f8da4012e0c9545b1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib390bd62760a4ca8915004678a850b79_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ff57a73247a47f5aa2e3b501764627b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb6ea0f24b104095965bec61b8cda0e6_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:MediceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i59843287b8de4d67b8e56c082207e5cd_1"></div><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:2.5pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV8yMDgz_5109aebf-0a67-46c2-b30e-57d242b6b998"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV8yMDgz_bc872895-024e-4cb6-b022-371a56f3e007">10-Q</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6YmZlN2ViMGE0YWY3NDMxZDkyNmUxODFmYTRjYjk1MWYvdGFibGVyYW5nZTpiZmU3ZWIwYTRhZjc0MzFkOTI2ZTE4MWZhNGNiOTUxZl8wLTAtMS0xLTM3MDM5_cc6a3a5b-fde2-4f5f-8a39-4bf088680df2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV8yMDY_0d96c41c-cdd7-4b28-b668-5b62654cc7bd"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV8yMDY_2dc4f377-bf9b-4980-8296-51c7e1b28074">March 31, 2022</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6Y2IyYzI2ZmEzMDNjNDEzNjg2ODc2YjNhNWE0NzNhYzIvdGFibGVyYW5nZTpjYjJjMjZmYTMwM2M0MTM2ODY4NzZiM2E1YTQ3M2FjMl8wLTAtMS0xLTM3MDM5_f4be9d90-d5c0-4c27-990e-215ba07b5d41">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from_________to_________</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV8yMDg5_65294989-a7ea-4309-ba1b-cda740f78169">001-40034</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="text-align:center"><img src="ck0001824293-20220331_g1.jpg" alt="ck0001824293-20220331_g1.jpg" style="height:63px;margin-bottom:5pt;vertical-align:text-bottom;width:200px"/></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV8yMDc4_c33932a5-34fc-4da4-90b7-acbc357965cd">VALLON PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6OTBhNWZmZmVhZWZhNDdhNWIwNjE2Yzc1NmQwNzc1ZWIvdGFibGVyYW5nZTo5MGE1ZmZmZWFlZmE0N2E1YjA2MTZjNzU2ZDA3NzVlYl8wLTAtMS0xLTM3MDM5_4c9743c9-8a6d-40bf-9f13-a37d1403792b">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6OTBhNWZmZmVhZWZhNDdhNWIwNjE2Yzc1NmQwNzc1ZWIvdGFibGVyYW5nZTo5MGE1ZmZmZWFlZmE0N2E1YjA2MTZjNzU2ZDA3NzVlYl8wLTItMS0xLTM3MDM5_2bd9e8fa-3e3b-4cbb-8ad9-df2cf1f8d0d7">82-4369909</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Identification No.)&#160;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6OTBhNWZmZmVhZWZhNDdhNWIwNjE2Yzc1NmQwNzc1ZWIvdGFibGVyYW5nZTo5MGE1ZmZmZWFlZmE0N2E1YjA2MTZjNzU2ZDA3NzVlYl8zLTAtMS0xLTM3MDM5L3RleHRyZWdpb246MGFkZDE1YTdkYzZhNDhkY2JmMWFmNzEyN2YwMGM1M2RfNQ_36351b2c-d25a-45eb-ba5c-90e5eed5cea5">100 N. 18th Street</ix:nonNumeric>, <ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6OTBhNWZmZmVhZWZhNDdhNWIwNjE2Yzc1NmQwNzc1ZWIvdGFibGVyYW5nZTo5MGE1ZmZmZWFlZmE0N2E1YjA2MTZjNzU2ZDA3NzVlYl8zLTAtMS0xLTM3MDM5L3RleHRyZWdpb246MGFkZDE1YTdkYzZhNDhkY2JmMWFmNzEyN2YwMGM1M2RfOQ_7160ab90-65c3-447d-b8cb-3efb8adbd44d">Suite 300</ix:nonNumeric>,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;<ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6OTBhNWZmZmVhZWZhNDdhNWIwNjE2Yzc1NmQwNzc1ZWIvdGFibGVyYW5nZTo5MGE1ZmZmZWFlZmE0N2E1YjA2MTZjNzU2ZDA3NzVlYl8zLTAtMS0xLTM3MDM5L3RleHRyZWdpb246MGFkZDE1YTdkYzZhNDhkY2JmMWFmNzEyN2YwMGM1M2RfMTQ_f274b74c-06b8-4bcb-b0f1-54024a416663">Philadelphia</ix:nonNumeric>, <ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6OTBhNWZmZmVhZWZhNDdhNWIwNjE2Yzc1NmQwNzc1ZWIvdGFibGVyYW5nZTo5MGE1ZmZmZWFlZmE0N2E1YjA2MTZjNzU2ZDA3NzVlYl8zLTAtMS0xLTM3MDM5L3RleHRyZWdpb246MGFkZDE1YTdkYzZhNDhkY2JmMWFmNzEyN2YwMGM1M2RfMTg_c3d8f23c-791a-4da2-a312-6b9c65213986">PA</ix:nonNumeric>  <ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6OTBhNWZmZmVhZWZhNDdhNWIwNjE2Yzc1NmQwNzc1ZWIvdGFibGVyYW5nZTo5MGE1ZmZmZWFlZmE0N2E1YjA2MTZjNzU2ZDA3NzVlYl8zLTAtMS0xLTM3MDM5L3RleHRyZWdpb246MGFkZDE1YTdkYzZhNDhkY2JmMWFmNzEyN2YwMGM1M2RfMjI_aca26395-0f79-4d48-87c5-63d5811b3dfa">19103</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of principal executive offices, including zip code)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> (<ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV80NjA_1520572f-740c-4c12-955f-6a9541b83b51">267</ix:nonNumeric>)-<ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV8yMDc5_e9ca650c-b85d-44fa-b32c-e1f6be34335b">207-3606</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6MmE2NDZjMzJkYjY4NDBlNGE5Y2UxZDg4N2FkMDE5ODMvdGFibGVyYW5nZToyYTY0NmMzMmRiNjg0MGU0YTljZTFkODg3YWQwMTk4M18xLTAtMS0xLTM3MDM5_37503efa-4b50-4a47-9cb8-79dc1bd76a5a">Common Stock, par value $0.0001<br/>per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6MmE2NDZjMzJkYjY4NDBlNGE5Y2UxZDg4N2FkMDE5ODMvdGFibGVyYW5nZToyYTY0NmMzMmRiNjg0MGU0YTljZTFkODg3YWQwMTk4M18xLTItMS0xLTM3MDM5_cae22647-3157-428f-9021-552663258201">VLON</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6MmE2NDZjMzJkYjY4NDBlNGE5Y2UxZDg4N2FkMDE5ODMvdGFibGVyYW5nZToyYTY0NmMzMmRiNjg0MGU0YTljZTFkODg3YWQwMTk4M18xLTQtMS0xLTM3MDM5L3RleHRyZWdpb246N2RjYmMwYjc1MzZkNGI5ZTg1N2UyNTIyYmM5N2Y2MjBfNA_91592248-eebe-4a4a-ac5f-94e8040a1379">The Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV8yMDgw_fb028e2d-e7ab-45ef-85b0-2175d4d18981">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV8yMDgy_837b937d-59c2-4b23-8ece-10250bc4f8d0">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6MmJjNGFjYjQwZTZjNDNhZmE5OGVmZjczZjJjYTEzYjIvdGFibGVyYW5nZToyYmM0YWNiNDBlNmM0M2FmYTk4ZWZmNzNmMmNhMTNiMl8xLTAtMS0xLTM3MDM5_ec884656-0018-4a6e-af73-5c025caa4d1b">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6MmJjNGFjYjQwZTZjNDNhZmE5OGVmZjczZjJjYTEzYjIvdGFibGVyYW5nZToyYmM0YWNiNDBlNmM0M2FmYTk4ZWZmNzNmMmNhMTNiMl8xLTMtMS0xLTM3MDM5_73a25934-1ebd-4f29-9295-1af84a3bc36f">x</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6MmJjNGFjYjQwZTZjNDNhZmE5OGVmZjczZjJjYTEzYjIvdGFibGVyYW5nZToyYmM0YWNiNDBlNmM0M2FmYTk4ZWZmNzNmMmNhMTNiMl8yLTEtMS0xLTM3MDM5_14e6a14e-ec5a-4718-a9c8-44b7a8bbc74f">x</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV8yMDg1_e3a309fa-e686-4e09-8498-3fd32b9f4ab4">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV8yMDg2_edc5430a-e3d4-4da7-807c-5a9326b80b60">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of May 6, 2022, <ix:nonFraction unitRef="shares" contextRef="i19484616c8c8480b9d94b951bcae0361_I20220506" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV8yMDE3_d898768b-6648-418b-954d-3d9c71871888">6,812,836</ix:nonFraction> shares of the Registrant&#8217;s Common Stock were outstanding.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i59843287b8de4d67b8e56c082207e5cd_7"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_13">PART&#160;I. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_13">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_16">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_19">Balance Sheets as of </a>March&#160;31, 2022<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_19"> (unaudited) and </a>December&#160;31, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_22">Statements of Operations and Comprehensive Loss (unaudited) for the thre</a>e <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_22">months ended</a> March&#160;31, 2022<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_22"> and </a>2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_25">Statements of Changes in Stockholders&#8217; Equity (Deficit) (unaudited) for the three months ended </a>March&#160;31, 2022<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_25"> and </a>2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statements of Cash Flows (unaudited) for the three months ended March&#160;31, 2022<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_28"> and </a>2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_31">Notes to Unaudited Interim Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_76">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_76">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_76">15</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_100">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_100">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_100">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_103">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_103">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_103">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_106">PART&#160;II. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_106">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_106">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_109">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_109">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_109">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_112">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_112">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_112">22</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_127">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_127">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_127">28</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_130">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i59843287b8de4d67b8e56c082207e5cd_130">29</a></span></div></td></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i59843287b8de4d67b8e56c082207e5cd_10"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements that are based on management&#8217;s beliefs and assumptions and on information currently available to management. Some of the statements in the sections captioned &#8220;Part I&#8212;Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and elsewhere in this Quarterly Report contain forward-looking statements. In some cases, you can identify forward-looking statements by the following words: &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements contained in this Quarterly Report include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the likelihood of our clinical trials and non-clinical studies demonstrating safety and efficacy of our product candidates, and other positive results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of initiation of our future clinical trials, and the reporting of data from our completed, current and future preclinical and clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the market opportunity for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and sales strategy;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competing therapies that are or may become available;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates of the number of patients in the United States who suffer from ADHD or narcolepsy and the number of patients that will enroll in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the beneficial characteristics, safety and efficacy of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing or likelihood of regulatory filings and approval for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans relating to the further development and manufacturing of our product candidates, including ADMIR;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expected potential benefits of strategic collaborations with third parties, including MEDICE Arzneimittel Putter GmbH &amp; Co. KG (Medice), which is affiliated with one of our principal stockholders, SALMON Pharma GMbH (Salmon Pharma), and represented by one member of our board of directors, and our ability to attract collaborators with development, regulatory and commercialization expertise;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">existing regulations and regulatory developments in the United States, the European Union, and other geographic territories;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to hire additional personnel, and our ability to attract and retain such personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our financial performance;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sufficiency of our existing capital resources to fund our future operating expenses and capital expenditure requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impacts of the COVID-19 pandemic on our operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain the listing of our common stock on The Nasdaq Capital Market; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify, evaluate and complete any strategic alternative that yields value for our stockholders.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report, we have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. You should refer to the &#8220;Risk Factors&#8221; section of our Annual Report on Form 10-K for the year ended December&#160;31, 2021 and this Quarterly Report for a discussion of other important factors that may cause actual results to differ materially from those expressed or implied by the forward-looking statements.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. If the forward-looking statements prove to be inaccurate; the inaccuracy may be material. In light of the significant uncertainties in these forward- looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this Quarterly Report represents our views as of the date of this Quarterly Report. We anticipate that subsequent events and developments will cause our views to change, however, except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein after we distribute this Quarterly Report, whether as a result of any new information, future events or otherwise. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report includes trademarks and registered trademarks of Vallon Pharmaceuticals, Inc. Products or service names of other companies mentioned in this Quarterly Report may be trademarks or registered trademarks of their respective owners.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this Quarterly Report, unless the context requires otherwise, the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Vallon Pharmaceuticals, Inc.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><div id="i59843287b8de4d67b8e56c082207e5cd_13"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="i59843287b8de4d67b8e56c082207e5cd_16"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="i59843287b8de4d67b8e56c082207e5cd_19"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMy0xLTEtMS0zNzAzOQ_88c1d296-5779-43e9-87cc-d062aabff24c">2,543</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMy0zLTEtMS0zNzAzOQ_68edc838-0ba7-4391-9a87-1112c067481d">3,702</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities, available-for-sale</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfNC0xLTEtMS0zNzAzOQ_bd23f59a-eed3-47bb-8deb-7f35db1d1508">2,634</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfNC0zLTEtMS0zNzAzOQ_ad8275b8-96c1-4da7-a76a-80ae7fc0608f">3,808</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfNS0xLTEtMS0zNzAzOQ_f8938792-3eea-4ec4-b377-2335121b47cb">580</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfNS0zLTEtMS0zNzAzOQ_275f3257-5afe-488f-8478-f191fec60b8e">619</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfNi0xLTEtMS0zNzAzOQ_dd834e7b-28b9-4aea-89c4-5ae1b5dd4af6">5,757</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfNi0zLTEtMS0zNzAzOQ_6a625bff-5a4c-40d2-9f32-e1ddcb2bc025">8,129</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfNy0xLTEtMS0zNzAzOQ_2db30fc5-ee8a-4071-90d2-8abb735a1b4b">187</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfNy0zLTEtMS0zNzAzOQ_adbe439f-2cd4-4a27-8b93-5853ec7bdf49">206</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfOS0xLTEtMS0zNzAzOQ_f4b3ce3b-45e2-4a07-b1ad-641ee2a0f02a">5,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfOS0zLTEtMS0zNzAzOQ_0e507170-3800-4b66-9910-b3967cb3de84">8,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMTMtMS0xLTEtMzcwMzk_5c898579-ac22-4f56-b08f-a5eea9efbdbe">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMTMtMy0xLTEtMzcwMzk_89f967f4-0529-4538-9e50-e50b043125da">918</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMTQtMS0xLTEtMzcwMzk_f2cb352e-bb84-46dd-b472-74d644ade284">1,205</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMTQtMy0xLTEtMzcwMzk_ac43f310-aeba-4ef1-9c71-0ed4a5444ac7">1,430</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMTYtMS0xLTEtMzcwMzk_401fa0bb-d16d-4a02-860b-f61975e273fc">100</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMTYtMy0xLTEtMzcwMzk_363c4ac7-b4b5-403d-a97c-9aa45a3e1818">97</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMTctMS0xLTEtMzcwMzk_6af95d89-4d6c-4fa3-8b55-3665d4655469">2,538</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMTctMy0xLTEtMzcwMzk_d35cc383-5664-4c1e-8997-540721621910">2,445</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMTktMS0xLTEtMzcwMzk_34973fd0-1180-4e0f-b44d-02289ca8a918">46</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMTktMy0xLTEtMzcwMzk_21c4e883-fb8a-43cb-b1e0-6c13ddb81aaf">72</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjAtMS0xLTEtMzcwMzk_55986d70-6e90-42ba-8301-03fcf03725b0">2,584</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjAtMy0xLTEtMzcwMzk_03892bcf-f19a-4b22-a3ca-6d36e3e48292">2,517</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 10)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjItMS0xLTEtMzcwMzk_2889a160-e2d3-4cdf-affc-f133a4ac6b3a"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjItMy0xLTEtMzcwMzk_e47a00bf-2800-47bf-852b-b8177524ff99"></ix:nonFraction></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjUtMC0xLTEtMzcwMzkvdGV4dHJlZ2lvbjo3ZGFkZDY4MGYxYTY0NDk2OWFjYTBlZDU0YTcyMWE4Y18xOA_9fc8495a-b40e-4eb2-a14b-fc3a3c9158ad"><ix:nonFraction unitRef="usdPerShare" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjUtMC0xLTEtMzcwMzkvdGV4dHJlZ2lvbjo3ZGFkZDY4MGYxYTY0NDk2OWFjYTBlZDU0YTcyMWE4Y18xOA_e9a53095-c071-407f-a528-9c96981ae121">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjUtMC0xLTEtMzcwMzkvdGV4dHJlZ2lvbjo3ZGFkZDY4MGYxYTY0NDk2OWFjYTBlZDU0YTcyMWE4Y18zMg_23c8a70c-e48c-44dc-bd7c-63636d3e07a7"><ix:nonFraction unitRef="shares" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjUtMC0xLTEtMzcwMzkvdGV4dHJlZ2lvbjo3ZGFkZDY4MGYxYTY0NDk2OWFjYTBlZDU0YTcyMWE4Y18zMg_41ff59d0-3625-4f63-a20e-840b15388abc">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of March&#160;31, 2022 and December&#160;31, 2021; <ix:nonFraction unitRef="shares" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjUtMC0xLTEtMzcwMzkvdGV4dHJlZ2lvbjo3ZGFkZDY4MGYxYTY0NDk2OWFjYTBlZDU0YTcyMWE4Y183MA_85ccdaaa-30a1-48bc-9d07-7e75ad0c594d"><ix:nonFraction unitRef="shares" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjUtMC0xLTEtMzcwMzkvdGV4dHJlZ2lvbjo3ZGFkZDY4MGYxYTY0NDk2OWFjYTBlZDU0YTcyMWE4Y183MA_94d16822-af49-4f87-86bf-e5efa738d2cb"><ix:nonFraction unitRef="shares" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjUtMC0xLTEtMzcwMzkvdGV4dHJlZ2lvbjo3ZGFkZDY4MGYxYTY0NDk2OWFjYTBlZDU0YTcyMWE4Y183MA_bb2a3809-0d3a-4353-a4bc-2910eba5c668"><ix:nonFraction unitRef="shares" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjUtMC0xLTEtMzcwMzkvdGV4dHJlZ2lvbjo3ZGFkZDY4MGYxYTY0NDk2OWFjYTBlZDU0YTcyMWE4Y183MA_f7f5365f-35f2-4906-98fd-bb020da4349a">6,812,836</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2022 and December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjUtMS0xLTEtMzcwMzk_ca4cdbf8-a7e9-4bf3-ba00-c50990722fad">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjUtMy0xLTEtMzcwMzk_bbf448ba-4857-4373-b098-0518b1e35cad">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in-capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjYtMS0xLTEtMzcwMzk_b0694392-b925-4bc3-97ea-5a38a402e2dc">27,903</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjYtMy0xLTEtMzcwMzk_ffd3e6d5-ad54-424d-841f-ff72a16a70a6">27,722</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjctMS0xLTEtMzcwMzk_53561b36-b49e-47fe-b0a8-5f891d77d3af">6</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjctMy0xLTEtMzcwMzk_bb62ba3c-5c12-44eb-8c6a-625cead417bf">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjgtMS0xLTEtMzcwMzk_af5139ce-ae02-4415-80a3-acb6035fe160">24,537</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjgtMy0xLTEtMzcwMzk_23909751-956f-4e6a-a70e-21c55be2c6ed">21,902</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjktMS0xLTEtMzcwMzk_1d71e7c2-1eb1-4001-b3ec-5228dbcc7be5">3,360</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjktMy0xLTEtMzcwMzk_03279103-43e5-4a40-9b99-cad17ecee63f">5,818</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMzAtMS0xLTEtMzcwMzk_a62409f2-a8ba-4d5d-a7e2-10699f82cf41">5,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMzAtMy0xLTEtMzcwMzk_2976d67c-bc34-48c1-ad4d-820a329c6306">8,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim financial statements.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i59843287b8de4d67b8e56c082207e5cd_22"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:10pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenue-related party</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMy0xLTEtMS0zNzAzOQ_9f5ce968-87a0-48f8-a62d-58b3d59a7d03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMy0zLTEtMS0zNzAzOQ_69ffb7de-fb8b-4079-9792-bda888ce3299">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfNS0xLTEtMS0zNzAzOQ_854d484d-719b-46ca-a2b8-e7bc4dea5944">1,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfNS0zLTEtMS0zNzAzOQ_eb032a3d-ac1f-421d-9b9e-c26baa179e66">1,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfNi0xLTEtMS0zNzAzOQ_f52509d0-fb8d-4629-a47c-a359b159a560">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfNi0zLTEtMS0zNzAzOQ_f6ee8ec5-085b-418b-8534-6406b876f5b4">830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28.35pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfNy0xLTEtMS0zNzAzOQ_9464df53-9b59-4d05-9170-f72133167ed0">2,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfNy0zLTEtMS0zNzAzOQ_3b9fddbe-c852-411d-a452-30e7bbe183ab">2,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfOC0xLTEtMS0zNzAzOQ_4b0def5b-b3b1-4263-9661-3b3564d42232">2,634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfOC0zLTEtMS0zNzAzOQ_8a756789-fcbf-418e-9296-d07d266c29f7">2,602</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfOS0xLTEtMS0zNzAzOQ_6e1fa1fa-5096-4e13-bb2d-e188e1dbba5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:OtherNonoperatingIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfOS0zLTEtMS0zNzAzOQ_94cf671c-a8aa-4d1e-a801-52b3f295f1af">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTAtMS0xLTEtMzcwMzk_81159514-70c9-40d7-945b-89bc1d053380">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTAtMy0xLTEtMzcwMzk_054cf793-7735-45b0-a0af-270b142d8c6f">89</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTEtMS0xLTEtMzcwMzk_a59f9320-c37c-4b6c-843f-34baef98d176">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTEtMy0xLTEtMzcwMzk_1c2049ad-f756-4885-b9e6-a9ad54058f81">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTItMS0xLTEtMzcwMzk_e372335f-e309-4b56-b3b1-71a9b20ce2ca">2,635</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTItMy0xLTEtMzcwMzk_86a594e9-4542-4cd6-99f5-d3ba59b24252">2,638</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Unrealized loss on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTQtMS0xLTEtMzcwMzk_385a004d-c1b3-47da-9c1d-dfe390c29a51">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTQtMy0xLTEtMzcwMzk_a22a5c0b-5817-4757-b0a3-681f2ab661d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTUtMS0xLTEtMzcwMzk_14845f91-55ff-468e-b5c1-6dee6a531dde">2,639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTUtMy0xLTEtMzcwMzk_5c9670e6-ff85-42bc-9fed-508071027017">2,638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share of common stock, basic and diluted</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTctMS0xLTEtMzcwMzk_fbb3fcab-144b-4271-aaa9-20ee981c7998"><ix:nonFraction unitRef="usdPerShare" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTctMS0xLTEtMzcwMzk_fe0a152e-6c5c-4650-9a59-30d31c596efe">0.39</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTctMy0xLTEtMzcwMzk_56b56faf-3c85-439d-933a-4684cf14dd13"><ix:nonFraction unitRef="usdPerShare" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="INF" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTctMy0xLTEtMzcwMzk_8d74278f-f2b7-4f2c-964f-62ce0953a198">0.46</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="INF" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTgtMS0xLTEtMzcwMzk_3b4dc841-fdee-4acb-b0a0-5c9ed94b7e5c"><ix:nonFraction unitRef="shares" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="INF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTgtMS0xLTEtMzcwMzk_c04045a5-e576-4e02-9597-bd568fdd766f">6,812,836</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="INF" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTgtMy0xLTEtMzcwMzk_ab12bf51-bfca-448b-9649-38992968d2a3"><ix:nonFraction unitRef="shares" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="INF" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTgtMy0xLTEtMzcwMzk_e1b45de4-5426-4572-a83e-7f1cf2d88943">5,710,270</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim financial statements.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i59843287b8de4d67b8e56c082207e5cd_25"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Changes in Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except shares)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.017%"></td><td style="width:0.1%"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional&#160;Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217; Equity&#160;(Deficit)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance,&#160;December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7614adf727b407d9dcfe9c7866dadec_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfMi0xLTEtMS0zNzAzOQ_9ef5bd30-8097-42ac-a43a-e1788dce59cb">4,506,216</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cf4793645e7478396bfebc5d1280046_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfMi01LTEtMS0zNzAzOQ_930785d0-c19b-46e7-871f-948c43c80435">11,145</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b89c603f01d4777a2dedbf1801d5be1_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfMi05LTEtMS0zNzAzOQ_d4a9cd14-5974-4395-b8d9-2e3216bb8928">12,599</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb04f7e476724b32ac14d93d1aecd6cd_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfMi0xMS0xLTEtMzcwMzk_60a2ce87-4f8b-44f8-b28a-22807b2a5baf">1,454</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ed8cb8b770442c18891f8011fdd7380_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfMy0xLTEtMS0zNzAzOQ_a5794912-8c55-408e-a73b-16c8c7c61354">54,906</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i112cbf6fe6d94f7e95aa68e4b3b82566_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfMy01LTEtMS0zNzAzOQ_650900c5-f5a3-48e3-9735-2a6c83ff3050">439</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfMy0xMS0xLTEtMzcwMzk_e23f87d3-df6e-4186-861c-f7003bfb4863">439</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for IPO, net of issuance expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ed8cb8b770442c18891f8011fdd7380_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfNC0xLTEtMS0zNzAzOQ_38d05a1b-b14f-4b8e-8e0f-5b93c7e78477">2,250,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i112cbf6fe6d94f7e95aa68e4b3b82566_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfNC01LTEtMS0zNzAzOQ_a6672868-bc5e-46ea-8ee8-a04d070448b8">15,104</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfNC0xMS0xLTEtMzcwMzk_ebad6994-f565-484e-b4eb-8c95a78f5979">15,104</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for services</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ed8cb8b770442c18891f8011fdd7380_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfNS0xLTEtMS0zNzAzOQ_36d6542a-7d85-4449-8b37-0afc42fba1a0">1,714</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i112cbf6fe6d94f7e95aa68e4b3b82566_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfNS01LTEtMS0zNzAzOQ_5552b994-0a86-4f86-8172-f8ee8b868c8e">9</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfNS0xMS0xLTEtMzcwMzk_983afa15-cfae-4f14-abb8-2381f772ff39">9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of Underwriters Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i112cbf6fe6d94f7e95aa68e4b3b82566_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfNi01LTEtMS0zNzAzOQ_cbbdc4f5-e4f8-454d-8079-ad7eba73e96f">399</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfNi0xMS0xLTEtMzcwMzk_b2f56369-43ee-4636-b36b-ac9f62da3d3c">399</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i112cbf6fe6d94f7e95aa68e4b3b82566_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfNy01LTEtMS0zNzAzOQ_bde875d6-9788-47c4-a469-7f1d57e0f8e1">168</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfNy0xMS0xLTEtMzcwMzk_4fb093ee-830f-4baa-93d3-ea85d34abe0e">168</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i696ce2800db940be9f493ce1a41cc843_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfOC05LTEtMS0zNzAzOQ_b2f3abc2-4e50-4c56-b044-669b16aff62b">2,638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfOC0xMS0xLTEtMzcwMzk_25fa4fd8-f99a-4c89-abce-8c4ade0d7088">2,638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3fb11e86e5bf43d385426e1375734dd6_I20210331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfOS0xLTEtMS0zNzAzOQ_ce841e37-83f9-446a-a12f-cdc44388994e">6,812,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52bc59ea9a964dd2878f917948cf15f6_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfOS01LTEtMS0zNzAzOQ_396bf65c-7acc-4deb-89de-8909e9c52eb9">27,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c36969402654f268647e2010c59c641_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfOS05LTEtMS0zNzAzOQ_5d57f48f-1162-4a6b-8b6e-c43c2ed4ad9e">15,237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibca337c014ca4895aaf539d38c0f5424_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfOS0xMS0xLTEtMzcwMzk_b4b1f3e0-6e3e-406e-8194-3ddf0697dfe1">12,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.017%"></td><td style="width:0.1%"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional&#160;Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217; Equity</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance,&#160;December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8c71d40ad8c8445783218c6cc8c9fd95_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfMi0xLTEtMS0zOTAzNg_e7cd55c6-9dcf-4062-b4e9-53d90c79e828">6,812,836</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e72d21b8d324c0ca3c1f71d2e152b0e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfMi01LTEtMS0zOTA0Mw_8060fd6f-4e40-43ec-a0e0-621212232e10">27,722</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47d3c892e0334a90bfe742b8fc3fb929_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfMi03LTEtMS0zOTA1Nw_d7c384cd-da9d-47fd-8680-ea96bd660f35">2</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d5ea48dd69c4c3fb4e49bd12780ad99_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfMi05LTEtMS00MDAxNQ_2c29072a-1e08-4547-9ac5-91f699d92d18">21,902</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfMi0xMS0xLTEtNDAwMjY_491f7357-abdc-4f87-b03d-fcbf470514c5">5,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff52b3f4d3964f18b58baec76585133c_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfMy01LTEtMS0zOTQxNA_a9ed3cab-d450-4328-bfe5-42544f47800e">181</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfMy0xMS0xLTEtNDAwMjY_daab2020-d7dc-4393-b97e-eda6dea465c4">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealizes loss on marketable securities, available-for-sale</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfNC03LTEtMS0zOTQyMA_8f50dcaa-b61d-4e82-91ca-19c2a1393fe0">4</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfNC0xMS0xLTEtNDAwMjY_adfec78b-d1f9-4ff2-b277-1102a35c569d">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i470300e9f67349a4a8f5ed6f67792df9_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfNS05LTEtMS0zOTQyNg_bf108d2b-fa5c-4e0c-929e-1895ed5aee6a">2,635</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfNS0xMS0xLTEtNDAwMjY_dfe27fbe-c5b0-4f17-85a8-766026fb4164">2,635</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0cec8f00f4844c59bf6b4e46fa04203_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfNi0xLTEtMS0zOTQzMw_3de0f940-a071-4225-a02c-61afa049c9af">6,812,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4e4d371903843b8a67b3c95775d3069_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfNi01LTEtMS00MDAwMA_c09955a6-07e7-4cce-bc9b-21dd16523182">27,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e4a9d93e6d448e682d05b667992ba82_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfNi03LTEtMS00MDAxMQ_1615af1c-0727-4d0a-a54b-a6868f8008ea">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaec88160062a4e4ebb51935d4831bccf_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfNi05LTEtMS00MDAyMA_f5a76080-a589-4900-912e-a51c3cf20d46">24,537</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfNi0xMS0xLTEtNDAwMjY_34b125ad-1e2f-40e3-9387-0fa1a6b4ba8f">3,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim financial statements. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i59843287b8de4d67b8e56c082207e5cd_28"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMy0xLTEtMS0zNzAzOQ_983da759-e77a-47ba-b840-ccaa5c594967">2,635</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMy0zLTEtMS0zNzAzOQ_82a726fe-1304-4abc-baba-d672b3162c30">2,638</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of finance lease right-of-use asset</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfNS0xLTEtMS0zNzAzOQ_9dc31d12-4ae0-4c25-95f8-9cae34fda310">19</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfNS0zLTEtMS0zNzAzOQ_ffe088c5-1988-4c16-8476-e652726dd997">18</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of marketable securities premiums</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfNi0xLTEtMS0zNzAzOQ_88083021-626a-4d48-a077-aebe76d7e582">16</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfNi0zLTEtMS0zNzAzOQ_057ef1e8-d372-4992-af65-d31f964e75f0">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfNy0xLTEtMS0zNzAzOQ_05643f2a-8621-4bab-93c2-0bfd2dc54432">181</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfNy0zLTEtMS0zNzAzOQ_2a03cbba-a3b3-452b-a141-a6c627d778dd">168</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of derivative liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfOC0xLTEtMS0zNzAzOQ_3ae9bebc-2455-4d7c-b024-c36f33a6e586">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfOC0zLTEtMS0zNzAzOQ_684594a9-7c1d-44ee-8bb1-c305789dd1cc">89</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forgiveness of PPP note</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" name="ck0001824293:ForgivenessOfDebtInstrument" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfOS0xLTEtMS0zNzAzOQ_b8d5badf-5051-4abb-b9a6-c4fb41e41d46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="ck0001824293:ForgivenessOfDebtInstrument" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfOS0zLTEtMS0zNzAzOQ_46c002c1-02a8-4155-b783-a06e8395445a">61</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest, depreciation and other expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" name="us-gaap:OtherNoncashExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMTAtMS0xLTEtMzcwMzk_6be9606e-0c82-40bc-8513-e2303a97ec5b">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:OtherNoncashExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMTAtMy0xLTEtMzcwMzk_8594630d-2601-4b50-bb3b-34a65281eda9">10</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMTItMS0xLTEtMzcwMzk_ebfbb5b5-f741-4bd7-9b45-05a4367f53a3">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMTItMy0xLTEtMzcwMzk_9101f616-5ac9-4d30-b451-a5bdcb378b15">793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMTMtMS0xLTEtMzcwMzk_324d0978-8288-483d-8f95-161dbd2d8a20">315</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMTMtMy0xLTEtMzcwMzk_2be259d0-3c6a-4cef-8f83-14bdef3dfe5a">121</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMTQtMS0xLTEtMzcwMzk_ea223740-771c-4b08-a7f0-af8674b4b988">225</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMTQtMy0xLTEtMzcwMzk_e33560cc-8781-4710-b34c-eeafe1403664">138</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMTUtMS0xLTEtMzcwMzk_56369353-1035-442c-80ee-4ed3a1bd937d">2,290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMTUtMy0xLTEtMzcwMzk_e88bd98b-cdfe-4460-bc38-095d4c259da4">2,948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMTgtMS0xLTEtMzcwMzk_84154619-9d2d-4748-934f-fc757b503c46">1,154</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMTgtMy0xLTEtMzcwMzk_48a83cf7-7c6e-4050-83ab-564802769774">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMjAtMS0xLTEtMzcwMzk_fcfa8f2e-9548-4424-b750-44f63aafdb57">1,154</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMjAtMy0xLTEtMzcwMzk_266e0f97-0379-485c-98c5-6be0076e5649">&#8212;</ix:nonFraction></span></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from common stock, net of offering expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMjQtMS0xLTEtMzcwMzk_c7a7cb41-3046-47b9-b893-a94b07f91847">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMjQtMy0xLTEtMzcwMzk_e303b6e7-922d-4669-90b3-fe922e452da4">15,503</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMjUtMS0xLTEtMzcwMzk_7b9c5c7b-28ce-4fd9-b0d8-9b1e63af319b">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMjUtMy0xLTEtMzcwMzk_be4c37d8-7bcc-492b-97e6-8a6f113db7cc">350</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of finance lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMjYtMS0xLTEtMzcwMzk_583372e3-0168-4aea-8188-0815c5eda7d9">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMjYtMy0xLTEtMzcwMzk_d60df4a0-9a87-4807-992d-b4d9f75e0890">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMjctMS0xLTEtMzcwMzk_e3d32a2a-b49c-4bb0-8d7f-75a4e9b12cff">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMjctMy0xLTEtMzcwMzk_08612644-85e0-4ef7-8d06-2250ff38d6a6">15,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMjktMS0xLTEtMzcwMzk_c54a8188-4588-4954-8bfd-d9b79f5919fe">1,159</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMjktMy0xLTEtMzcwMzk_69f43bcf-389b-4fd7-a7d2-41d1530fcb8e">12,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, at beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMzAtMS0xLTEtMzcwMzk_73b6599e-c45f-42b8-b660-dc469064b5a2">3,702</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb04f7e476724b32ac14d93d1aecd6cd_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMzAtMy0xLTEtMzcwMzk_e72ccbca-248a-40a3-86b7-1eb44b0705e7">109</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMzEtMS0xLTEtMzcwMzk_bfbef8bc-33c0-46c5-a7a2-f7d93825f374">2,543</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibca337c014ca4895aaf539d38c0f5424_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMzEtMy0xLTEtMzcwMzk_33bd7a79-2740-4113-871c-b0549481c678">12,980</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of cash flows information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncash financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of convertible notes to common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMzQtMS0xLTEtMzcwMzk_59618747-de3c-47b7-a04e-f93da508e0d0">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMzQtMy0xLTEtMzcwMzk_3bcfdecf-1679-46da-bb20-858736293210">350</ix:nonFraction></span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim financial statements.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i59843287b8de4d67b8e56c082207e5cd_31"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vallon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div id="i59843287b8de4d67b8e56c082207e5cd_34"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8zNC9mcmFnOjE5OTU4ZDdiN2UwYzQzYjJhNzAxMWRkNDgyNWM1ODY1L3RleHRyZWdpb246MTk5NThkN2I3ZTBjNDNiMmE3MDExZGQ0ODI1YzU4NjVfMjI0Ng_48e50f13-e904-4b96-a703-9bb93f460f65" continuedAt="i6a7259e498b845f0af5a30af9f225618" escape="true">ORGANIZATION AND DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><ix:continuation id="i6a7259e498b845f0af5a30af9f225618"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vallon Pharmaceuticals, Inc. (Vallon or the Company), based in Philadelphia, PA was incorporated in Delaware on January 11, 2018, which is the date of inception.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. The Company&#8217;s lead investigational product candidate, ADAIR, is a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine (the main active ingredient in Adderall&#174;) for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. In March 2022, the Company announced that its SEAL study for ADAIR did not reach its primary endpoint, and there is no assurance that ADAIR will receive approval by the U.S. Food and Drug Administration (the FDA). In addition to ADAIR, the Company completed formulation development work and selected the final formulation of its second product candidate, ADMIR, an abuse deterrent formulation of methylphenidate (Ritalin&#174;), for the treatment of ADHD.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEAL study (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tudy to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">valuate the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">buse </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation), was the Company&#8217;s pivotal intranasal human abuse liability study assessing the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability of snorting professional laboratory-manipulated ADAIR 30 mg when compared to crushed d-amphetamine sulfate and placebo in recreational drug users. ADAIR was prepared for snorting by a pharmacist using a multi-step technique that had been developed by a professional laboratory and agreed upon by the FDA. The SEAL study enrolled <ix:nonFraction unitRef="participant" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="0" name="ck0001824293:ClinicalResearchStudyNumberOfParticipantsEnrolled" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8zNC9mcmFnOjE5OTU4ZDdiN2UwYzQzYjJhNzAxMWRkNDgyNWM1ODY1L3RleHRyZWdpb246MTk5NThkN2I3ZTBjNDNiMmE3MDExZGQ0ODI1YzU4NjVfMTY0OTI2NzQ0ODI1OA_ccdabd40-c4d9-4533-940a-14967e8c3daf">55</ix:nonFraction> subjects, of whom <ix:nonFraction unitRef="participant" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="0" name="ck0001824293:ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8zNC9mcmFnOjE5OTU4ZDdiN2UwYzQzYjJhNzAxMWRkNDgyNWM1ODY1L3RleHRyZWdpb246MTk5NThkN2I3ZTBjNDNiMmE3MDExZGQ0ODI1YzU4NjVfMTY0OTI2NzQ0ODI2Mg_36fd3d70-c564-4d5c-a477-73e9735a91c3">53</ix:nonFraction> completed the study and <ix:nonFraction unitRef="participant" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="0" name="ck0001824293:ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8zNC9mcmFnOjE5OTU4ZDdiN2UwYzQzYjJhNzAxMWRkNDgyNWM1ODY1L3RleHRyZWdpb246MTk5NThkN2I3ZTBjNDNiMmE3MDExZGQ0ODI1YzU4NjVfMTY0OTI2NzQ0ODI2Ng_5e1f5b82-aba3-4dfc-aec8-fd58ef3d82a6">52</ix:nonFraction> were included in the final analysis. The study involved a four-way crossover design to evaluate professionally manipulated, intranasal ADAIR 30 mg, crushed intranasal dextroamphetamine, ADAIR 30 mg taken orally, and placebo. All subjects were non-dependent recreational stimulant users with an additional history of recreational intranasal drug use.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEAL study did not meet its primary endpoint, which was E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">max</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Drug Liking. ADAIR scored similarly to what was observed in an earlier proof-of-concept study, however, reference dextroamphetamine did not score as high as expected and as seen in the previous study, thus driving the lack of statistical significance. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is continuing to assess the best path forward for the ADAIR and ADMIR development programs. In addition, the Company has engaged Ladenburg Thalmann &amp; Co. Inc. (Ladenburg) to evaluate its strategic alternatives with the goal of maximizing stockholder value. Ladenburg has been engaged to advise the Company on the strategic review process, which could include, without limitation, exploring the potential for a possible merger, business combination, investment into the Company, or a purchase, license or other acquisition of assets. In the meantime, and in conjunction with the exploration of strategic alternatives, the Company is streamlining its operations in order to preserve its capital and cash resources.</span></div></ix:continuation><div id="i59843287b8de4d67b8e56c082207e5cd_37"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8zNy9mcmFnOmU2ZWMzNTU2ZGZkYTRjNmE4MjYwOGFiNGY2NWE5NDg2L3RleHRyZWdpb246ZTZlYzM1NTZkZmRhNGM2YTgyNjA4YWI0ZjY1YTk0ODZfMjA2Mg_ac31e79b-9503-4569-a2e2-3b5f03f5e02b" continuedAt="i7c8f531f567d496fa0580c027637bf37" escape="true">LIQUIDITY</ix:nonNumeric></span></div><ix:continuation id="i7c8f531f567d496fa0580c027637bf37" continuedAt="i49a3ea6b0ce046239d48329805c0122f"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception and has incurred $<ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8zNy9mcmFnOmU2ZWMzNTU2ZGZkYTRjNmE4MjYwOGFiNGY2NWE5NDg2L3RleHRyZWdpb246ZTZlYzM1NTZkZmRhNGM2YTgyNjA4YWI0ZjY1YTk0ODZfMzg0ODI5MDY5OTI4OQ_af5139ce-ae02-4415-80a3-acb6035fe160">24,537</ix:nonFraction> in accumulated deficit through March&#160;31, 2022. The Company has financed its working capital requirements to date through the issuance of common stock, convertible notes, short-term promissory notes, and a Paycheck Protection Program (PPP) promissory note.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2021, the Company completed a $<ix:nonFraction unitRef="usd" contextRef="iac76cfecf8b945eda2c37283b0d1bafa_D20210101-20210131" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8zNy9mcmFnOmU2ZWMzNTU2ZGZkYTRjNmE4MjYwOGFiNGY2NWE5NDg2L3RleHRyZWdpb246ZTZlYzM1NTZkZmRhNGM2YTgyNjA4YWI0ZjY1YTk0ODZfNzQ3_046f0ac4-652c-4cf2-9902-a07fb00b8eb9">350</ix:nonFraction> convertible note financing and in February 2021, the Company completed the inital public offering (IPO) of the Company&#8217;s common stock, raising net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i459e0d6af0f74d42a0f684f536cfd55c_D20210201-20210228" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8zNy9mcmFnOmU2ZWMzNTU2ZGZkYTRjNmE4MjYwOGFiNGY2NWE5NDg2L3RleHRyZWdpb246ZTZlYzM1NTZkZmRhNGM2YTgyNjA4YWI0ZjY1YTk0ODZfODQz_18a8ae15-9fd9-41b8-bbcd-4d6a500f06a4">15,500</ix:nonFraction>. As of March&#160;31, 2022, the Company had cash, cash equivalents and marketable securities of approximately $<ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8zNy9mcmFnOmU2ZWMzNTU2ZGZkYTRjNmE4MjYwOGFiNGY2NWE5NDg2L3RleHRyZWdpb246ZTZlYzM1NTZkZmRhNGM2YTgyNjA4YWI0ZjY1YTk0ODZfMzg0ODI5MDY5OTI5NA_77dfc247-8d3b-4089-9985-b71c735e1877">5,177</ix:nonFraction>.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects to incur ongoing expenses as it evaluates its plans for the ADAIR and ADMIR programs and strategic alternatives after it announced in March 2022 that the SEAL study of ADAIR for the treatment of ADHD failed to meet statistical </span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><ix:continuation id="i49a3ea6b0ce046239d48329805c0122f"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significance for its primary endpoint. The Company is currently assessing the best path forward for the ADAIR and ADMIR programs and has no other product candidates undergoing clinical trials. The Company&#8217;s future capital requirements are difficult to forecast and will depend on many factors, including but not limited to the terms and timing of any strategic alternatives including a merger or business combination, asset acquisitions or sales, collaborations or licensing arrangements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company raises additional funds by issuing equity securities, its stockholders may experience dilution. Any future debt financing may impose upon it covenants that restrict our operations, including limitations on its ability to incur liens or additional debt, pay dividends, repurchase its common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any equity or debt financing may contain terms that are not favorable to the Company or its stockholders. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce or terminate some or all of its development programs and clinical trials. The Company may also be required to sell or license to other parties&#8217; rights to develop or commercialize its drug candidates that it would prefer to retain. Therefore, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company expects to continue to incur expenses and operating losses at least for the foreseeable future as it evaluates future plans for the ADAIR and ADMIR programs as well as its strategic alternatives.</span></div></ix:continuation><div id="i59843287b8de4d67b8e56c082207e5cd_40"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80MC9mcmFnOjhiZDE1MTdhZWUyMDRmMjY5NjljOTM0ZDVhNWZjMGNiL3RleHRyZWdpb246OGJkMTUxN2FlZTIwNGYyNjk2OWM5MzRkNWE1ZmMwY2JfNjQ4Mw_9c1c0531-67f9-4673-9456-29a602ca58aa" continuedAt="i6d4b2b4288df4fc6a7b38fff906002a1" escape="true">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i6d4b2b4288df4fc6a7b38fff906002a1" continuedAt="ie885e82142924b858ebb903b084028f2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80MC9mcmFnOjhiZDE1MTdhZWUyMDRmMjY5NjljOTM0ZDVhNWZjMGNiL3RleHRyZWdpb246OGJkMTUxN2FlZTIwNGYyNjk2OWM5MzRkNWE1ZmMwY2JfNjQ4NA_ffafc73d-8969-4f31-a5af-1ef202fd6c01" continuedAt="icc5e5df040fd4f05ba386b2f7fc356fd" escape="true">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission. References in this Quarterly Report on Form 10-Q to &#8220;authoritative guidance&#8221; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2021 balance sheet was derived from audited financial statements. </ix:nonNumeric></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icc5e5df040fd4f05ba386b2f7fc356fd">In the opinion of management, the unaudited interim financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2022, and the results of operations and stockholders&#8217; equity (deficit) for the three months ended March&#160;31, 2022 and 2021 and cash flows for the three months ended March&#160;31, 2022 and 2021. Results of operations for the three months ended March&#160;31, 2022, are not necessarily indicative of the operating results that may be expected for the year ending December&#160;31, 2022. The unaudited interim financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December&#160;31, 2021, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on February&#160;14, 2022.</ix:continuation> </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recapitalization</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the closing of the  IPO (Note 7), the Company effected a one-for-40 reverse stock split of its common stock. All share and per share amounts, excluding the number of authorized shares and par value, contained in these financial statements and accompanying notes, and this Quarterly Report on Form 10-Q give retroactive effect to the reverse split.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80MC9mcmFnOjhiZDE1MTdhZWUyMDRmMjY5NjljOTM0ZDVhNWZjMGNiL3RleHRyZWdpb246OGJkMTUxN2FlZTIwNGYyNjk2OWM5MzRkNWE1ZmMwY2JfNjQ3OQ_0ce7d069-b866-4327-86d7-76a2a76fa158" continuedAt="idf531cdf85794da9bb0669c1fa7e58e3" escape="true">Use of Estimates</ix:nonNumeric></span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idf531cdf85794da9bb0669c1fa7e58e3">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the unaudited interim financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</ix:continuation> </span></div><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80MC9mcmFnOjhiZDE1MTdhZWUyMDRmMjY5NjljOTM0ZDVhNWZjMGNiL3RleHRyZWdpb246OGJkMTUxN2FlZTIwNGYyNjk2OWM5MzRkNWE1ZmMwY2JfNjQ4MA_c3d7a53f-90a2-4eae-b0ba-d6b01a2139cb" continuedAt="ibf89c2f88dda4736b47517d54f5e6ca1" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of debt securities that are designated as available-for-sale. Marketable debt securities are recorded at fair value and unrealized holding gains or losses are reported as a component of accumulated other comprehensive income (loss). </span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><ix:continuation id="ie885e82142924b858ebb903b084028f2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibf89c2f88dda4736b47517d54f5e6ca1">Realized gains or losses resulting from the sale of these securities are determined based on the specific identification of the securities sold. An impairment charge is recognized when the decline in the fair value of a debt security below the amortized cost basis is determined to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the duration and severity of any decline in fair value below the amortized cost basis, any adverse changes in the financial condition of the issuers and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.</ix:continuation></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80MC9mcmFnOjhiZDE1MTdhZWUyMDRmMjY5NjljOTM0ZDVhNWZjMGNiL3RleHRyZWdpb246OGJkMTUxN2FlZTIwNGYyNjk2OWM5MzRkNWE1ZmMwY2JfNjQ4MQ_6c5f3917-2005-4c46-89f3-c9b938760b27" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are recorded as a cumulative adjustment in the period the estimates are revised. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80MC9mcmFnOjhiZDE1MTdhZWUyMDRmMjY5NjljOTM0ZDVhNWZjMGNiL3RleHRyZWdpb246OGJkMTUxN2FlZTIwNGYyNjk2OWM5MzRkNWE1ZmMwY2JfNjQ4Mg_f99bf0d0-6c55-4b09-9990-51c651e1f270" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the applicability and impact of all ASUs issued during the quarter ended March 31, 2022 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i59843287b8de4d67b8e56c082207e5cd_46"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RleHRyZWdpb246NTYwZDAyNWIzMDI4NGFmNWJiNWQ2NzVmMWVhNzA1YzdfMjU0Mg_7a7d256e-3cdd-4c58-9732-21cf904dbfe0" continuedAt="i19e53a49f6a940bb92fa5df29bda6fa0" escape="true">MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i19e53a49f6a940bb92fa5df29bda6fa0" continuedAt="i6c90ddec74a44c4d923bd63368fcb346"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RleHRyZWdpb246NTYwZDAyNWIzMDI4NGFmNWJiNWQ2NzVmMWVhNzA1YzdfMjU0Mw_1f06d583-a036-453f-ac75-677c22aaa6c7" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s available for sale securities as of the dates indicated:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.794%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Marketable Securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Corporate bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if636725079b740db9f7e05e222c86d29_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjE5MzMyMjg0Y2Q1ODQ3OTM5Mjc5OWY2ZDEwNGJmMDI3L3RhYmxlcmFuZ2U6MTkzMzIyODRjZDU4NDc5MzkyNzk5ZjZkMTA0YmYwMjdfNC0xLTEtMS0zNzAzOQ_b68346c0-3cd4-487a-94da-25763ebf588d">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if636725079b740db9f7e05e222c86d29_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjE5MzMyMjg0Y2Q1ODQ3OTM5Mjc5OWY2ZDEwNGJmMDI3L3RhYmxlcmFuZ2U6MTkzMzIyODRjZDU4NDc5MzkyNzk5ZjZkMTA0YmYwMjdfNC0zLTEtMS0zNzAzOQ_0ed4c103-0970-44ba-a4c7-805c694e3437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if636725079b740db9f7e05e222c86d29_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjE5MzMyMjg0Y2Q1ODQ3OTM5Mjc5OWY2ZDEwNGJmMDI3L3RhYmxlcmFuZ2U6MTkzMzIyODRjZDU4NDc5MzkyNzk5ZjZkMTA0YmYwMjdfNC01LTEtMS0zNzAzOQ_ccc74de7-fde0-4796-8a3e-ad57dc20d144">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if636725079b740db9f7e05e222c86d29_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjE5MzMyMjg0Y2Q1ODQ3OTM5Mjc5OWY2ZDEwNGJmMDI3L3RhYmxlcmFuZ2U6MTkzMzIyODRjZDU4NDc5MzkyNzk5ZjZkMTA0YmYwMjdfNC03LTEtMS0zNzAzOQ_b270feec-bad3-417d-a187-cff1582c0113">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5006cf101226413bb3ec2ab87613cd4e_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjE5MzMyMjg0Y2Q1ODQ3OTM5Mjc5OWY2ZDEwNGJmMDI3L3RhYmxlcmFuZ2U6MTkzMzIyODRjZDU4NDc5MzkyNzk5ZjZkMTA0YmYwMjdfNS0xLTEtMS0zNzAzOQ_52054cd6-b633-4c65-93ea-e72b38a37293">2,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5006cf101226413bb3ec2ab87613cd4e_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjE5MzMyMjg0Y2Q1ODQ3OTM5Mjc5OWY2ZDEwNGJmMDI3L3RhYmxlcmFuZ2U6MTkzMzIyODRjZDU4NDc5MzkyNzk5ZjZkMTA0YmYwMjdfNS0zLTEtMS0zNzAzOQ_f372463f-9aec-47b9-ac8d-e4e8ca27b9fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5006cf101226413bb3ec2ab87613cd4e_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjE5MzMyMjg0Y2Q1ODQ3OTM5Mjc5OWY2ZDEwNGJmMDI3L3RhYmxlcmFuZ2U6MTkzMzIyODRjZDU4NDc5MzkyNzk5ZjZkMTA0YmYwMjdfNS01LTEtMS0zNzAzOQ_24581bd7-c0ae-469a-977f-e08e5c7d85e5">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5006cf101226413bb3ec2ab87613cd4e_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjE5MzMyMjg0Y2Q1ODQ3OTM5Mjc5OWY2ZDEwNGJmMDI3L3RhYmxlcmFuZ2U6MTkzMzIyODRjZDU4NDc5MzkyNzk5ZjZkMTA0YmYwMjdfNS03LTEtMS0zNzAzOQ_1ec7fd6c-ef23-42ef-9aa1-665cc2f3bea9">2,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjE5MzMyMjg0Y2Q1ODQ3OTM5Mjc5OWY2ZDEwNGJmMDI3L3RhYmxlcmFuZ2U6MTkzMzIyODRjZDU4NDc5MzkyNzk5ZjZkMTA0YmYwMjdfNi0xLTEtMS0zNzAzOQ_ba534344-c3e0-46f4-b93d-9e948af9e879">2,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjE5MzMyMjg0Y2Q1ODQ3OTM5Mjc5OWY2ZDEwNGJmMDI3L3RhYmxlcmFuZ2U6MTkzMzIyODRjZDU4NDc5MzkyNzk5ZjZkMTA0YmYwMjdfNi0zLTEtMS0zNzAzOQ_c25b496d-79b2-4558-80a2-fd3f21181d66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjE5MzMyMjg0Y2Q1ODQ3OTM5Mjc5OWY2ZDEwNGJmMDI3L3RhYmxlcmFuZ2U6MTkzMzIyODRjZDU4NDc5MzkyNzk5ZjZkMTA0YmYwMjdfNi01LTEtMS0zNzAzOQ_41a56a66-9b20-4e9d-93ac-b740ff5177bd">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjE5MzMyMjg0Y2Q1ODQ3OTM5Mjc5OWY2ZDEwNGJmMDI3L3RhYmxlcmFuZ2U6MTkzMzIyODRjZDU4NDc5MzkyNzk5ZjZkMTA0YmYwMjdfNi03LTEtMS0zNzAzOQ_22dc81d2-1c66-4f05-834e-5dafec332d7b">2,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.794%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Marketable Securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Corporate bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic295d867cba3424dbf9d11196a15a2b7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOmQ4ZWZiODIwOTIyOTQ3YzRhOTk3ODc5OGZhMTAzM2NiL3RhYmxlcmFuZ2U6ZDhlZmI4MjA5MjI5NDdjNGE5OTc4Nzk4ZmExMDMzY2JfNC0xLTEtMS00NDEwNA_9d04487c-f8f7-49b6-8350-a6da603b6796">1,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic295d867cba3424dbf9d11196a15a2b7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOmQ4ZWZiODIwOTIyOTQ3YzRhOTk3ODc5OGZhMTAzM2NiL3RhYmxlcmFuZ2U6ZDhlZmI4MjA5MjI5NDdjNGE5OTc4Nzk4ZmExMDMzY2JfNC0zLTEtMS00NDQzMA_7e2603e3-fb7b-46b5-a1f8-fd5b5fe4dfef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic295d867cba3424dbf9d11196a15a2b7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOmQ4ZWZiODIwOTIyOTQ3YzRhOTk3ODc5OGZhMTAzM2NiL3RhYmxlcmFuZ2U6ZDhlZmI4MjA5MjI5NDdjNGE5OTc4Nzk4ZmExMDMzY2JfNC01LTEtMS00NDExNA_4cf63af3-f102-47c9-8256-39141be40bf7">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic295d867cba3424dbf9d11196a15a2b7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOmQ4ZWZiODIwOTIyOTQ3YzRhOTk3ODc5OGZhMTAzM2NiL3RhYmxlcmFuZ2U6ZDhlZmI4MjA5MjI5NDdjNGE5OTc4Nzk4ZmExMDMzY2JfNC03LTEtMS00NDQzNQ_f2fe36a4-ab6b-40ac-a3bf-1459b1fbe773">1,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6895b671b37a41a2983fb05af80a2952_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOmQ4ZWZiODIwOTIyOTQ3YzRhOTk3ODc5OGZhMTAzM2NiL3RhYmxlcmFuZ2U6ZDhlZmI4MjA5MjI5NDdjNGE5OTc4Nzk4ZmExMDMzY2JfNS0xLTEtMS00NDEwNA_181198ef-156c-4541-8004-4c37da7b576b">2,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6895b671b37a41a2983fb05af80a2952_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOmQ4ZWZiODIwOTIyOTQ3YzRhOTk3ODc5OGZhMTAzM2NiL3RhYmxlcmFuZ2U6ZDhlZmI4MjA5MjI5NDdjNGE5OTc4Nzk4ZmExMDMzY2JfNS0zLTEtMS00NDQzMA_d4d46b86-4474-4f13-8eb1-852eabae14fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6895b671b37a41a2983fb05af80a2952_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOmQ4ZWZiODIwOTIyOTQ3YzRhOTk3ODc5OGZhMTAzM2NiL3RhYmxlcmFuZ2U6ZDhlZmI4MjA5MjI5NDdjNGE5OTc4Nzk4ZmExMDMzY2JfNS01LTEtMS00NDExNA_771efd4f-f28e-4eb4-97d2-998e4dc976c1">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6895b671b37a41a2983fb05af80a2952_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOmQ4ZWZiODIwOTIyOTQ3YzRhOTk3ODc5OGZhMTAzM2NiL3RhYmxlcmFuZ2U6ZDhlZmI4MjA5MjI5NDdjNGE5OTc4Nzk4ZmExMDMzY2JfNS03LTEtMS00NDQzNQ_e0d9138d-8e09-47a9-8de3-8554df09073f">2,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOmQ4ZWZiODIwOTIyOTQ3YzRhOTk3ODc5OGZhMTAzM2NiL3RhYmxlcmFuZ2U6ZDhlZmI4MjA5MjI5NDdjNGE5OTc4Nzk4ZmExMDMzY2JfNi0xLTEtMS00NDQyNw_5679570d-b67b-461b-8d8a-4c7b645622dd">3,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOmQ4ZWZiODIwOTIyOTQ3YzRhOTk3ODc5OGZhMTAzM2NiL3RhYmxlcmFuZ2U6ZDhlZmI4MjA5MjI5NDdjNGE5OTc4Nzk4ZmExMDMzY2JfNi0zLTEtMS00NDQzMA_2a2db0a4-d673-4474-a8fc-9764067a2bde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOmQ4ZWZiODIwOTIyOTQ3YzRhOTk3ODc5OGZhMTAzM2NiL3RhYmxlcmFuZ2U6ZDhlZmI4MjA5MjI5NDdjNGE5OTc4Nzk4ZmExMDMzY2JfNi01LTEtMS00NDQzMg_2cb68465-1177-4e41-9845-6cd3e1cf45c2">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOmQ4ZWZiODIwOTIyOTQ3YzRhOTk3ODc5OGZhMTAzM2NiL3RhYmxlcmFuZ2U6ZDhlZmI4MjA5MjI5NDdjNGE5OTc4Nzk4ZmExMDMzY2JfNi03LTEtMS00NDQzNQ_31c7c65e-3ab8-4a49-bbee-4b0897b9c024">3,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, all of the Company&#8217;s marketable securities were classified as Level 2 assets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. The carrying amounts reported in the balance sheets for cash and cash equivalents, marketable securities, prepaid expenses and other current assets, accounts payable, accrued expenses, and note payable approximate their fair value based on the short-term maturity of these instruments.</span></div></ix:continuation><div><span><br/></span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><ix:continuation id="i6c90ddec74a44c4d923bd63368fcb346"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the embedded derivative liability identified in the 2021 Convertible Notes (Note 6)  was a Level 3 fair value measurement. As of February&#160;12, 2021, the embedded derivative was remeasured based upon the conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1c4b8521c9f140c7a9592f7f41d732a6_I20210212" decimals="INF" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RleHRyZWdpb246NTYwZDAyNWIzMDI4NGFmNWJiNWQ2NzVmMWVhNzA1YzdfMjAyNQ_62747a35-ac5d-4c25-a182-1973759ce818">8.00</ix:nonFraction> per share upon closing of the IPO. As such, an expense of $<ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RleHRyZWdpb246NTYwZDAyNWIzMDI4NGFmNWJiNWQ2NzVmMWVhNzA1YzdfMjA4Ng_f9352d60-5f11-4e2c-8956-ecf260804437">89</ix:nonFraction> was recorded during the three months ended March&#160;31, 2021.</span></div><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RleHRyZWdpb246NTYwZDAyNWIzMDI4NGFmNWJiNWQ2NzVmMWVhNzA1YzdfMjU0NQ_509d17df-456a-442c-b6b2-2ff51872415f" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our investments in marketable debt securities with state contractual maturity dates, accounted for as available-for-sale securities and classified by the contractual maturity date of the securities:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.611%"><tr><td style="width:1.0%"></td><td style="width:84.956%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.281%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjNhYWMzNzQ2MzAxMTRhMGQ5NmFiODA1NTI4YmQ2NDdiL3RhYmxlcmFuZ2U6M2FhYzM3NDYzMDExNGEwZDk2YWI4MDU1MjhiZDY0N2JfMS0yLTEtMS0zNzAzOQ_e9fa0371-56b8-41a2-afdd-ac3fb1076632">2,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in 1-5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjNhYWMzNzQ2MzAxMTRhMGQ5NmFiODA1NTI4YmQ2NDdiL3RhYmxlcmFuZ2U6M2FhYzM3NDYzMDExNGEwZDk2YWI4MDU1MjhiZDY0N2JfMi0yLTEtMS0zNzAzOQ_7a356c0c-0674-4c2f-abac-4e912914cf2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in 5-10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjNhYWMzNzQ2MzAxMTRhMGQ5NmFiODA1NTI4YmQ2NDdiL3RhYmxlcmFuZ2U6M2FhYzM3NDYzMDExNGEwZDk2YWI4MDU1MjhiZDY0N2JfMy0yLTEtMS0zNzAzOQ_27b391c7-00a8-4e46-9dfb-8b1c8f716c32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after 10 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjNhYWMzNzQ2MzAxMTRhMGQ5NmFiODA1NTI4YmQ2NDdiL3RhYmxlcmFuZ2U6M2FhYzM3NDYzMDExNGEwZDk2YWI4MDU1MjhiZDY0N2JfNC0yLTEtMS0zNzAzOQ_cdb28471-7fc0-4ba2-87e6-9013810d6e29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjNhYWMzNzQ2MzAxMTRhMGQ5NmFiODA1NTI4YmQ2NDdiL3RhYmxlcmFuZ2U6M2FhYzM3NDYzMDExNGEwZDk2YWI4MDU1MjhiZDY0N2JfNS0yLTEtMS0zNzAzOQ_7c155f84-7682-4ea5-8908-cb1de8d6e74c">2,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i59843287b8de4d67b8e56c082207e5cd_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80OS9mcmFnOjgwMThmNzVlZDkzNTQ1Y2I4MDlhYzcwYjUyZWFiNzI1L3RleHRyZWdpb246ODAxOGY3NWVkOTM1NDVjYjgwOWFjNzBiNTJlYWI3MjVfNjg_31df70a6-1ed1-49a1-a7ef-e310e85ccf86" continuedAt="ica0940227c1949ad9caa91aaeaef9871" escape="true">ACCRUED EXPENSES</ix:nonNumeric></span></div><ix:continuation id="ica0940227c1949ad9caa91aaeaef9871"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80OS9mcmFnOjgwMThmNzVlZDkzNTQ1Y2I4MDlhYzcwYjUyZWFiNzI1L3RleHRyZWdpb246ODAxOGY3NWVkOTM1NDVjYjgwOWFjNzBiNTJlYWI3MjVfNjk_99ba5e5a-00ee-4d75-9d88-c6666f3785d5" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="ck0001824293:AccruedResearchAndDevelopmentCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80OS9mcmFnOjgwMThmNzVlZDkzNTQ1Y2I4MDlhYzcwYjUyZWFiNzI1L3RhYmxlOmU0YWMxNjljOTAwZTQ2MGViYTJkNDcyNmUxNzA4NjMyL3RhYmxlcmFuZ2U6ZTRhYzE2OWM5MDBlNDYwZWJhMmQ0NzI2ZTE3MDg2MzJfMS0xLTEtMS0zNzAzOQ_fd020485-15f7-4cad-96cb-158c84e55887">640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="ck0001824293:AccruedResearchAndDevelopmentCostsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80OS9mcmFnOjgwMThmNzVlZDkzNTQ1Y2I4MDlhYzcwYjUyZWFiNzI1L3RhYmxlOmU0YWMxNjljOTAwZTQ2MGViYTJkNDcyNmUxNzA4NjMyL3RhYmxlcmFuZ2U6ZTRhYzE2OWM5MDBlNDYwZWJhMmQ0NzI2ZTE3MDg2MzJfMS0zLTEtMS0zNzAzOQ_000eba7d-4c0c-45aa-8729-ce04e8d5f195">894</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80OS9mcmFnOjgwMThmNzVlZDkzNTQ1Y2I4MDlhYzcwYjUyZWFiNzI1L3RhYmxlOmU0YWMxNjljOTAwZTQ2MGViYTJkNDcyNmUxNzA4NjMyL3RhYmxlcmFuZ2U6ZTRhYzE2OWM5MDBlNDYwZWJhMmQ0NzI2ZTE3MDg2MzJfMi0xLTEtMS0zNzAzOQ_f83dab67-410e-4bbc-8d94-8679f8643c8d">102</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80OS9mcmFnOjgwMThmNzVlZDkzNTQ1Y2I4MDlhYzcwYjUyZWFiNzI1L3RhYmxlOmU0YWMxNjljOTAwZTQ2MGViYTJkNDcyNmUxNzA4NjMyL3RhYmxlcmFuZ2U6ZTRhYzE2OWM5MDBlNDYwZWJhMmQ0NzI2ZTE3MDg2MzJfMi0zLTEtMS0zNzAzOQ_87e54944-2b50-49d4-8f50-b71becbb0954">183</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80OS9mcmFnOjgwMThmNzVlZDkzNTQ1Y2I4MDlhYzcwYjUyZWFiNzI1L3RhYmxlOmU0YWMxNjljOTAwZTQ2MGViYTJkNDcyNmUxNzA4NjMyL3RhYmxlcmFuZ2U6ZTRhYzE2OWM5MDBlNDYwZWJhMmQ0NzI2ZTE3MDg2MzJfMy0xLTEtMS0zNzAzOQ_21a199aa-059f-45ec-a89e-2637d672f9a9">406</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80OS9mcmFnOjgwMThmNzVlZDkzNTQ1Y2I4MDlhYzcwYjUyZWFiNzI1L3RhYmxlOmU0YWMxNjljOTAwZTQ2MGViYTJkNDcyNmUxNzA4NjMyL3RhYmxlcmFuZ2U6ZTRhYzE2OWM5MDBlNDYwZWJhMmQ0NzI2ZTE3MDg2MzJfMy0zLTEtMS0zNzAzOQ_00694c53-3b51-44e3-a148-125ac659063b">291</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing related</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="ck0001824293:AccruedLicensingFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80OS9mcmFnOjgwMThmNzVlZDkzNTQ1Y2I4MDlhYzcwYjUyZWFiNzI1L3RhYmxlOmU0YWMxNjljOTAwZTQ2MGViYTJkNDcyNmUxNzA4NjMyL3RhYmxlcmFuZ2U6ZTRhYzE2OWM5MDBlNDYwZWJhMmQ0NzI2ZTE3MDg2MzJfNC0xLTEtMS0zNzAzOQ_9a629396-15cd-41a0-ba99-9d99a96b4f94">57</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="ck0001824293:AccruedLicensingFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80OS9mcmFnOjgwMThmNzVlZDkzNTQ1Y2I4MDlhYzcwYjUyZWFiNzI1L3RhYmxlOmU0YWMxNjljOTAwZTQ2MGViYTJkNDcyNmUxNzA4NjMyL3RhYmxlcmFuZ2U6ZTRhYzE2OWM5MDBlNDYwZWJhMmQ0NzI2ZTE3MDg2MzJfNC0zLTEtMS0zNzAzOQ_7254d291-5c4b-4ca7-8dd7-625e188af622">62</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80OS9mcmFnOjgwMThmNzVlZDkzNTQ1Y2I4MDlhYzcwYjUyZWFiNzI1L3RhYmxlOmU0YWMxNjljOTAwZTQ2MGViYTJkNDcyNmUxNzA4NjMyL3RhYmxlcmFuZ2U6ZTRhYzE2OWM5MDBlNDYwZWJhMmQ0NzI2ZTE3MDg2MzJfNi0xLTEtMS0zNzAzOQ_e7f0a55f-7e76-435e-bf90-f81a5a90bcbe">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80OS9mcmFnOjgwMThmNzVlZDkzNTQ1Y2I4MDlhYzcwYjUyZWFiNzI1L3RhYmxlOmU0YWMxNjljOTAwZTQ2MGViYTJkNDcyNmUxNzA4NjMyL3RhYmxlcmFuZ2U6ZTRhYzE2OWM5MDBlNDYwZWJhMmQ0NzI2ZTE3MDg2MzJfNi0zLTEtMS0zNzAzOQ_d814254a-4bb3-45d4-adaa-2686644e1728">1,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i59843287b8de4d67b8e56c082207e5cd_52"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81Mi9mcmFnOjFiNjgzY2ZlZDk4YzRmNDU5MTc4YzM2MTMwNzMzMDRmL3RleHRyZWdpb246MWI2ODNjZmVkOThjNGY0NTkxNzhjMzYxMzA3MzMwNGZfMTcwOA_2c1bf00d-4ca8-4fb9-b354-80ea5ba2f830" continuedAt="ie5cc4b741c0c4a54878ce7cf3c5124e1" escape="true">PPP NOTE AND CONVERTIBLE NOTES</ix:nonNumeric></span></div><ix:continuation id="ie5cc4b741c0c4a54878ce7cf3c5124e1"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company issued a promissory note under the PPP (the PPP Note) totaling $<ix:nonFraction unitRef="usd" contextRef="i908364284b2449eaa88060f3a0a6fa84_I20200531" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81Mi9mcmFnOjFiNjgzY2ZlZDk4YzRmNDU5MTc4YzM2MTMwNzMzMDRmL3RleHRyZWdpb246MWI2ODNjZmVkOThjNGY0NTkxNzhjMzYxMzA3MzMwNGZfMTIx_ebf783ca-ef02-4c31-acd5-b99f4d3cc4d0">61</ix:nonFraction>. The PPP Note had a stated interest rate of <ix:nonFraction unitRef="number" contextRef="i908364284b2449eaa88060f3a0a6fa84_I20200531" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81Mi9mcmFnOjFiNjgzY2ZlZDk4YzRmNDU5MTc4YzM2MTMwNzMzMDRmL3RleHRyZWdpb246MWI2ODNjZmVkOThjNGY0NTkxNzhjMzYxMzA3MzMwNGZfMTY4_2252ea94-302a-4c7a-a7ea-6ca0df63bc45">1</ix:nonFraction>% and had a <ix:nonNumeric contextRef="ieace1ee3e7294bcc9238b92ee0af49d2_D20200501-20200531" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81Mi9mcmFnOjFiNjgzY2ZlZDk4YzRmNDU5MTc4YzM2MTMwNzMzMDRmL3RleHRyZWdpb246MWI2ODNjZmVkOThjNGY0NTkxNzhjMzYxMzA3MzMwNGZfMTcwOQ_20b8ce54-7002-4988-8eed-f7f3baa4e50d">two-year</ix:nonNumeric> maturity. Payments were required to be made over a <ix:nonNumeric contextRef="ieace1ee3e7294bcc9238b92ee0af49d2_D20200501-20200531" name="ck0001824293:DebtInstrumentPaymentTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81Mi9mcmFnOjFiNjgzY2ZlZDk4YzRmNDU5MTc4YzM2MTMwNzMzMDRmL3RleHRyZWdpb246MWI2ODNjZmVkOThjNGY0NTkxNzhjMzYxMzA3MzMwNGZfMjQw_5b3ae355-62c2-44bd-ba8a-d0c2850ee907">1.5</ix:nonNumeric>-year period beginning November 1, 2020, unless forgiven. In January 2021, the Company was notified that the loan along with accumulated interest had been forgiven. As a result, the Company recorded income from the extinguishment of its obligation in accordance with ASC 405-20-40-1, disclosed in the amount of $<ix:nonFraction unitRef="usd" contextRef="iac76cfecf8b945eda2c37283b0d1bafa_D20210101-20210131" decimals="-3" name="ck0001824293:ForgivenessOfDebtInstrument" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81Mi9mcmFnOjFiNjgzY2ZlZDk4YzRmNDU5MTc4YzM2MTMwNzMzMDRmL3RleHRyZWdpb246MWI2ODNjZmVkOThjNGY0NTkxNzhjMzYxMzA3MzMwNGZfNTQy_118261fc-6924-40e7-950a-676015f8b0b3">61</ix:nonFraction> included in other income on the accompanying statements of operations and comprehensive loss. The Small Business Administration (SBA) reserves the right to audit any PPP loan, regardless of size. These audits may occur after forgiveness has been granted. In accordance with the CARES Act, all borrowers are required to maintain the PPP loan documentation for six years after the PPP loan was forgiven or repaid in full and to provide that documentation to the SBA upon request.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#8217;s Chief Executive Officer, pursuant to which the Company issued convertible promissory notes (the 2021 Convertible Notes), for cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i6f0dc3494c1646ab80c715e4bcf2f8e2_D20210101-20210131" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81Mi9mcmFnOjFiNjgzY2ZlZDk4YzRmNDU5MTc4YzM2MTMwNzMzMDRmL3RleHRyZWdpb246MWI2ODNjZmVkOThjNGY0NTkxNzhjMzYxMzA3MzMwNGZfOTIz_0acfaa84-d1b3-44c2-b6cf-928c6daec3e8">350</ix:nonFraction>. The 2021 Convertible Notes bore an interest rate of <ix:nonFraction unitRef="number" contextRef="i7820e87649a24600869cfef32d0d6f5b_I20210131" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81Mi9mcmFnOjFiNjgzY2ZlZDk4YzRmNDU5MTc4YzM2MTMwNzMzMDRmL3RleHRyZWdpb246MWI2ODNjZmVkOThjNGY0NTkxNzhjMzYxMzA3MzMwNGZfOTc3_7817e33e-05b8-44a8-ba32-7265d77edd37">7.0</ix:nonFraction>% per annum, non-compounding, and had a maturity date of September&#160;30, 2021. The 2021 Convertible Notes converted into <ix:nonFraction unitRef="shares" contextRef="i0ae8348a777d4256870275ec7f5b29c4_D20211101-20211101" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81Mi9mcmFnOjFiNjgzY2ZlZDk4YzRmNDU5MTc4YzM2MTMwNzMzMDRmL3RleHRyZWdpb246MWI2ODNjZmVkOThjNGY0NTkxNzhjMzYxMzA3MzMwNGZfMTA5NQ_4bdb71e6-0ec9-4266-9727-4689b150beb6">54,906</ix:nonFraction> shares of the Company&#8217;s common stock upon completion of the IPO. The Company identified the mandatory conversion into shares of the Company&#8217;s common stock as a redemption feature, which requires bifurcation from the 2021 Convertible Notes and treated it as a derivative liability under ASC 815 as the redemption feature was not clearly and closely related to the debt. The Company evaluated the fair value of the derivative liability. Upon the conversion of the 2021 Convertible Notes to common stock at the closing of the IPO, the embedded derivative liability was remeasured and removed from the balance sheet.</span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i59843287b8de4d67b8e56c082207e5cd_55"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RleHRyZWdpb246ZDRlYWYxNGE0MDBlNDQ3Yzg1NDQyM2Y1YzkzMTgyMjhfMTI1MA_38b7980b-d670-4c18-8674-1e62720ef6fc" continuedAt="i09f7cefd2ea742bd9bd1c7a0293cf5c1" escape="true">STOCKHOLDERS&#8217; EQUITY </ix:nonNumeric></span></div><ix:continuation id="i09f7cefd2ea742bd9bd1c7a0293cf5c1"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company completed the IPO of <ix:nonFraction unitRef="shares" contextRef="i459e0d6af0f74d42a0f684f536cfd55c_D20210201-20210228" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RleHRyZWdpb246ZDRlYWYxNGE0MDBlNDQ3Yzg1NDQyM2Y1YzkzMTgyMjhfOTI_19133a7e-98d4-408c-a55a-1769541f6948">2,250,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4ab34f687d26476ca4c37cdeaec3802c_I20210228" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RleHRyZWdpb246ZDRlYWYxNGE0MDBlNDQ3Yzg1NDQyM2Y1YzkzMTgyMjhfMTQ4_f82d4a12-d31b-4271-941d-0f9de0c2c1c8">8.00</ix:nonFraction> per share. The gross proceeds from the IPO, before deducting underwriting discounts, commissions and other offering expenses payable by the Company, were $<ix:nonFraction unitRef="usd" contextRef="i459e0d6af0f74d42a0f684f536cfd55c_D20210201-20210228" decimals="-3" name="ck0001824293:ProceedsFromIssuanceInitialPublicOfferingGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RleHRyZWdpb246ZDRlYWYxNGE0MDBlNDQ3Yzg1NDQyM2Y1YzkzMTgyMjhfMzA1_a63a38f4-7a91-4d50-b718-1043a3d695a1">18,000</ix:nonFraction>. Underwriting discounts and expenses totaled $<ix:nonFraction unitRef="usd" contextRef="i459e0d6af0f74d42a0f684f536cfd55c_D20210201-20210228" decimals="-3" name="ck0001824293:StockIssuanceCostsDiscountsAndCommissions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RleHRyZWdpb246ZDRlYWYxNGE0MDBlNDQ3Yzg1NDQyM2Y1YzkzMTgyMjhfMzUz_a4a6f415-f8d2-4e81-90d9-64e2d526483b">1,600</ix:nonFraction> and the Company incurred approximately $<ix:nonFraction unitRef="usd" contextRef="i63431f71e5c74bdbb2b0f31ac2cafe55_D20210201-20210228" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RleHRyZWdpb246ZDRlYWYxNGE0MDBlNDQ3Yzg1NDQyM2Y1YzkzMTgyMjhfMzk1_fd588b08-80f5-4c0b-bda5-30a3f51b65fb">905</ix:nonFraction> of additional expenses related to completing the IPO for aggregate net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i459e0d6af0f74d42a0f684f536cfd55c_D20210201-20210228" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RleHRyZWdpb246ZDRlYWYxNGE0MDBlNDQ3Yzg1NDQyM2Y1YzkzMTgyMjhfNjIy_56745675-647f-4bae-9e7d-125ed3f7aeb9">15,500</ix:nonFraction>. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the IPO, the Company granted the underwriters warrants (the Underwriters' Warrants) to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="icfbaf3deac01401e89ec75e6ea05ae13_I20210228" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RleHRyZWdpb246ZDRlYWYxNGE0MDBlNDQ3Yzg1NDQyM2Y1YzkzMTgyMjhfNzgw_358d185d-540e-468c-a5fc-65a959b001e2">112,500</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="icfbaf3deac01401e89ec75e6ea05ae13_I20210228" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RleHRyZWdpb246ZDRlYWYxNGE0MDBlNDQ3Yzg1NDQyM2Y1YzkzMTgyMjhfODMw_7aa83075-687b-41e9-87d7-eaa431af51f2">10.00</ix:nonFraction> per share. The Underwriters&#8217; Warrants have a <ix:nonNumeric contextRef="icfbaf3deac01401e89ec75e6ea05ae13_I20210228" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RleHRyZWdpb246ZDRlYWYxNGE0MDBlNDQ3Yzg1NDQyM2Y1YzkzMTgyMjhfMTY0OTI2NzQ0Mjk1NA_f494057e-a26f-4057-bfbd-883a8cd20ca6">five-year</ix:nonNumeric> term and were not exercisable prior to August 12, 2021. All of the Underwriters&#8217; Warrants were outstanding as of March&#160;31, 2022. The warrants were classified as equity and the fair value of $<ix:nonFraction unitRef="usd" contextRef="i6d2639da3a56431abd41a0af1356176b_D20210201-20210228" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RleHRyZWdpb246ZDRlYWYxNGE0MDBlNDQ3Yzg1NDQyM2Y1YzkzMTgyMjhfMTA2Mw_4b033e42-e2ca-4b31-9fa0-3e6955cf1808">399</ix:nonFraction> is reflected as additional paid-in capital. <ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RleHRyZWdpb246ZDRlYWYxNGE0MDBlNDQ3Yzg1NDQyM2Y1YzkzMTgyMjhfMTI1MQ_264ad72c-5ea0-44cf-98f9-f9b5b5f3697c" continuedAt="i398d21a4af534034afd8b1299dd9cadd" escape="true">The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions:</ix:nonNumeric></span></div><div style="margin-top:8pt"><ix:continuation id="i398d21a4af534034afd8b1299dd9cadd"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1911bf6daa244c328b316073998944ff_I20220331" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RhYmxlOjUyNGRhYmNhNzRkZjQwNjVhYTM1OTA5OTM1ZmFjYjM0L3RhYmxlcmFuZ2U6NTI0ZGFiY2E3NGRmNDA2NWFhMzU5MDk5MzVmYWNiMzRfMC0xLTEtMS0zNzAzOQ_fd79f01e-321e-4bc5-962b-001f6ea41334">85.0</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c74df4f8925487f845fee1c71e9e072_I20220331" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RhYmxlOjUyNGRhYmNhNzRkZjQwNjVhYTM1OTA5OTM1ZmFjYjM0L3RhYmxlcmFuZ2U6NTI0ZGFiY2E3NGRmNDA2NWFhMzU5MDk5MzVmYWNiMzRfMS0xLTEtMS0zNzAzOQ_ad44aacf-9287-4f2e-a005-f06a197b43c4">2.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4fc7bd8d7fea4e7eba01520925d56116_I20220331" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RhYmxlOjUyNGRhYmNhNzRkZjQwNjVhYTM1OTA5OTM1ZmFjYjM0L3RhYmxlcmFuZ2U6NTI0ZGFiY2E3NGRmNDA2NWFhMzU5MDk5MzVmYWNiMzRfMi0xLTEtMS0zNzAzOQ_27c21fe3-137e-4551-bf1b-e655b9bf03d7">0.0</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id978ce266ef042feb765030a9e74ad19_I20220331" decimals="5" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RhYmxlOjUyNGRhYmNhNzRkZjQwNjVhYTM1OTA5OTM1ZmFjYjM0L3RhYmxlcmFuZ2U6NTI0ZGFiY2E3NGRmNDA2NWFhMzU5MDk5MzVmYWNiMzRfMy0xLTEtMS0zNzAzOQ_b9be663b-17f0-4485-9e68-848dfa7b854d">0.155</ix:nonFraction>&#160;%</span></td></tr></table></ix:continuation></div></ix:continuation><div id="i59843287b8de4d67b8e56c082207e5cd_58"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RleHRyZWdpb246NGFkY2MzMmU0Nzg2NDdmMWI1YzJiZmE3ZDVlY2M2NTJfMTk2Ng_80bba8b0-20fd-456f-b9bb-5142bad4591e" continuedAt="id044ca3c47b6444fb9acb125e090465a" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="id044ca3c47b6444fb9acb125e090465a" continuedAt="iec2c75ce215f474e8a6e1a5861c6b174"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RleHRyZWdpb246NGFkY2MzMmU0Nzg2NDdmMWI1YzJiZmE3ZDVlY2M2NTJfMTk2Nw_426e06fb-cd2a-4d7c-95a9-d6518a3f5502" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation related to stock options issued under the Company&#8217;s 2018 Equity Incentive Plan (2018 Plan) in the following expense categories of its accompanying statements of operations for the three months ended March&#160;31, 2022 and 2021:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0c5dc3daa51452a98594f5d3f6b538f_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjE3MzA2YWQxMGVmMjQzODQ5NzFiMzNlMzljN2I3ZTBiL3RhYmxlcmFuZ2U6MTczMDZhZDEwZWYyNDM4NDk3MWIzM2UzOWM3YjdlMGJfMi0xLTEtMS0zNzAzOQ_5e37710a-d85b-40a6-bc46-8d06cb4b08f1">18</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i009ef9a9802043c7a795e51fb1ac96b0_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjE3MzA2YWQxMGVmMjQzODQ5NzFiMzNlMzljN2I3ZTBiL3RhYmxlcmFuZ2U6MTczMDZhZDEwZWYyNDM4NDk3MWIzM2UzOWM3YjdlMGJfMi0zLTEtMS0zNzAzOQ_a95957b2-1522-45fb-ba42-76706868d46c">20</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e848c92cf53437f8da4012e0c9545b1_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjE3MzA2YWQxMGVmMjQzODQ5NzFiMzNlMzljN2I3ZTBiL3RhYmxlcmFuZ2U6MTczMDZhZDEwZWYyNDM4NDk3MWIzM2UzOWM3YjdlMGJfMy0xLTEtMS0zNzAzOQ_c1325ccb-f6bf-4519-8356-289587ce8684">163</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib390bd62760a4ca8915004678a850b79_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjE3MzA2YWQxMGVmMjQzODQ5NzFiMzNlMzljN2I3ZTBiL3RhYmxlcmFuZ2U6MTczMDZhZDEwZWYyNDM4NDk3MWIzM2UzOWM3YjdlMGJfMy0zLTEtMS0zNzAzOQ_8d7ce951-12ad-4fe7-af07-9c88eb22b8a0">148</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjE3MzA2YWQxMGVmMjQzODQ5NzFiMzNlMzljN2I3ZTBiL3RhYmxlcmFuZ2U6MTczMDZhZDEwZWYyNDM4NDk3MWIzM2UzOWM3YjdlMGJfNC0xLTEtMS0zNzAzOQ_1c199218-454a-46d0-8f49-7ebb00dbd350">181</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjE3MzA2YWQxMGVmMjQzODQ5NzFiMzNlMzljN2I3ZTBiL3RhYmxlcmFuZ2U6MTczMDZhZDEwZWYyNDM4NDk3MWIzM2UzOWM3YjdlMGJfNC0zLTEtMS0zNzAzOQ_515734cc-2742-41cf-a021-92a3a93f8ae4">168</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted stock options to purchase its common stock to employees and consultants under the 2018 Plan, under which the Company may issue stock options, restricted stock and other equity-based awards. The Company has also granted certain stock options outside of the 2018  Plan. Stock options granted by the Company generally have a contractual life of up to <ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RleHRyZWdpb246NGFkY2MzMmU0Nzg2NDdmMWI1YzJiZmE3ZDVlY2M2NTJfNjcz_63a9ac55-e4a8-4ac9-8624-c925d5fdec56">10</ix:nonNumeric> years. As of March&#160;31, 2022, all equity awards granted from the 2018 Plan were in the form of stock options.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures equity-based awards granted to employees, and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for equity awards is the date of grant, and equity-based compensation costs are recognized as expense over the requisite service period, which is the vesting period or for certain performance-based awards. The Company records the expense for these awards if it concludes that it is probable that the performance condition will be achieved.</span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><ix:continuation id="iec2c75ce215f474e8a6e1a5861c6b174" continuedAt="ifbaf8c5181f245cc9c3bcaad8843e722"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RleHRyZWdpb246NGFkY2MzMmU0Nzg2NDdmMWI1YzJiZmE3ZDVlY2M2NTJfMTk2NA_350326b9-49d5-40b4-b5d4-ffd658703af8" escape="true"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the three months ended March&#160;31, 2022:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term&#160;(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjAxZDhkNGY2Zjk0ZDRjZjRhM2RlZmY5NzZhNzg4N2U3L3RhYmxlcmFuZ2U6MDFkOGQ0ZjZmOTRkNGNmNGEzZGVmZjk3NmE3ODg3ZTdfMS0xLTEtMS0zNzAzOQ_d1621c63-92b6-43be-8f38-0dc8deec1b26">708,490</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjAxZDhkNGY2Zjk0ZDRjZjRhM2RlZmY5NzZhNzg4N2U3L3RhYmxlcmFuZ2U6MDFkOGQ0ZjZmOTRkNGNmNGEzZGVmZjk3NmE3ODg3ZTdfMS0zLTEtMS0zNzAzOQ_98d3b68c-0dc5-4227-ad74-b0bde31bfdbd">3.60</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4ff57a73247a47f5aa2e3b501764627b_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjAxZDhkNGY2Zjk0ZDRjZjRhM2RlZmY5NzZhNzg4N2U3L3RhYmxlcmFuZ2U6MDFkOGQ0ZjZmOTRkNGNmNGEzZGVmZjk3NmE3ODg3ZTdfMS01LTEtMS0zNzAzOQ_d7d9e0ba-c67d-47e8-a2e3-a6abc25668a3">8.64</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjAxZDhkNGY2Zjk0ZDRjZjRhM2RlZmY5NzZhNzg4N2U3L3RhYmxlcmFuZ2U6MDFkOGQ0ZjZmOTRkNGNmNGEzZGVmZjk3NmE3ODg3ZTdfMi0xLTEtMS0zNzAzOQ_b43ba746-715f-4e0f-b933-ada949462508">182,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjAxZDhkNGY2Zjk0ZDRjZjRhM2RlZmY5NzZhNzg4N2U3L3RhYmxlcmFuZ2U6MDFkOGQ0ZjZmOTRkNGNmNGEzZGVmZjk3NmE3ODg3ZTdfMi0zLTEtMS0zNzAzOQ_82abdeed-9ed5-4e6b-9233-71cf985904da">5.80</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjAxZDhkNGY2Zjk0ZDRjZjRhM2RlZmY5NzZhNzg4N2U3L3RhYmxlcmFuZ2U6MDFkOGQ0ZjZmOTRkNGNmNGEzZGVmZjk3NmE3ODg3ZTdfNS0xLTEtMS0zNzAzOQ_f699e8e5-19ed-46f4-9616-c34f7b9eed99">890,490</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjAxZDhkNGY2Zjk0ZDRjZjRhM2RlZmY5NzZhNzg4N2U3L3RhYmxlcmFuZ2U6MDFkOGQ0ZjZmOTRkNGNmNGEzZGVmZjk3NmE3ODg3ZTdfNS0zLTEtMS0zNzAzOQ_fe5be9a6-45bb-4618-becc-a89fb3636dee">4.05</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjAxZDhkNGY2Zjk0ZDRjZjRhM2RlZmY5NzZhNzg4N2U3L3RhYmxlcmFuZ2U6MDFkOGQ0ZjZmOTRkNGNmNGEzZGVmZjk3NmE3ODg3ZTdfNS01LTEtMS0zNzAzOQ_e74252b5-9951-4b81-815f-ae65e343027c">8.70</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjAxZDhkNGY2Zjk0ZDRjZjRhM2RlZmY5NzZhNzg4N2U3L3RhYmxlcmFuZ2U6MDFkOGQ0ZjZmOTRkNGNmNGEzZGVmZjk3NmE3ODg3ZTdfNi0xLTEtMS0zNzAzOQ_c54b4a68-5fe2-45b5-91f8-536e2c598d78">253,388</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjAxZDhkNGY2Zjk0ZDRjZjRhM2RlZmY5NzZhNzg4N2U3L3RhYmxlcmFuZ2U6MDFkOGQ0ZjZmOTRkNGNmNGEzZGVmZjk3NmE3ODg3ZTdfNi0zLTEtMS0zNzAzOQ_209be1bb-1197-47d7-84a8-7597d44c2d21">3.22</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjAxZDhkNGY2Zjk0ZDRjZjRhM2RlZmY5NzZhNzg4N2U3L3RhYmxlcmFuZ2U6MDFkOGQ0ZjZmOTRkNGNmNGEzZGVmZjk3NmE3ODg3ZTdfNi01LTEtMS0zNzAzOQ_39e30e2b-cbac-45cd-b7bb-1cef554b0e9c">7.89</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RleHRyZWdpb246NGFkY2MzMmU0Nzg2NDdmMWI1YzJiZmE3ZDVlY2M2NTJfMTk2NQ_87bc3913-4db9-4ee3-abcb-db001f376c3f" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.874%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOmM4YzU5NTBkMjExYjRhOWY4MzkwOTZlMjc2NjEwNTJmL3RhYmxlcmFuZ2U6YzhjNTk1MGQyMTFiNGE5ZjgzOTA5NmUyNzY2MTA1MmZfMi0xLTEtMS0zNzAzOQ_eb78279b-560c-4827-a831-b15adaa929e7">88.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOmM4YzU5NTBkMjExYjRhOWY4MzkwOTZlMjc2NjEwNTJmL3RhYmxlcmFuZ2U6YzhjNTk1MGQyMTFiNGE5ZjgzOTA5NmUyNzY2MTA1MmZfMi0zLTEtMS0zNzAzOQ_d7d36158-6bad-493e-a32a-d102883c9a3b">80.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOmM4YzU5NTBkMjExYjRhOWY4MzkwOTZlMjc2NjEwNTJmL3RhYmxlcmFuZ2U6YzhjNTk1MGQyMTFiNGE5ZjgzOTA5NmUyNzY2MTA1MmZfMy0xLTEtMS0zNzAzOQ_6caa50ae-aad6-4226-9d6c-bdfce59ef62e">6.06</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOmM4YzU5NTBkMjExYjRhOWY4MzkwOTZlMjc2NjEwNTJmL3RhYmxlcmFuZ2U6YzhjNTk1MGQyMTFiNGE5ZjgzOTA5NmUyNzY2MTA1MmZfMy0zLTEtMS0zNzAzOQ_422088f4-88ef-4833-929e-9b37a5141b4a">5.66</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOmM4YzU5NTBkMjExYjRhOWY4MzkwOTZlMjc2NjEwNTJmL3RhYmxlcmFuZ2U6YzhjNTk1MGQyMTFiNGE5ZjgzOTA5NmUyNzY2MTA1MmZfNC0xLTEtMS0zNzAzOQ_dcc200f4-4f83-41d5-a9ab-0d75369bdd72">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOmM4YzU5NTBkMjExYjRhOWY4MzkwOTZlMjc2NjEwNTJmL3RhYmxlcmFuZ2U6YzhjNTk1MGQyMTFiNGE5ZjgzOTA5NmUyNzY2MTA1MmZfNC0zLTEtMS0zNzAzOQ_346c7046-efcd-44e4-89c4-9e5102a06c84">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOmM4YzU5NTBkMjExYjRhOWY4MzkwOTZlMjc2NjEwNTJmL3RhYmxlcmFuZ2U6YzhjNTk1MGQyMTFiNGE5ZjgzOTA5NmUyNzY2MTA1MmZfNS0xLTEtMS0zNzAzOQ_3b445ef4-9fab-4daa-9ef8-0f542eedd657">1.95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOmM4YzU5NTBkMjExYjRhOWY4MzkwOTZlMjc2NjEwNTJmL3RhYmxlcmFuZ2U6YzhjNTk1MGQyMTFiNGE5ZjgzOTA5NmUyNzY2MTA1MmZfNS0zLTEtMS0zNzAzOQ_e97927ea-9a08-441e-ac3b-381733a0a940">0.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="4" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOmM4YzU5NTBkMjExYjRhOWY4MzkwOTZlMjc2NjEwNTJmL3RhYmxlcmFuZ2U6YzhjNTk1MGQyMTFiNGE5ZjgzOTA5NmUyNzY2MTA1MmZfNi0xLTEtMS0zNzAzOQ_be455e2b-6c03-41bb-a54e-94fe75d4e959">4.29</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibca337c014ca4895aaf539d38c0f5424_I20210331" decimals="4" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOmM4YzU5NTBkMjExYjRhOWY4MzkwOTZlMjc2NjEwNTJmL3RhYmxlcmFuZ2U6YzhjNTk1MGQyMTFiNGE5ZjgzOTA5NmUyNzY2MTA1MmZfNi0zLTEtMS0zNzAzOQ_4569b6e8-5657-4018-adc4-f87640d5c01e">4.92</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifbaf8c5181f245cc9c3bcaad8843e722">As of March&#160;31, 2022, the unrecognized compensation cost related to unvested stock options expected to vest was $<ix:nonFraction unitRef="usd" contextRef="if3397d410ba3402b845134ba54257a68_I20220331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RleHRyZWdpb246NGFkY2MzMmU0Nzg2NDdmMWI1YzJiZmE3ZDVlY2M2NTJfMzg0ODI5MDY5OTIyNA_cbc13c00-1aee-4ede-8299-aa98fe781871">1,486</ix:nonFraction>. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of <ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RleHRyZWdpb246NGFkY2MzMmU0Nzg2NDdmMWI1YzJiZmE3ZDVlY2M2NTJfMzg0ODI5MDY5OTIyOA_a4192795-99c6-4a92-88bf-6e81958b1256">3.17</ix:nonNumeric> years.</ix:continuation> </span></div><div id="i59843287b8de4d67b8e56c082207e5cd_61"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF82MS9mcmFnOjJkMWFiNTE0ODMwYTRkODZiMTVmYzRhNzRkOTFkNmJkL3RleHRyZWdpb246MmQxYWI1MTQ4MzBhNGQ4NmIxNWZjNGE3NGQ5MWQ2YmRfMTQ2Ng_feaaffed-606b-43c8-8cdd-c9226c849632" continuedAt="ic70d9d1c78c248deb37fdd81960e145d" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><ix:continuation id="ic70d9d1c78c248deb37fdd81960e145d"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company entered into a license agreement with Medice which grants Medice an exclusive license, with the right to grant sublicenses, to develop, use, manufacture, market and sell ADAIR throughout Europe. Medice is responsible for obtaining regulatory approval of ADAIR in the licensed territory. Under the license agreement, Medice paid Vallon a $<ix:nonFraction unitRef="usd" contextRef="idb6ea0f24b104095965bec61b8cda0e6_D20200101-20200131" decimals="-3" name="ck0001824293:RelatedPartyTransactionLicenseAgreementUpfrontPayment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF82MS9mcmFnOjJkMWFiNTE0ODMwYTRkODZiMTVmYzRhNzRkOTFkNmJkL3RleHRyZWdpb246MmQxYWI1MTQ4MzBhNGQ4NmIxNWZjNGE3NGQ5MWQ2YmRfMzkx_06fe118a-cdd4-44f8-b3b3-00344b9dce8f">100</ix:nonFraction> upfront payment and is required to pay milestone payments upon first obtaining regulatory approval to market and sell ADAIR in any country, territory or region in the licensed territory and upon achieving certain annual net sales thresholds. Medice will also pay tiered royalties on annual net sales of ADAIR at rates in the low double-digits. The initial term of the license agreement will expire <ix:nonNumeric contextRef="idb6ea0f24b104095965bec61b8cda0e6_D20200101-20200131" name="ck0001824293:RelatedPartyTransactionLicenseAgreementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF82MS9mcmFnOjJkMWFiNTE0ODMwYTRkODZiMTVmYzRhNzRkOTFkNmJkL3RleHRyZWdpb246MmQxYWI1MTQ4MzBhNGQ4NmIxNWZjNGE3NGQ5MWQ2YmRfNzky_60d85445-03fb-4b59-90db-8cbb2d871bad">five years</ix:nonNumeric> after the date on which Medice first obtains regulatory approval in any country, territory or region in the licensed territory.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#8217;s Chief Executive Officer, pursuant to which the Company issued the 2021 Convertible Notes for cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i6f0dc3494c1646ab80c715e4bcf2f8e2_D20210101-20210131" decimals="-3" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF82MS9mcmFnOjJkMWFiNTE0ODMwYTRkODZiMTVmYzRhNzRkOTFkNmJkL3RleHRyZWdpb246MmQxYWI1MTQ4MzBhNGQ4NmIxNWZjNGE3NGQ5MWQ2YmRfMTIyOA_61edd20b-8200-45cd-aa1f-8c6cdb4f6113">350</ix:nonFraction>. The 2021 Convertible Notes bore an interest rate of <ix:nonFraction unitRef="number" contextRef="i7820e87649a24600869cfef32d0d6f5b_I20210131" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF82MS9mcmFnOjJkMWFiNTE0ODMwYTRkODZiMTVmYzRhNzRkOTFkNmJkL3RleHRyZWdpb246MmQxYWI1MTQ4MzBhNGQ4NmIxNWZjNGE3NGQ5MWQ2YmRfMTI4Mg_afac81db-d0dc-4030-956a-4084e52a1585">7.0</ix:nonFraction>% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes converted into <ix:nonFraction unitRef="shares" contextRef="i6f0dc3494c1646ab80c715e4bcf2f8e2_D20210101-20210131" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF82MS9mcmFnOjJkMWFiNTE0ODMwYTRkODZiMTVmYzRhNzRkOTFkNmJkL3RleHRyZWdpb246MmQxYWI1MTQ4MzBhNGQ4NmIxNWZjNGE3NGQ5MWQ2YmRfMTQwMA_8a50b591-72c7-4783-b46e-2e955d789610">54,906</ix:nonFraction> shares of the Company&#8217;s common stock upon completion of the IPO.</span></div></ix:continuation><div id="i59843287b8de4d67b8e56c082207e5cd_67"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF82Ny9mcmFnOmVmNjhkNTc3OGIzMDRlNWViNzU1YjdhZDJkMTY3ZGY0L3RleHRyZWdpb246ZWY2OGQ1Nzc4YjMwNGU1ZWI3NTViN2FkMmQxNjdkZjRfMTg2Mg_c6178a44-2018-4d85-9a14-4ea973ba58e3" continuedAt="i43b30f1ecfbc4672a0581057ed152ffd" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i43b30f1ecfbc4672a0581057ed152ffd" continuedAt="id14bf4d67c0c456b99c53beb3470ff90"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.</span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><ix:continuation id="id14bf4d67c0c456b99c53beb3470ff90"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Impact</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The global COVID-19 pandemic continues to present uncertainty and unforeseeable new risks to the Company&#8217;s operations and business plan. The Company has closely monitored recent COVID-19 developments, including the lifting of COVID-19 safety measures, the drop in vaccination rates, the implementation of, and reaction to, vaccine mandates, the spread of various coronavirus strains such as the Delta variant, and supply chain and labor shortages. In light of these developments, the full impact of the COVID-19 pandemic on the Company&#8217;s business, operations and clinical development plans remains uncertain and will vary depending on the pandemic&#8217;s future impact on the Company&#8217;s clinical trial enrollment, clinical trial sites, CROs, third-party manufacturers, and other third parties with whom we do business, as well as any legal or regulatory consequences resulting therefrom. To the extent possible, the Company is conducting business as usual, with necessary or advisable modifications to employee travel and with most of its employees and consultants working remotely. The Company will continue to actively monitor the COVID-19 pandemic and may take further actions that alter its operations, including those that may be required by federal, state or local authorities, or that the Company determines are in the best interests of its employees and other third parties with whom the Company does business.</span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i59843287b8de4d67b8e56c082207e5cd_76"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing elsewhere in this Quarterly Report, and the audited financial statements (and notes thereto), and management&#8217;s discussion and analysis of financial condition and results of operations for the year ended December 31, 2021, included in our Annual Report on Form 10-K that was filed with the SEC on February 14, 2022. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Quarterly Report, our actual results could differ materially from the results described in, or implied by, these forward-looking statements.</span></div><div id="i59843287b8de4d67b8e56c082207e5cd_79"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel medications for CNS disorders with a focus on abuse-deterrent medications. Our lead investigational product candidate, ADAIR, is a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine (the main active ingredient in Adderall&#174;), which we were developing  for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. In March 2022, we announced that our SEAL study for ADAIR did not reach its primary endpoint, and there is no assurance that ADAIR will receive approval by the U.S. Food and Drug Administration (the FDA). In addition to ADAIR, we completed formulation development work and selected the final formulation of our second product candidate, ADMIR, an abuse deterrent formulation of methylphenidate (Ritalin&#174;), for the treatment of ADHD.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEAL study (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tudy to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">valuate the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">buse </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation), was our pivotal intranasal human abuse liability study assessing the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability of snorting professional laboratory-manipulated ADAIR 30 mg when compared to crushed d-amphetamine sulfate and placebo in recreational drug users. ADAIR was prepared for snorting by a pharmacist using a multi-step technique that had been developed by a professional laboratory and agreed upon by the FDA. The SEAL study enrolled 55 subjects, of whom 53 completed the study and 52 were included in the final analysis. The study involved a four-way crossover design to evaluate professionally manipulated, intranasal ADAIR 30 mg, crushed intranasal dextroamphetamine, ADAIR 30 mg taken orally, and placebo. All subjects were non-dependent recreational stimulant users with an additional history of recreational intranasal drug use.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEAL study did not meet its primary endpoint, which was E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">max</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Drug Liking. ADAIR scored similarly to what was observed in an earlier proof-of-concept study, however, reference dextroamphetamine did not score as high as expected and as seen in the previous study, thus driving the lack of statistical significance. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to assess the best path forward for the ADAIR and ADMIR development programs. In addition, we have engaged Ladenburg Thalmann &amp; Co. Inc. (Ladenburg) to evaluate our strategic alternatives with the goal of maximizing stockholder value. Ladenburg has been engaged to advise us on the strategic review process, which could include, without limitation, exploring the potential for a possible merger, business combination, investment into the Company, or a purchase, license or other acquisition of assets. In the meantime, and in conjunction with the exploration of strategic alternatives, we are streamlining our operations in order to preserve our capital and cash resources.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, we entered into a license agreement with Medice, which grants Medice an exclusive license to develop, use, manufacture, market and sell ADAIR throughout Europe. Under the license agreement, Medice paid us a $0.1 million upfront payment and will pay milestone payments of up to $6.3&#160;million in aggregate upon achieving certain regulatory and sales milestones. We are also entitled to low-double digit tiered royalties on net sales of ADAIR. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The global COVID-19 pandemic continues to present uncertainty and unforeseeable new risks to our operations and business plan. We have closely monitored recent COVID-19 developments, including the lifting of COVID-19 safety measures, the drop in vaccination rates, the implementation of, and reaction to, vaccine mandates, the spread of various coronavirus strains such as the Delta variant, and supply chain and labor shortages. In light of these developments, the full impact of the COVID-19 pandemic on our business, operations and clinical development plans remains uncertain and will vary depending on the pandemic&#8217;s future impact on our clinical trial enrollment, clinical trial sites, CROs, third-party manufacturers, and other third parties with whom we do business, as well as any legal or regulatory consequences resulting therefrom. To the extent possible, we are conducting business as usual, with necessary or advisable modifications to employee travel and with most of our employees and consultants working remotely. We will continue to actively monitor the COVID-19 pandemic and may take further actions that alter our operations, including those that may be required by federal, state or local authorities, or that we determine are in the best interests of our employees and other third parties with whom we do business.</span></div><div id="i59843287b8de4d67b8e56c082207e5cd_82"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Revenues - Related Party</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from the sale of any products, and we do not expect to generate significant revenues unless or until we obtain regulatory approval of and commercialize ADAIR. Substantially all of our revenue to date has been generated by the license agreement with Medice from which we received a $0.1 million license fee in January 2020. No licensing revenue was received during the three months ended March&#160;31, 2022 or 2021. We do not expect to generate any additional revenue from the license agreement with Medice in the near future. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include personnel costs associated with research and development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses have consisted primarily of in-process research and development expenses, costs related to  the development program for ADAIR, commercial manufacturing of ADAIR and formulation development for ADMIR. Research and development costs are expensed as incurred. These expenses include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee -related expenses, such as salaries, bonuses and benefits, consultant-related expenses such as consultant fees and bonuses, stock-based compensation, overhead related expenses and travel related expenses for our research and development personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with contract research organizations (CROs), as well as consultants that support the implementation of our clinical and non-clinical studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing and packaging costs in connection with conducting clinical trials and for stability and other studies required to support an NDA filing as well as manufacturing drug product for commercial launch;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">formulation, research and development expenses related to ADMIR; and other products we may choose to develop; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs for sponsored research.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically use our employee, consultant and infrastructure resources across our research and development programs. Although we track certain outsourced development costs by product candidate, we do not allocate personnel costs or other internal costs to specific product candidates.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to significantly decrease our research and development expenses as we consider our future plans regarding ADAIR and ADMIR programs as well as strategic alternatives. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of compensation and consulting related expenses for executives and other administrative personnel, professional fees and other corporate expenses, including legal and accounting fees, travel expenses, facilities-related expenses, and consulting services relating to our formation and corporate matters.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate increased costs associated with being a public company, including expenses related to services associated with maintaining compliance with The Nasdaq Capital Market and SEC requirements, directors and officers insurance, increased legal and accounting costs and investor relations costs.  Our general and administrative expenses may also increase due to increases in professional and advisory fees as we evaluate our strategic alternatives.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income consists of income recognized as a result of the extinguishment of the promissory note issued to us under the Paycheck Protection Program (PPP) as a result of the forgiveness of the note. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revaluation of Derivative Instruments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a Convertible Promissory Note Purchase Agreement pursuant to which we issued $350,000 in convertible promissory notes (the 2021 Convertible Notes). The 2021 Convertible Notes automatically converted into 54,906 shares of our common stock concurrently with the closing of the IPO. We identified the mandatory conversion into shares our common stock as a redemption feature, which requires bifurcation from the 2021 Convertible Notes and treated it as a derivative liability under ASC 815 as the redemption feature was not clearly and closely related to the debt. We evaluated the fair value of the derivative liability at issuance. Upon the conversion of the 2021 Convertible Notes to common stock at the closing of the IPO, the embedded derivative liability was remeasured and removed from the balance sheet.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense, net</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net,  consists of interest earned on our cash, cash equivalents and marketable securities held with institutional banks, the amortization of discounts and accretion of premiums on marketable securities and interest expense on our finance lease of equipment utilized in the commercial scale manufacturing of ADAIR.</span></div><div id="i59843287b8de4d67b8e56c082207e5cd_85"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended March&#160;31, 2022 and 2021 </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the periods indicated (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenue-from related party</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,634</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,602</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,634)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,602)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,635)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,638)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $1.3 million and $1.8 million for the three months ended March&#160;31, 2022 and 2021, respectively. The $0.5 million decrease in research and development expenses was primarily due to a decrease of $0.5 million in expenses related to the registration development program of ADAIR. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $1.4 million and $0.8 million for the three months ended March&#160;31, 2022 and 2021, respectively. The $0.5 million increase was primarily related to increased costs for directors and officers insurance of $0.2 million, personnel expenses, including stock compensation, of $0.1 million,  public company expenses of $0.1 million and consulting fees of $0.1 million.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we issued a promissory note under the PPP totaling $61,000. As of December 31, 2020, we had utilized the entire proceeds from such note for payroll costs (greater than 75%), costs related to health care benefits and rent payments. In January 2021, we were notified that the note along with accumulated interest had been forgiven. As a result, we recorded income from the extinguishment of the obligation in accordance with ASC 405-20-40-1.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revaluation of Derivative Liability</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, pursuant to ASC 815, we revalued the embedded derivative liability associated with the 2021 Convertible Notes, resulting in an $89,000 decrease in the fair value of the derivative liability.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense, net</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net, was $1,000 and $8,000 for the three months ended March&#160;31, 2022 and 2021, respectively.</span></div><div id="i59843287b8de4d67b8e56c082207e5cd_88"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred losses and expect to continue to incur losses for the foreseeable future. We incurred net losses of $2.6 million for each the three months ended March&#160;31, 2022 and 2021. As of March&#160;31, 2022, we had an accumulated deficit of $24.5 million. In March 2022, we announced that the SEAL study of ADAIR for the treatment of ADHD did not meet statistical significance for its primary endpoint. We are continuing to evaluate the best path forward for the ADAIR and ADMIR programs and have also commenced a process of evaluating strategic alternatives to maximize stockholder value.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our working capital requirements to date through the issuance of common stock, convertible notes, short-term promissory notes, and a PPP promissory note. As of March&#160;31, 2022, we had $5.2 million in cash, cash equivalents and marketable securities. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,948)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,159)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,871&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022 and 2021, $2.3 million and $2.9 million were used in operating activities, respectively. The $0.6 million decrease was primarily due to a $0.8 million decrease in prepaid and other current assets and a $0.2 million decrease in accounts payable, offset by increases accrued expenses of $0.4 million. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $1.2 million for the three months ended March&#160;31, 2022, which was related to the sale of marketable securities. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $23,000 for the three months ended March&#160;31, 2022, which was related to payments of our finance lease. Net cash provided by financing activities was $15.8 million for the three months ended March&#160;31, 2021 and was primarily related to the net proceeds from our IPO and 2021 Convertible Notes financings.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Convertible Note Financing</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including SALMON Pharma GmbH (Salmon Pharma), an affiliate of Medice, and David Baker, our Chief Executive Officer, pursuant to which we issued convertible promissory notes (the 2021 Convertible Notes) for cash proceeds of $350,000. The 2021 Convertible Notes bear an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes were convertible into shares of our capital stock offered to investors in any subsequent equity financing after the date of their issuance in which we issued any of our equity securities (a Qualified Financing) and were convertible at a twenty percent discount to the price per share offered in such Qualified Financing. Such Qualified Financing included the initial public offering of our common stock, consummated in February 2021; therefore, the 2021 Convertible Notes converted into an aggregate of 54,906 shares of our common stock immediately prior to the closing of the IPO, as agreed upon among the parties thereto.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from the sale of any products. Substantially all of our revenue to date has been generated by the Medice license agreement from which we received a $0.1 million license fee in January 2020. We do not know when, or if, we will generate any revenue. In March 2022, we announced that the SEAL study of ADAIR for the treatment of ADHD did not meet statistical significance for its primary endpoint and that we are evaluating our strategic alternatives with the goal of maximizing stockholder value. We are continuing to assess the best path forward for the development of the ADAIR and ADMIR programs and have no other product candidate undergoing clinical trials. We expect to incur ongoing expenses as we assess these programs and evaluate our strategic options. Our future capital requirements are difficult to forecast and will depend on many factors, including but not limited to the terms and timing of any strategic alternatives including a merger or business combination, asset acquisitions or sales, collaborations or licensing arrangements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing may impose upon us covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any equity or debt financing may contain terms that are not favorable to us or our stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce or terminate some or all of our development programs and clinical trials. We may also be required to sell or license to other parties&#8217; rights to develop or commercialize our drug candidates that we would prefer to retain. Therefore, there is substantial doubt about our ability to continue as a going concern. We expect to continue to incur expenses and operating losses at least for the foreseeable future as we evaluate future plans for the ADAIR and ADMIR programs as well as our strategic alternatives.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the &#8220;Risk Factors&#8221; section on this Form 10-Q for additional risks associated with our substantial capital requirements.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i59843287b8de4d67b8e56c082207e5cd_91"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></div><div id="i59843287b8de4d67b8e56c082207e5cd_94"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our unaudited interim financial statements, which have been prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances. Actual results could differ from those estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s critical accounting policies are described in Note 3, &#8220;Summary of Significant Accounting Policies,&#8221; in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on February&#160;14, 2022. There have been no material changes to the significant accounting policies during the three months ended March&#160;31, 2022, except for items mentioned in Note 3 of the unaudited interim financial statements in this Quarterly Report on Form 10-Q.</span></div><div id="i59843287b8de4d67b8e56c082207e5cd_97"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and may remain an emerging growth company for up to five years. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced disclosure about our executive compensation arrangements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">no non-binding stockholder advisory votes on executive compensation or golden parachute arrangements; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have taken advantage of reduced reporting requirements in this report and may continue to do so until such time that we are no longer an emerging growth company. We will remain an &#8220;emerging growth company&#8221; until the earliest of (a) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more, (b) December 31, 2026, the last day of the fiscal year following the fifth anniversary of the completion of the our IPO, (c) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years or (d) the date on which we are deemed to be a large accelerated filer under the rules of the SEC. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. We have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies.</span></div><div id="i59843287b8de4d67b8e56c082207e5cd_100"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable to a smaller reporting company.</span></div><div id="i59843287b8de4d67b8e56c082207e5cd_103"></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of our disclosure controls and procedures (as defined in the Securities Exchange Act of 1934 Rules 13a-15(e) or 15d-15(e)) as of March&#160;31, 2022. We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the evaluation of our disclosure controls and procedures as of March&#160;31, 2022, our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures, as defined above, are effective.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Rules 13a-15(f) and 15d-15(f)) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that occurred during the fiscal quarter covered by this report that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.</span></div><div><span><br/></span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i59843287b8de4d67b8e56c082207e5cd_106"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i59843287b8de4d67b8e56c082207e5cd_109"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i59843287b8de4d67b8e56c082207e5cd_112"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2021, except as set forth below.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to execute on our business strategy is subject to a number of risks, which are discussed more fully below in this section. You should carefully consider these risks before making an investment in our common stock. These risks include, among others, the following</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our activities to evaluate and pursue strategic alternatives may not be successful.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not successfully consummate a strategic transaction, our board of directors may decide to pursue a dissolution and liquidation of the company. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are substantially dependent on our remaining employees to facilitate the consummation of a strategic transaction. We could lose such key employees, in particular, as a result of the ADAIR data.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our prospects were highly dependent on a single product candidate, ADAIR. As the SEAL study of ADAIR did not meet its predefined clinical endpoint, we are currently assessing the best path forward for ADAIR and have been evaluating other strategic alternatives to maximize stockholder value, which we may not be successful in.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have no approved products and a limited operating history, which may make it difficult to evaluate our technology and product development capabilities and predict our future performance.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future. </span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are currently assessing the best path forward for ADAIR, and any further development of ADAIR or the development of any new product will require additional capital to fund our operations, which we may not be able to obtain.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Negative perception of any product candidate that we develop could adversely affect our ability to conduct our business or obtain regulatory approvals for such product candidate.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market price of our common stock is expected to be volatile. In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies.</span></div><div style="margin-top:8pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to Our Evaluation of Strategic Alternatives</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our activities to evaluate and pursue strategic alternatives may not be successful.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we announced that topline data from our SEAL study of ADAIR for the treatment of ADHD did not meet statistical significance for the primary endpoint of  E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">max</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Drug Liking. We are continuing to assess the best path forward for the ADAIR and ADMIR programs and we have commenced a process of evaluating strategic alternatives to maximize stockholder value. We have engaged a financial advisory firm to help explore our available strategic alternatives, including a possible merger, business combination, asset acquisitions or sales, and collaboration and licensing arrangements. We have significantly reduced our research and development activities to reduce operating expenses while we evaluate these opportunities. We expect to devote significant time and resources to identifying and evaluating strategic transactions; however, there can be no assurance that such activities will result in any agreements or transactions that will enhance stockholder value. In addition, potential strategic transactions that require stockholder </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval may not be approved by our stockholders or a counterparty&#8217;s stockholders. Further, any strategic transaction that is completed ultimately may not deliver the anticipated benefits or enhance stockholder value.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may acquire additional businesses, products or product candidates. Integrating any newly acquired business, product or product candidate could be expensive and time-consuming. We may not be able to integrate any acquired business, product or product candidate successfully. If we do acquire any additional business, products, or product candidates, our future financial performance will depend, in part, on our ability to manage any future growth effectively and our ability to integrate any such acquired businesses, products or product candidates.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any strategic transaction may require us to incur non-recurring or other charges, may increase our near- and long-term expenditures and may pose significant integration challenges or disrupt our management or business, which could adversely affect our operations and financial results. For example, these transactions may entail numerous operational and financial risks, including:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposure to unknown liabilities;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incurrence of substantial debt or dilutive issuances of equity securities to pay for acquisitions;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">higher than anticipated acquisition and/or integration costs;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">write downs of assets or goodwill or impairment charges;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased amortization expenses;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to retain our key employees or our other service providers or those of any acquired businesses.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, there can be no assurance that we will undertake or successfully complete any strategic transactions of the nature described above and any transactions that we do complete may be subject to the foregoing or other risks and could have a material adverse effect on our business, financial condition and prospects</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not successfully consummate a strategic transaction, our board of directors may decide to pursue a dissolution and liquidation of the Company. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that the process to identify a strategic transaction will result in a successfully consummated transaction. If no transaction is completed, our board of directors may decide to pursue a dissolution and liquidation of the Company. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such decision and, ultimately, such liquidation, since the amount of cash available for distribution will continue to decrease as we fund our operations while we evaluate our strategic alternatives. In addition, if our board of directors were to approve and recommend, and our stockholders were to approve, a dissolution and liquidation of the Company, we would be required under Delaware corporate law to pay our outstanding obligations, as well as to make reasonable provisions for contingent and unknown obligations, prior to making any distributions in liquidation to our stockholders. Our commitments and contingent liabilities may include (i) regulatory and clinical obligations; (ii) obligations under our employment and related agreements with certain employees that provide for severance and other payments following a termination of employment occurring for various reasons, including a change in control; and (iii) potential litigation against us, and other various claims and legal actions arising in the ordinary course of business. As a result of this requirement, a portion of our assets may need to be reserved pending the resolution of such obligations. In addition, we may be subject to litigation or other claims related to a dissolution and liquidation of the Company. If a dissolution and liquidation were pursued, our board of directors, in consultation with our advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. Accordingly, holders of our common stock could lose all or a significant portion of their investment in the event of a liquidation, dissolution or winding up of the Company.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our prospects were highly dependent on a single product candidate, ADAIR, and while we are assessing the best path forward for ADAIR, we may not complete the development or commercialization of ADAIR</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our long-term prospects were highly dependent on future acceptance and revenues from our lead product candidate, ADAIR. In March 2022, we announced that topline data from our SEAL study of ADAIR for the treatment of ADHD did not meet statistical significance for the primary endpoint of E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:1.4pt;vertical-align:baseline">max</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Drug Liking and that, given that result, we are currently assessing the best path forward for ADAIR. Any further development of ADAIR would require substantial capital and time to complete, and there is no guarantee that any future clinical trial, if pursued, would be timely or successful, or that ADAIR would be approved or, if approved, that commercialization would be successful. Concurrently, we have been evaluating strategic alternatives to maximize stockholder value, which could involve, without limitation, exploring the potential for a possible merger, business combination, investment into the Company, or a purchase, license or other acquisition of assets. However, there is no assurance that we will be successful in our pursuit of a strategic alternative, failure of which may have a material adverse impact on our business, financial condition, and results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on our remaining employees to facilitate the consummation of a strategic transaction. We could lose such key employees, in particular, as a result of the ADAIR data.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash conservation activities may yield unintended consequences, such as attrition and reduced employee morale, which may cause remaining employees to seek alternative employment. Our ability to successfully complete a strategic transaction depends in large part on our ability to retain certain personnel, particularly David Baker, our Chief Executive Officer, and Leanne Kelly, our Chief Financial Officer. Despite our efforts to retain these employees, one or more may terminate their employment on short notice. The loss of the services of any of these employees could potentially harm our ability to evaluate and pursue strategic alternatives, as well as fulfill our reporting obligations as a public company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition among biotechnology companies for qualified employees is intense, and our ability to retain our key employees is critical to our ability to effectively manage our resources and consummate a strategic transaction. If we develop new product candidates, such development would require expertise from a number of different disciplines, some of which are not widely available. The results of the SEAL study of ADAIR will likely make it more challenging to retain qualified personnel and more difficult to recruit personnel in the future, if necessary. If we fail to attract new personnel or fails to retain and motivate our current personnel, our business and future growth prospects and our ability to consummate a strategic transaction would be harmed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to Our Business, Technology and Industry</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have no approved products and have a limited operating history, which may make it difficult to evaluate our technology and product development capabilities and predict our future performance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale and have not generated any revenue from product sales. Our ability to generate product revenue or profits was dependent on the successful development and eventual commercialization of ADAIR. Given that the topline data from our SEAL study of ADAIR for the treatment of ADHD failed to meet statistical significance for the primary endpoint of  E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">max</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Drug Liking ad we are assessing the best path forward for the ADAIR program, we may never be able to develop or commercialize a marketable product.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and future programs and product candidates will require additional discovery research, preclinical development, clinical development, regulatory approval to commercialize the product, manufacturing validation, obtaining manufacturing supply, capacity and expertise, building of a commercial and distribution organization, substantial investment and significant marketing efforts before we generate any revenue from product sales. In addition, any drug product candidate must be approved for marketing by the FDA or certain other health regulatory agencies before we may commercialize any product in the respective jurisdictions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our limited operating history may make it difficult to evaluate our, or any new, technology and industry and predict its future performance. Our short history as an operating company makes any assessment of our future success or viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early-stage companies in evolving fields. If we do not address these risks successfully, our business will suffer. Similarly, we expect that our financial condition and operating results will </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. As a result, our stockholders should not rely upon the results of any quarterly or annual period as an indicator of future operating performance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred net losses in every year since our inception and we anticipate that we will continue to incur net losses in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company with a limited operating history. Investment in product development in the healthcare industry, including of biopharmaceutical products, is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We have no products approved for commercial sale and have not generated any revenue from product sales to date. As a result, we are not profitable and have incurred losses in each period since our inception. For the three months ended March&#160;31, 2022, we reported a net loss of $2.6 million. As of March&#160;31, 2022, we had an accumulated deficit of $24.5 million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable, we or any potential future collaborator must develop and eventually commercialize products with significant market potential at an adequate profit margin after cost of goods sold and other expenses. This will require us to be successful in a range of challenging activities, including completing clinical trials, manufacturing, marketing and selling products for which we may obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is significant enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of the Company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional capital will be required to fund our operations, ADAIR product development activities or the development of any new product. If we fail to obtain necessary financing, we will not be able to complete the development and commercialization of product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our operations have consumed substantial amounts of cash since inception. While we plan to significantly decrease our research and development expenses as we assess the best path forward for ADAIR, we expect to continue to spend a considerable amount of resources on pursuing strategic opportunities. Furthermore, to further the development of ADAIR or any other product candidates, we would be required to spend substantial amounts to conduct clinical trials of such programs, to validate the manufacturing process and specifications for any such product candidate, to seek regulatory approvals for such product candidate and to launch and commercialize any products for which we receive regulatory approval, including potentially building our own commercial organization. As of March&#160;31, 2022, we had $5.2 million of cash, cash equivalents and marketable securities on hand. Our future capital requirements and the period for which our existing resources will support our operations may vary significantly from what we currently expect and may change if our business plan changes from our current expected operating plan. Our monthly spending levels will vary based on development and corporate activities. Because of the uncertainty regarding our future development pathway, we are unable to estimate the actual funds we will require for development of any potential product candidate and any approved marketing and commercialization activities. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and structure of any strategic options that we pursue;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms of any collaboration agreements we may choose to initiate or conclude;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA, and other comparable foreign regulatory authorities;</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or failure in obtaining the necessary approvals from regulators or institutional review boards (IRBs) in order to commence a clinical trial at a prospective trial site, or their suspension or termination of a clinical trial once commenced;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of third-party contractors, such as contract research organizations (CROs), or investigators to comply with regulatory requirements, including Good Clinical Practices (GCPs);</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">governmental or regulatory delays and changes in regulation or policy relating to the development and commercialization of a product candidate by the FDA or other comparable foreign regulatory authorities;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">undertaking and completing additional pre-clinical studies to generate data required to support the clinical development of a product candidate;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to enroll sufficient patients to complete a protocol;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty in having patients complete a trial or return for post-treatment follow-up;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical sites deviating from trial protocol or dropping out of a trial;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">problems with biopharmaceutical product candidate storage, stability and distribution;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to add new or additional clinical trial sites;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">varying interpretations of the data generated from our preclinical or clinical trials;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to manufacture, or obtain from third parties, adequate supply of biopharmaceutical product candidate sufficient to complete our preclinical studies and clinical trials;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of establishing, maintaining, and overseeing a quality system compliant with current good manufacturing practice requirements (cGMPs) and a supply chain for the development and manufacture of our product candidate;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of establishing, expanding and scaling manufacturing capabilities;</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of establishing sales, marketing and distribution capabilities for any product candidate for which we may receive regulatory approval in regions where we choose to commercialize its products on our own; and</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential unforeseen business disruptions or market fluctuations that delay our product development or clinical trials and increase our costs or expenses, such as business or operational disruptions, delays, or system failures due to malware, unauthorized access, terrorism, war, natural disasters, strikes, geopolitical conflicts, restrictions on trade, import or export restrictions, or public health crises, such as the current COVID-19 outbreak.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any committed external source of funds or other support for our development efforts, and we cannot be certain that additional funding will be available on acceptable terms, or at all. Until we can generate sufficient product or royalty revenue to finance our cash requirements, which we may never do, we expect to finance its future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. If we raise additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. Further, to the extent that we raise additional capital through the sale of common stock or securities convertible into or exchangeable for common stock, each existing investors&#8217; ownership interest will be diluted. If we raise additional capital through debt financing, we would be subject to fixed payment obligations and may be subject to covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends or acquiring or licensing intellectual property rights. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to its product candidate, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. We also could be required to seek collaborators for one or more of our current or future </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or technologies that we otherwise would seek to develop or commercialize ourself. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our other research and development initiatives. Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span></div><div id="i59843287b8de4d67b8e56c082207e5cd_115"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Securities.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i59843287b8de4d67b8e56c082207e5cd_118"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i59843287b8de4d67b8e56c082207e5cd_121"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i59843287b8de4d67b8e56c082207e5cd_124"></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i59843287b8de4d67b8e56c082207e5cd_127"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921022369/tm2030737d19_ex3-1.htm">Amended and Restated Certificate of Incorporation of Vallon Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K, filed with the SEC on February 16, 2021).</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921022369/tm2030737d19_ex3-3.htm">Amended and Restated Bylaws of Vallon Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.3 to the Current Report on Form 8-K, filed with the SEC on February 16, 2021).</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001824293/000110465921022369/tm2030737d19_ex3-2.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation of Vallon Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K, filed with the SEC on February 16, 2021).</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex311_ceo302cert33122.htm">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex312_cfo302cert33122.htm">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex321_ceosection906cert331.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex322_cfosection906cert331.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iXBRL Instance Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, exhibits are filed herewith.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, except to the extent specifically incorporated by reference into such filing.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i59843287b8de4d67b8e56c082207e5cd_130"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i59843287b8de4d67b8e56c082207e5cd_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.815%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VALLON PHARMACEUTICALS, INC.</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 9, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Leanne M. Kelly</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name: Leanne M. Kelly</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title: Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex311_ceo302cert33122.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia18c474a985b4b75a909a2f34422e718_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 31.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt"><font><br></font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, David Baker, certify that&#58;</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I have reviewed this Quarterly Report on Form 10-Q of Vallon Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 31.1</font></div></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.726%"><tr><td style="width:1.0%"></td><td style="width:31.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; May&#160;9, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; David Baker</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">David Baker</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex312_cfo302cert33122.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iaca31ac0f2fc463dbd204452c08a5a30_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 31.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt"><font><br></font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, Leanne M. Kelly, certify that&#58;</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I have reviewed this Quarterly Report on Form 10-Q of Vallon Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 31.2</font></div></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.299%"><tr><td style="width:1.0%"></td><td style="width:29.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; May&#160;9, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Leanne M. Kelly</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Leanne M. Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex321_ceosection906cert331.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic2e1c5f8fd5043e1b06420ac9bb41e8e_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 32.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, David Baker, President and Chief Executive Officer of Vallon Pharmaceuticals, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the Quarterly Report on Form 10-Q of the Company for the quarter ended March&#160;31, 2022 (the &#8220;Quarterly Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.281%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; May&#160;9, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; David Baker</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">David Baker</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ex322_cfosection906cert331.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i74ddb9ef922e43cba493969419b65632_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 32.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, Leanne M. Kelly,  Chief Financial Officer of Vallon Pharmaceuticals, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the Quarterly Report on Form 10-Q of the Company for the quarter ended March&#160;31, 2022 (the &#8220;Quarterly Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; May&#160;9, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Leanne M. Kelly</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Leanne M. Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>ck0001824293-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:817af30f-ec0d-4f27-a9e3-e41325810995,g:c8a142b5-1941-49b7-ac1b-a5b54ada4279-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ck0001824293="http://www.vallon-pharma.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.vallon-pharma.com/20220331">
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.vallon-pharma.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheets" roleURI="http://www.vallon-pharma.com/role/BalanceSheets">
        <link:definition>1001002 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsParenthetical" roleURI="http://www.vallon-pharma.com/role/BalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofOperationsandComprehensiveLoss" roleURI="http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofChangesinStockholdersEquityDeficit" roleURI="http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit">
        <link:definition>1004005 - Statement - Statements of Changes in Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofCashFlows" roleURI="http://www.vallon-pharma.com/role/StatementsofCashFlows">
        <link:definition>1005006 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDDESCRIPTIONOFBUSINESS" roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS">
        <link:definition>2101101 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails">
        <link:definition>2402401 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIQUIDITY" roleURI="http://www.vallon-pharma.com/role/LIQUIDITY">
        <link:definition>2103102 - Disclosure - LIQUIDITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIQUIDITYDetails" roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails">
        <link:definition>2404402 - Disclosure - LIQUIDITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2105103 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2206201 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>2407403 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS" roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS">
        <link:definition>2108104 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables" roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables">
        <link:definition>2309301 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails" roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails">
        <link:definition>2410404 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of the Company&#8217;s Available for Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails">
        <link:definition>2411405 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails" roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails">
        <link:definition>2412406 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Investments Classified by Contractual Maturity Date (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSES" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES">
        <link:definition>2113105 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESTables" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables">
        <link:definition>2314302 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESDetails" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails">
        <link:definition>2415407 - Disclosure - ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PPPNOTEANDCONVERTIBLENOTES" roleURI="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES">
        <link:definition>2116106 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PPPNOTEANDCONVERTIBLENOTESDetails" roleURI="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails">
        <link:definition>2417408 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY">
        <link:definition>2118107 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>2319303 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDetails">
        <link:definition>2420409 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails">
        <link:definition>2421410 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Estimate of the Fair Value of the Warrants and Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>2122108 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>2323304 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>2424411 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>2425412 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails">
        <link:definition>2426413 - Disclosure - STOCK-BASED COMPENSATION - Activity of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails">
        <link:definition>2427414 - Disclosure - STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>2128109 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSDetails" roleURI="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails">
        <link:definition>2429415 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2130110 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ck0001824293_MediceMember" abstract="true" name="MediceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" abstract="true" name="ConvertiblePromissoryNotePurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" abstract="false" name="AccruedGeneralAndAdministrativeExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ForgivenessOfDebtInstrument" abstract="false" name="ForgivenessOfDebtInstrument" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_AccruedLicensingFeesCurrent" abstract="false" name="AccruedLicensingFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment" abstract="false" name="RelatedPartyTransactionLicenseAgreementUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled" abstract="false" name="ClinicalResearchStudyNumberOfParticipantsEnrolled" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ck0001824293_DebtInstrumentPaymentTerm" abstract="false" name="DebtInstrumentPaymentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ck0001824293_PaycheckProtectionProgramCARESActMember" abstract="true" name="PaycheckProtectionProgramCARESActMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" abstract="true" name="AffiliateOfMediceAndDavidBakerCEOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis" abstract="false" name="ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy" abstract="false" name="ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross" abstract="false" name="ProceedsFromIssuanceInitialPublicOfferingGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuanceCostsDiscountsAndCommissions" abstract="false" name="StockIssuanceCostsDiscountsAndCommissions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_RelatedPartyTransactionLicenseAgreementTerm" abstract="false" name="RelatedPartyTransactionLicenseAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ck0001824293_StockIssuanceCostsOfferingExpenses" abstract="false" name="StockIssuanceCostsOfferingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>ck0001824293-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:817af30f-ec0d-4f27-a9e3-e41325810995,g:c8a142b5-1941-49b7-ac1b-a5b54ada4279-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BalanceSheets" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#BalanceSheets"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c9314567-5201-4226-a6a8-75ebe90fce0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_62291286-082e-4ede-bbe4-1664ca80b96a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c9314567-5201-4226-a6a8-75ebe90fce0a" xlink:to="loc_us-gaap_Liabilities_62291286-082e-4ede-bbe4-1664ca80b96a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9c61518b-598d-44bb-a493-6039f8f1103b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c9314567-5201-4226-a6a8-75ebe90fce0a" xlink:to="loc_us-gaap_StockholdersEquity_9c61518b-598d-44bb-a493-6039f8f1103b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a21fc45e-b254-4bc7-ac95-1c302d2fd92f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c9314567-5201-4226-a6a8-75ebe90fce0a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a21fc45e-b254-4bc7-ac95-1c302d2fd92f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2ece9009-afa4-4533-b464-2c264fd74394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_bd69c762-544a-4426-a839-87afef41e62b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2ece9009-afa4-4533-b464-2c264fd74394" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_bd69c762-544a-4426-a839-87afef41e62b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7bd8cb5d-fb32-4e66-bd6d-7f1481e0f96d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2ece9009-afa4-4533-b464-2c264fd74394" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7bd8cb5d-fb32-4e66-bd6d-7f1481e0f96d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_42339f33-07fb-43ca-badf-06f46c27354e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2ece9009-afa4-4533-b464-2c264fd74394" xlink:to="loc_us-gaap_AccountsPayableCurrent_42339f33-07fb-43ca-badf-06f46c27354e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e80899f1-a27e-48ac-a4b3-ffec955ecfe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_78604e84-d3cd-479f-a831-d51faa584a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e80899f1-a27e-48ac-a4b3-ffec955ecfe9" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_78604e84-d3cd-479f-a831-d51faa584a2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_77be9a0f-dc68-4691-b968-90c6340afe1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e80899f1-a27e-48ac-a4b3-ffec955ecfe9" xlink:to="loc_us-gaap_LiabilitiesCurrent_77be9a0f-dc68-4691-b968-90c6340afe1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f3b4008b-ecd2-4d6c-ab51-ad514933a633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ffe496d2-4f03-4422-ae6c-d70ed57929cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f3b4008b-ecd2-4d6c-ab51-ad514933a633" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ffe496d2-4f03-4422-ae6c-d70ed57929cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_11223938-607e-431c-9cc9-6481712bcd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f3b4008b-ecd2-4d6c-ab51-ad514933a633" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_11223938-607e-431c-9cc9-6481712bcd7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_9b93e88b-792f-48f8-832d-836939368e76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f3b4008b-ecd2-4d6c-ab51-ad514933a633" xlink:to="loc_us-gaap_CommonStockValueOutstanding_9b93e88b-792f-48f8-832d-836939368e76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_68552ab0-8f4e-4f03-8d9c-942aeb62100e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f3b4008b-ecd2-4d6c-ab51-ad514933a633" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_68552ab0-8f4e-4f03-8d9c-942aeb62100e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e9f14c07-dcaf-4e0c-a008-8732e5fdcfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_81ef03ab-58eb-4cec-8de8-e058137d9809" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e9f14c07-dcaf-4e0c-a008-8732e5fdcfc6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_81ef03ab-58eb-4cec-8de8-e058137d9809" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0561815c-3318-47bf-869a-7698797ebaf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e9f14c07-dcaf-4e0c-a008-8732e5fdcfc6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0561815c-3318-47bf-869a-7698797ebaf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f81af99d-c820-440c-89d2-985793bc8d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e9f14c07-dcaf-4e0c-a008-8732e5fdcfc6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f81af99d-c820-440c-89d2-985793bc8d1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_879d8ca4-86ac-43c0-9eca-75db7c00099f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6c0b4d79-b7f8-4e2e-b971-3a2572861d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_879d8ca4-86ac-43c0-9eca-75db7c00099f" xlink:to="loc_us-gaap_AssetsCurrent_6c0b4d79-b7f8-4e2e-b971-3a2572861d98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4e9174b2-7822-45bf-9a71-ee310441308f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_879d8ca4-86ac-43c0-9eca-75db7c00099f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4e9174b2-7822-45bf-9a71-ee310441308f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#StatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7c5f4e84-3790-4381-b78e-f9f9f5fa4f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e1cc73f9-55ff-481b-8ff0-5668b1bab64f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_7c5f4e84-3790-4381-b78e-f9f9f5fa4f21" xlink:to="loc_us-gaap_OperatingExpenses_e1cc73f9-55ff-481b-8ff0-5668b1bab64f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73146307-1a8f-4f07-8d59-3456d5d5461a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_7c5f4e84-3790-4381-b78e-f9f9f5fa4f21" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73146307-1a8f-4f07-8d59-3456d5d5461a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d3d4442e-09cc-48a1-8c8d-b45e332e1c38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_95888b64-30c8-40b9-a577-07a3ef402508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d3d4442e-09cc-48a1-8c8d-b45e332e1c38" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_95888b64-30c8-40b9-a577-07a3ef402508" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_003583a0-b79a-4eb8-b6a5-af96c92473c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d3d4442e-09cc-48a1-8c8d-b45e332e1c38" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_003583a0-b79a-4eb8-b6a5-af96c92473c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7fc128a5-7862-44ba-99fd-8c7de381a27b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b4bf7b3e-9040-4608-8755-a1c98c99a60c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7fc128a5-7862-44ba-99fd-8c7de381a27b" xlink:to="loc_us-gaap_NetIncomeLoss_b4bf7b3e-9040-4608-8755-a1c98c99a60c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b2ba76ba-3bf9-4da3-b662-bd72dbfe65a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7fc128a5-7862-44ba-99fd-8c7de381a27b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b2ba76ba-3bf9-4da3-b662-bd72dbfe65a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_41f652a0-f100-4333-8b02-662c25ebdadd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_26eff62e-92a3-4311-abd8-440c908b59f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_41f652a0-f100-4333-8b02-662c25ebdadd" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_26eff62e-92a3-4311-abd8-440c908b59f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_003a32a3-a87f-42be-a7d9-bee327290f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_41f652a0-f100-4333-8b02-662c25ebdadd" xlink:to="loc_us-gaap_OperatingIncomeLoss_003a32a3-a87f-42be-a7d9-bee327290f9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome_c7512cf5-ff85-4b94-a0e6-b9ab0b9ed13e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_41f652a0-f100-4333-8b02-662c25ebdadd" xlink:to="loc_us-gaap_OtherNonoperatingIncome_c7512cf5-ff85-4b94-a0e6-b9ab0b9ed13e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_18443f71-d2ce-4670-a96b-1b5a8069e735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_41f652a0-f100-4333-8b02-662c25ebdadd" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_18443f71-d2ce-4670-a96b-1b5a8069e735" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#StatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_70e27806-03e9-4756-ac4c-18c49e050dca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_733c9ce8-ae5a-44de-ae84-7f371d4550cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_70e27806-03e9-4756-ac4c-18c49e050dca" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_733c9ce8-ae5a-44de-ae84-7f371d4550cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_30986081-75c0-40a3-8330-ab0767ced248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_70e27806-03e9-4756-ac4c-18c49e050dca" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_30986081-75c0-40a3-8330-ab0767ced248" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_28553f5a-6bf9-495d-9bbe-d161c45cc7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_70e27806-03e9-4756-ac4c-18c49e050dca" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_28553f5a-6bf9-495d-9bbe-d161c45cc7d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c07e5f2d-1905-48d0-a129-163ca736b1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1aa9ad54-d543-49ad-8114-2afa87795170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c07e5f2d-1905-48d0-a129-163ca736b1f2" xlink:to="loc_us-gaap_NetIncomeLoss_1aa9ad54-d543-49ad-8114-2afa87795170" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_ea05ee19-c8c4-429b-a937-d2153bb7e53b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c07e5f2d-1905-48d0-a129-163ca736b1f2" xlink:to="loc_us-gaap_OtherNoncashExpense_ea05ee19-c8c4-429b-a937-d2153bb7e53b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3ddc7b69-e6ea-4efb-81d6-0ed35d8f4fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c07e5f2d-1905-48d0-a129-163ca736b1f2" xlink:to="loc_us-gaap_ShareBasedCompensation_3ddc7b69-e6ea-4efb-81d6-0ed35d8f4fa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cf053ff9-a0bd-4f1f-b516-b7679ca6d01f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c07e5f2d-1905-48d0-a129-163ca736b1f2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_cf053ff9-a0bd-4f1f-b516-b7679ca6d01f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a7a684aa-afde-415c-9bc1-d84044a73640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c07e5f2d-1905-48d0-a129-163ca736b1f2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a7a684aa-afde-415c-9bc1-d84044a73640" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b55f7c23-3eb4-4f9f-8cbd-3a7ac088564d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c07e5f2d-1905-48d0-a129-163ca736b1f2" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b55f7c23-3eb4-4f9f-8cbd-3a7ac088564d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ForgivenessOfDebtInstrument_c4a422b2-040b-417a-8f6b-25279f06de70" xlink:href="ck0001824293-20220331.xsd#ck0001824293_ForgivenessOfDebtInstrument"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c07e5f2d-1905-48d0-a129-163ca736b1f2" xlink:to="loc_ck0001824293_ForgivenessOfDebtInstrument_c4a422b2-040b-417a-8f6b-25279f06de70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_45940bc1-e8b1-435b-9ad1-b688ab502036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c07e5f2d-1905-48d0-a129-163ca736b1f2" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_45940bc1-e8b1-435b-9ad1-b688ab502036" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6e254597-5a3c-442e-abec-7526ce82e5da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c07e5f2d-1905-48d0-a129-163ca736b1f2" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_6e254597-5a3c-442e-abec-7526ce82e5da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d22a0250-4dd8-4d41-8bb5-acdcf9d05dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c07e5f2d-1905-48d0-a129-163ca736b1f2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d22a0250-4dd8-4d41-8bb5-acdcf9d05dc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_74b5a4b8-2f96-4fa8-be5b-d8ce5c904940" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_72a5434a-2eac-43c2-ab2e-88a06ccc0f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_74b5a4b8-2f96-4fa8-be5b-d8ce5c904940" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_72a5434a-2eac-43c2-ab2e-88a06ccc0f3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c9aacf1-4570-4836-8bf7-3c278a3868b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_74b5a4b8-2f96-4fa8-be5b-d8ce5c904940" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c9aacf1-4570-4836-8bf7-3c278a3868b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5f06f34f-bd69-467d-b69c-62f30804914e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_74b5a4b8-2f96-4fa8-be5b-d8ce5c904940" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5f06f34f-bd69-467d-b69c-62f30804914e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c02db9e2-d4eb-46ea-90cf-9332674faaea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_8093c613-e287-449b-ac38-ecdcebe1e1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c02db9e2-d4eb-46ea-90cf-9332674faaea" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_8093c613-e287-449b-ac38-ecdcebe1e1e8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_00acfc68-ee2e-497d-9104-3b9b0e058fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_525e57bf-744d-4416-85fe-eb74607257bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_00acfc68-ee2e-497d-9104-3b9b0e058fb8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_525e57bf-744d-4416-85fe-eb74607257bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_528be6c9-2e2c-445c-9835-99f9b75b88b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_00acfc68-ee2e-497d-9104-3b9b0e058fb8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_528be6c9-2e2c-445c-9835-99f9b75b88b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b50da618-0e90-4674-afaa-01ba27fbb230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_00acfc68-ee2e-497d-9104-3b9b0e058fb8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b50da618-0e90-4674-afaa-01ba27fbb230" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_001cd7ba-6fb2-4762-aa8e-e526427a5b02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_3f0b7c3f-b3ec-4791-9bbf-a351cf5a4724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_001cd7ba-6fb2-4762-aa8e-e526427a5b02" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_3f0b7c3f-b3ec-4791-9bbf-a351cf5a4724" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_1ef5e3a9-f76e-4fc6-8d8b-901372a522a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_001cd7ba-6fb2-4762-aa8e-e526427a5b02" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_1ef5e3a9-f76e-4fc6-8d8b-901372a522a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_79657e4b-3d2a-4789-85ad-70b2e30642c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_001cd7ba-6fb2-4762-aa8e-e526427a5b02" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_79657e4b-3d2a-4789-85ad-70b2e30642c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_b807efd8-8a13-4b35-8cdc-69eefcb7a98a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_001cd7ba-6fb2-4762-aa8e-e526427a5b02" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_b807efd8-8a13-4b35-8cdc-69eefcb7a98a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#ACCRUEDEXPENSESDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_40aba90e-2b01-4617-bebc-cce6d52c8623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_aacb8522-78f3-4d4a-92de-48ecf9768e08" xlink:href="ck0001824293-20220331.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_40aba90e-2b01-4617-bebc-cce6d52c8623" xlink:to="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_aacb8522-78f3-4d4a-92de-48ecf9768e08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedLicensingFeesCurrent_046a77a7-28a5-48d0-aebf-8768802fbcaf" xlink:href="ck0001824293-20220331.xsd#ck0001824293_AccruedLicensingFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_40aba90e-2b01-4617-bebc-cce6d52c8623" xlink:to="loc_ck0001824293_AccruedLicensingFeesCurrent_046a77a7-28a5-48d0-aebf-8768802fbcaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_289f2347-a87f-4730-a915-dadcbb2343d7" xlink:href="ck0001824293-20220331.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_40aba90e-2b01-4617-bebc-cce6d52c8623" xlink:to="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_289f2347-a87f-4730-a915-dadcbb2343d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_948539e2-e5a9-4328-a911-b2dab5607baa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_40aba90e-2b01-4617-bebc-cce6d52c8623" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_948539e2-e5a9-4328-a911-b2dab5607baa" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>ck0001824293-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:817af30f-ec0d-4f27-a9e3-e41325810995,g:c8a142b5-1941-49b7-ac1b-a5b54ada4279-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#StatementsofChangesinStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit" xlink:type="extended" id="if3266a2696c74ece9eba419d6c106ef1_StatementsofChangesinStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_98aba0a2-9687-4e9d-82d8-6f0c0c65cebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_98aba0a2-9687-4e9d-82d8-6f0c0c65cebe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f8fb9d6e-9a15-43e8-ae7d-4a83e8182ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_StockholdersEquity_f8fb9d6e-9a15-43e8-ae7d-4a83e8182ec2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_efccf9fc-4944-4f62-a758-8cec1130a483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_efccf9fc-4944-4f62-a758-8cec1130a483" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0165e129-c988-4ab2-9d39-183f368fad13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0165e129-c988-4ab2-9d39-183f368fad13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e059e458-efdc-46e9-bf10-5f79ef6ca041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e059e458-efdc-46e9-bf10-5f79ef6ca041" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fb202bbe-7a27-4aad-98b0-0ba48e54c536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fb202bbe-7a27-4aad-98b0-0ba48e54c536" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_5fd1cdf3-c331-48dc-a005-03053ca41901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_5fd1cdf3-c331-48dc-a005-03053ca41901" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_d0208ca8-363e-4767-a1ad-58f7c734d6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_d0208ca8-363e-4767-a1ad-58f7c734d6aa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_8a3d331a-0a0e-48e1-979c-6327a7bf6f23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_8a3d331a-0a0e-48e1-979c-6327a7bf6f23" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b448ea94-ecaf-4b9c-b68b-3cb7b670d43f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b448ea94-ecaf-4b9c-b68b-3cb7b670d43f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5e3c8ca0-28d5-43f7-8290-f2c7117ba5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5e3c8ca0-28d5-43f7-8290-f2c7117ba5c5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0d6545b5-f018-4793-a813-6c735f479c96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_NetIncomeLoss_0d6545b5-f018-4793-a813-6c735f479c96" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_11e3f00f-3a1c-4db2-ae7d-5d638b5aeb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fb612243-b89c-4ac9-9307-3b294a4dda4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f5833732-dd8e-488e-b9e4-7210ea0b47e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_StatementTable_f5833732-dd8e-488e-b9e4-7210ea0b47e1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_24e5edcb-2e9d-401b-9196-d43cd2523bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f5833732-dd8e-488e-b9e4-7210ea0b47e1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_24e5edcb-2e9d-401b-9196-d43cd2523bbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_24e5edcb-2e9d-401b-9196-d43cd2523bbd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_24e5edcb-2e9d-401b-9196-d43cd2523bbd" xlink:to="loc_us-gaap_EquityComponentDomain_24e5edcb-2e9d-401b-9196-d43cd2523bbd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_01999cb2-92cb-497d-8d53-3214d0c3f79a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_24e5edcb-2e9d-401b-9196-d43cd2523bbd" xlink:to="loc_us-gaap_EquityComponentDomain_01999cb2-92cb-497d-8d53-3214d0c3f79a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b036fb53-e5ba-4b2f-8f47-2002ad7d1c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_01999cb2-92cb-497d-8d53-3214d0c3f79a" xlink:to="loc_us-gaap_CommonStockMember_b036fb53-e5ba-4b2f-8f47-2002ad7d1c90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_41e26966-6eee-4e91-a7e2-8224361c899e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_01999cb2-92cb-497d-8d53-3214d0c3f79a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_41e26966-6eee-4e91-a7e2-8224361c899e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bd20f2dd-ba18-4d1b-9419-9184a3c8f641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_01999cb2-92cb-497d-8d53-3214d0c3f79a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bd20f2dd-ba18-4d1b-9419-9184a3c8f641" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a82995ae-7503-4808-96a0-c0e8871b9b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_01999cb2-92cb-497d-8d53-3214d0c3f79a" xlink:to="loc_us-gaap_RetainedEarningsMember_a82995ae-7503-4808-96a0-c0e8871b9b79" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#LIQUIDITYDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="extended" id="i89198b10439e4f61879a87c13dba7314_LIQUIDITYDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_73ac62ae-6dad-4ba1-946e-4478443f7032" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1f6cf96a-ed49-409e-ae14-ef316057d5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_73ac62ae-6dad-4ba1-946e-4478443f7032" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1f6cf96a-ed49-409e-ae14-ef316057d5cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_4ef32b0c-8127-40a8-bb80-d8defad0029a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_73ac62ae-6dad-4ba1-946e-4478443f7032" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_4ef32b0c-8127-40a8-bb80-d8defad0029a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7fd26f41-525d-4aa7-a96a-a6404bde65c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_73ac62ae-6dad-4ba1-946e-4478443f7032" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7fd26f41-525d-4aa7-a96a-a6404bde65c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_f5bcd6bc-c001-473a-9125-9d52839438bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_73ac62ae-6dad-4ba1-946e-4478443f7032" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_f5bcd6bc-c001-473a-9125-9d52839438bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3946ac2f-9199-43a5-85ff-87e004266de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_73ac62ae-6dad-4ba1-946e-4478443f7032" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3946ac2f-9199-43a5-85ff-87e004266de9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_08420464-5ac5-45cb-b8ee-5bbabb8d1449" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3946ac2f-9199-43a5-85ff-87e004266de9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_08420464-5ac5-45cb-b8ee-5bbabb8d1449" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_08420464-5ac5-45cb-b8ee-5bbabb8d1449_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_08420464-5ac5-45cb-b8ee-5bbabb8d1449" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_08420464-5ac5-45cb-b8ee-5bbabb8d1449_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_64e35a1b-74a7-47b1-a123-38a433cbb19d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_08420464-5ac5-45cb-b8ee-5bbabb8d1449" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_64e35a1b-74a7-47b1-a123-38a433cbb19d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_eb9dfd9e-7afe-46b0-b652-251feb367391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_64e35a1b-74a7-47b1-a123-38a433cbb19d" xlink:to="loc_us-gaap_IPOMember_eb9dfd9e-7afe-46b0-b652-251feb367391" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails" xlink:type="extended" id="ib650d1b9eb5b42669ffd43b67c4b642e_MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_7b5ad9af-394f-4675-ba54-360dbb11e282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d1d3f8f1-7733-4af7-b15b-ff68ba0f9c78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_7b5ad9af-394f-4675-ba54-360dbb11e282" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d1d3f8f1-7733-4af7-b15b-ff68ba0f9c78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_49f7b7ef-c396-4daa-93bd-605b8bdc97bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_7b5ad9af-394f-4675-ba54-360dbb11e282" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_49f7b7ef-c396-4daa-93bd-605b8bdc97bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_19543d50-cb7f-4ac8-bf61-bbe2af8eea59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_7b5ad9af-394f-4675-ba54-360dbb11e282" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_19543d50-cb7f-4ac8-bf61-bbe2af8eea59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_862819eb-766f-4032-8fec-06df309a178b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_7b5ad9af-394f-4675-ba54-360dbb11e282" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_862819eb-766f-4032-8fec-06df309a178b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_966fa3e7-1873-4a0f-bbce-81fb31ad6c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_7b5ad9af-394f-4675-ba54-360dbb11e282" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_966fa3e7-1873-4a0f-bbce-81fb31ad6c08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5140ac57-1172-49a0-94f1-15beab069074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_966fa3e7-1873-4a0f-bbce-81fb31ad6c08" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5140ac57-1172-49a0-94f1-15beab069074" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5140ac57-1172-49a0-94f1-15beab069074_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5140ac57-1172-49a0-94f1-15beab069074" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5140ac57-1172-49a0-94f1-15beab069074_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5cbf464d-e3f4-4d43-94b3-c3ed4bcad03d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5140ac57-1172-49a0-94f1-15beab069074" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5cbf464d-e3f4-4d43-94b3-c3ed4bcad03d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_075bdad9-afa3-41ac-b8e3-6de9c3f7e0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5cbf464d-e3f4-4d43-94b3-c3ed4bcad03d" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_075bdad9-afa3-41ac-b8e3-6de9c3f7e0e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_a9bf03c7-8a6e-458a-8b95-3ba24263ae0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5cbf464d-e3f4-4d43-94b3-c3ed4bcad03d" xlink:to="loc_us-gaap_MunicipalBondsMember_a9bf03c7-8a6e-458a-8b95-3ba24263ae0a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#PPPNOTEANDCONVERTIBLENOTESDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails" xlink:type="extended" id="i3e51ff98836a45e1b6b3d433828794ef_PPPNOTEANDCONVERTIBLENOTESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_a33c75c4-f471-4660-bfbe-0abdd7eda53f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ab778386-d71a-4d59-ba01-ad62e8701830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a33c75c4-f471-4660-bfbe-0abdd7eda53f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ab778386-d71a-4d59-ba01-ad62e8701830" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1cea8a46-f9f8-4f8a-b3de-05405f778b73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a33c75c4-f471-4660-bfbe-0abdd7eda53f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1cea8a46-f9f8-4f8a-b3de-05405f778b73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_469b8a6b-9988-4603-8784-1685281e0ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a33c75c4-f471-4660-bfbe-0abdd7eda53f" xlink:to="loc_us-gaap_DebtInstrumentTerm_469b8a6b-9988-4603-8784-1685281e0ff8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentPaymentTerm_4ee7e4b4-0ca3-438c-895e-eeb09c2c14e9" xlink:href="ck0001824293-20220331.xsd#ck0001824293_DebtInstrumentPaymentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a33c75c4-f471-4660-bfbe-0abdd7eda53f" xlink:to="loc_ck0001824293_DebtInstrumentPaymentTerm_4ee7e4b4-0ca3-438c-895e-eeb09c2c14e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ForgivenessOfDebtInstrument_807733bd-6f95-4fe1-a876-8a95ec1c3f2c" xlink:href="ck0001824293-20220331.xsd#ck0001824293_ForgivenessOfDebtInstrument"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a33c75c4-f471-4660-bfbe-0abdd7eda53f" xlink:to="loc_ck0001824293_ForgivenessOfDebtInstrument_807733bd-6f95-4fe1-a876-8a95ec1c3f2c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_8c781a7d-a27f-4c92-8ed8-d0d5b67e30f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a33c75c4-f471-4660-bfbe-0abdd7eda53f" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_8c781a7d-a27f-4c92-8ed8-d0d5b67e30f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_5a253ed2-a23f-4fec-8a92-fc2dd466596b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a33c75c4-f471-4660-bfbe-0abdd7eda53f" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_5a253ed2-a23f-4fec-8a92-fc2dd466596b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_0f17b612-b072-4542-9005-bc3c000dae60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a33c75c4-f471-4660-bfbe-0abdd7eda53f" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_0f17b612-b072-4542-9005-bc3c000dae60" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_556b7bdb-e6d5-4748-bdf3-5186fc876e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a33c75c4-f471-4660-bfbe-0abdd7eda53f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_556b7bdb-e6d5-4748-bdf3-5186fc876e7e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a94f6a90-4087-4cf3-b973-3e3c96c5d23d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_556b7bdb-e6d5-4748-bdf3-5186fc876e7e" xlink:to="loc_us-gaap_DebtInstrumentAxis_a94f6a90-4087-4cf3-b973-3e3c96c5d23d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a94f6a90-4087-4cf3-b973-3e3c96c5d23d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a94f6a90-4087-4cf3-b973-3e3c96c5d23d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a94f6a90-4087-4cf3-b973-3e3c96c5d23d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d33e37c9-9a3b-4126-92d9-d29e92f15bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a94f6a90-4087-4cf3-b973-3e3c96c5d23d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d33e37c9-9a3b-4126-92d9-d29e92f15bba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaycheckProtectionProgramCARESActMember_a5f632b6-a6cc-44ec-9041-fbc73ad8abda" xlink:href="ck0001824293-20220331.xsd#ck0001824293_PaycheckProtectionProgramCARESActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d33e37c9-9a3b-4126-92d9-d29e92f15bba" xlink:to="loc_ck0001824293_PaycheckProtectionProgramCARESActMember_a5f632b6-a6cc-44ec-9041-fbc73ad8abda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3657595a-b0ad-49c9-8817-e72573dbdd7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_556b7bdb-e6d5-4748-bdf3-5186fc876e7e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3657595a-b0ad-49c9-8817-e72573dbdd7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3657595a-b0ad-49c9-8817-e72573dbdd7b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3657595a-b0ad-49c9-8817-e72573dbdd7b" xlink:to="loc_us-gaap_RelatedPartyDomain_3657595a-b0ad-49c9-8817-e72573dbdd7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e10007e6-1c85-4eab-aa36-1c5dcd8b9d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3657595a-b0ad-49c9-8817-e72573dbdd7b" xlink:to="loc_us-gaap_RelatedPartyDomain_e10007e6-1c85-4eab-aa36-1c5dcd8b9d1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_4c83d419-d695-49cc-8d97-1f4873320f97" xlink:href="ck0001824293-20220331.xsd#ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e10007e6-1c85-4eab-aa36-1c5dcd8b9d1f" xlink:to="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_4c83d419-d695-49cc-8d97-1f4873320f97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_c1c6ed98-c47c-4f2e-b569-0d0b202e82c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_556b7bdb-e6d5-4748-bdf3-5186fc876e7e" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_c1c6ed98-c47c-4f2e-b569-0d0b202e82c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_c1c6ed98-c47c-4f2e-b569-0d0b202e82c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c1c6ed98-c47c-4f2e-b569-0d0b202e82c9" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_c1c6ed98-c47c-4f2e-b569-0d0b202e82c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_ece72a60-aaf1-40cb-b7a5-9d748aacf337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c1c6ed98-c47c-4f2e-b569-0d0b202e82c9" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_ece72a60-aaf1-40cb-b7a5-9d748aacf337" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_ed6ae9b6-3f78-4342-bd2a-c1486a4ec36b" xlink:href="ck0001824293-20220331.xsd#ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_ece72a60-aaf1-40cb-b7a5-9d748aacf337" xlink:to="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_ed6ae9b6-3f78-4342-bd2a-c1486a4ec36b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_bd2b0fef-2c7b-4abc-90db-f4252a12961d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_556b7bdb-e6d5-4748-bdf3-5186fc876e7e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_bd2b0fef-2c7b-4abc-90db-f4252a12961d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bd2b0fef-2c7b-4abc-90db-f4252a12961d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bd2b0fef-2c7b-4abc-90db-f4252a12961d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_bd2b0fef-2c7b-4abc-90db-f4252a12961d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_191618c5-85eb-424b-bd05-8ea5e35360fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bd2b0fef-2c7b-4abc-90db-f4252a12961d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_191618c5-85eb-424b-bd05-8ea5e35360fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_3cd63d1a-35be-49ed-8941-0961d562e48c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_191618c5-85eb-424b-bd05-8ea5e35360fe" xlink:to="loc_us-gaap_OverAllotmentOptionMember_3cd63d1a-35be-49ed-8941-0961d562e48c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#STOCKHOLDERSEQUITYDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="extended" id="ic9b3e76c16b243e69d00e3e7934d0148_STOCKHOLDERSEQUITYDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f544c39a-62d7-4b60-9a1d-ba931b4ad927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ad5747e2-e293-4a25-8d4d-c22764c8c308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f544c39a-62d7-4b60-9a1d-ba931b4ad927" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ad5747e2-e293-4a25-8d4d-c22764c8c308" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_7cbe4f62-48d0-41e1-9691-7e14132beb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f544c39a-62d7-4b60-9a1d-ba931b4ad927" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_7cbe4f62-48d0-41e1-9691-7e14132beb6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross_00f3ccaa-889e-4fe6-84d1-52e4203d089a" xlink:href="ck0001824293-20220331.xsd#ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f544c39a-62d7-4b60-9a1d-ba931b4ad927" xlink:to="loc_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross_00f3ccaa-889e-4fe6-84d1-52e4203d089a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_74ef9b3e-4182-4212-8391-e370633b4703" xlink:href="ck0001824293-20220331.xsd#ck0001824293_StockIssuanceCostsDiscountsAndCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f544c39a-62d7-4b60-9a1d-ba931b4ad927" xlink:to="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_74ef9b3e-4182-4212-8391-e370633b4703" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_0dee9175-4c3c-4a90-935e-19b1b5e94be2" xlink:href="ck0001824293-20220331.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f544c39a-62d7-4b60-9a1d-ba931b4ad927" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_0dee9175-4c3c-4a90-935e-19b1b5e94be2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_40881f70-a2b6-4b80-9dd9-30994b0b56f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f544c39a-62d7-4b60-9a1d-ba931b4ad927" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_40881f70-a2b6-4b80-9dd9-30994b0b56f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a610bab6-36fb-4070-a1a7-e4e9d03bae98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f544c39a-62d7-4b60-9a1d-ba931b4ad927" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a610bab6-36fb-4070-a1a7-e4e9d03bae98" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1bda07bf-d7e7-42c7-9714-7e407696e4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f544c39a-62d7-4b60-9a1d-ba931b4ad927" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1bda07bf-d7e7-42c7-9714-7e407696e4d3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_4f30f961-1eba-48c2-842c-a3fe4c980690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f544c39a-62d7-4b60-9a1d-ba931b4ad927" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_4f30f961-1eba-48c2-842c-a3fe4c980690" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_f4e83b3c-42a5-419e-aaba-711b5f750148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_f544c39a-62d7-4b60-9a1d-ba931b4ad927" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_f4e83b3c-42a5-419e-aaba-711b5f750148" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6f934ba7-24ac-47a9-8364-e4065e3ba46f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_f544c39a-62d7-4b60-9a1d-ba931b4ad927" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6f934ba7-24ac-47a9-8364-e4065e3ba46f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e2260623-5f00-47c7-8be7-0483a944327d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6f934ba7-24ac-47a9-8364-e4065e3ba46f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e2260623-5f00-47c7-8be7-0483a944327d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2260623-5f00-47c7-8be7-0483a944327d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e2260623-5f00-47c7-8be7-0483a944327d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e2260623-5f00-47c7-8be7-0483a944327d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a9f1b6d0-baf4-42dc-aa0a-5ffcaf1a02c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e2260623-5f00-47c7-8be7-0483a944327d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a9f1b6d0-baf4-42dc-aa0a-5ffcaf1a02c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_dc980f94-1c0f-4d6e-af27-efc99f9c603b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a9f1b6d0-baf4-42dc-aa0a-5ffcaf1a02c1" xlink:to="loc_us-gaap_IPOMember_dc980f94-1c0f-4d6e-af27-efc99f9c603b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_d9521ef2-c566-4693-b233-0daedacf4715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a9f1b6d0-baf4-42dc-aa0a-5ffcaf1a02c1" xlink:to="loc_us-gaap_OverAllotmentOptionMember_d9521ef2-c566-4693-b233-0daedacf4715" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="extended" id="i8906735719aa4e8bb77beed297844a0c_STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_233e6424-c00b-4bde-8b39-92f3b8dad8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_3d141fb6-30d6-4322-9fab-5652ffcf0561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_233e6424-c00b-4bde-8b39-92f3b8dad8bd" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_3d141fb6-30d6-4322-9fab-5652ffcf0561" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a68551b2-14e7-4b1f-99b1-4ad5fb9062d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_233e6424-c00b-4bde-8b39-92f3b8dad8bd" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a68551b2-14e7-4b1f-99b1-4ad5fb9062d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1abf982c-3daa-427e-8243-e4197136725d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a68551b2-14e7-4b1f-99b1-4ad5fb9062d6" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1abf982c-3daa-427e-8243-e4197136725d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1abf982c-3daa-427e-8243-e4197136725d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1abf982c-3daa-427e-8243-e4197136725d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1abf982c-3daa-427e-8243-e4197136725d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_96f01cd3-9720-4208-a93f-32297be40f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1abf982c-3daa-427e-8243-e4197136725d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_96f01cd3-9720-4208-a93f-32297be40f99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_dd92e964-f353-48ab-b65a-962df6031d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_96f01cd3-9720-4208-a93f-32297be40f99" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_dd92e964-f353-48ab-b65a-962df6031d2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_0cb57a09-1829-4f71-8ef5-71b170bb0d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_96f01cd3-9720-4208-a93f-32297be40f99" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_0cb57a09-1829-4f71-8ef5-71b170bb0d40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_df673188-ea5c-4c92-aeb7-fe20ad01d15a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_96f01cd3-9720-4208-a93f-32297be40f99" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_df673188-ea5c-4c92-aeb7-fe20ad01d15a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_f0936542-2de9-4451-8ee1-936ea442cea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_96f01cd3-9720-4208-a93f-32297be40f99" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_f0936542-2de9-4451-8ee1-936ea442cea4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended" id="ie75817496d0c42eeb9704fa541692e1f_STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_97ba928a-1615-4396-a190-6cef472b5f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_cb626cb9-e92b-41f1-a493-87f780589d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_97ba928a-1615-4396-a190-6cef472b5f63" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_cb626cb9-e92b-41f1-a493-87f780589d32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3b15a240-33cf-4a32-b9ee-474f77159b26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_97ba928a-1615-4396-a190-6cef472b5f63" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3b15a240-33cf-4a32-b9ee-474f77159b26" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3707908d-298e-4290-9e13-c1bc93b4f9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3b15a240-33cf-4a32-b9ee-474f77159b26" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3707908d-298e-4290-9e13-c1bc93b4f9e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3707908d-298e-4290-9e13-c1bc93b4f9e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3707908d-298e-4290-9e13-c1bc93b4f9e5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3707908d-298e-4290-9e13-c1bc93b4f9e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5490f901-39cf-4d15-9c0d-88684429d446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3707908d-298e-4290-9e13-c1bc93b4f9e5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5490f901-39cf-4d15-9c0d-88684429d446" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e35f5c1b-b547-4e25-8d0c-bded3373a46e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5490f901-39cf-4d15-9c0d-88684429d446" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e35f5c1b-b547-4e25-8d0c-bded3373a46e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3261545c-5d4a-4b8d-b22e-ed0578e1c129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5490f901-39cf-4d15-9c0d-88684429d446" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3261545c-5d4a-4b8d-b22e-ed0578e1c129" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended" id="i1e5c2e017e844277940203c339565aac_RELATEDPARTYTRANSACTIONSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_9db3c947-520b-4cae-998d-1f05628767e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment_9a68ccf1-2a37-428c-9181-fcd46909b263" xlink:href="ck0001824293-20220331.xsd#ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9db3c947-520b-4cae-998d-1f05628767e9" xlink:to="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment_9a68ccf1-2a37-428c-9181-fcd46909b263" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm_bdbb8b24-caf2-4d65-9a8b-b79a884eebbe" xlink:href="ck0001824293-20220331.xsd#ck0001824293_RelatedPartyTransactionLicenseAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9db3c947-520b-4cae-998d-1f05628767e9" xlink:to="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm_bdbb8b24-caf2-4d65-9a8b-b79a884eebbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_1b7d68cf-c095-4f95-80ef-e75e4fd36d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9db3c947-520b-4cae-998d-1f05628767e9" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_1b7d68cf-c095-4f95-80ef-e75e4fd36d71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b185ca67-5f82-4825-b893-e53f39786726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9db3c947-520b-4cae-998d-1f05628767e9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b185ca67-5f82-4825-b893-e53f39786726" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_b4d619c9-0dbb-4524-a61c-f68e5211ac02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9db3c947-520b-4cae-998d-1f05628767e9" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_b4d619c9-0dbb-4524-a61c-f68e5211ac02" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403a42da-8813-4ea4-939e-47e1530dca9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9db3c947-520b-4cae-998d-1f05628767e9" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403a42da-8813-4ea4-939e-47e1530dca9f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fd9a5a00-4653-4231-82ab-bb1bd4df985e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403a42da-8813-4ea4-939e-47e1530dca9f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fd9a5a00-4653-4231-82ab-bb1bd4df985e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_fd9a5a00-4653-4231-82ab-bb1bd4df985e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fd9a5a00-4653-4231-82ab-bb1bd4df985e" xlink:to="loc_us-gaap_RelatedPartyDomain_fd9a5a00-4653-4231-82ab-bb1bd4df985e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4f22d9d6-51d0-462a-882a-813a424330e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fd9a5a00-4653-4231-82ab-bb1bd4df985e" xlink:to="loc_us-gaap_RelatedPartyDomain_4f22d9d6-51d0-462a-882a-813a424330e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_MediceMember_2824a711-3728-4827-a0b3-7d3b3a388a02" xlink:href="ck0001824293-20220331.xsd#ck0001824293_MediceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4f22d9d6-51d0-462a-882a-813a424330e1" xlink:to="loc_ck0001824293_MediceMember_2824a711-3728-4827-a0b3-7d3b3a388a02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_6226b4c8-6d2d-4a18-a947-19c5809f608d" xlink:href="ck0001824293-20220331.xsd#ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4f22d9d6-51d0-462a-882a-813a424330e1" xlink:to="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_6226b4c8-6d2d-4a18-a947-19c5809f608d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_11db0fcc-27dc-40c4-ae0a-a051817417b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403a42da-8813-4ea4-939e-47e1530dca9f" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_11db0fcc-27dc-40c4-ae0a-a051817417b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_11db0fcc-27dc-40c4-ae0a-a051817417b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_11db0fcc-27dc-40c4-ae0a-a051817417b4" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_11db0fcc-27dc-40c4-ae0a-a051817417b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_59692fd6-0cd9-44d8-9237-5368b8e37c39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_11db0fcc-27dc-40c4-ae0a-a051817417b4" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_59692fd6-0cd9-44d8-9237-5368b8e37c39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_82983b75-4924-459d-8fa8-b51cb8c9f50c" xlink:href="ck0001824293-20220331.xsd#ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_59692fd6-0cd9-44d8-9237-5368b8e37c39" xlink:to="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_82983b75-4924-459d-8fa8-b51cb8c9f50c" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>ck0001824293-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:817af30f-ec0d-4f27-a9e3-e41325810995,g:c8a142b5-1941-49b7-ac1b-a5b54ada4279-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment_54d0fc1a-2810-4a52-a56c-dab5f461d3a5_terseLabel_en-US" xlink:label="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received under license agreement</link:label>
    <link:label id="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment_label_en-US" xlink:label="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, License Agreement, Upfront Payment</link:label>
    <link:label id="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment_documentation_en-US" xlink:label="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, License Agreement, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment" xlink:href="ck0001824293-20220331.xsd#ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment" xlink:to="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_d7bfb064-9116-426d-9ee1-aa49a408ace1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_9838f7b1-2bfd-4139-bc68-958c80ff9faf_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_0e54ae24-4628-491a-b01c-3e8398f7ec3c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5eb9680f-c9d3-4b92-a51d-bc25649c0fc9_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f3327894-5505-4865-b7bc-3c44cac44144_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_bd4bbd40-322c-4ef7-8a70-59a56273d469_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll and related</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d1b7cad8-4e91-4ea1-91e3-a56f59078242_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_193cb388-6f3e-4fad-8a30-5cd0eb8a609d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm_c4a56804-5608-4b04-8bcd-a8621f1c4b90_terseLabel_en-US" xlink:label="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, term</link:label>
    <link:label id="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm_label_en-US" xlink:label="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, License Agreement, Term</link:label>
    <link:label id="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm_documentation_en-US" xlink:label="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, License Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm" xlink:href="ck0001824293-20220331.xsd#ck0001824293_RelatedPartyTransactionLicenseAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm" xlink:to="lab_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_6e2f9b7e-679b-4325-aa28-0fef590a2613_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of option on grant date (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_54732514-15ed-4c19-b814-a593b73bc6cb_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b789fd73-9934-46bd-a737-fdbfcc9fe460_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_31d1d650-5f75-4f0e-aef2-d6b427703275_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_02f9e461-f891-4e54-93cc-2ea343479977_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8abbd16c-3a66-4ec7-88aa-745b8e3f3a3f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock awards, contractual life (up to)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_66c3dee2-ca90-4940-8776-33eeb5145ed7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_a66556b2-cd0d-4cd9-a24e-ff6ae35516f7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_ff5714d7-4772-4a31-a9b7-62fc825d45e7_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_7f6c813d-0243-4273-9d8a-89fa6bb6d88b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in-capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_e41a46c2-8da6-41e3-b9a3-31365dd965d5_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_806e45e2-6c73-45e3-9350-1dea889b5905_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_288de9c2-7cf0-47ee-9445-e87c8fb9820d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_99e50483-fc58-463c-a354-9ab7c2e2323c_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fda92ac4-df4c-4001-b6db-49fad28bdef5_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_b90e9efc-b831-40c9-9209-bfdbccca0a71_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8e2dcb04-eb28-4087-a382-98fc7476b8ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4ad026b3-fe5c-4f92-b0c3-2c0746745180_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_5e6126d1-0e65-49b1-8d02-32441479c64c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_02fc2dba-6447-4f95-a0fb-884f7252eb6b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the Company&#8217;s Available for Sale Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_2b614fd0-b286-4333-a77b-0c6db0f32f78_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_58404b1e-4fff-4226-959a-109272db36fa_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedLicensingFeesCurrent_9c3b8cd4-1e6b-4894-a394-a3f5b15ae1c0_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedLicensingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing related</link:label>
    <link:label id="lab_ck0001824293_AccruedLicensingFeesCurrent_label_en-US" xlink:label="lab_ck0001824293_AccruedLicensingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Licensing Fees, Current</link:label>
    <link:label id="lab_ck0001824293_AccruedLicensingFeesCurrent_documentation_en-US" xlink:label="lab_ck0001824293_AccruedLicensingFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Licensing Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedLicensingFeesCurrent" xlink:href="ck0001824293-20220331.xsd#ck0001824293_AccruedLicensingFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedLicensingFeesCurrent" xlink:to="lab_ck0001824293_AccruedLicensingFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0bee5213-5fda-46ae-ac71-7f15bfd4f826_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_3fb873f6-1ad5-4194-b1fb-da210792e5d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a26ff0d2-dd84-4403-b615-da29af80bed4_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_05054789-db8d-4f09-90b6-767dd5b3fbe0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c0716cca-2c79-45f0-98a1-aee560fc9d82_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Underwriters Warrants</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_9775184b-95c1-4ca5-af93-03083179ea01_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant issued reflected in additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncome_2a008c65-d4c7-45c4-9b03-0513c210ef47_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncome_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncome" xlink:to="lab_us-gaap_OtherNonoperatingIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3856b57f-204d-4420-854a-e2089990e967_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_03b7993a-3698-4303-9078-1ae3c1fa7c29_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_490e12b0-e71f-438a-ba48-571c816756aa_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f352a055-33b5-4d44-9b41-619770c1f78e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_02491aff-c727-4702-ae4b-2c72fb3e1955_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_0c605925-1963-41f8-b9f0-4094ac628770_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_MediceMember_349b6393-3af3-4b94-a0b6-e69b6a3605f2_terseLabel_en-US" xlink:label="lab_ck0001824293_MediceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medice</link:label>
    <link:label id="lab_ck0001824293_MediceMember_label_en-US" xlink:label="lab_ck0001824293_MediceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medice [Member]</link:label>
    <link:label id="lab_ck0001824293_MediceMember_documentation_en-US" xlink:label="lab_ck0001824293_MediceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_MediceMember" xlink:href="ck0001824293-20220331.xsd#ck0001824293_MediceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_MediceMember" xlink:to="lab_ck0001824293_MediceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_a9c3bda8-8850-48db-93c0-1f73680e459e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_fd269db1-54b9-4d58-94da-d273950ca068_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_22a60f79-ca61-4d06-8534-061df8b47c75_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1d7065dd-a7da-46dc-8d1f-589e16cee8d4_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealizes loss on marketable securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_242a8d9f-37e8-426d-9527-94428b786cc6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes, converted, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_11e09d14-6e7d-44a2-9faf-c4f0ccc8a6d5_terseLabel_en-US" xlink:label="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Promissory Note Purchase Agreement</link:label>
    <link:label id="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_label_en-US" xlink:label="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Promissory Note Purchase Agreement [Member]</link:label>
    <link:label id="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_documentation_en-US" xlink:label="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Promissory Note Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:href="ck0001824293-20220331.xsd#ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:to="lab_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_a2346a6b-de50-400c-a50e-7ebcc9f3da3a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense recognized on embedded derivative</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_fd8ad890-f1d9-4216-bbbe-521c3008d8b4_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_a4938cf3-aa13-4fe8-88c1-dc4c37465c8f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_947d62cc-29d9-4fb1-9954-67c16bd43508_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term&#160;(years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a62b6616-d16c-4edf-b409-be298d701687_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_16f0e77f-80e4-403f-93a8-053517a86d2a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_42eb8915-568d-4162-af72-2310120a8fa3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_809129de-85f4-455c-bc2b-5791a8703136_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Estimated Fair Value of Investments Classified by Contractual Maturity Date</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3d0e37b1-fd0e-4f1b-917b-76c26ff59f9e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bf619da9-2ebf-4cd3-827b-cd479c414c7a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f1d679f6-fa2b-462a-94f6-02d600f4a22a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_3e11bb6a-de5c-42b2-be50-0215584856e0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8db72483-1ce4-4fa4-8d1d-85c57d3b6178_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f72872a5-80ea-4945-961d-b464891724d4_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f2000a3f-a391-4c81-a642-1511f8ec94cc_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_91c086a0-1deb-4771-b2fa-c93a7da9cff4_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_f2dd1d24-d02c-4c17-8517-48413acf2118_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fe4bfb4b-84b7-43a3-bb0e-d3d588dbf54b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_43bd1018-854c-4c6f-b222-6049ec37325e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_51b7171a-472c-4e43-9bfe-5ca62f339958_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity of Stock Options Granted</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a8e5bbd4-0471-4e75-a496-c33475b6fdb9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2e319e43-8540-48f4-a7d0-93382e61f7bc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for convertible notes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_b752be7a-a4a9-4e38-9ac9-076d5e66a9e1_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c808ede5-1f89-4ce1-b9ab-fe8be13ce80f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_0cb5b4c1-25b7-4e6c-ba04-410ae66a8289_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_de913650-c7f3-4a44-9cf3-7e75f33555e2_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fb757e72-74c1-4ac6-86dd-d225ec861493_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_910f1fe1-3af5-4e9b-987d-668b3b6ebf69_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_a42b6620-97b7-4355-8718-842746e5dfc9_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b33e2e1f-b2f5-40fd-918c-c3a1fd5fbdac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy_1f5c179e-8af3-4c70-adcb-1a5010b89177_terseLabel_en-US" xlink:label="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of subjects that completed the SEAL study</link:label>
    <link:label id="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy_label_en-US" xlink:label="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Research Study, Number of Participants, Completed the Study</link:label>
    <link:label id="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy_documentation_en-US" xlink:label="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Research Study, Number of Participants, Completed the Study</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy" xlink:href="ck0001824293-20220331.xsd#ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy" xlink:to="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled_8300f0cd-7d0d-491c-830e-8783cd04c2c1_terseLabel_en-US" xlink:label="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of subjects enrolled in the SEAL study</link:label>
    <link:label id="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled_label_en-US" xlink:label="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Research Study, Number of Participants Enrolled</link:label>
    <link:label id="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled_documentation_en-US" xlink:label="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Research Study, Number of Participants Enrolled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled" xlink:href="ck0001824293-20220331.xsd#ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled" xlink:to="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_49a86ee5-b04c-4fc8-b0cb-95cb873085b9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of finance lease liability</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5e4932c9-8725-47cf-8e74-432db46917b8_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_d2237320-faca-4a4c-8e0c-e2e3a0830cf2_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_d6ea1a35-d491-404e-ac82-5ba704aa7e51_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c95189ef-93ce-4251-a589-ddc3e88f9b70_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross_67dc65d0-78fb-4c2e-b0e4-53de9022873e_terseLabel_en-US" xlink:label="lab_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from stock offering</link:label>
    <link:label id="lab_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross_label_en-US" xlink:label="lab_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering, Gross</link:label>
    <link:label id="lab_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross_documentation_en-US" xlink:label="lab_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:href="ck0001824293-20220331.xsd#ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:to="lab_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_e9073236-c821-4f06-b014-42747432a809_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of common stock, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_eddd147d-8473-4ee7-9248-da4e11bb1dc1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b5374cdb-aefe-444d-95d1-d58c6348d259_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_9273b72a-e463-4f24-85eb-f3bcb3fd991d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_bceb99ce-842e-44ba-9499-5694192a021c_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_a762f81a-4184-453b-b2ca-d05b13c45d71_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_0f69a386-1734-4bba-aa34-4c3a33bb84ba_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs, discounts and commissions</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_label_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs, Discounts And Commissions</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs, Discounts And Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions" xlink:href="ck0001824293-20220331.xsd#ck0001824293_StockIssuanceCostsDiscountsAndCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions" xlink:to="lab_ck0001824293_StockIssuanceCostsDiscountsAndCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_7417b141-804e-40b2-893a-22389e70e9d2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_9ddfd8d0-810f-4b84-9617-5f98cde3b3ba_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_b56e443c-f6b0-4824-ba2d-07267ca359e2_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dcf1ba68-c1ab-43bb-aa2f-fe1f886f45be_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_dc42adc5-7477-4850-832c-f847e959eb27_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of common stock, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_c7c39837-3ab9-41ff-a510-188345e794f5_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_label_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Costs, Current</link:label>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research and Development Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:href="ck0001824293-20220331.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_3244a660-c7b8-4a00-8bc4-756b89f231b1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_8bb1532d-116e-4901-b279-312cbb79c02e_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d0e6e24d-cd43-4954-b11a-559de5d53622_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_e2fc0f0a-8b83-4d83-b4e3-bec05348cccd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b17d04cf-4cf9-4b90-909c-8b19352ef76a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_fd22a33a-71e9-4337-ac8f-39cb54c8fb9e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_31867bef-33ba-43c4-a8b2-362e7dae4765_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for convertible notes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_86611f43-7859-4121-be5d-0c5fadaf8f00_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_d767b09f-290a-4fba-a00e-7d1ef34d795f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis_2e80ba6c-2398-46de-9daf-a34412b11156_terseLabel_en-US" xlink:label="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of subjects included in the final SEAL study analysis</link:label>
    <link:label id="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis_label_en-US" xlink:label="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Research Study, Number of Participants, Included in Final Study Analysis</link:label>
    <link:label id="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis_documentation_en-US" xlink:label="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Research Study, Number of Participants, Included in Final Study Analysis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis" xlink:href="ck0001824293-20220331.xsd#ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis" xlink:to="lab_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_283083f9-d6e3-42cc-a604-88dcf8078f01_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashExpense_7a28e663-c4e5-434b-bfa5-c0002bbea095_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest, depreciation and other expense</link:label>
    <link:label id="lab_us-gaap_OtherNoncashExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashExpense" xlink:to="lab_us-gaap_OtherNoncashExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_78c5e986-d210-4397-9d0d-2b575f77ee8d_verboseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional offering expense</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_label_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs, Offering Expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Costs, Offering Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:href="ck0001824293-20220331.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:to="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d3890d50-e7cd-4f83-af60-edc7bda0c9c6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_6f430f62-e351-4dfc-a7e0-2af437ed00a9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from common stock, net of offering expenses</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_91ea440a-da68-40bc-9503-3e53323ffd34_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_f1d17617-b49c-4742-b838-bb322a2a61dc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from convertible notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f9821461-1a51-4cbd-bc02-3ddcf706891d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_886224c8-d301-4e78-a321-2738eceaff57_terseLabel_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIQUIDITY</link:label>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_label_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_96738289-0d14-4355-abe4-89c9480f9294_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9e28fcce-3d07-44d7-bb36-d366f1e156dd_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_cb3ddb06-a4c7-4c8b-9f63-731f33f982d1_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d3e7e976-5943-4e94-af3d-4314fd70901d_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_1a90a2b4-1be1-4c79-aaf1-50b3870c7118_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in 5-10 years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_d7071c5c-442b-4772-a89c-3f2fa570e06a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PaycheckProtectionProgramCARESActMember_4830928e-84a7-48f3-967c-67337d3fabff_terseLabel_en-US" xlink:label="lab_ck0001824293_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act</link:label>
    <link:label id="lab_ck0001824293_PaycheckProtectionProgramCARESActMember_label_en-US" xlink:label="lab_ck0001824293_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act [Member]</link:label>
    <link:label id="lab_ck0001824293_PaycheckProtectionProgramCARESActMember_documentation_en-US" xlink:label="lab_ck0001824293_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaycheckProtectionProgramCARESActMember" xlink:href="ck0001824293-20220331.xsd#ck0001824293_PaycheckProtectionProgramCARESActMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PaycheckProtectionProgramCARESActMember" xlink:to="lab_ck0001824293_PaycheckProtectionProgramCARESActMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_19bb0988-6467-48f0-92b1-28ea86bd1925_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_label_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued General and Administrative Expenses, Current</link:label>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_documentation_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued General and Administrative Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:href="ck0001824293-20220331.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:to="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9369f477-05bf-4258-a23d-23af843372e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_4f3103c3-208b-4731-92f9-47c796aacf9b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_0b29a983-6ad2-4eb2-bab3-1aa0e34fd217_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_7077f161-8f62-42ac-badb-22c48d65be39_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, maturity</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e4031851-76e0-4189-acb1-c8a0e1d301d2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_7eb85345-81d2-4dad-a328-9361bf935337_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after 10 years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_1c91c115-0c85-4e2e-ae84-f410fde20b09_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_b81ee367-02cc-4bdc-98aa-fafc00687eb0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_6d72fec3-1548-4a05-9b9f-b10a4933d62a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_b72aae5b-f8d9-4c77-987d-102b64a8b81b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_e527faac-b22e-48b7-9c8b-30a347ac68d0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for IPO, net of issuance expenses</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_d44c4653-684d-4315-8040-37dedd7290c0_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f5a597ee-487e-4f6a-85c3-68625d0ca584_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_53a0e77b-c06f-440a-a390-3a9f758fd259_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPP NOTE AND CONVERTIBLE NOTES</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0e15ef12-be6d-4196-b7cb-bdd5751d95d0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Ending Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ef323eac-e349-4102-93bf-db7e3bf910f7_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_525aeca2-6ef4-4bdf-b1d7-d952431935da_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_92292eee-5cea-44ea-bf3a-b7c97791620d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_57f5882d-1e9b-402d-90bf-11c54dbd6d97_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cebf69dd-e0ea-4c48-98c2-bbc1c66f9630_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning Balance (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_67fa9d9c-4c87-4220-b2fe-c6de1631d48f_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending Balance (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_793cc600-ddf8-4c59-a9d9-98da628dfa01_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8a5a1ec1-1f62-46d6-a037-a96796390e92_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for IPO, net of issuance expenses (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_b682fac3-8bd8-44af-8402-3933cdf7c001_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_dddde4d8-35fe-450a-bd97-af587c83daab_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Beginning Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8dea4037-d7fb-49b8-a277-5c67a95436a4_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Ending Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_332d64ec-8147-4919-b5f1-37769b9f6f4f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_ebe3ce0e-bf64-4d79-8cf3-f9d1888c5e7c_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_20d1f1a4-1f24-41cb-a048-149a4f1cfefd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation, weighted average amortization period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2f51aa30-233b-43b1-b7bc-0967817501e5_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_9872e9c6-05f0-4172-907f-0212f0b6c81e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 10)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_21ff6513-b61a-469f-ba83-523ae15d9f89_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_30bc7183-9aa3-4270-8802-01baa2bbdc38_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ff18f73d-8919-41d4-95c5-f52661274463_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_885ea5df-659f-4378-9779-94d95c9a37a4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Balance Ending (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_7f315ea7-9cf9-4d1e-ae84-c23955f960c2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of finance lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_91dd485f-1792-45bb-81be-8c0f0ec3fe6f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_408dde4e-482f-412c-b800-22d0117c999d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ForgivenessOfDebtInstrument_488de3b2-c8c6-439e-8b56-15ae41ee6c54_negatedLabel_en-US" xlink:label="lab_ck0001824293_ForgivenessOfDebtInstrument" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness of PPP note</link:label>
    <link:label id="lab_ck0001824293_ForgivenessOfDebtInstrument_f95921ef-9b9d-493e-917e-03a3341b8e22_terseLabel_en-US" xlink:label="lab_ck0001824293_ForgivenessOfDebtInstrument" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness of PPP note</link:label>
    <link:label id="lab_ck0001824293_ForgivenessOfDebtInstrument_label_en-US" xlink:label="lab_ck0001824293_ForgivenessOfDebtInstrument" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness Of Debt Instrument</link:label>
    <link:label id="lab_ck0001824293_ForgivenessOfDebtInstrument_documentation_en-US" xlink:label="lab_ck0001824293_ForgivenessOfDebtInstrument" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgiveness Of Debt Instrument</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ForgivenessOfDebtInstrument" xlink:href="ck0001824293-20220331.xsd#ck0001824293_ForgivenessOfDebtInstrument"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ForgivenessOfDebtInstrument" xlink:to="lab_ck0001824293_ForgivenessOfDebtInstrument" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4380dbbc-25e0-44c8-b31f-80ffd6683ce9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_8b485e1a-368f-49d9-ab59-5afcc28f3730_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of marketable securities premiums</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_fc3c7464-4edc-4acf-8b69-f96162f27206_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3af8404d-15c1-43c0-9d46-a6c7f51cc5a0_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a1b9468b-86d1-43cd-a120-0213df6a5e7e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_d1212502-5bb7-4239-b5bc-f4c4e32f457f_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_74cd6f10-d59f-4591-9b20-2634c24e83cb_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_431203ab-af45-43c2-955c-85827f06f236_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e7669fe2-3106-4ea0-92b1-3517c9067419_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtInstrumentPaymentTerm_e1816980-2df8-4d13-9c42-b26e56ba9de2_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtInstrumentPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, payment term</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentPaymentTerm_label_en-US" xlink:label="lab_ck0001824293_DebtInstrumentPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Term</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentPaymentTerm_documentation_en-US" xlink:label="lab_ck0001824293_DebtInstrumentPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Payment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentPaymentTerm" xlink:href="ck0001824293-20220331.xsd#ck0001824293_DebtInstrumentPaymentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtInstrumentPaymentTerm" xlink:to="lab_ck0001824293_DebtInstrumentPaymentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_b3f12bae-9263-4395-a080-a4d1217636bb_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_7eac1770-e435-4afd-af63-4b7d3b8d038c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_018578c4-7fa6-46ef-a043-f413c82d04e8_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2e5ba47e-40e2-4cc5-89a3-8041043c767e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_5b930a56-9cbc-45f2-97cb-f19b3a2fa97f_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8a22e866-cc2c-4542-a3a9-e97fd363ca45_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8766b053-f479-4bc1-b0a3-824236a33930_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_505c8994-21c1-47eb-946d-aa530aa6d3c2_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_6b912429-1fb8-4016-8c89-b7c1cd80de03_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b055c783-39bb-4ebd-8adf-6ec6425e6ab1_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fa664d03-9335-4522-b191-7f02fe5d4d5b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenue-related party</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_3b002497-7212-4b25-a105-34abf02f6d39_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriters' Allotment</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_9cc495c4-184a-413d-a1c9-304e3e3240f5_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and marketable securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_fa5b7103-fa6c-41d1-ab01-d3d9ed3009c6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_39d696d5-1035-405c-b357-b8fbd993a5f5_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9916e7ad-14f4-43fa-b831-7409d11bddb1_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_13123aaf-3311-4df6-ad3a-cd3eb88dac24_terseLabel_en-US" xlink:label="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salmon Pharma, Affiliate of Medice and David Baker, CEO</link:label>
    <link:label id="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_label_en-US" xlink:label="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliate of Medice and David Baker, CEO [Member]</link:label>
    <link:label id="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_documentation_en-US" xlink:label="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliate of Medice and David Baker, CEO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" xlink:href="ck0001824293-20220331.xsd#ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" xlink:to="lab_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_dcfa6bd5-666f-448f-98bf-4e388747c5af_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for services</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_aa0c9d04-15d6-464b-a36f-8d64cf5b6ece_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_792ca0aa-aa7d-4fed-b1cf-7807eefb8391_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_cc42e218-2f7f-4a5b-9a54-004ca175cce0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8aba6073-962e-46b6-bda9-93a12259feb7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6ae2b092-1222-48a7-b309-0cc479a20b9a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_b2785999-53dc-4b2a-95c0-18b90655d717_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bc140333-a424-43a4-89ec-7c7a49ad72bf_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_5c0784ed-90c0-406f-91b4-eff881466d85_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_9b2a36a1-ac7e-4914-b73d-82d4c78243bb_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in 1-5 years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_25ce1320-05f3-48fc-aeee-f947586b1373_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_01de5a6e-e017-415f-898d-00574ecd41e7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_3b6a3f6d-1ca4-4da0-848a-185046cb3330_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_71ea2624-de06-49f3-ab9d-9888efb093bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_8e9e4576-f8f9-4e0c-b802-32655ab0aead_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional&#160;Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7eed25ba-ab19-4212-b028-29071d27de0b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c00faee4-1fe2-497c-8dcf-fbe15bb89eea_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_e0eeb221-e85c-4691-9276-11e6936fe294_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_a7a7f5e7-0b23-40c5-92ca-bcb67b7028bc_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revaluation of derivative liability</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_cb764e3c-d4cc-42c2-9478-d96af37d6b96_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revaluation of derivative liability</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_123e5827-1bce-4109-b10a-1dcc0c7fe625_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_983364bd-6a20-4e0e-bda7-a339f5424df5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_6275becd-0d8c-463a-81af-f5017c9d99ed_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_c51b571f-9222-4a05-b985-a18bd034e2f7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fb701fac-8b54-4a8e-bf85-09190c747276_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_6b4fdc60-5526-43cb-b2ab-941fbfb9211d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_7839d148-26c1-4758-a7a1-33c2c77cddc4_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7e1b7d1d-2da0-4614-990f-779f49d95f0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8e4dca2d-8d73-4daf-aad7-262a8a8657b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c2d50908-feb1-442f-bfdb-843c03258d54_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_03ce1ad5-966d-452d-9061-15e96e104f25_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f5eabc28-6938-48ff-8cfd-60d602c5eb91_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_cb3dc57e-1b99-4aab-b7b5-a4f6c7e59942_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_cba1931b-5a42-4b3a-8165-f1129d3064cf_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_1d87edbf-7be4-4b7a-8f67-5f2c3b634fb2_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_9421afbd-b0fe-45c8-8c85-e82e62cd7f32_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_aa862f60-ce80-4d00-be20-8139a842d129_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for services (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_9c700109-72d1-49e3-916e-2c9840c6d35f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_ace33042-9fe7-4416-a858-4de49a4ffaf1_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_af66726d-267a-4074-a888-c53ddd88bf96_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e3ef35d9-bcca-4c0e-9f1e-9d2aee0c8d17_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_a85a6a15-d464-4fe1-8283-3a5bc7943155_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_9ff1b0d6-03a6-4a33-b90c-200b1e623ef0_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1fd89ebe-741a-4470-b30b-ceebb9f535e6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in 1 year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_38331401-1d3c-482c-a261-fb8e0650ae6c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible notes to common stock</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_8474a911-86b1-4777-a12c-2e7d60ea7985_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_fcfc2013-f057-4c43-977d-ef397dc1baad_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_8aed7162-e318-4398-9805-32c4dba4e60e_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>ck0001824293-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:817af30f-ec0d-4f27-a9e3-e41325810995,g:c8a142b5-1941-49b7-ac1b-a5b54ada4279-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/Cover" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f659990a-9a4f-4d6c-b857-dbe0154b5371" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_DocumentType_f659990a-9a4f-4d6c-b857-dbe0154b5371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_c4fe99c6-c51d-450f-bd02-8003d6bba5d8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_DocumentQuarterlyReport_c4fe99c6-c51d-450f-bd02-8003d6bba5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ec48eda0-5fd0-4e9f-a49c-013ac87569ff" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_DocumentPeriodEndDate_ec48eda0-5fd0-4e9f-a49c-013ac87569ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_d1c9b909-c31e-42a9-84a5-2dddf32c7192" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_DocumentTransitionReport_d1c9b909-c31e-42a9-84a5-2dddf32c7192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_0378f49b-23da-4e48-84c3-0b2c3713d87d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_EntityFileNumber_0378f49b-23da-4e48-84c3-0b2c3713d87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1c7e0375-5cfc-4fb5-aa65-6d3bff6feda1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_EntityRegistrantName_1c7e0375-5cfc-4fb5-aa65-6d3bff6feda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_460751c3-07d2-4b84-90ac-4d41b658eedf" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_EntityIncorporationStateCountryCode_460751c3-07d2-4b84-90ac-4d41b658eedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_74ae6f6d-3e7a-46e2-b3c5-5a7faaf15988" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_EntityTaxIdentificationNumber_74ae6f6d-3e7a-46e2-b3c5-5a7faaf15988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_46b3ce49-616b-4289-990e-32709eaebd9c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_EntityAddressAddressLine1_46b3ce49-616b-4289-990e-32709eaebd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_ace56a0f-56d5-4d1f-ae38-47050ef8c051" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_EntityAddressAddressLine2_ace56a0f-56d5-4d1f-ae38-47050ef8c051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_209efea4-ebbc-4d2e-829b-5f1213c3acfe" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_EntityAddressCityOrTown_209efea4-ebbc-4d2e-829b-5f1213c3acfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_3ab43c4f-5643-439b-9806-eb47ef7c55d3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_EntityAddressStateOrProvince_3ab43c4f-5643-439b-9806-eb47ef7c55d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_67452275-a429-47da-a68d-df28ad8a72f8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_EntityAddressPostalZipCode_67452275-a429-47da-a68d-df28ad8a72f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_bdca83d4-b7a7-4581-82fe-e9531bfbd494" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_CityAreaCode_bdca83d4-b7a7-4581-82fe-e9531bfbd494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b98c6d9f-bb13-4d2a-8d7e-947c7fabb491" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_LocalPhoneNumber_b98c6d9f-bb13-4d2a-8d7e-947c7fabb491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_219a2ea6-b98d-4113-9b75-19f4fd3d05b3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_Security12bTitle_219a2ea6-b98d-4113-9b75-19f4fd3d05b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_bb2a5f2d-3577-40f5-a736-c294d3f60a99" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_TradingSymbol_bb2a5f2d-3577-40f5-a736-c294d3f60a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c58687d5-00f4-41b3-ad97-ef77db1e3619" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_SecurityExchangeName_c58687d5-00f4-41b3-ad97-ef77db1e3619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_b10dc8dc-30f1-4adf-a529-064809f7e7fb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_EntityCurrentReportingStatus_b10dc8dc-30f1-4adf-a529-064809f7e7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_dde7a87f-5b00-4ec7-9cd2-bf79835d3382" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_EntityInteractiveDataCurrent_dde7a87f-5b00-4ec7-9cd2-bf79835d3382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d1b1580f-9823-4d64-83c4-c533bb07c26b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_EntityFilerCategory_d1b1580f-9823-4d64-83c4-c533bb07c26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_9c9cf3ab-e922-4e1c-9d1b-e07c4630145f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_EntitySmallBusiness_9c9cf3ab-e922-4e1c-9d1b-e07c4630145f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_9bcbe456-e917-4a6d-bb99-e4de4bdd81a3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_EntityEmergingGrowthCompany_9bcbe456-e917-4a6d-bb99-e4de4bdd81a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_5a58189e-bec3-4c28-a549-544f3a82c811" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_EntityExTransitionPeriod_5a58189e-bec3-4c28-a549-544f3a82c811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_577231de-4d0f-4c43-afad-22bcd428d075" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_EntityShellCompany_577231de-4d0f-4c43-afad-22bcd428d075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_53dad52a-392d-4b6b-8eb6-de098cdef3b7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_53dad52a-392d-4b6b-8eb6-de098cdef3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a1536d0f-4680-414d-8411-be1cd26ef1a9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_EntityCentralIndexKey_a1536d0f-4680-414d-8411-be1cd26ef1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_44cc2dbf-7520-433d-a35e-de18cf5286d0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_CurrentFiscalYearEndDate_44cc2dbf-7520-433d-a35e-de18cf5286d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_88957d4b-bca5-4463-8852-9f06c52e8389" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_DocumentFiscalYearFocus_88957d4b-bca5-4463-8852-9f06c52e8389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_904ded3b-2666-433b-a2aa-77cf5e29898d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_DocumentFiscalPeriodFocus_904ded3b-2666-433b-a2aa-77cf5e29898d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e36e8dae-0549-4003-9057-b2015398a233" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f32d82ea-600c-458b-a3b0-f5d9f5dd547c" xlink:to="loc_dei_AmendmentFlag_e36e8dae-0549-4003-9057-b2015398a233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BalanceSheets" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#BalanceSheets"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_40a1bdc4-a7c5-451a-aa76-65cf6821f56c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5930e69e-0b68-44b6-aa9e-63ec80859fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_40a1bdc4-a7c5-451a-aa76-65cf6821f56c" xlink:to="loc_us-gaap_AssetsAbstract_5930e69e-0b68-44b6-aa9e-63ec80859fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3aea0217-2f21-4245-a87e-b9a517018fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5930e69e-0b68-44b6-aa9e-63ec80859fd3" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3aea0217-2f21-4245-a87e-b9a517018fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_18d3b010-3fd5-4498-aedc-b102dd71c3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3aea0217-2f21-4245-a87e-b9a517018fc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_18d3b010-3fd5-4498-aedc-b102dd71c3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_65cd2b04-129f-4a3b-80b6-572a0e9191a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3aea0217-2f21-4245-a87e-b9a517018fc7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_65cd2b04-129f-4a3b-80b6-572a0e9191a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dcda8b9b-d055-48d9-8987-d0c9dbd20632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3aea0217-2f21-4245-a87e-b9a517018fc7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_dcda8b9b-d055-48d9-8987-d0c9dbd20632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1f62ccb0-b861-49a6-8a49-bc35c5330ade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3aea0217-2f21-4245-a87e-b9a517018fc7" xlink:to="loc_us-gaap_AssetsCurrent_1f62ccb0-b861-49a6-8a49-bc35c5330ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_80f82c99-4ca1-416d-a2b7-ef46db57812e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5930e69e-0b68-44b6-aa9e-63ec80859fd3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_80f82c99-4ca1-416d-a2b7-ef46db57812e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5770c590-e5c3-4a05-8be4-6396938bad58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5930e69e-0b68-44b6-aa9e-63ec80859fd3" xlink:to="loc_us-gaap_Assets_5770c590-e5c3-4a05-8be4-6396938bad58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8bb58849-b03c-4760-8bc5-5c1546f5a082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_40a1bdc4-a7c5-451a-aa76-65cf6821f56c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8bb58849-b03c-4760-8bc5-5c1546f5a082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_d31e298e-f396-4ba4-9445-7fe85bb23ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8bb58849-b03c-4760-8bc5-5c1546f5a082" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_d31e298e-f396-4ba4-9445-7fe85bb23ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2871e787-ea01-4493-851f-9ae3231dbe31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d31e298e-f396-4ba4-9445-7fe85bb23ec7" xlink:to="loc_us-gaap_AccountsPayableCurrent_2871e787-ea01-4493-851f-9ae3231dbe31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_66c18bdf-1ecf-40b6-b951-51d6b0235bff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d31e298e-f396-4ba4-9445-7fe85bb23ec7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_66c18bdf-1ecf-40b6-b951-51d6b0235bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_f12f2ea6-e717-474b-a3f4-5e229b5cea03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d31e298e-f396-4ba4-9445-7fe85bb23ec7" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_f12f2ea6-e717-474b-a3f4-5e229b5cea03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9784568c-551b-40c9-b99e-3f654970ce9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d31e298e-f396-4ba4-9445-7fe85bb23ec7" xlink:to="loc_us-gaap_LiabilitiesCurrent_9784568c-551b-40c9-b99e-3f654970ce9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b81e58fb-4341-4bf9-a189-a3ee79966deb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8bb58849-b03c-4760-8bc5-5c1546f5a082" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b81e58fb-4341-4bf9-a189-a3ee79966deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f1bbb452-3e8e-4943-9081-57680fe79b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8bb58849-b03c-4760-8bc5-5c1546f5a082" xlink:to="loc_us-gaap_Liabilities_f1bbb452-3e8e-4943-9081-57680fe79b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_cf803702-ff1d-4599-aadc-a40e4aaa732c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8bb58849-b03c-4760-8bc5-5c1546f5a082" xlink:to="loc_us-gaap_CommitmentsAndContingencies_cf803702-ff1d-4599-aadc-a40e4aaa732c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_87f61676-8556-4bba-9b64-63aae12dd7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8bb58849-b03c-4760-8bc5-5c1546f5a082" xlink:to="loc_us-gaap_StockholdersEquityAbstract_87f61676-8556-4bba-9b64-63aae12dd7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_283b631c-ba8d-493b-a8d5-6fe81d0fe2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_87f61676-8556-4bba-9b64-63aae12dd7bf" xlink:to="loc_us-gaap_CommonStockValueOutstanding_283b631c-ba8d-493b-a8d5-6fe81d0fe2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_09bb7335-5271-4ec8-9814-0ec1c5d5e157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_87f61676-8556-4bba-9b64-63aae12dd7bf" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_09bb7335-5271-4ec8-9814-0ec1c5d5e157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d86ba6a0-f97d-4f80-80b6-7a7bb91a0aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_87f61676-8556-4bba-9b64-63aae12dd7bf" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d86ba6a0-f97d-4f80-80b6-7a7bb91a0aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ecc6c641-033c-4c1a-b06a-489d52b5e723" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_87f61676-8556-4bba-9b64-63aae12dd7bf" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ecc6c641-033c-4c1a-b06a-489d52b5e723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8f33b696-e671-4151-9385-6dacfca6e35d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_87f61676-8556-4bba-9b64-63aae12dd7bf" xlink:to="loc_us-gaap_StockholdersEquity_8f33b696-e671-4151-9385-6dacfca6e35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_af92b2c1-bf00-4ce8-8735-aad43f50e78c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_87f61676-8556-4bba-9b64-63aae12dd7bf" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_af92b2c1-bf00-4ce8-8735-aad43f50e78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#BalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3d9b1462-8a91-4572-b714-8aec1948f316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_01227f3b-034b-440e-8ba7-6661a970e004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3d9b1462-8a91-4572-b714-8aec1948f316" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_01227f3b-034b-440e-8ba7-6661a970e004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_09083e4d-c586-44b3-ae2d-e95f0f0f485b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3d9b1462-8a91-4572-b714-8aec1948f316" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_09083e4d-c586-44b3-ae2d-e95f0f0f485b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a55a02de-9d38-4195-be68-f11a378e5ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3d9b1462-8a91-4572-b714-8aec1948f316" xlink:to="loc_us-gaap_CommonStockSharesIssued_a55a02de-9d38-4195-be68-f11a378e5ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a4de9320-d608-44d0-9849-eafeb2d98728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3d9b1462-8a91-4572-b714-8aec1948f316" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a4de9320-d608-44d0-9849-eafeb2d98728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#StatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_e0d78ad6-b37d-4de2-9dd9-80e121ec37d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_90a1f4c0-c524-4015-b78a-17f3dfcd5948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0d78ad6-b37d-4de2-9dd9-80e121ec37d6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_90a1f4c0-c524-4015-b78a-17f3dfcd5948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_120293c5-0988-45fd-8dfb-c764426f02d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0d78ad6-b37d-4de2-9dd9-80e121ec37d6" xlink:to="loc_us-gaap_OperatingExpensesAbstract_120293c5-0988-45fd-8dfb-c764426f02d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4cf2388d-40bf-4077-99de-6c0ff2b105ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_120293c5-0988-45fd-8dfb-c764426f02d1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4cf2388d-40bf-4077-99de-6c0ff2b105ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_56fde214-8bbc-4368-b739-f5499daf6a86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_120293c5-0988-45fd-8dfb-c764426f02d1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_56fde214-8bbc-4368-b739-f5499daf6a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5e91e0cf-6f51-452c-a009-0aa4e7e5ad50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_120293c5-0988-45fd-8dfb-c764426f02d1" xlink:to="loc_us-gaap_OperatingExpenses_5e91e0cf-6f51-452c-a009-0aa4e7e5ad50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_47efd3e8-d1f0-4f4b-b864-a54bb94120c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0d78ad6-b37d-4de2-9dd9-80e121ec37d6" xlink:to="loc_us-gaap_OperatingIncomeLoss_47efd3e8-d1f0-4f4b-b864-a54bb94120c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncome_e321cd3e-2201-44ca-a86f-5bd0b2dc558f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0d78ad6-b37d-4de2-9dd9-80e121ec37d6" xlink:to="loc_us-gaap_OtherNonoperatingIncome_e321cd3e-2201-44ca-a86f-5bd0b2dc558f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_4751bf65-a550-4750-bb4f-481c551b5efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0d78ad6-b37d-4de2-9dd9-80e121ec37d6" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_4751bf65-a550-4750-bb4f-481c551b5efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_b861744a-e2b0-41e1-a651-7708d1814b95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0d78ad6-b37d-4de2-9dd9-80e121ec37d6" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_b861744a-e2b0-41e1-a651-7708d1814b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ce6739ab-4a5b-4816-b92b-7d57b7afc8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0d78ad6-b37d-4de2-9dd9-80e121ec37d6" xlink:to="loc_us-gaap_NetIncomeLoss_ce6739ab-4a5b-4816-b92b-7d57b7afc8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_aa153ddd-d23e-4105-b444-5f528cef11b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0d78ad6-b37d-4de2-9dd9-80e121ec37d6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_aa153ddd-d23e-4105-b444-5f528cef11b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_12f0b099-8869-4d47-ba5b-656df6fd7fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_aa153ddd-d23e-4105-b444-5f528cef11b2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_12f0b099-8869-4d47-ba5b-656df6fd7fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b0e36e0a-d6cc-4bb3-9732-41fc3b25c18f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0d78ad6-b37d-4de2-9dd9-80e121ec37d6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_b0e36e0a-d6cc-4bb3-9732-41fc3b25c18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6ff66727-9af8-4fdf-943d-8d02f54bb81a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0d78ad6-b37d-4de2-9dd9-80e121ec37d6" xlink:to="loc_us-gaap_EarningsPerShareBasic_6ff66727-9af8-4fdf-943d-8d02f54bb81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_760196be-8e33-4c70-8503-23349a624a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0d78ad6-b37d-4de2-9dd9-80e121ec37d6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_760196be-8e33-4c70-8503-23349a624a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6e7de696-14f7-488f-80b0-9f9844bfce72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0d78ad6-b37d-4de2-9dd9-80e121ec37d6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6e7de696-14f7-488f-80b0-9f9844bfce72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fb810ea1-25a3-4b94-87ef-90f9b098bace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e0d78ad6-b37d-4de2-9dd9-80e121ec37d6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fb810ea1-25a3-4b94-87ef-90f9b098bace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#StatementsofChangesinStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_4585df47-d359-490f-9b7c-e5771b1ce378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f5833732-dd8e-488e-b9e4-7210ea0b47e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_4585df47-d359-490f-9b7c-e5771b1ce378" xlink:to="loc_us-gaap_StatementTable_f5833732-dd8e-488e-b9e4-7210ea0b47e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_24e5edcb-2e9d-401b-9196-d43cd2523bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f5833732-dd8e-488e-b9e4-7210ea0b47e1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_24e5edcb-2e9d-401b-9196-d43cd2523bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_01999cb2-92cb-497d-8d53-3214d0c3f79a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_24e5edcb-2e9d-401b-9196-d43cd2523bbd" xlink:to="loc_us-gaap_EquityComponentDomain_01999cb2-92cb-497d-8d53-3214d0c3f79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b036fb53-e5ba-4b2f-8f47-2002ad7d1c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_01999cb2-92cb-497d-8d53-3214d0c3f79a" xlink:to="loc_us-gaap_CommonStockMember_b036fb53-e5ba-4b2f-8f47-2002ad7d1c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_41e26966-6eee-4e91-a7e2-8224361c899e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_01999cb2-92cb-497d-8d53-3214d0c3f79a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_41e26966-6eee-4e91-a7e2-8224361c899e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bd20f2dd-ba18-4d1b-9419-9184a3c8f641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_01999cb2-92cb-497d-8d53-3214d0c3f79a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bd20f2dd-ba18-4d1b-9419-9184a3c8f641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a82995ae-7503-4808-96a0-c0e8871b9b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_01999cb2-92cb-497d-8d53-3214d0c3f79a" xlink:to="loc_us-gaap_RetainedEarningsMember_a82995ae-7503-4808-96a0-c0e8871b9b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f5833732-dd8e-488e-b9e4-7210ea0b47e1" xlink:to="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_98aba0a2-9687-4e9d-82d8-6f0c0c65cebe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_98aba0a2-9687-4e9d-82d8-6f0c0c65cebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f8fb9d6e-9a15-43e8-ae7d-4a83e8182ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_StockholdersEquity_f8fb9d6e-9a15-43e8-ae7d-4a83e8182ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_efccf9fc-4944-4f62-a758-8cec1130a483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_efccf9fc-4944-4f62-a758-8cec1130a483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0165e129-c988-4ab2-9d39-183f368fad13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_0165e129-c988-4ab2-9d39-183f368fad13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e059e458-efdc-46e9-bf10-5f79ef6ca041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e059e458-efdc-46e9-bf10-5f79ef6ca041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fb202bbe-7a27-4aad-98b0-0ba48e54c536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_fb202bbe-7a27-4aad-98b0-0ba48e54c536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_5fd1cdf3-c331-48dc-a005-03053ca41901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_5fd1cdf3-c331-48dc-a005-03053ca41901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_d0208ca8-363e-4767-a1ad-58f7c734d6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_d0208ca8-363e-4767-a1ad-58f7c734d6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_8a3d331a-0a0e-48e1-979c-6327a7bf6f23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_8a3d331a-0a0e-48e1-979c-6327a7bf6f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b448ea94-ecaf-4b9c-b68b-3cb7b670d43f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b448ea94-ecaf-4b9c-b68b-3cb7b670d43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5e3c8ca0-28d5-43f7-8290-f2c7117ba5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5e3c8ca0-28d5-43f7-8290-f2c7117ba5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0d6545b5-f018-4793-a813-6c735f479c96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_NetIncomeLoss_0d6545b5-f018-4793-a813-6c735f479c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_11e3f00f-3a1c-4db2-ae7d-5d638b5aeb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_11e3f00f-3a1c-4db2-ae7d-5d638b5aeb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fb612243-b89c-4ac9-9307-3b294a4dda4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6954ad21-d5a4-40fc-9afc-9b00d8e65462" xlink:to="loc_us-gaap_StockholdersEquity_fb612243-b89c-4ac9-9307-3b294a4dda4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#StatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_d06335bc-d187-4896-9021-d4c79b23a184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_30d7457a-3c26-48dd-bd82-c7c248706217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d06335bc-d187-4896-9021-d4c79b23a184" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_30d7457a-3c26-48dd-bd82-c7c248706217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e2ac643d-77a5-43bf-aa5d-4dee92910c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_30d7457a-3c26-48dd-bd82-c7c248706217" xlink:to="loc_us-gaap_NetIncomeLoss_e2ac643d-77a5-43bf-aa5d-4dee92910c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e1f8ef5-0094-4c57-93e1-ef2b5d779756" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_30d7457a-3c26-48dd-bd82-c7c248706217" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e1f8ef5-0094-4c57-93e1-ef2b5d779756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_fe9e2359-86d0-442d-95e2-eb73bc316605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e1f8ef5-0094-4c57-93e1-ef2b5d779756" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_fe9e2359-86d0-442d-95e2-eb73bc316605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_557a4bca-8e71-473a-81be-92b008ca18fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e1f8ef5-0094-4c57-93e1-ef2b5d779756" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_557a4bca-8e71-473a-81be-92b008ca18fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_97fd2356-66d6-496e-82d5-4d4505c96a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e1f8ef5-0094-4c57-93e1-ef2b5d779756" xlink:to="loc_us-gaap_ShareBasedCompensation_97fd2356-66d6-496e-82d5-4d4505c96a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_85a2f8a4-b898-4393-a60e-fb7fb35869ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e1f8ef5-0094-4c57-93e1-ef2b5d779756" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_85a2f8a4-b898-4393-a60e-fb7fb35869ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ForgivenessOfDebtInstrument_0d10461a-ec51-4329-8af3-6da353622e8d" xlink:href="ck0001824293-20220331.xsd#ck0001824293_ForgivenessOfDebtInstrument"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e1f8ef5-0094-4c57-93e1-ef2b5d779756" xlink:to="loc_ck0001824293_ForgivenessOfDebtInstrument_0d10461a-ec51-4329-8af3-6da353622e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashExpense_92b7b608-41e8-43f2-8432-b355d4655a38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e1f8ef5-0094-4c57-93e1-ef2b5d779756" xlink:to="loc_us-gaap_OtherNoncashExpense_92b7b608-41e8-43f2-8432-b355d4655a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_422973f7-133f-4b6a-89f9-14af1b06cf9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e1f8ef5-0094-4c57-93e1-ef2b5d779756" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_422973f7-133f-4b6a-89f9-14af1b06cf9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_66f62f5e-4a94-4044-bb0c-d0c92e15118f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_422973f7-133f-4b6a-89f9-14af1b06cf9b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_66f62f5e-4a94-4044-bb0c-d0c92e15118f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5419b08b-ae0d-4300-a855-de69a83abfaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_422973f7-133f-4b6a-89f9-14af1b06cf9b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5419b08b-ae0d-4300-a855-de69a83abfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ccde16a1-f1f5-48f5-9c65-c404302a1ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_422973f7-133f-4b6a-89f9-14af1b06cf9b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ccde16a1-f1f5-48f5-9c65-c404302a1ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c6bbffa1-49f5-4879-8300-e528b0e63d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9e1f8ef5-0094-4c57-93e1-ef2b5d779756" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c6bbffa1-49f5-4879-8300-e528b0e63d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aad3501a-9602-440f-a3b6-6288ce3e2e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d06335bc-d187-4896-9021-d4c79b23a184" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aad3501a-9602-440f-a3b6-6288ce3e2e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_3bf948b6-9452-4409-a5ec-49965b64cd61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aad3501a-9602-440f-a3b6-6288ce3e2e48" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_3bf948b6-9452-4409-a5ec-49965b64cd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_96a6fe75-1021-43fe-a50c-aec4dfb7f3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_aad3501a-9602-440f-a3b6-6288ce3e2e48" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_96a6fe75-1021-43fe-a50c-aec4dfb7f3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ef81792d-f1e7-48da-848f-da8858074794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d06335bc-d187-4896-9021-d4c79b23a184" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ef81792d-f1e7-48da-848f-da8858074794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_f7cb7e0d-7e7d-44d2-a38d-7cfdebb1b73e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ef81792d-f1e7-48da-848f-da8858074794" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_f7cb7e0d-7e7d-44d2-a38d-7cfdebb1b73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_f75443d6-bc8a-48e7-9e62-aa236ccd4864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ef81792d-f1e7-48da-848f-da8858074794" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_f75443d6-bc8a-48e7-9e62-aa236ccd4864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_ca655768-9c0a-45a3-a84e-037d9d081bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ef81792d-f1e7-48da-848f-da8858074794" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_ca655768-9c0a-45a3-a84e-037d9d081bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e9358226-65af-411a-be7a-898cb3b011ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ef81792d-f1e7-48da-848f-da8858074794" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e9358226-65af-411a-be7a-898cb3b011ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ad05571c-5f43-4293-b982-65000facf2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d06335bc-d187-4896-9021-d4c79b23a184" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ad05571c-5f43-4293-b982-65000facf2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_999079bf-2d68-4604-b2d2-8968756e4099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d06335bc-d187-4896-9021-d4c79b23a184" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_999079bf-2d68-4604-b2d2-8968756e4099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_18be390a-a9db-4e52-8de2-4820434c1564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d06335bc-d187-4896-9021-d4c79b23a184" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_18be390a-a9db-4e52-8de2-4820434c1564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1e9deebd-e468-4be5-9ab1-67043bc2ee40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d06335bc-d187-4896-9021-d4c79b23a184" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1e9deebd-e468-4be5-9ab1-67043bc2ee40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_fd9697dd-eb00-4950-8f01-dd00a6b1d138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1e9deebd-e468-4be5-9ab1-67043bc2ee40" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_fd9697dd-eb00-4950-8f01-dd00a6b1d138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#ORGANIZATIONANDDESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83a498b6-5062-4216-bf3f-82c710331939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_f9e4875d-ff26-4aa2-81fb-c89aff6ae3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_83a498b6-5062-4216-bf3f-82c710331939" xlink:to="loc_us-gaap_NatureOfOperations_f9e4875d-ff26-4aa2-81fb-c89aff6ae3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8ed0013c-9692-4afb-85d2-8c641a860103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled_de29d82c-fda8-425f-89d9-2a9d85db8cac" xlink:href="ck0001824293-20220331.xsd#ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8ed0013c-9692-4afb-85d2-8c641a860103" xlink:to="loc_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled_de29d82c-fda8-425f-89d9-2a9d85db8cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy_e59876e0-0cb4-4627-95b3-7046dcf26055" xlink:href="ck0001824293-20220331.xsd#ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8ed0013c-9692-4afb-85d2-8c641a860103" xlink:to="loc_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy_e59876e0-0cb4-4627-95b3-7046dcf26055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis_ecd7634a-3c28-4d42-87b7-b50d1af0dcdf" xlink:href="ck0001824293-20220331.xsd#ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8ed0013c-9692-4afb-85d2-8c641a860103" xlink:to="loc_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis_ecd7634a-3c28-4d42-87b7-b50d1af0dcdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITY" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#LIQUIDITY"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5af19ab2-dc8f-4d46-87f5-9c133cdacdbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_f07ffed8-cfbb-4f5f-841c-43d578cd3952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5af19ab2-dc8f-4d46-87f5-9c133cdacdbe" xlink:to="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_f07ffed8-cfbb-4f5f-841c-43d578cd3952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#LIQUIDITYDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bc23de4d-fa12-4268-b341-0e477b597f91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3946ac2f-9199-43a5-85ff-87e004266de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bc23de4d-fa12-4268-b341-0e477b597f91" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3946ac2f-9199-43a5-85ff-87e004266de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_08420464-5ac5-45cb-b8ee-5bbabb8d1449" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3946ac2f-9199-43a5-85ff-87e004266de9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_08420464-5ac5-45cb-b8ee-5bbabb8d1449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_64e35a1b-74a7-47b1-a123-38a433cbb19d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_08420464-5ac5-45cb-b8ee-5bbabb8d1449" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_64e35a1b-74a7-47b1-a123-38a433cbb19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_eb9dfd9e-7afe-46b0-b652-251feb367391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_64e35a1b-74a7-47b1-a123-38a433cbb19d" xlink:to="loc_us-gaap_IPOMember_eb9dfd9e-7afe-46b0-b652-251feb367391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_73ac62ae-6dad-4ba1-946e-4478443f7032" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3946ac2f-9199-43a5-85ff-87e004266de9" xlink:to="loc_us-gaap_ClassOfStockLineItems_73ac62ae-6dad-4ba1-946e-4478443f7032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1f6cf96a-ed49-409e-ae14-ef316057d5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_73ac62ae-6dad-4ba1-946e-4478443f7032" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1f6cf96a-ed49-409e-ae14-ef316057d5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_4ef32b0c-8127-40a8-bb80-d8defad0029a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_73ac62ae-6dad-4ba1-946e-4478443f7032" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_4ef32b0c-8127-40a8-bb80-d8defad0029a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7fd26f41-525d-4aa7-a96a-a6404bde65c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_73ac62ae-6dad-4ba1-946e-4478443f7032" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7fd26f41-525d-4aa7-a96a-a6404bde65c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_f5bcd6bc-c001-473a-9125-9d52839438bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_73ac62ae-6dad-4ba1-946e-4478443f7032" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_f5bcd6bc-c001-473a-9125-9d52839438bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b9334638-ae20-40de-adea-efee8360163e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_12f0c83d-ff77-477b-8f50-18ae7dca0d28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b9334638-ae20-40de-adea-efee8360163e" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_12f0c83d-ff77-477b-8f50-18ae7dca0d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_02f4bfed-9c32-45ba-a8c1-2a5dc4d58735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_77b8c0e1-70cf-4a8f-8fb1-cd2c7124b5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_02f4bfed-9c32-45ba-a8c1-2a5dc4d58735" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_77b8c0e1-70cf-4a8f-8fb1-cd2c7124b5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_a3202c23-36eb-4e54-8365-88c51c134554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_02f4bfed-9c32-45ba-a8c1-2a5dc4d58735" xlink:to="loc_us-gaap_UseOfEstimates_a3202c23-36eb-4e54-8365-88c51c134554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_332b5094-685d-4b68-a970-d960c3cfdebc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_02f4bfed-9c32-45ba-a8c1-2a5dc4d58735" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_332b5094-685d-4b68-a970-d960c3cfdebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_9314f0a9-cb4d-4858-adc9-691dbe6c2bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_02f4bfed-9c32-45ba-a8c1-2a5dc4d58735" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_9314f0a9-cb4d-4858-adc9-691dbe6c2bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1948d7eb-8087-4d01-9b0a-356c3a10f6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_02f4bfed-9c32-45ba-a8c1-2a5dc4d58735" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1948d7eb-8087-4d01-9b0a-356c3a10f6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1d041190-49ec-4feb-8edf-6ad90ac753fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_324f6ba5-accf-4d22-9f35-cf336a339431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1d041190-49ec-4feb-8edf-6ad90ac753fa" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_324f6ba5-accf-4d22-9f35-cf336a339431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e9ea0c7f-3a20-4c90-8447-b7da52352957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_aba2339b-73eb-40b4-a4b8-82e89b487ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e9ea0c7f-3a20-4c90-8447-b7da52352957" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_aba2339b-73eb-40b4-a4b8-82e89b487ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d8f160bc-3eea-4418-94c3-29bee93710c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_bb20753c-6021-4f62-960d-377b3e5fda59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d8f160bc-3eea-4418-94c3-29bee93710c4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_bb20753c-6021-4f62-960d-377b3e5fda59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_420c8774-e189-43a5-8a12-24a87c42322e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d8f160bc-3eea-4418-94c3-29bee93710c4" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_420c8774-e189-43a5-8a12-24a87c42322e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4e5d64b2-3c4c-4d49-9541-684a0c7f2dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_966fa3e7-1873-4a0f-bbce-81fb31ad6c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4e5d64b2-3c4c-4d49-9541-684a0c7f2dc0" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_966fa3e7-1873-4a0f-bbce-81fb31ad6c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5140ac57-1172-49a0-94f1-15beab069074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_966fa3e7-1873-4a0f-bbce-81fb31ad6c08" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5140ac57-1172-49a0-94f1-15beab069074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5cbf464d-e3f4-4d43-94b3-c3ed4bcad03d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5140ac57-1172-49a0-94f1-15beab069074" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5cbf464d-e3f4-4d43-94b3-c3ed4bcad03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_075bdad9-afa3-41ac-b8e3-6de9c3f7e0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5cbf464d-e3f4-4d43-94b3-c3ed4bcad03d" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_075bdad9-afa3-41ac-b8e3-6de9c3f7e0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_a9bf03c7-8a6e-458a-8b95-3ba24263ae0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5cbf464d-e3f4-4d43-94b3-c3ed4bcad03d" xlink:to="loc_us-gaap_MunicipalBondsMember_a9bf03c7-8a6e-458a-8b95-3ba24263ae0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_7b5ad9af-394f-4675-ba54-360dbb11e282" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_966fa3e7-1873-4a0f-bbce-81fb31ad6c08" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_7b5ad9af-394f-4675-ba54-360dbb11e282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d1d3f8f1-7733-4af7-b15b-ff68ba0f9c78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_7b5ad9af-394f-4675-ba54-360dbb11e282" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d1d3f8f1-7733-4af7-b15b-ff68ba0f9c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_49f7b7ef-c396-4daa-93bd-605b8bdc97bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_7b5ad9af-394f-4675-ba54-360dbb11e282" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_49f7b7ef-c396-4daa-93bd-605b8bdc97bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_19543d50-cb7f-4ac8-bf61-bbe2af8eea59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_7b5ad9af-394f-4675-ba54-360dbb11e282" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_19543d50-cb7f-4ac8-bf61-bbe2af8eea59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_862819eb-766f-4032-8fec-06df309a178b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_7b5ad9af-394f-4675-ba54-360dbb11e282" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_862819eb-766f-4032-8fec-06df309a178b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ae3d090b-ffe0-4bcf-846f-43ce39e4977c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_f8124cdc-c645-4f3c-866a-df8c858721f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ae3d090b-ffe0-4bcf-846f-43ce39e4977c" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_f8124cdc-c645-4f3c-866a-df8c858721f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_fc2191ca-8808-402c-817e-0b32c4fd1679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ae3d090b-ffe0-4bcf-846f-43ce39e4977c" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_fc2191ca-8808-402c-817e-0b32c4fd1679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3375059f-2c05-426e-88f6-73e8ca930b13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_545e1041-36ac-4d83-b548-fecd347cb3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3375059f-2c05-426e-88f6-73e8ca930b13" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_545e1041-36ac-4d83-b548-fecd347cb3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_f7192e13-c7a7-4cd8-8c8f-5f0dca745256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3375059f-2c05-426e-88f6-73e8ca930b13" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_f7192e13-c7a7-4cd8-8c8f-5f0dca745256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_dc96a093-33c3-49f9-8d03-8bd1ce296063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3375059f-2c05-426e-88f6-73e8ca930b13" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_dc96a093-33c3-49f9-8d03-8bd1ce296063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_9ff4eaf8-7ebb-4442-805b-ff1dbb2dc103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3375059f-2c05-426e-88f6-73e8ca930b13" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_9ff4eaf8-7ebb-4442-805b-ff1dbb2dc103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b7a7442d-75ce-461a-b6e9-784951cb07ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3375059f-2c05-426e-88f6-73e8ca930b13" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b7a7442d-75ce-461a-b6e9-784951cb07ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#ACCRUEDEXPENSES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_cb7b9a89-0536-4984-8445-445e10b4bc19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_2fac80a3-97da-4fb3-aa6f-ceaa006430c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_cb7b9a89-0536-4984-8445-445e10b4bc19" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_2fac80a3-97da-4fb3-aa6f-ceaa006430c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#ACCRUEDEXPENSESTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_b0638e72-858c-4c4b-ba3a-4fe9f64fbea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d82879ce-50a3-4c2b-89ee-73a4018c2369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b0638e72-858c-4c4b-ba3a-4fe9f64fbea0" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d82879ce-50a3-4c2b-89ee-73a4018c2369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#ACCRUEDEXPENSESDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_28aebf60-584d-494e-a2a6-f5000e1c32eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_dac8deb4-1c14-4d31-9ba7-9c8a8ef6a0ea" xlink:href="ck0001824293-20220331.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_28aebf60-584d-494e-a2a6-f5000e1c32eb" xlink:to="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_dac8deb4-1c14-4d31-9ba7-9c8a8ef6a0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_920bb08c-9526-4d32-9f9c-29622b66d083" xlink:href="ck0001824293-20220331.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_28aebf60-584d-494e-a2a6-f5000e1c32eb" xlink:to="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_920bb08c-9526-4d32-9f9c-29622b66d083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c026415f-47d0-44dd-a9bc-d64651fb899e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_28aebf60-584d-494e-a2a6-f5000e1c32eb" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c026415f-47d0-44dd-a9bc-d64651fb899e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedLicensingFeesCurrent_0ec8fca1-83cb-4c35-ae60-13e4a072cac5" xlink:href="ck0001824293-20220331.xsd#ck0001824293_AccruedLicensingFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_28aebf60-584d-494e-a2a6-f5000e1c32eb" xlink:to="loc_ck0001824293_AccruedLicensingFeesCurrent_0ec8fca1-83cb-4c35-ae60-13e4a072cac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_be415725-f84b-4849-90f1-20d4adc4e16c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_28aebf60-584d-494e-a2a6-f5000e1c32eb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_be415725-f84b-4849-90f1-20d4adc4e16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#PPPNOTEANDCONVERTIBLENOTES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e34353c6-50c6-488c-9fc6-a82e44f2f732" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1bc35e38-fa3b-491d-89b3-76670f42d712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e34353c6-50c6-488c-9fc6-a82e44f2f732" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1bc35e38-fa3b-491d-89b3-76670f42d712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#PPPNOTEANDCONVERTIBLENOTESDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_363ce7ce-ca60-4232-a52a-16c1cb1a4568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_556b7bdb-e6d5-4748-bdf3-5186fc876e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_363ce7ce-ca60-4232-a52a-16c1cb1a4568" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_556b7bdb-e6d5-4748-bdf3-5186fc876e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a94f6a90-4087-4cf3-b973-3e3c96c5d23d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_556b7bdb-e6d5-4748-bdf3-5186fc876e7e" xlink:to="loc_us-gaap_DebtInstrumentAxis_a94f6a90-4087-4cf3-b973-3e3c96c5d23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d33e37c9-9a3b-4126-92d9-d29e92f15bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a94f6a90-4087-4cf3-b973-3e3c96c5d23d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d33e37c9-9a3b-4126-92d9-d29e92f15bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaycheckProtectionProgramCARESActMember_a5f632b6-a6cc-44ec-9041-fbc73ad8abda" xlink:href="ck0001824293-20220331.xsd#ck0001824293_PaycheckProtectionProgramCARESActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d33e37c9-9a3b-4126-92d9-d29e92f15bba" xlink:to="loc_ck0001824293_PaycheckProtectionProgramCARESActMember_a5f632b6-a6cc-44ec-9041-fbc73ad8abda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3657595a-b0ad-49c9-8817-e72573dbdd7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_556b7bdb-e6d5-4748-bdf3-5186fc876e7e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3657595a-b0ad-49c9-8817-e72573dbdd7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e10007e6-1c85-4eab-aa36-1c5dcd8b9d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3657595a-b0ad-49c9-8817-e72573dbdd7b" xlink:to="loc_us-gaap_RelatedPartyDomain_e10007e6-1c85-4eab-aa36-1c5dcd8b9d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_4c83d419-d695-49cc-8d97-1f4873320f97" xlink:href="ck0001824293-20220331.xsd#ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e10007e6-1c85-4eab-aa36-1c5dcd8b9d1f" xlink:to="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_4c83d419-d695-49cc-8d97-1f4873320f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_c1c6ed98-c47c-4f2e-b569-0d0b202e82c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_556b7bdb-e6d5-4748-bdf3-5186fc876e7e" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_c1c6ed98-c47c-4f2e-b569-0d0b202e82c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_ece72a60-aaf1-40cb-b7a5-9d748aacf337" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c1c6ed98-c47c-4f2e-b569-0d0b202e82c9" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_ece72a60-aaf1-40cb-b7a5-9d748aacf337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_ed6ae9b6-3f78-4342-bd2a-c1486a4ec36b" xlink:href="ck0001824293-20220331.xsd#ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_ece72a60-aaf1-40cb-b7a5-9d748aacf337" xlink:to="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_ed6ae9b6-3f78-4342-bd2a-c1486a4ec36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_bd2b0fef-2c7b-4abc-90db-f4252a12961d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_556b7bdb-e6d5-4748-bdf3-5186fc876e7e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_bd2b0fef-2c7b-4abc-90db-f4252a12961d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_191618c5-85eb-424b-bd05-8ea5e35360fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_bd2b0fef-2c7b-4abc-90db-f4252a12961d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_191618c5-85eb-424b-bd05-8ea5e35360fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_3cd63d1a-35be-49ed-8941-0961d562e48c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_191618c5-85eb-424b-bd05-8ea5e35360fe" xlink:to="loc_us-gaap_OverAllotmentOptionMember_3cd63d1a-35be-49ed-8941-0961d562e48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_a33c75c4-f471-4660-bfbe-0abdd7eda53f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_556b7bdb-e6d5-4748-bdf3-5186fc876e7e" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_a33c75c4-f471-4660-bfbe-0abdd7eda53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ab778386-d71a-4d59-ba01-ad62e8701830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a33c75c4-f471-4660-bfbe-0abdd7eda53f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ab778386-d71a-4d59-ba01-ad62e8701830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1cea8a46-f9f8-4f8a-b3de-05405f778b73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a33c75c4-f471-4660-bfbe-0abdd7eda53f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1cea8a46-f9f8-4f8a-b3de-05405f778b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_469b8a6b-9988-4603-8784-1685281e0ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a33c75c4-f471-4660-bfbe-0abdd7eda53f" xlink:to="loc_us-gaap_DebtInstrumentTerm_469b8a6b-9988-4603-8784-1685281e0ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentPaymentTerm_4ee7e4b4-0ca3-438c-895e-eeb09c2c14e9" xlink:href="ck0001824293-20220331.xsd#ck0001824293_DebtInstrumentPaymentTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a33c75c4-f471-4660-bfbe-0abdd7eda53f" xlink:to="loc_ck0001824293_DebtInstrumentPaymentTerm_4ee7e4b4-0ca3-438c-895e-eeb09c2c14e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ForgivenessOfDebtInstrument_807733bd-6f95-4fe1-a876-8a95ec1c3f2c" xlink:href="ck0001824293-20220331.xsd#ck0001824293_ForgivenessOfDebtInstrument"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a33c75c4-f471-4660-bfbe-0abdd7eda53f" xlink:to="loc_ck0001824293_ForgivenessOfDebtInstrument_807733bd-6f95-4fe1-a876-8a95ec1c3f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_8c781a7d-a27f-4c92-8ed8-d0d5b67e30f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a33c75c4-f471-4660-bfbe-0abdd7eda53f" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_8c781a7d-a27f-4c92-8ed8-d0d5b67e30f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_5a253ed2-a23f-4fec-8a92-fc2dd466596b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a33c75c4-f471-4660-bfbe-0abdd7eda53f" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_5a253ed2-a23f-4fec-8a92-fc2dd466596b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_0f17b612-b072-4542-9005-bc3c000dae60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a33c75c4-f471-4660-bfbe-0abdd7eda53f" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_0f17b612-b072-4542-9005-bc3c000dae60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_dd32762d-f142-451b-82a1-84528cc87a13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_85d29198-1898-4169-9df2-e910cd8f27b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dd32762d-f142-451b-82a1-84528cc87a13" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_85d29198-1898-4169-9df2-e910cd8f27b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_23b692ba-c3ea-4292-acab-2fb8188f4e85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_f3c5aafa-fc4a-41d1-8f61-1418fef7a984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_23b692ba-c3ea-4292-acab-2fb8188f4e85" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_f3c5aafa-fc4a-41d1-8f61-1418fef7a984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#STOCKHOLDERSEQUITYDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e2aadde4-c5d0-4b7e-98a3-59ee872341d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6f934ba7-24ac-47a9-8364-e4065e3ba46f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e2aadde4-c5d0-4b7e-98a3-59ee872341d3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6f934ba7-24ac-47a9-8364-e4065e3ba46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e2260623-5f00-47c7-8be7-0483a944327d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6f934ba7-24ac-47a9-8364-e4065e3ba46f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e2260623-5f00-47c7-8be7-0483a944327d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a9f1b6d0-baf4-42dc-aa0a-5ffcaf1a02c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e2260623-5f00-47c7-8be7-0483a944327d" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a9f1b6d0-baf4-42dc-aa0a-5ffcaf1a02c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_dc980f94-1c0f-4d6e-af27-efc99f9c603b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a9f1b6d0-baf4-42dc-aa0a-5ffcaf1a02c1" xlink:to="loc_us-gaap_IPOMember_dc980f94-1c0f-4d6e-af27-efc99f9c603b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_d9521ef2-c566-4693-b233-0daedacf4715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a9f1b6d0-baf4-42dc-aa0a-5ffcaf1a02c1" xlink:to="loc_us-gaap_OverAllotmentOptionMember_d9521ef2-c566-4693-b233-0daedacf4715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_f544c39a-62d7-4b60-9a1d-ba931b4ad927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6f934ba7-24ac-47a9-8364-e4065e3ba46f" xlink:to="loc_us-gaap_ClassOfStockLineItems_f544c39a-62d7-4b60-9a1d-ba931b4ad927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ad5747e2-e293-4a25-8d4d-c22764c8c308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f544c39a-62d7-4b60-9a1d-ba931b4ad927" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ad5747e2-e293-4a25-8d4d-c22764c8c308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_7cbe4f62-48d0-41e1-9691-7e14132beb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f544c39a-62d7-4b60-9a1d-ba931b4ad927" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_7cbe4f62-48d0-41e1-9691-7e14132beb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross_00f3ccaa-889e-4fe6-84d1-52e4203d089a" xlink:href="ck0001824293-20220331.xsd#ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f544c39a-62d7-4b60-9a1d-ba931b4ad927" xlink:to="loc_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross_00f3ccaa-889e-4fe6-84d1-52e4203d089a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_74ef9b3e-4182-4212-8391-e370633b4703" xlink:href="ck0001824293-20220331.xsd#ck0001824293_StockIssuanceCostsDiscountsAndCommissions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f544c39a-62d7-4b60-9a1d-ba931b4ad927" xlink:to="loc_ck0001824293_StockIssuanceCostsDiscountsAndCommissions_74ef9b3e-4182-4212-8391-e370633b4703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_0dee9175-4c3c-4a90-935e-19b1b5e94be2" xlink:href="ck0001824293-20220331.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f544c39a-62d7-4b60-9a1d-ba931b4ad927" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_0dee9175-4c3c-4a90-935e-19b1b5e94be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_40881f70-a2b6-4b80-9dd9-30994b0b56f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f544c39a-62d7-4b60-9a1d-ba931b4ad927" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_40881f70-a2b6-4b80-9dd9-30994b0b56f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a610bab6-36fb-4070-a1a7-e4e9d03bae98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f544c39a-62d7-4b60-9a1d-ba931b4ad927" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a610bab6-36fb-4070-a1a7-e4e9d03bae98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1bda07bf-d7e7-42c7-9714-7e407696e4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f544c39a-62d7-4b60-9a1d-ba931b4ad927" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1bda07bf-d7e7-42c7-9714-7e407696e4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_4f30f961-1eba-48c2-842c-a3fe4c980690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f544c39a-62d7-4b60-9a1d-ba931b4ad927" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_4f30f961-1eba-48c2-842c-a3fe4c980690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_f4e83b3c-42a5-419e-aaba-711b5f750148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_f544c39a-62d7-4b60-9a1d-ba931b4ad927" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_f4e83b3c-42a5-419e-aaba-711b5f750148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d7a56678-a725-4767-b1ed-7b9784baaf33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a68551b2-14e7-4b1f-99b1-4ad5fb9062d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d7a56678-a725-4767-b1ed-7b9784baaf33" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a68551b2-14e7-4b1f-99b1-4ad5fb9062d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1abf982c-3daa-427e-8243-e4197136725d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a68551b2-14e7-4b1f-99b1-4ad5fb9062d6" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1abf982c-3daa-427e-8243-e4197136725d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_96f01cd3-9720-4208-a93f-32297be40f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1abf982c-3daa-427e-8243-e4197136725d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_96f01cd3-9720-4208-a93f-32297be40f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_dd92e964-f353-48ab-b65a-962df6031d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_96f01cd3-9720-4208-a93f-32297be40f99" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_dd92e964-f353-48ab-b65a-962df6031d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_0cb57a09-1829-4f71-8ef5-71b170bb0d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_96f01cd3-9720-4208-a93f-32297be40f99" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_0cb57a09-1829-4f71-8ef5-71b170bb0d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_df673188-ea5c-4c92-aeb7-fe20ad01d15a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_96f01cd3-9720-4208-a93f-32297be40f99" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_df673188-ea5c-4c92-aeb7-fe20ad01d15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_f0936542-2de9-4451-8ee1-936ea442cea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_96f01cd3-9720-4208-a93f-32297be40f99" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_f0936542-2de9-4451-8ee1-936ea442cea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_233e6424-c00b-4bde-8b39-92f3b8dad8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a68551b2-14e7-4b1f-99b1-4ad5fb9062d6" xlink:to="loc_us-gaap_ClassOfStockLineItems_233e6424-c00b-4bde-8b39-92f3b8dad8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_3d141fb6-30d6-4322-9fab-5652ffcf0561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_233e6424-c00b-4bde-8b39-92f3b8dad8bd" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_3d141fb6-30d6-4322-9fab-5652ffcf0561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_775d96b5-b003-45af-a066-374c496096f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f9adf339-b229-4275-a7b7-69bce8e7e5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_775d96b5-b003-45af-a066-374c496096f2" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f9adf339-b229-4275-a7b7-69bce8e7e5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f250b7d1-4d48-4702-90f8-340328101a71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_bf07f4ce-29b3-429a-aa8c-925e5e87d92f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f250b7d1-4d48-4702-90f8-340328101a71" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_bf07f4ce-29b3-429a-aa8c-925e5e87d92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_00be82da-b189-4fbd-8994-7d967360f5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f250b7d1-4d48-4702-90f8-340328101a71" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_00be82da-b189-4fbd-8994-7d967360f5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d95e1351-6470-4d70-9503-feeb8cfe89d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f250b7d1-4d48-4702-90f8-340328101a71" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d95e1351-6470-4d70-9503-feeb8cfe89d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3504c4e1-86f5-4498-8183-24137366204c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3b15a240-33cf-4a32-b9ee-474f77159b26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3504c4e1-86f5-4498-8183-24137366204c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3b15a240-33cf-4a32-b9ee-474f77159b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3707908d-298e-4290-9e13-c1bc93b4f9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3b15a240-33cf-4a32-b9ee-474f77159b26" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3707908d-298e-4290-9e13-c1bc93b4f9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5490f901-39cf-4d15-9c0d-88684429d446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3707908d-298e-4290-9e13-c1bc93b4f9e5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5490f901-39cf-4d15-9c0d-88684429d446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e35f5c1b-b547-4e25-8d0c-bded3373a46e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5490f901-39cf-4d15-9c0d-88684429d446" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e35f5c1b-b547-4e25-8d0c-bded3373a46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3261545c-5d4a-4b8d-b22e-ed0578e1c129" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5490f901-39cf-4d15-9c0d-88684429d446" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3261545c-5d4a-4b8d-b22e-ed0578e1c129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_97ba928a-1615-4396-a190-6cef472b5f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3b15a240-33cf-4a32-b9ee-474f77159b26" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_97ba928a-1615-4396-a190-6cef472b5f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_cb626cb9-e92b-41f1-a493-87f780589d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_97ba928a-1615-4396-a190-6cef472b5f63" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_cb626cb9-e92b-41f1-a493-87f780589d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cae97c8d-3f8b-46f4-924f-8760eab2c5df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_59766074-5e02-4827-abd1-be1606eb3986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cae97c8d-3f8b-46f4-924f-8760eab2c5df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_59766074-5e02-4827-abd1-be1606eb3986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_426f2efd-7778-4a23-a58f-c31fde149e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cae97c8d-3f8b-46f4-924f-8760eab2c5df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_426f2efd-7778-4a23-a58f-c31fde149e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e1279994-0f90-4755-adf9-14b07cfb9006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cae97c8d-3f8b-46f4-924f-8760eab2c5df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e1279994-0f90-4755-adf9-14b07cfb9006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_544fad93-9905-44c6-b314-a661def09578" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_db2fc5d1-f037-4781-ac96-ddde2a3c50cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_544fad93-9905-44c6-b314-a661def09578" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_db2fc5d1-f037-4781-ac96-ddde2a3c50cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_92877cf2-5d27-40ad-86c1-02bf64231137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_db2fc5d1-f037-4781-ac96-ddde2a3c50cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_92877cf2-5d27-40ad-86c1-02bf64231137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_582199b4-96ae-42ee-bd0e-0be7b8ce2053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_db2fc5d1-f037-4781-ac96-ddde2a3c50cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_582199b4-96ae-42ee-bd0e-0be7b8ce2053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3139c3d6-4aa0-4817-bf7d-af8096b6e327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_db2fc5d1-f037-4781-ac96-ddde2a3c50cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3139c3d6-4aa0-4817-bf7d-af8096b6e327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_fd5206b1-7412-4820-aa2a-ca074949e8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_db2fc5d1-f037-4781-ac96-ddde2a3c50cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_fd5206b1-7412-4820-aa2a-ca074949e8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1e9d94b-dff1-4e7c-bb4f-c34b122257f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_544fad93-9905-44c6-b314-a661def09578" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1e9d94b-dff1-4e7c-bb4f-c34b122257f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6876654b-a0bb-433f-9e3a-8ce08085c4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1e9d94b-dff1-4e7c-bb4f-c34b122257f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6876654b-a0bb-433f-9e3a-8ce08085c4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1cebc3ad-521a-4032-ae10-ed532c7f956a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1e9d94b-dff1-4e7c-bb4f-c34b122257f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1cebc3ad-521a-4032-ae10-ed532c7f956a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_561347af-bbad-4fee-ab59-a78628a2d016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1e9d94b-dff1-4e7c-bb4f-c34b122257f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_561347af-bbad-4fee-ab59-a78628a2d016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b1f08559-34cc-4df9-afb0-4e7159c65b03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d1e9d94b-dff1-4e7c-bb4f-c34b122257f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b1f08559-34cc-4df9-afb0-4e7159c65b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_db797f4a-3806-4d55-afbc-98491713ad3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_544fad93-9905-44c6-b314-a661def09578" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_db797f4a-3806-4d55-afbc-98491713ad3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_74d567bc-71a5-466f-bf9c-3a951d21b104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_db797f4a-3806-4d55-afbc-98491713ad3d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_74d567bc-71a5-466f-bf9c-3a951d21b104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cc5d4001-61e6-484b-a171-54fc45337a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_db797f4a-3806-4d55-afbc-98491713ad3d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_cc5d4001-61e6-484b-a171-54fc45337a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_fba45351-087f-4b62-9f31-9316bc19c351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_db797f4a-3806-4d55-afbc-98491713ad3d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_fba45351-087f-4b62-9f31-9316bc19c351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8a5ac768-8370-48c3-9d8d-4ca926a27af2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e7489ac9-f280-47ed-974b-6369d7fd1dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8a5ac768-8370-48c3-9d8d-4ca926a27af2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_e7489ac9-f280-47ed-974b-6369d7fd1dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_380b98b0-90ed-4a95-a6c8-03503bf5d3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8a5ac768-8370-48c3-9d8d-4ca926a27af2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_380b98b0-90ed-4a95-a6c8-03503bf5d3eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6e593ce5-9c51-4329-8c09-930af2826962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8a5ac768-8370-48c3-9d8d-4ca926a27af2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6e593ce5-9c51-4329-8c09-930af2826962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_29aba51e-226b-49df-aa7d-f2ca48ca9122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8a5ac768-8370-48c3-9d8d-4ca926a27af2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_29aba51e-226b-49df-aa7d-f2ca48ca9122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_66677c61-c26b-4503-bad4-756db6b3458e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8a5ac768-8370-48c3-9d8d-4ca926a27af2" xlink:to="loc_us-gaap_SharePrice_66677c61-c26b-4503-bad4-756db6b3458e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_d5045331-860b-4bab-ad2a-62240b49472c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_afa062e7-9e79-474d-b636-b7b612526819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_d5045331-860b-4bab-ad2a-62240b49472c" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_afa062e7-9e79-474d-b636-b7b612526819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_46465f01-844f-46d5-8b3b-97111dee14dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403a42da-8813-4ea4-939e-47e1530dca9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_46465f01-844f-46d5-8b3b-97111dee14dc" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403a42da-8813-4ea4-939e-47e1530dca9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fd9a5a00-4653-4231-82ab-bb1bd4df985e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403a42da-8813-4ea4-939e-47e1530dca9f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fd9a5a00-4653-4231-82ab-bb1bd4df985e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4f22d9d6-51d0-462a-882a-813a424330e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fd9a5a00-4653-4231-82ab-bb1bd4df985e" xlink:to="loc_us-gaap_RelatedPartyDomain_4f22d9d6-51d0-462a-882a-813a424330e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_MediceMember_2824a711-3728-4827-a0b3-7d3b3a388a02" xlink:href="ck0001824293-20220331.xsd#ck0001824293_MediceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4f22d9d6-51d0-462a-882a-813a424330e1" xlink:to="loc_ck0001824293_MediceMember_2824a711-3728-4827-a0b3-7d3b3a388a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_6226b4c8-6d2d-4a18-a947-19c5809f608d" xlink:href="ck0001824293-20220331.xsd#ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4f22d9d6-51d0-462a-882a-813a424330e1" xlink:to="loc_ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember_6226b4c8-6d2d-4a18-a947-19c5809f608d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_11db0fcc-27dc-40c4-ae0a-a051817417b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403a42da-8813-4ea4-939e-47e1530dca9f" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_11db0fcc-27dc-40c4-ae0a-a051817417b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_59692fd6-0cd9-44d8-9237-5368b8e37c39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_11db0fcc-27dc-40c4-ae0a-a051817417b4" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_59692fd6-0cd9-44d8-9237-5368b8e37c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_82983b75-4924-459d-8fa8-b51cb8c9f50c" xlink:href="ck0001824293-20220331.xsd#ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_59692fd6-0cd9-44d8-9237-5368b8e37c39" xlink:to="loc_ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember_82983b75-4924-459d-8fa8-b51cb8c9f50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_9db3c947-520b-4cae-998d-1f05628767e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_403a42da-8813-4ea4-939e-47e1530dca9f" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_9db3c947-520b-4cae-998d-1f05628767e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment_9a68ccf1-2a37-428c-9181-fcd46909b263" xlink:href="ck0001824293-20220331.xsd#ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9db3c947-520b-4cae-998d-1f05628767e9" xlink:to="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment_9a68ccf1-2a37-428c-9181-fcd46909b263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm_bdbb8b24-caf2-4d65-9a8b-b79a884eebbe" xlink:href="ck0001824293-20220331.xsd#ck0001824293_RelatedPartyTransactionLicenseAgreementTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9db3c947-520b-4cae-998d-1f05628767e9" xlink:to="loc_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm_bdbb8b24-caf2-4d65-9a8b-b79a884eebbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_1b7d68cf-c095-4f95-80ef-e75e4fd36d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9db3c947-520b-4cae-998d-1f05628767e9" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_1b7d68cf-c095-4f95-80ef-e75e4fd36d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b185ca67-5f82-4825-b893-e53f39786726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9db3c947-520b-4cae-998d-1f05628767e9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b185ca67-5f82-4825-b893-e53f39786726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_b4d619c9-0dbb-4524-a61c-f68e5211ac02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9db3c947-520b-4cae-998d-1f05628767e9" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_b4d619c9-0dbb-4524-a61c-f68e5211ac02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="ck0001824293-20220331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d8e926ef-04e3-4603-88d3-1e5bd5d4a483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bb879b5a-c181-4466-a159-6ba855b69c66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d8e926ef-04e3-4603-88d3-1e5bd5d4a483" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bb879b5a-c181-4466-a159-6ba855b69c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ck0001824293-20220331_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ck0001824293-20220331_g1.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7OP/_P!A^P_]*(Z_M5'2OS/C[^+1]'^:/ILA^"?J@HHHK\_/>"BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M':Z'>'Q3\/II3)?>$=2G(M'+'+26\F&:VE//S("K9RR/@8_IB_8*_;E\%_\
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M?S3T5[%/@; 1^.4G\TOT_4XY9Y7>R2^__,_HR_XB\?V;/^A(^.'_ ()]+_\
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M.<Y ?X/_ .#M']F'Q-K M;W1?BYX=A*Y^UZAH=H\(.X#&+>[E?."3]S&%/?
M/\V]%>M_J3EO+;WO6_\ P+''_;6(O?3[C^MO]GC_ (+:?LN?M.WT%EX9^+_A
MNVU2XD$,=CKGFZ+<22'HB"Z6,2$]O++9/'7BOJ:WN([NWCEBD22*10Z.AW*Z
MGD$'N#ZU_#]7U-^P3_P6,^.G_!/35[.+PAXLN=5\)0R*9_"VLNUWI<R \K&K
M'=;DC^*%D.<9W 8KQL?P):+E@ZE_*7^:_P OF=N'SR[M6C\U_D?UO45\C?\
M!+'_ (+&?#7_ (*B^")%T1F\,^/])@676?"M[,'GMQP#-;R8 N(-W&\!67(W
MHFY<_7-? 8C#U:%1TJT>62W3/>IU(SCS0=T%%%%8EA1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#;1^$%_P"!_B1X<LO$6@7PW*DR[9K*7!"SP2#YHI5R<.I!P2#D$@_S7_\
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M,?PK-HULUIXP^+-];^9IWAN*;Y+,-]V>]=<F*/G<$X>3&%P,NOSM_P %K/\
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M,-V 0@C!;=^@'C[Q_H?PK\%ZGXC\2ZMI^@Z#HMNUW?ZA?3K!;VD2C+.[L0%
M]ZXW]K#]KKX?_L2_!O4/'7Q'\06N@Z#8_(F\[KB^F()6""/[TLK8.%7L"3@
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M.!6#PD,.NBU]=W^)\'BZ[K5I5._Y= J6RLIM3O8;>WAEN+BX=8XHHT+/(Y.
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M6W1!114ME93:G>PV]O#+<7%PZQQ11H6>1R<!5 Y)). !UKV3C(J*_1?]B_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#A_CW^S/\/?VI?"4.A?$;P;X=\::3:W NX+;5[%+I;>8
M@21[AE&VDC*D$AB.A(JQ\$OV>_ O[-G@X>'_ (?^$/#O@W1=YE:ST>PCM(Y'
M/5W" ;V/]YLGWKL**T]K/D]G=V[=/N)Y5?FMJ?SL_P#!P'_P71U[]I+QUXG^
M!OPSO9=)^&NAWDFF:YJ$#%;CQ1/"Y61-P^[:*ZD!1_K=NXDJ0M?E#7U5_P %
M8_\ @EUXV_X)F_M!W>DZU#<:IX-UZXEN/#7B%5+0ZC#NSY<C?PW" @.AY/WA
ME2#7RK7[EDF'PM+!P6#UBU>_=]6_/\MCXC'5*LJS]MO^0445-I^GW&KW\%K:
MP375U=2+%##$A>25V.%55')8D@ #DDUZQR$FB7][I6LV=UILUU;:A;3I+:S6
MSLDT4JL"C(R_,&# $$<@XQ7]G7[)D_BJY_97^&<GCHS-XWD\*:6WB$RC$AU$
MV<1N=W^UYV_/O7Y<_P#!"[_@W>M?@F-%^,?QXTF"^\9CRK_P]X6N%W0^'V^\
MEQ=+TDNAP5C.5B/)S(!Y?ZX>._'FB?"_P=J7B'Q)JVFZ#H.CP-<WVH7]PMO;
M6D2]7>1B%51ZDU^3\79Q0QE6-##Z\E]>[?1>7YO8^LRG!SHQ<ZFE^G^9K5Q_
M[0NE^)-<^ 7CBR\'3);>+KSP_?P:',_W8KYK:1;=CR.!*4/4=.HZU\KV7_!Q
M-^Q]?^/%\/I\7+=;AKHV@O)-$U".PW@XR;AH!&(\\>83LQSNV\U]H:/K%GXA
MTFUU#3[JWOK&]B6>WN;>42PSQL 5=&4D,I!!!!P0:^5K86OAVG6@X]5=-7^_
M<]2%6%2_(T_1G\2'B32-1\/^(K^PU>UO+'5K&YDM[VWO(VCN+>=&*R)(K ,K
MJP(8, 000>:I5_3C_P %I/\ @@WX8_X*):!>>-_ \>G^%_C)90Y2Z*^59^)%
M0'$%UC@2'@+/@D8"MN4#;_-A\6?A-XE^!/Q(UCP?XPT74/#OB;P_<&UU#3KV
M/RYK:08/(Z$$$,K#*LK*RD@@G]FR7/*&8T[PTDMX]O-=UYGQN-P,\/+75=&<
M[1117N'"%?O)_P &=_@[QCIGPO\ C-KEY'>P^ ]5U#3K?2S*2(9[^%)_M31@
M]Q');*S#@X4<E>/DO_@BA_P;_P"O?MYWNG?$;XG0ZAX;^#\,HEMX1N@OO%>U
ME.R+H8[9AD-..3R(^<NG]'7PY^'.@_"'P)I/ACPOI-AH/A_0[9+2PT^RA$4%
MK$HP%51T_F223DFOSWC#/J$J4L!2]YMJ[Z*SO;U[]CZ#*,#-25>>BZ>?_ -J
MBOGS]L?_ (*H? 7]@?5K/3?BC\0M/T'6M0C$T.E06T^H7YB.0)6AMT=XXSM8
M!W"JQ4@$D8K5_8[_ ."COP5_;WTZ]F^%7CS2_$UQIHW7E@8Y;._M5S@.UO.J
M2["> X4J3QG-?GKP>(5+V[@^3O9V^_8^@]M#FY+J_:^I^&G_  =I:MXPN/\
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M2/\ DU/X9?\ 8J:7_P"D<5?GO'WP4?67Z'T.0[S^7ZGH5%%%?FI]&%?SF_\
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M_P#8;U?_ -*WK]":_/;_ (-?_P#E$7X1_P"PWJ__ *5O7Z$U^#YU_P C"O\
MXY?FS[O!_P"[P]%^05^%?_!Y+_R-_P"S_P#]>>N_^AZ?7[J5^%?_  >2_P#(
MW_L__P#7GKO_ *'I]>APC_R-:7_;W_I+.?-O]UE\OS1^)]%%%?M!\8%?VA?L
MD?\ )J?PR_[%32__ $CBK^+VO[0OV2/^34_AE_V*FE_^D<5?GO'WP4?67Z'T
M.0[S^7ZGH5%%%?FI]&%?SF_\'>7_ "DE\$?]DTL?_3IJM?T95_.;_P '>7_*
M27P1_P!DTL?_ $Z:K7UG!?\ R,E_A9Y6<_[L_5'Y6T445^P'R!U_[/O_ "7O
MP/\ ]A^P_P#2B.O[51TK^*K]GW_DO?@?_L/V'_I1'7]JHZ5^9\??Q:/H_P T
M?39#\$_5!1117Y^>\?C3_P 'BOQ472_@9\%O!*LY;7-=O]<8#&U19V\<*[N<
M@G[<V."#M;D8Y_!&OV@_X/'+R1_BU\"[=F_<Q:1JTBKCHS36P8_B%7\J_%^O
MVCA&"CE=-KK=_P#DS/C<VDWBI?+\D%%%%?2'FG]57_!O!\!HO@-_P2;^&:^7
M&E]XPCG\47KJFWS6NY2T)/J1;+;KG_9K[:KR/]@'P<GP\_83^"^@QR+.NC^!
MM%LS,L7EB8QV$*E]N3@L06QD\GJ>M>N5_/V/K.KB:E5]9-_B??T(\E.,>R04
M445R&H4444 %?@7_ ,'@_P "(O#_ ,>OA)\2+:UF#>)]%N]"O9E4F/?92I+%
MN/0.RW;@9Y(B/7:<?OI7Y(?\'@.C13_L3_#'4&QYUKXW%NGRC.V2PN6;GKUB
M7CO^ KZ#A6LZ>9TK=;K[TSS\TBI8:5_ZU/YZJ***_;#XL*_L&_X)6_$^X^,?
M_!-[X(^(KRX^U7UYX-TZ*ZG[S3PP+#(Q[9+QL3CC)/2OX^:_JK_X-T=6N=9_
MX(T?!>:ZFDN)4BU>!6<Y(CCUF_CC7Z*BJH]@*^%X\IWPE.IVE;[T_P#(]S(I
M?O91\OU_X)]8_&[_ )(QXN_[ MY_Z(>OXHZ_M<^-W_)&/%W_ &!;S_T0]?Q1
MUR\ ?#7_ .W?_;C;/OL?/] HHHK]$/G3]=_^#/[X76^O?M>?%'QA+YC3^&_"
MD6FP+C]VIO+I'+'C[P%H0.1P[<'J/Z#:_"O_ (,VO^1P_: _Z\]!_P#0]0K]
MU*_&>+Y-YK43Z<O_ *2G^I]EE"MA8_/\V%%%%?,GI!1110!\$_\ !S#!'-_P
M1W^)#,BLT5]H[(2,E#_:=L,CT."1]":_EQK^I'_@Y=_Y0Z?$S_K\T;_TZ6M?
MRW5^L<"_[A+_ !O\HGRF>?[PO1?FPHHHK[0\8_I\_P"#8#_E$5X1_P"PUJ__
M *5O7Z$5^>__  ; ?\HBO"/_ &&M7_\ 2MZ_0BOP?.O^1A7_ ,<OS9]W@_\
M=X>B_(****\LZ0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHKQ7_ (* _MC:3^PS^S#KWCK4#;S:A$GV/1+*
M1L?VC?R*WDQ8ZE1AG?'(2-SVKIP>$K8JO##4%S3FTDN[9CB<13P]*5>L[1BF
MV^R1\%_\'#W_  49_L/2_P#A0O@^_P 7E\B7/BZY@EPT,)P\5CD<@OQ)(./D
MV+R'8#\_/^":_P"W#J7[!7[3NE>+8OM%SX=O<:?XAL(V_P"/NR=AN91T,D9
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MU;'JG+X:FGSZ?CI\SR\VP_M*',MXZ_YG\]-%%%?L1\>?5G_!%/\ ;&'[$/\
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M>A^9M%%%?LQ\:%?UA?\ ! ;P2WP__P""0'P1L6:1S<:7=:EEUVG%W?W5T!]
M)@ >X -?R?PPO<3+'&K222$*JJ,LQ/0 5_9W^Q[\&O\ AG;]D_X:> _F,G@_
MPQIVD2LP^:22"VCC=C[LZL3CC)KX+CVM;#TJ7>3?W*WZGO9##]Y*?E;[_P#A
MC?\ C=_R1CQ=_P!@6\_]$/7\4=?VN?&[_DC'B[_L"WG_ *(>OXHZPX ^&O\
M]N_^W&F??8^?Z!1117Z(?.G[8?\ !FU_R.'[0'_7GH/_ *'J%?NI7X5_\&;7
M_(X?M ?]>>@_^AZA7[J5^+\6_P#(UJ_]N_\ I*/LLI_W6/S_ #84445\V>D%
M%%% 'P9_P<N_\H=/B9_U^:-_Z=+6OY;J_J1_X.7?^4.GQ,_Z_-&_].EK7\MU
M?K' O^X3_P ;_P#28GRF>?[PO1?FPHHHK[0\8_I\_P"#8#_E$5X1_P"PUJ__
M *5O7Z$5^>__  ; ?\HBO"/_ &&M7_\ 2MZ_0BOP?.O^1A7_ ,<OS9]W@_\
M=X>B_(****\LZ0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'9.S\[-!1117.;!1110 4444 %%%% !1110 4444 %<E\>O@QHO[1?P4\5^
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M**BO))?D*=24W>3;]0HHJ;3]/N-7OX+6U@FNKJZD6*&&)"\DKL<*JJ.2Q)
M'))K4@AK]5?^#=__ ((G7'[6?CO2_C9\3-,*?"WPW=^=HVGW"X_X2B]A<8+*
M?O6D3CYL\2.NSE1(*[3_ (([_P#!LYKGQ3U'2/B1^T5I]WX>\*KLN[#P;+F'
M4=6Z,IO1]ZWA]8CB5NA\L#YOWOT#P_8^%-$M-,TNRM=.TVPB6"VM;:)8H;>-
M1A41% "J ,  8%?GW$O%48Q>$P3NWHY+IY+S\^G37;Z#+<K;:JUEZ+_,N*NU
M< 8 X ':BBBOS0^D.7^-W_)&/%W_ &!;S_T0]?Q1U_:Y\;O^2,>+O^P+>?\
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MPG^T;\,]5\&^.-!T[Q+X9UJ(PW=A>Q[XY!V8'JKJ>5=2&4@$$$9K\._V_O\
M@TR\6>%]6U#Q!^SUX@M?$VCR%YD\+Z[<K:ZC;=2(H+IL0S#/ \TQ$#&6<Y:O
MWNHKT,MSC%8"7-AY:/=/5/Y?JM3GQ.#I5U:HOGU/XY?C'_P3C^/?P U6:S\7
M?!_XA:0UN0&G.B3SVC9.!MN(U:)^>,JYYKQ6O[A**^MI<?5$OWE%-^4K?HSR
M99#&_NS_  O_ )'\5?@#]GGQ_P#%>".3PMX'\8>)8YLB-]*T:YO%?#;3@QHV
M<-QQWXKW_P"$W_!#;]K+XSVUO/I/P0\86,-P?E?6UAT4J-VW)6\>)@._3D<C
M(Q7]:M%95N/,0_X5**]6W_D7#(::^*3?X?YF'\,H=5M_AMX>CUZ-8M<CTRV7
M44602!+@1+YH##AL/NY'!K<HHKX-ZNY[IYK^U;^R)\/?VV/A'>>"?B3X<L_$
M6AW1WH)!LGLI<$":"4?-%(,G#*1P2#D$@_A7^W3_ ,&H?Q5^$FH7FK?!'5K7
MXF^'0=T6E7T\5AKD"\#&6VV\V/F.X-&Q P(R>O\ 0]17KY7GF+P#_<2TZIZI
M_P"7RL<F*P5*NOWBU[]3^,WXP?L/_&3]G^YO(_&OPM\?>&5L=WG3W^A7,5L
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M]S+.(L7@*3HT+6;OJKZV2_0X<3E]&O+GJ7OL?S2_\0IG[5'_ %3;_P *!_\
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MV]0 /E45_2!\2/!R?$3X=Z]X?DF:WCUS3KC3VE4?-&)8FC+#W&[-?RV_M!_
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MLTH9=A98S$WY(VO97>K27XL_0^BOQU_X)]?\%O\ XW_M+?ME^ ? OB1_"/\
M8?B/4&MKS[+I1BFV"*1_E;S#@Y4=J_8JNOB3AC&Y'B(X;&VYI1YERNZM=KLN
MQS9'GV%S:B\1A+\J=G=6ULG^H4445\Z>T%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_L$_L1>)OV\OC[I_@_08Y+?3XR+G6]5*9ATFT!PTC=B[?=1.K,1T 8C^D/\
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MN>(O^_5O_P#&Z/\ A\/^TQ_T5SQ%_P!^K?\ ^-U^FW_$,O\  ?\ Z&WXN?\
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MX$A/'W8O,/2OBG4=/N-(U">TNX)K6ZM9&BFAF0I)$ZG#*RGD,"""#R"*Z*O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU9^C3MY6ZG].\&Y]4S;+EB*RM.+<7V;23NO6_P!]PHHHKX<^K"BBB@ HHHH
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M+E(EBG?N%5HBF>@,X!ZBOQ0K^GO!S*\)2RAXZG9U:C:D^J2>D?+2TO.Z[(_
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M !1110!_*'\8O^2N^*O^PQ=_^CGK]F/^#8[_ ),Z\=?]CE)_Z0VE?C/\8O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT.,N,L+D&$]I/WJLO@AW?=]HKJ_DM3AX5X7Q&<XCEC[M./Q2[>2[M_ANR_\
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M%OX!\!^)/%4T9VI=:G/'I=J_^TH ED(]F5"?;K7T64\)9QF6N"P\I+O:T?\
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M8-N-6NF^T?>?X72^;1^RM%?SS^//^"]?[3?C6XW6_C;3_#L/_/#2]$M%4_\
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MS[O+\TPN.I>VPE13CY=/5;I^3%HHHKS#N"BBB@ HHHH **** "BBB@ HHHH
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MZ6M_V[>_ROT/5****_G<_:@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M_E#^,7_)7?%7_88N_P#T<]?LQ_P;'?\ )G7CK_L<I/\ TAM*_&?XQ?\ )7?%
M7_88N_\ T<]?LQ_P;'?\F=>.O^QRD_\ 2&TK^J_%+_DEOG3_ #/Y[X _Y*)^
MDS])****_E0_H0**** "BBB@ HHHH *_!S_@Y$\4Q^(/^"A%E:1LK-H?A&QL
MI /X6::ZGP?PG!_&OW=O[Z'2[&:ZN)(X;>WC:661SM6-5&2Q/8 #-?R__MW_
M +0:?M4?M@?$#Q] 6:Q\0:L[6)8%6-I$%AM\@@$'R8X\@C@U^Q>"^7SJYO4Q
M?V:<&K^<FDE]RD_D?F7BEC84\LAA_M3DONBKM_>TOF>T?\$'?",WBG_@I]\/
MYHUW0Z+#J6H7')R%%A/&I''_ #TDCZXXS]#_ $/5^,?_  ;&? N76OC5\0/B
M-/%)]ET#28]"M6/W'GN9%ED([[D2W4?2;W&/V<KS_&#'1K\0.G%_PX1B_767
M_MQV^&>$E1R53DOCE*7Y1_\ ;0K\;?\ @Z(_Y*U\)?\ L$7_ /Z.BK]DJ_&W
M_@Z(_P"2M?"7_L$7_P#Z.BKB\*?^2FH>D_\ TB1U^(?_ "(*_P#VY_Z7$^1_
M^"//_*2_X1_]A=__ $GFK]_OVM?VL?!_[%WP4U/QSXTO'ATZQQ';VL&&NM2N
M&^Y! A(W.WU 50S,0JDC^?K_ ()%ZE;Z-_P4=^%=Y=S1V]K:ZG+--+(VU(D6
MUF+,Q/0  DFM;_@J!^W=KG_!1C]J5I-)%_<^$])N#I7A'2H8G:2968+YWE8W
M&>X8*<8W >6G.WG]8XQX0EGW$U&%1\M&G23F_+GG:*\WKKT2;Z6?YUPOQ+')
M\@J3BKU9U&H+SY8ZOR7XMI=;F+^W]_P4Q^(?[?WC>2;7;V32?"-K,6TOPW:2
ML+.T7/RO)T\Z;'61AP2=H13MKT#]D'_@AG\;?VJM.L]9N]/M? /A>\ D2_U[
M='<7$9_BBME!D;/!!?RU(Y#&OT'_ ."2_P#P10T/]F31-+^('Q/L;77?B1=1
MQW5IIT\8DM?"^1D*!DK)<C/S2<A",)T+M^AU?-<0>)^'RR/]E\,TXQA#3GM=
M7_NKK_BE>[UL]W[F3\ UL?+^T,_G*4Y:\M[/_MY]/\*M;OT7YH_"[_@V0^%N
MA6UN_B[QYXV\17D>#*NGK;Z;;2GTVLDSA>O20'W%>@2?\&Z7[.;VPC$'C96!
M8^8-;^8Y P.8\<8)''<YSQC[NHK\UK<>\0U9<\L7._D^5?<K(^[H\(Y+3CRQ
MPT/FKO[W=GY7_&+_ (-@?"M[IK/\/_B9X@TV\4Y6+Q#:0WT<HQ]TO (2G./F
MV-].]?G7^V+_ ,$T/B]^PY/YWC;P[YF@O((HM>TMS=:9*QZ*9,!HV)X"RJA.
M#@&OZ9*H^)/#6G^,= O-)U:QL]3TO4(F@NK2ZA6:&XC889'1@0RD=017TF1^
M+6=8.HEC)*M3ZII*7RDEOZIGA9MX;Y5BH/ZM'V4^C5VOG%O\K'\I/PX^)7B#
MX0^-=/\ $?A?6-0T'7-+E$UK>V4QBFA8>A'4'H0<@@D$$$BOWF_X)&?\%<-,
M_;K\+1^$_%DEKI?Q4TFWW3Q*!'#KT2CFY@'0..KQCI]Y?ER%^!O^"TO_  2+
MA_8]U#_A9'P[M;AOAOJEPL5]8Y,A\.7#G"#<26-O(W"EON,0A)W)GX2^&?Q*
MUSX._$'1_%/AO4+C2=>T&Z2\LKJ%L-#(AR/8@]"IX8$@@@D5^R9ME.5<:Y0L
M5AG:=GRRM[T9+>,O+NOFNC?YCEN99CPIF3PV(5X?:CTDOYH^?;[GY?UB45X]
M^P=^UKIO[;7[+OAGX@6*QV]UJ$/V?5+-"2+&^C^6>(9YV[OF4GDHZ'O7L-?R
MCB\+5PU>>'KJTX-IKLT[,_HC#XBG7I1K4G>,DFGW3U05\C_\%N-*\<O^P%XE
MUGP#XD\0>'=2\,S0ZC??V3=M:RWM@&V3QLZD,%57$IVD$B(CD$@_7%9_BSPK
MI_CKPMJ6BZM:QWVE:Q:RV5Y;2?<N(9%*.AQS@J2./6NG*<=]2QM+%N*DH23:
M:NFD]5KW1CF&$^M86IA[N/-%JZW5UO\ (_E)\*>#/$7Q8\4C3]#TG6O$NMWK
M-(+:QM9;RZG).6;8@9F.3R<=Z^OO@5_P0$_:(^,<4-SJ6B:/X#L9"I\SQ!?!
M)BAY)$,(DD! _A<)SQQUK]VO@Y\ O!/[/?AI='\#^%="\+:> -T6G6:0^:1W
M=@-SM_M,2?>NNK]=S?QJQM1N&6T8TX]Y>\_N5DO3WC\URWPKPD/>QU5S?9>Z
MOOU;_ _*GX6_\&O?AVTMU?QM\5-:U"5N6AT33(K-8_823-+N^NQ?I7N'A+_@
MW>_9O\.6L4=YIOB[7VCQNEO]<=&D^OD+$.?8"ON:BO@L7X@<18AWGBYK_#:/
M_I*1]AA^#<EH*T,-%^JYO_2KGQNW_! W]EXC_D0]0'N/$6H<?^1J\O\ C%_P
M;5?!OQA93/X/\1^,/!M^8RL0DFCU*S5L<,T;JLAYZ@2C/M7Z,45SX?C?/Z,^
M>&,J-^<G)?=*Z_ VK<*Y/5CR2PT+>44G]ZL_Q/YS_P!N/_@CC\7OV(;*YUN]
ML;?Q=X+@)+:[HRM(EJG8W,1&^'W8[HP>-Y)%?/OP-^//B[]FSXD6/BWP1KM]
MX>U[3S^[N;9_]8F03'(IRLD;8&Y'!4XY%?U775K'?6LD,T<<T,RE)(W4,KJ1
M@@@\$$<8-?AY_P %SO\ @E78_LM:[#\4OAYI\=GX"UVX%OJ6EV\>(]!NV^ZR
M#/$$O("X 1QM'#*!^U\#^)4<WG_9.<QCSS5D[>[/^[);)OIT>UD[7_+.+.!'
MEL?[2RJ3Y8ZM7UCYQ>]EUZK>[6WZ/?\ !+;_ (*<Z#_P4-^%TBS1V^C_ !!\
M/PI_;FDJWR.#\HNK?)RT+'@CDQL0K9RK/]4U_+;^QU^U#KG[''[17AOX@:#)
M)YVC7(^V6JN534;1N)K=^Q#IG&<[6"L.5!K^GCX<_$#2_BO\/]$\3Z'<K>:-
MXAL8=1L9P,>;#*@=#CL=K#CL:_-?$K@V.28U5<*OW%6[C_=:WCZ=5Y::VN?=
M\"\42S;".%?^+3LGYI[2_1^?K8VJ***_-3[@*S_%G_(JZG_UZ2_^@&M"L_Q9
M_P BKJ?_ %Z2_P#H!JJ?Q(4MC^2^OZ</^";&LKJ7_!/?X,W#2[DB\&Z;$SO\
MNWR[9$/X#;CZ"OYCZ_3[]H+_ (*(W'P;_P""*GP5^'_A?5"GBCX@Z+/9WES
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MJ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML_AK]+/V=/V</!_[*7PIT_P9X'TB'1]#T\%@H.Z6YD/WI97/,DC8Y8^@ P
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M.B?"K3;G?;VO,=QKKH?EGN>?N@C<D71<@ME@-OJ7_!R+^TQXKUW]IG3?A?\
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MY.4^&_\ V+,O_I4]?I'A/_R4E'TG_P"DL^'\1?\ D0U?6/\ Z4CYO_X(F_\
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M/#X+R>'])N7UC7]8D2YUW6)(_+;4)E!"*J9.R) S!5R3\S$DEC7:_LF?L?\
M@7]BOX56_A+P)I*6%FN)+R[DQ)>:I-CF:>3 +L><#A5'RJ%4 5XE_P %,O\
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M?6/_ *4CYO\ ^")O_*4/X4?]?=[_ .F^ZK^CBOYQ_P#@B;_RE#^%'_7W>_\
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MJ4I<(\TG=OV=_O1^!\!Q4>)'&.B7/^I^FU%%%?RL?T(%9_BS_D5=3_Z])?\
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M*_%^+/\ D>8S_K[4_P#2Y'ZAPW_R*<+_ ->X?^DH;-,MO$TDC+''&"S,QP%
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MEM\G.P?,F3MW#"5^U7P?^.'@_P#: \'0^(/!/B31_$VCS_=N=/N5F5#_ '7
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MJUN5=^Y^>\*\!O)L8\7[?GO%QMRVW:=[\S[=B:BBBORD_0@HHHH **** "O
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MBL>Z?M/=:M?EW\[/\CY_B;(O[7P3P?/R:IWM?;RNOS/P%_X-\/\ E)=X=_[
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
@@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224800229640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 06, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VALLON PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-4369909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 N. 18th Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">207-3606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VLON<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001824293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224800017496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,543<span></span>
</td>
<td class="nump">$ 3,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities, available-for-sale</a></td>
<td class="nump">2,634<span></span>
</td>
<td class="nump">3,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">580<span></span>
</td>
<td class="nump">619<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">5,757<span></span>
</td>
<td class="nump">8,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">5,944<span></span>
</td>
<td class="nump">8,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,233<span></span>
</td>
<td class="nump">918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,205<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,538<span></span>
</td>
<td class="nump">2,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,584<span></span>
</td>
<td class="nump">2,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">27,903<span></span>
</td>
<td class="nump">27,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(24,537)<span></span>
</td>
<td class="num">(21,902)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">3,360<span></span>
</td>
<td class="nump">5,818<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 5,944<span></span>
</td>
<td class="nump">$ 8,335<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224799986152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">6,812,836<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">6,812,836<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224800025944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License revenue-related party</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,271<span></span>
</td>
<td class="nump">1,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,363<span></span>
</td>
<td class="nump">830<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,634<span></span>
</td>
<td class="nump">2,602<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,634)<span></span>
</td>
<td class="num">(2,602)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Revaluation of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest expense, net</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,635)<span></span>
</td>
<td class="num">(2,638)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on investments</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (2,639)<span></span>
</td>
<td class="num">$ (2,638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic (in usd per share)</a></td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.46)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock, diluted (in usd per share)</a></td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.46)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">6,812,836<span></span>
</td>
<td class="nump">5,710,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">6,812,836<span></span>
</td>
<td class="nump">5,710,270<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224799065688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th"><div>Additional&#160;Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, shares (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,506,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="num">$ (1,454)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,599)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock for convertible notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock for convertible notes</a></td>
<td class="nump">439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for IPO, net of issuance expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for IPO, net of issuance expenses</a></td>
<td class="nump">15,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of Underwriters Warrants</a></td>
<td class="nump">399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealizes loss on marketable securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,638)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, shares (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 12,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,237)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, shares (in shares) at Dec. 31, 2021</a></td>
<td class="nump">6,812,836<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 5,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,722<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">(21,902)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealizes loss on marketable securities, available-for-sale</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,635)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,635)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, shares (in shares) at Mar. 31, 2022</a></td>
<td class="nump">6,812,836<span></span>
</td>
<td class="nump">6,812,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 3,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,903<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
<td class="num">$ (24,537)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224796014440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,635)<span></span>
</td>
<td class="num">$ (2,638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance lease right-of-use asset</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of marketable securities premiums</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Revaluation of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_ForgivenessOfDebtInstrument', window );">Forgiveness of PPP note</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(61)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash interest, depreciation and other expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">39<span></span>
</td>
<td class="num">(793)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">315<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(225)<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="num">(2,290)<span></span>
</td>
<td class="num">(2,948)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sale of marketable securities</a></td>
<td class="nump">1,154<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash provided by investing activities</a></td>
<td class="nump">1,154<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from common stock, net of offering expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease liability</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash (used in) provided by financing activities</a></td>
<td class="num">(23)<span></span>
</td>
<td class="nump">15,819<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(1,159)<span></span>
</td>
<td class="nump">12,871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, at beginning of period</a></td>
<td class="nump">3,702<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, at end of period</a></td>
<td class="nump">2,543<span></span>
</td>
<td class="nump">12,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible notes to common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ForgivenessOfDebtInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forgiveness Of Debt Instrument</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ForgivenessOfDebtInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224798415144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">ORGANIZATION AND DESCRIPTION OF BUSINESS</a></td>
<td class="text">ORGANIZATION AND DESCRIPTION OF BUSINESS<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vallon Pharmaceuticals, Inc. (Vallon or the Company), based in Philadelphia, PA was incorporated in Delaware on January 11, 2018, which is the date of inception.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. The Company&#8217;s lead investigational product candidate, ADAIR, is a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine (the main active ingredient in Adderall&#174;) for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. In March 2022, the Company announced that its SEAL study for ADAIR did not reach its primary endpoint, and there is no assurance that ADAIR will receive approval by the U.S. Food and Drug Administration (the FDA). In addition to ADAIR, the Company completed formulation development work and selected the final formulation of its second product candidate, ADMIR, an abuse deterrent formulation of methylphenidate (Ritalin&#174;), for the treatment of ADHD.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEAL study (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tudy to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">valuate the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">buse </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation), was the Company&#8217;s pivotal intranasal human abuse liability study assessing the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability of snorting professional laboratory-manipulated ADAIR 30 mg when compared to crushed d-amphetamine sulfate and placebo in recreational drug users. ADAIR was prepared for snorting by a pharmacist using a multi-step technique that had been developed by a professional laboratory and agreed upon by the FDA. The SEAL study enrolled 55 subjects, of whom 53 completed the study and 52 were included in the final analysis. The study involved a four-way crossover design to evaluate professionally manipulated, intranasal ADAIR 30 mg, crushed intranasal dextroamphetamine, ADAIR 30 mg taken orally, and placebo. All subjects were non-dependent recreational stimulant users with an additional history of recreational intranasal drug use.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEAL study did not meet its primary endpoint, which was E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">max</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Drug Liking. ADAIR scored similarly to what was observed in an earlier proof-of-concept study, however, reference dextroamphetamine did not score as high as expected and as seen in the previous study, thus driving the lack of statistical significance. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is continuing to assess the best path forward for the ADAIR and ADMIR development programs. In addition, the Company has engaged Ladenburg Thalmann &amp; Co. Inc. (Ladenburg) to evaluate its strategic alternatives with the goal of maximizing stockholder value. Ladenburg has been engaged to advise the Company on the strategic review process, which could include, without limitation, exploring the potential for a possible merger, business combination, investment into the Company, or a purchase, license or other acquisition of assets. In the meantime, and in conjunction with the exploration of strategic alternatives, the Company is streamlining its operations in order to preserve its capital and cash resources.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224797725608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">LIQUIDITY</a></td>
<td class="text">LIQUIDITY<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception and has incurred $24,537 in accumulated deficit through March&#160;31, 2022. The Company has financed its working capital requirements to date through the issuance of common stock, convertible notes, short-term promissory notes, and a Paycheck Protection Program (PPP) promissory note.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2021, the Company completed a $350 convertible note financing and in February 2021, the Company completed the inital public offering (IPO) of the Company&#8217;s common stock, raising net proceeds of $15,500. As of March&#160;31, 2022, the Company had cash, cash equivalents and marketable securities of approximately $5,177.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects to incur ongoing expenses as it evaluates its plans for the ADAIR and ADMIR programs and strategic alternatives after it announced in March 2022 that the SEAL study of ADAIR for the treatment of ADHD failed to meet statistical </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significance for its primary endpoint. The Company is currently assessing the best path forward for the ADAIR and ADMIR programs and has no other product candidates undergoing clinical trials. The Company&#8217;s future capital requirements are difficult to forecast and will depend on many factors, including but not limited to the terms and timing of any strategic alternatives including a merger or business combination, asset acquisitions or sales, collaborations or licensing arrangements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company raises additional funds by issuing equity securities, its stockholders may experience dilution. Any future debt financing may impose upon it covenants that restrict our operations, including limitations on its ability to incur liens or additional debt, pay dividends, repurchase its common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any equity or debt financing may contain terms that are not favorable to the Company or its stockholders. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce or terminate some or all of its development programs and clinical trials. The Company may also be required to sell or license to other parties&#8217; rights to develop or commercialize its drug candidates that it would prefer to retain. Therefore, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company expects to continue to incur expenses and operating losses at least for the foreseeable future as it evaluates future plans for the ADAIR and ADMIR programs as well as its strategic alternatives.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224798392136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission. References in this Quarterly Report on Form 10-Q to &#8220;authoritative guidance&#8221; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2021 balance sheet was derived from audited financial statements. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the unaudited interim financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2022, and the results of operations and stockholders&#8217; equity (deficit) for the three months ended March&#160;31, 2022 and 2021 and cash flows for the three months ended March&#160;31, 2022 and 2021. Results of operations for the three months ended March&#160;31, 2022, are not necessarily indicative of the operating results that may be expected for the year ending December&#160;31, 2022. The unaudited interim financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December&#160;31, 2021, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on February&#160;14, 2022. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recapitalization</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the closing of the  IPO (Note 7), the Company effected a one-for-40 reverse stock split of its common stock. All share and per share amounts, excluding the number of authorized shares and par value, contained in these financial statements and accompanying notes, and this Quarterly Report on Form 10-Q give retroactive effect to the reverse split.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the unaudited interim financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s results of operations could either benefit from, or be adversely affected by, any such change in estimate. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of debt securities that are designated as available-for-sale. Marketable debt securities are recorded at fair value and unrealized holding gains or losses are reported as a component of accumulated other comprehensive income (loss). </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains or losses resulting from the sale of these securities are determined based on the specific identification of the securities sold. An impairment charge is recognized when the decline in the fair value of a debt security below the amortized cost basis is determined to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the duration and severity of any decline in fair value below the amortized cost basis, any adverse changes in the financial condition of the issuers and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are recorded as a cumulative adjustment in the period the estimates are revised. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the applicability and impact of all ASUs issued during the quarter ended March 31, 2022 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224798686776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS</a></td>
<td class="text">MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s available for sale securities as of the dates indicated:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Marketable Securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Corporate bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,634&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Marketable Securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Corporate bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,810&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,808&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, all of the Company&#8217;s marketable securities were classified as Level 2 assets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. The carrying amounts reported in the balance sheets for cash and cash equivalents, marketable securities, prepaid expenses and other current assets, accounts payable, accrued expenses, and note payable approximate their fair value based on the short-term maturity of these instruments.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the embedded derivative liability identified in the 2021 Convertible Notes (Note 6)  was a Level 3 fair value measurement. As of February&#160;12, 2021, the embedded derivative was remeasured based upon the conversion price of $8.00 per share upon closing of the IPO. As such, an expense of $89 was recorded during the three months ended March&#160;31, 2021.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our investments in marketable debt securities with state contractual maturity dates, accounted for as available-for-sale securities and classified by the contractual maturity date of the securities:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.611%"><tr><td style="width:1.0%"/><td style="width:84.956%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.363%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in 1-5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in 5-10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after 10 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,634&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224798387528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text">ACCRUED EXPENSES<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing related</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224798362216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PPP NOTE AND CONVERTIBLE NOTES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">PPP NOTE AND CONVERTIBLE NOTES</a></td>
<td class="text">PPP NOTE AND CONVERTIBLE NOTES<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company issued a promissory note under the PPP (the PPP Note) totaling $61. The PPP Note had a stated interest rate of 1% and had a two-year maturity. Payments were required to be made over a 1.5-year period beginning November 1, 2020, unless forgiven. In January 2021, the Company was notified that the loan along with accumulated interest had been forgiven. As a result, the Company recorded income from the extinguishment of its obligation in accordance with ASC 405-20-40-1, disclosed in the amount of $61 included in other income on the accompanying statements of operations and comprehensive loss. The Small Business Administration (SBA) reserves the right to audit any PPP loan, regardless of size. These audits may occur after forgiveness has been granted. In accordance with the CARES Act, all borrowers are required to maintain the PPP loan documentation for six years after the PPP loan was forgiven or repaid in full and to provide that documentation to the SBA upon request.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#8217;s Chief Executive Officer, pursuant to which the Company issued convertible promissory notes (the 2021 Convertible Notes), for cash proceeds of $350. The 2021 Convertible Notes bore an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September&#160;30, 2021. The 2021 Convertible Notes converted into 54,906 shares of the Company&#8217;s common stock upon completion of the IPO. The Company identified the mandatory conversion into shares of the Company&#8217;s common stock as a redemption feature, which requires bifurcation from the 2021 Convertible Notes and treated it as a derivative liability under ASC 815 as the redemption feature was not clearly and closely related to the debt. The Company evaluated the fair value of the derivative liability. Upon the conversion of the 2021 Convertible Notes to common stock at the closing of the IPO, the embedded derivative liability was remeasured and removed from the balance sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224797623624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY <div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company completed the IPO of 2,250,000 shares of common stock at a public offering price of $8.00 per share. The gross proceeds from the IPO, before deducting underwriting discounts, commissions and other offering expenses payable by the Company, were $18,000. Underwriting discounts and expenses totaled $1,600 and the Company incurred approximately $905 of additional expenses related to completing the IPO for aggregate net proceeds of approximately $15,500. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the IPO, the Company granted the underwriters warrants (the Underwriters' Warrants) to purchase an aggregate of 112,500 shares of common stock at an exercise price of $10.00 per share. The Underwriters&#8217; Warrants have a five-year term and were not exercisable prior to August 12, 2021. All of the Underwriters&#8217; Warrants were outstanding as of March&#160;31, 2022. The warrants were classified as equity and the fair value of $399 is reflected as additional paid-in capital. The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.155&#160;%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224801032632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation related to stock options issued under the Company&#8217;s 2018 Equity Incentive Plan (2018 Plan) in the following expense categories of its accompanying statements of operations for the three months ended March&#160;31, 2022 and 2021:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168</span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has granted stock options to purchase its common stock to employees and consultants under the 2018 Plan, under which the Company may issue stock options, restricted stock and other equity-based awards. The Company has also granted certain stock options outside of the 2018  Plan. Stock options granted by the Company generally have a contractual life of up to 10 years. As of March&#160;31, 2022, all equity awards granted from the 2018 Plan were in the form of stock options.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures equity-based awards granted to employees, and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for equity awards is the date of grant, and equity-based compensation costs are recognized as expense over the requisite service period, which is the vesting period or for certain performance-based awards. The Company records the expense for these awards if it concludes that it is probable that the performance condition will be achieved.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the three months ended March&#160;31, 2022:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term&#160;(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,490</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.64</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,000</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.80</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890,490</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.70</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,388</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.89</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.874%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.06</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.66</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.92</span></td></tr></table></div>As of March&#160;31, 2022, the unrecognized compensation cost related to unvested stock options expected to vest was $1,486. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of 3.17 years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224797757592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONS<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the Company entered into a license agreement with Medice which grants Medice an exclusive license, with the right to grant sublicenses, to develop, use, manufacture, market and sell ADAIR throughout Europe. Medice is responsible for obtaining regulatory approval of ADAIR in the licensed territory. Under the license agreement, Medice paid Vallon a $100 upfront payment and is required to pay milestone payments upon first obtaining regulatory approval to market and sell ADAIR in any country, territory or region in the licensed territory and upon achieving certain annual net sales thresholds. Medice will also pay tiered royalties on annual net sales of ADAIR at rates in the low double-digits. The initial term of the license agreement will expire five years after the date on which Medice first obtains regulatory approval in any country, territory or region in the licensed territory.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#8217;s Chief Executive Officer, pursuant to which the Company issued the 2021 Convertible Notes for cash proceeds of $350. The 2021 Convertible Notes bore an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes converted into 54,906 shares of the Company&#8217;s common stock upon completion of the IPO.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224797673752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Impact</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The global COVID-19 pandemic continues to present uncertainty and unforeseeable new risks to the Company&#8217;s operations and business plan. The Company has closely monitored recent COVID-19 developments, including the lifting of COVID-19 safety measures, the drop in vaccination rates, the implementation of, and reaction to, vaccine mandates, the spread of various coronavirus strains such as the Delta variant, and supply chain and labor shortages. In light of these developments, the full impact of the COVID-19 pandemic on the Company&#8217;s business, operations and clinical development plans remains uncertain and will vary depending on the pandemic&#8217;s future impact on the Company&#8217;s clinical trial enrollment, clinical trial sites, CROs, third-party manufacturers, and other third parties with whom we do business, as well as any legal or regulatory consequences resulting therefrom. To the extent possible, the Company is conducting business as usual, with necessary or advisable modifications to employee travel and with most of its employees and consultants working remotely. The Company will continue to actively monitor the COVID-19 pandemic and may take further actions that alter its operations, including those that may be required by federal, state or local authorities, or that the Company determines are in the best interests of its employees and other third parties with whom the Company does business.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224799996568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting</a></td>
<td class="text">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission. References in this Quarterly Report on Form 10-Q to &#8220;authoritative guidance&#8221; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2021 balance sheet was derived from audited financial statements. In the opinion of management, the unaudited interim financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of March&#160;31, 2022, and the results of operations and stockholders&#8217; equity (deficit) for the three months ended March&#160;31, 2022 and 2021 and cash flows for the three months ended March&#160;31, 2022 and 2021. Results of operations for the three months ended March&#160;31, 2022, are not necessarily indicative of the operating results that may be expected for the year ending December&#160;31, 2022. The unaudited interim financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December&#160;31, 2021, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on February&#160;14, 2022.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the unaudited interim financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s results of operations could either benefit from, or be adversely affected by, any such change in estimate.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities consist of debt securities that are designated as available-for-sale. Marketable debt securities are recorded at fair value and unrealized holding gains or losses are reported as a component of accumulated other comprehensive income (loss). </span></div>Realized gains or losses resulting from the sale of these securities are determined based on the specific identification of the securities sold. An impairment charge is recognized when the decline in the fair value of a debt security below the amortized cost basis is determined to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the duration and severity of any decline in fair value below the amortized cost basis, any adverse changes in the financial condition of the issuers and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amounts are recorded as a cumulative adjustment in the period the estimates are revised. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the applicability and impact of all ASUs issued during the quarter ended March 31, 2022 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224797623624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of the Company&#8217;s Available for Sale Securities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s available for sale securities as of the dates indicated:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Marketable Securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Corporate bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,634&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.794%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Marketable Securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Corporate bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,810&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,808&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of Estimated Fair Value of Investments Classified by Contractual Maturity Date</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our investments in marketable debt securities with state contractual maturity dates, accounted for as available-for-sale securities and classified by the contractual maturity date of the securities:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.611%"><tr><td style="width:1.0%"/><td style="width:84.956%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.363%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.281%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in 1 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in 1-5 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due in 5-10 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after 10 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,634&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224798393816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing related</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224797760952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text">The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.155&#160;%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224801883624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation related to stock options issued under the Company&#8217;s 2018 Equity Incentive Plan (2018 Plan) in the following expense categories of its accompanying statements of operations for the three months ended March&#160;31, 2022 and 2021:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Activity of Stock Options Granted</a></td>
<td class="text"><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the three months ended March&#160;31, 2022:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term&#160;(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708,490</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.64</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,000</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.80</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890,490</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.70</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,388</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.89</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.874%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.06</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.66</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of option on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.92</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224801809944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>participant</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled', window );">Number of subjects enrolled in the SEAL study</a></td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy', window );">Number of subjects that completed the SEAL study</a></td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis', window );">Number of subjects included in the final SEAL study analysis</a></td>
<td class="nump">52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Research Study, Number of Participants, Completed the Study</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Research Study, Number of Participants Enrolled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Research Study, Number of Participants, Included in Final Study Analysis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224798478936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="nump">$ 15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224798670728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th"><div>Feb. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="nump">0.025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224796046248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of the Company&#8217;s Available for Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="nump">$ 2,640<span></span>
</td>
<td class="nump">$ 3,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">2,634<span></span>
</td>
<td class="nump">3,808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="nump">349<span></span>
</td>
<td class="nump">1,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">349<span></span>
</td>
<td class="nump">1,152<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="nump">2,291<span></span>
</td>
<td class="nump">2,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 2,285<span></span>
</td>
<td class="nump">$ 2,656<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224798698888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Feb. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Expense recognized on embedded derivative</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224798991048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Investments Classified by Contractual Maturity Date (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in 1 year</a></td>
<td class="nump">$ 2,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due in 1-5 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Due in 5-10 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">Due after 10 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 2,634<span></span>
</td>
<td class="nump">$ 3,808<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224800104040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent', window );">Research and development</a></td>
<td class="nump">$ 640<span></span>
</td>
<td class="nump">$ 894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent', window );">General and administrative</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related</a></td>
<td class="nump">406<span></span>
</td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_AccruedLicensingFeesCurrent', window );">Licensing related</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 1,205<span></span>
</td>
<td class="nump">$ 1,430<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued General and Administrative Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedLicensingFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Licensing Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedLicensingFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Research and Development Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224795766840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PPP NOTE AND CONVERTIBLE NOTES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_ForgivenessOfDebtInstrument', window );">Forgiveness of PPP note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters' Allotment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants outstanding, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember', window );">Salmon Pharma, Affiliate of Medice and David Baker, CEO | Convertible Promissory Note Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Convertible notes, converted, shares issued (in shares)</a></td>
<td class="nump">54,906<span></span>
</td>
<td class="nump">54,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ck0001824293_PaycheckProtectionProgramCARESActMember', window );">Paycheck Protection Program, CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_DebtInstrumentPaymentTerm', window );">Debt instrument, payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtInstrumentPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Payment Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtInstrumentPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ForgivenessOfDebtInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forgiveness Of Debt Instrument</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ForgivenessOfDebtInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ck0001824293_PaycheckProtectionProgramCARESActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ck0001824293_PaycheckProtectionProgramCARESActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224799125640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Additional offering expense</a></td>
<td class="nump">$ 905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant issued reflected in additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross', window );">Gross proceeds from stock offering</a></td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsDiscountsAndCommissions', window );">Stock issuance costs, discounts and commissions</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="nump">$ 15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters' Allotment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants granted (in shares)</a></td>
<td class="nump">112,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants outstanding, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant issued reflected in additional paid-in capital</a></td>
<td class="nump">$ 399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance Initial Public Offering, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuanceCostsDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Discounts And Commissions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuanceCostsDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuanceCostsOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuanceCostsOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224798637496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Estimate of the Fair Value of the Warrants and Assumptions (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.00155<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224798512728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 181<span></span>
</td>
<td class="nump">$ 168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 163<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224800192776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock awards, contractual life (up to)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 1,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation, weighted average amortization period</a></td>
<td class="text">3 years 2 months 1 day<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224799128968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Activity of Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning Balance (in shares)</a></td>
<td class="nump">708,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending Balance (in shares)</a></td>
<td class="nump">890,490<span></span>
</td>
<td class="nump">708,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, Ending Balance (in shares)</a></td>
<td class="nump">253,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning Balance (in usd per share)</a></td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share)</a></td>
<td class="nump">5.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending Balance (in usd per share)</a></td>
<td class="nump">4.05<span></span>
</td>
<td class="nump">$ 3.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Ending Balance (in usd per share)</a></td>
<td class="nump">$ 3.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual term&#160;(years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Beginning Balance (years)</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">8 years 7 months 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, Ending Balance (years)</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">8 years 7 months 20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, Balance Ending (years)</a></td>
<td class="text">7 years 10 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224798963672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">88.65%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">6 years 21 days<span></span>
</td>
<td class="text">5 years 7 months 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.95%<span></span>
</td>
<td class="nump">0.69%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of option on grant date (in dollars per share)</a></td>
<td class="nump">$ 4.29<span></span>
</td>
<td class="nump">$ 4.92<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140224798613000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_MediceMember', window );">Medice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment', window );">Upfront payment received under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm', window );">License agreement, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember', window );">Salmon Pharma, Affiliate of Medice and David Baker, CEO | Convertible Promissory Note Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Convertible notes, converted, shares issued (in shares)</a></td>
<td class="nump">54,906<span></span>
</td>
<td class="nump">54,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_RelatedPartyTransactionLicenseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, License Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_RelatedPartyTransactionLicenseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, License Agreement, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_MediceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_MediceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>ck0001824293-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ck0001824293="http://www.vallon-pharma.com/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ck0001824293-20220331.xsd" xlink:type="simple"/>
    <context id="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i19484616c8c8480b9d94b951bcae0361_I20220506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2022-05-06</instant>
        </period>
    </context>
    <context id="if3397d410ba3402b845134ba54257a68_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i55dd8e26998945bf948e411d61ec483e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie7614adf727b407d9dcfe9c7866dadec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9cf4793645e7478396bfebc5d1280046_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b89c603f01d4777a2dedbf1801d5be1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idb04f7e476724b32ac14d93d1aecd6cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6ed8cb8b770442c18891f8011fdd7380_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i112cbf6fe6d94f7e95aa68e4b3b82566_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i696ce2800db940be9f493ce1a41cc843_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3fb11e86e5bf43d385426e1375734dd6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i52bc59ea9a964dd2878f917948cf15f6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6c36969402654f268647e2010c59c641_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibca337c014ca4895aaf539d38c0f5424_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8c71d40ad8c8445783218c6cc8c9fd95_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e72d21b8d324c0ca3c1f71d2e152b0e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i47d3c892e0334a90bfe742b8fc3fb929_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d5ea48dd69c4c3fb4e49bd12780ad99_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff52b3f4d3964f18b58baec76585133c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i470300e9f67349a4a8f5ed6f67792df9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id0cec8f00f4844c59bf6b4e46fa04203_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if4e4d371903843b8a67b3c95775d3069_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8e4a9d93e6d448e682d05b667992ba82_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaec88160062a4e4ebb51935d4831bccf_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iac76cfecf8b945eda2c37283b0d1bafa_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i459e0d6af0f74d42a0f684f536cfd55c_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i49ad1f772a4248b5984122466ba426db_D20210212-20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-12</endDate>
        </period>
    </context>
    <context id="if636725079b740db9f7e05e222c86d29_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5006cf101226413bb3ec2ab87613cd4e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic295d867cba3424dbf9d11196a15a2b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6895b671b37a41a2983fb05af80a2952_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1c4b8521c9f140c7a9592f7f41d732a6_I20210212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="i908364284b2449eaa88060f3a0a6fa84_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="ieace1ee3e7294bcc9238b92ee0af49d2_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i6f0dc3494c1646ab80c715e4bcf2f8e2_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i7820e87649a24600869cfef32d0d6f5b_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i0ae8348a777d4256870275ec7f5b29c4_D20211101-20211101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ck0001824293:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:AffiliateOfMediceAndDavidBakerCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="i4ab34f687d26476ca4c37cdeaec3802c_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="i63431f71e5c74bdbb2b0f31ac2cafe55_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="icfbaf3deac01401e89ec75e6ea05ae13_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="i6d2639da3a56431abd41a0af1356176b_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i1911bf6daa244c328b316073998944ff_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3c74df4f8925487f845fee1c71e9e072_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4fc7bd8d7fea4e7eba01520925d56116_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id978ce266ef042feb765030a9e74ad19_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic0c5dc3daa51452a98594f5d3f6b538f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i009ef9a9802043c7a795e51fb1ac96b0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0e848c92cf53437f8da4012e0c9545b1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib390bd62760a4ca8915004678a850b79_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4ff57a73247a47f5aa2e3b501764627b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idb6ea0f24b104095965bec61b8cda0e6_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ck0001824293:MediceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="participant">
        <measure>ck0001824293:participant</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80L2ZyYWc6M2FlZmQ5YmI1NmMxNGI2NzhiNzE0Yzg0MDE4NGI0YmMvdGFibGU6MzBkMzA3YzhmZDkzNDk1Nzk0YTdlMzYxYWUxMGFiYmMvdGFibGVyYW5nZTozMGQzMDdjOGZkOTM0OTU3OTRhN2UzNjFhZTEwYWJiY18yOS0xLTEtMS0zNzAzOQ_e63eee76-064a-4cad-b209-ebadd78a33a6">0001824293</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80L2ZyYWc6M2FlZmQ5YmI1NmMxNGI2NzhiNzE0Yzg0MDE4NGI0YmMvdGFibGU6MzBkMzA3YzhmZDkzNDk1Nzk0YTdlMzYxYWUxMGFiYmMvdGFibGVyYW5nZTozMGQzMDdjOGZkOTM0OTU3OTRhN2UzNjFhZTEwYWJiY18zMC0xLTEtMS0zNzAzOQ_e05f4f2b-295c-4b69-9816-e4888bd9e7b2">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80L2ZyYWc6M2FlZmQ5YmI1NmMxNGI2NzhiNzE0Yzg0MDE4NGI0YmMvdGFibGU6MzBkMzA3YzhmZDkzNDk1Nzk0YTdlMzYxYWUxMGFiYmMvdGFibGVyYW5nZTozMGQzMDdjOGZkOTM0OTU3OTRhN2UzNjFhZTEwYWJiY18zMS0xLTEtMS0zNzAzOQ_f40ac4cc-6ac8-4be5-83ee-191b0139378c">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80L2ZyYWc6M2FlZmQ5YmI1NmMxNGI2NzhiNzE0Yzg0MDE4NGI0YmMvdGFibGU6MzBkMzA3YzhmZDkzNDk1Nzk0YTdlMzYxYWUxMGFiYmMvdGFibGVyYW5nZTozMGQzMDdjOGZkOTM0OTU3OTRhN2UzNjFhZTEwYWJiY18zMi0xLTEtMS0zNzAzOQ_44a65ee2-572b-4bd8-9281-7ab7940a73e3">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80L2ZyYWc6M2FlZmQ5YmI1NmMxNGI2NzhiNzE0Yzg0MDE4NGI0YmMvdGFibGU6MzBkMzA3YzhmZDkzNDk1Nzk0YTdlMzYxYWUxMGFiYmMvdGFibGVyYW5nZTozMGQzMDdjOGZkOTM0OTU3OTRhN2UzNjFhZTEwYWJiY18zMy0xLTEtMS0zNzAzOQ_2436b887-4206-4264-9fd3-f79dbd0b6a73">false</dei:AmendmentFlag>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i49ad1f772a4248b5984122466ba426db_D20210212-20210212"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80My9mcmFnOmFlNGVjN2Q4NWMyOTRjMGU5M2U4MzZjYzM0OWJmN2NjL3RhYmxlOjE0NWUwMjJlYTZmYTQxODU5NWNmODFmMDc1MjgwY2MwL3RhYmxlcmFuZ2U6MTQ1ZTAyMmVhNmZhNDE4NTk1Y2Y4MWYwNzUyODBjYzBfMS0xLTEtMS0zNzAzOQ_8d10f7e1-1cb0-435c-a507-7f90e884a66e"
      unitRef="number">0.025</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV8yMDgz_5109aebf-0a67-46c2-b30e-57d242b6b998">10-Q</dei:DocumentType>
    <dei:DocumentType
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV8yMDgz_bc872895-024e-4cb6-b022-371a56f3e007">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6YmZlN2ViMGE0YWY3NDMxZDkyNmUxODFmYTRjYjk1MWYvdGFibGVyYW5nZTpiZmU3ZWIwYTRhZjc0MzFkOTI2ZTE4MWZhNGNiOTUxZl8wLTAtMS0xLTM3MDM5_cc6a3a5b-fde2-4f5f-8a39-4bf088680df2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV8yMDY_0d96c41c-cdd7-4b28-b668-5b62654cc7bd">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV8yMDY_2dc4f377-bf9b-4980-8296-51c7e1b28074">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6Y2IyYzI2ZmEzMDNjNDEzNjg2ODc2YjNhNWE0NzNhYzIvdGFibGVyYW5nZTpjYjJjMjZmYTMwM2M0MTM2ODY4NzZiM2E1YTQ3M2FjMl8wLTAtMS0xLTM3MDM5_f4be9d90-d5c0-4c27-990e-215ba07b5d41">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV8yMDg5_65294989-a7ea-4309-ba1b-cda740f78169">001-40034</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV8yMDc4_c33932a5-34fc-4da4-90b7-acbc357965cd">VALLON PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6OTBhNWZmZmVhZWZhNDdhNWIwNjE2Yzc1NmQwNzc1ZWIvdGFibGVyYW5nZTo5MGE1ZmZmZWFlZmE0N2E1YjA2MTZjNzU2ZDA3NzVlYl8wLTAtMS0xLTM3MDM5_4c9743c9-8a6d-40bf-9f13-a37d1403792b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6OTBhNWZmZmVhZWZhNDdhNWIwNjE2Yzc1NmQwNzc1ZWIvdGFibGVyYW5nZTo5MGE1ZmZmZWFlZmE0N2E1YjA2MTZjNzU2ZDA3NzVlYl8wLTItMS0xLTM3MDM5_2bd9e8fa-3e3b-4cbb-8ad9-df2cf1f8d0d7">82-4369909</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6OTBhNWZmZmVhZWZhNDdhNWIwNjE2Yzc1NmQwNzc1ZWIvdGFibGVyYW5nZTo5MGE1ZmZmZWFlZmE0N2E1YjA2MTZjNzU2ZDA3NzVlYl8zLTAtMS0xLTM3MDM5L3RleHRyZWdpb246MGFkZDE1YTdkYzZhNDhkY2JmMWFmNzEyN2YwMGM1M2RfNQ_36351b2c-d25a-45eb-ba5c-90e5eed5cea5">100 N. 18th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6OTBhNWZmZmVhZWZhNDdhNWIwNjE2Yzc1NmQwNzc1ZWIvdGFibGVyYW5nZTo5MGE1ZmZmZWFlZmE0N2E1YjA2MTZjNzU2ZDA3NzVlYl8zLTAtMS0xLTM3MDM5L3RleHRyZWdpb246MGFkZDE1YTdkYzZhNDhkY2JmMWFmNzEyN2YwMGM1M2RfOQ_7160ab90-65c3-447d-b8cb-3efb8adbd44d">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6OTBhNWZmZmVhZWZhNDdhNWIwNjE2Yzc1NmQwNzc1ZWIvdGFibGVyYW5nZTo5MGE1ZmZmZWFlZmE0N2E1YjA2MTZjNzU2ZDA3NzVlYl8zLTAtMS0xLTM3MDM5L3RleHRyZWdpb246MGFkZDE1YTdkYzZhNDhkY2JmMWFmNzEyN2YwMGM1M2RfMTQ_f274b74c-06b8-4bcb-b0f1-54024a416663">Philadelphia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6OTBhNWZmZmVhZWZhNDdhNWIwNjE2Yzc1NmQwNzc1ZWIvdGFibGVyYW5nZTo5MGE1ZmZmZWFlZmE0N2E1YjA2MTZjNzU2ZDA3NzVlYl8zLTAtMS0xLTM3MDM5L3RleHRyZWdpb246MGFkZDE1YTdkYzZhNDhkY2JmMWFmNzEyN2YwMGM1M2RfMTg_c3d8f23c-791a-4da2-a312-6b9c65213986">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6OTBhNWZmZmVhZWZhNDdhNWIwNjE2Yzc1NmQwNzc1ZWIvdGFibGVyYW5nZTo5MGE1ZmZmZWFlZmE0N2E1YjA2MTZjNzU2ZDA3NzVlYl8zLTAtMS0xLTM3MDM5L3RleHRyZWdpb246MGFkZDE1YTdkYzZhNDhkY2JmMWFmNzEyN2YwMGM1M2RfMjI_aca26395-0f79-4d48-87c5-63d5811b3dfa">19103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV80NjA_1520572f-740c-4c12-955f-6a9541b83b51">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV8yMDc5_e9ca650c-b85d-44fa-b32c-e1f6be34335b">207-3606</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6MmE2NDZjMzJkYjY4NDBlNGE5Y2UxZDg4N2FkMDE5ODMvdGFibGVyYW5nZToyYTY0NmMzMmRiNjg0MGU0YTljZTFkODg3YWQwMTk4M18xLTAtMS0xLTM3MDM5_37503efa-4b50-4a47-9cb8-79dc1bd76a5a">Common Stock, par value $0.0001per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6MmE2NDZjMzJkYjY4NDBlNGE5Y2UxZDg4N2FkMDE5ODMvdGFibGVyYW5nZToyYTY0NmMzMmRiNjg0MGU0YTljZTFkODg3YWQwMTk4M18xLTItMS0xLTM3MDM5_cae22647-3157-428f-9021-552663258201">VLON</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6MmE2NDZjMzJkYjY4NDBlNGE5Y2UxZDg4N2FkMDE5ODMvdGFibGVyYW5nZToyYTY0NmMzMmRiNjg0MGU0YTljZTFkODg3YWQwMTk4M18xLTQtMS0xLTM3MDM5L3RleHRyZWdpb246N2RjYmMwYjc1MzZkNGI5ZTg1N2UyNTIyYmM5N2Y2MjBfNA_91592248-eebe-4a4a-ac5f-94e8040a1379">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV8yMDgw_fb028e2d-e7ab-45ef-85b0-2175d4d18981">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV8yMDgy_837b937d-59c2-4b23-8ece-10250bc4f8d0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6MmJjNGFjYjQwZTZjNDNhZmE5OGVmZjczZjJjYTEzYjIvdGFibGVyYW5nZToyYmM0YWNiNDBlNmM0M2FmYTk4ZWZmNzNmMmNhMTNiMl8xLTAtMS0xLTM3MDM5_ec884656-0018-4a6e-af73-5c025caa4d1b">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6MmJjNGFjYjQwZTZjNDNhZmE5OGVmZjczZjJjYTEzYjIvdGFibGVyYW5nZToyYmM0YWNiNDBlNmM0M2FmYTk4ZWZmNzNmMmNhMTNiMl8xLTMtMS0xLTM3MDM5_73a25934-1ebd-4f29-9295-1af84a3bc36f">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGFibGU6MmJjNGFjYjQwZTZjNDNhZmE5OGVmZjczZjJjYTEzYjIvdGFibGVyYW5nZToyYmM0YWNiNDBlNmM0M2FmYTk4ZWZmNzNmMmNhMTNiMl8yLTEtMS0xLTM3MDM5_14e6a14e-ec5a-4718-a9c8-44b7a8bbc74f">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV8yMDg1_e3a309fa-e686-4e09-8498-3fd32b9f4ab4">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV8yMDg2_edc5430a-e3d4-4da7-807c-5a9326b80b60">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i19484616c8c8480b9d94b951bcae0361_I20220506"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xL2ZyYWc6ZGEyMDJiOTQwMmMyNDFjNzk0YmY3YTIwOTRjOTQ1MzEvdGV4dHJlZ2lvbjpkYTIwMmI5NDAyYzI0MWM3OTRiZjdhMjA5NGM5NDUzMV8yMDE3_d898768b-6648-418b-954d-3d9c71871888"
      unitRef="shares">6812836</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMy0xLTEtMS0zNzAzOQ_88c1d296-5779-43e9-87cc-d062aabff24c"
      unitRef="usd">2543000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMy0zLTEtMS0zNzAzOQ_68edc838-0ba7-4391-9a87-1112c067481d"
      unitRef="usd">3702000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfNC0xLTEtMS0zNzAzOQ_bd23f59a-eed3-47bb-8deb-7f35db1d1508"
      unitRef="usd">2634000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfNC0zLTEtMS0zNzAzOQ_ad8275b8-96c1-4da7-a76a-80ae7fc0608f"
      unitRef="usd">3808000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfNS0xLTEtMS0zNzAzOQ_f8938792-3eea-4ec4-b377-2335121b47cb"
      unitRef="usd">580000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfNS0zLTEtMS0zNzAzOQ_275f3257-5afe-488f-8478-f191fec60b8e"
      unitRef="usd">619000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfNi0xLTEtMS0zNzAzOQ_dd834e7b-28b9-4aea-89c4-5ae1b5dd4af6"
      unitRef="usd">5757000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfNi0zLTEtMS0zNzAzOQ_6a625bff-5a4c-40d2-9f32-e1ddcb2bc025"
      unitRef="usd">8129000</us-gaap:AssetsCurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfNy0xLTEtMS0zNzAzOQ_2db30fc5-ee8a-4071-90d2-8abb735a1b4b"
      unitRef="usd">187000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfNy0zLTEtMS0zNzAzOQ_adbe439f-2cd4-4a27-8b93-5853ec7bdf49"
      unitRef="usd">206000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfOS0xLTEtMS0zNzAzOQ_f4b3ce3b-45e2-4a07-b1ad-641ee2a0f02a"
      unitRef="usd">5944000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfOS0zLTEtMS0zNzAzOQ_0e507170-3800-4b66-9910-b3967cb3de84"
      unitRef="usd">8335000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMTMtMS0xLTEtMzcwMzk_5c898579-ac22-4f56-b08f-a5eea9efbdbe"
      unitRef="usd">1233000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMTMtMy0xLTEtMzcwMzk_89f967f4-0529-4538-9e50-e50b043125da"
      unitRef="usd">918000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMTQtMS0xLTEtMzcwMzk_f2cb352e-bb84-46dd-b472-74d644ade284"
      unitRef="usd">1205000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMTQtMy0xLTEtMzcwMzk_ac43f310-aeba-4ef1-9c71-0ed4a5444ac7"
      unitRef="usd">1430000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMTYtMS0xLTEtMzcwMzk_401fa0bb-d16d-4a02-860b-f61975e273fc"
      unitRef="usd">100000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMTYtMy0xLTEtMzcwMzk_363c4ac7-b4b5-403d-a97c-9aa45a3e1818"
      unitRef="usd">97000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMTctMS0xLTEtMzcwMzk_6af95d89-4d6c-4fa3-8b55-3665d4655469"
      unitRef="usd">2538000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMTctMy0xLTEtMzcwMzk_d35cc383-5664-4c1e-8997-540721621910"
      unitRef="usd">2445000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMTktMS0xLTEtMzcwMzk_34973fd0-1180-4e0f-b44d-02289ca8a918"
      unitRef="usd">46000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMTktMy0xLTEtMzcwMzk_21c4e883-fb8a-43cb-b1e0-6c13ddb81aaf"
      unitRef="usd">72000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjAtMS0xLTEtMzcwMzk_55986d70-6e90-42ba-8301-03fcf03725b0"
      unitRef="usd">2584000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjAtMy0xLTEtMzcwMzk_03892bcf-f19a-4b22-a3ca-6d36e3e48292"
      unitRef="usd">2517000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjItMS0xLTEtMzcwMzk_2889a160-e2d3-4cdf-affc-f133a4ac6b3a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjItMy0xLTEtMzcwMzk_e47a00bf-2800-47bf-852b-b8177524ff99"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjUtMC0xLTEtMzcwMzkvdGV4dHJlZ2lvbjo3ZGFkZDY4MGYxYTY0NDk2OWFjYTBlZDU0YTcyMWE4Y18xOA_9fc8495a-b40e-4eb2-a14b-fc3a3c9158ad"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjUtMC0xLTEtMzcwMzkvdGV4dHJlZ2lvbjo3ZGFkZDY4MGYxYTY0NDk2OWFjYTBlZDU0YTcyMWE4Y18xOA_e9a53095-c071-407f-a528-9c96981ae121"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjUtMC0xLTEtMzcwMzkvdGV4dHJlZ2lvbjo3ZGFkZDY4MGYxYTY0NDk2OWFjYTBlZDU0YTcyMWE4Y18zMg_23c8a70c-e48c-44dc-bd7c-63636d3e07a7"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjUtMC0xLTEtMzcwMzkvdGV4dHJlZ2lvbjo3ZGFkZDY4MGYxYTY0NDk2OWFjYTBlZDU0YTcyMWE4Y18zMg_41ff59d0-3625-4f63-a20e-840b15388abc"
      unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjUtMC0xLTEtMzcwMzkvdGV4dHJlZ2lvbjo3ZGFkZDY4MGYxYTY0NDk2OWFjYTBlZDU0YTcyMWE4Y183MA_85ccdaaa-30a1-48bc-9d07-7e75ad0c594d"
      unitRef="shares">6812836</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjUtMC0xLTEtMzcwMzkvdGV4dHJlZ2lvbjo3ZGFkZDY4MGYxYTY0NDk2OWFjYTBlZDU0YTcyMWE4Y183MA_94d16822-af49-4f87-86bf-e5efa738d2cb"
      unitRef="shares">6812836</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjUtMC0xLTEtMzcwMzkvdGV4dHJlZ2lvbjo3ZGFkZDY4MGYxYTY0NDk2OWFjYTBlZDU0YTcyMWE4Y183MA_bb2a3809-0d3a-4353-a4bc-2910eba5c668"
      unitRef="shares">6812836</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjUtMC0xLTEtMzcwMzkvdGV4dHJlZ2lvbjo3ZGFkZDY4MGYxYTY0NDk2OWFjYTBlZDU0YTcyMWE4Y183MA_f7f5365f-35f2-4906-98fd-bb020da4349a"
      unitRef="shares">6812836</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValueOutstanding
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjUtMS0xLTEtMzcwMzk_ca4cdbf8-a7e9-4bf3-ba00-c50990722fad"
      unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjUtMy0xLTEtMzcwMzk_bbf448ba-4857-4373-b098-0518b1e35cad"
      unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjYtMS0xLTEtMzcwMzk_b0694392-b925-4bc3-97ea-5a38a402e2dc"
      unitRef="usd">27903000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjYtMy0xLTEtMzcwMzk_ffd3e6d5-ad54-424d-841f-ff72a16a70a6"
      unitRef="usd">27722000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjctMS0xLTEtMzcwMzk_53561b36-b49e-47fe-b0a8-5f891d77d3af"
      unitRef="usd">-6000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjctMy0xLTEtMzcwMzk_bb62ba3c-5c12-44eb-8c6a-625cead417bf"
      unitRef="usd">-2000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjgtMS0xLTEtMzcwMzk_af5139ce-ae02-4415-80a3-acb6035fe160"
      unitRef="usd">-24537000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjgtMy0xLTEtMzcwMzk_23909751-956f-4e6a-a70e-21c55be2c6ed"
      unitRef="usd">-21902000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjktMS0xLTEtMzcwMzk_1d71e7c2-1eb1-4001-b3ec-5228dbcc7be5"
      unitRef="usd">3360000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMjktMy0xLTEtMzcwMzk_03279103-43e5-4a40-9b99-cad17ecee63f"
      unitRef="usd">5818000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMzAtMS0xLTEtMzcwMzk_a62409f2-a8ba-4d5d-a7e2-10699f82cf41"
      unitRef="usd">5944000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8xOS9mcmFnOjc2Mzc2ODM4ZTNhZjQyNTY5OWQ3OTAxNDRmM2RlZTI1L3RhYmxlOjljNmNiZjliNDk3NzRkNmNiYTk5M2RjY2UzMDY4MjViL3RhYmxlcmFuZ2U6OWM2Y2JmOWI0OTc3NGQ2Y2JhOTkzZGNjZTMwNjgyNWJfMzAtMy0xLTEtMzcwMzk_2976d67c-bc34-48c1-ad4d-820a329c6306"
      unitRef="usd">8335000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMy0xLTEtMS0zNzAzOQ_9f5ce968-87a0-48f8-a62d-58b3d59a7d03"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMy0zLTEtMS0zNzAzOQ_69ffb7de-fb8b-4079-9792-bda888ce3299"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfNS0xLTEtMS0zNzAzOQ_854d484d-719b-46ca-a2b8-e7bc4dea5944"
      unitRef="usd">1271000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfNS0zLTEtMS0zNzAzOQ_eb032a3d-ac1f-421d-9b9e-c26baa179e66"
      unitRef="usd">1772000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfNi0xLTEtMS0zNzAzOQ_f52509d0-fb8d-4629-a47c-a359b159a560"
      unitRef="usd">1363000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfNi0zLTEtMS0zNzAzOQ_f6ee8ec5-085b-418b-8534-6406b876f5b4"
      unitRef="usd">830000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfNy0xLTEtMS0zNzAzOQ_9464df53-9b59-4d05-9170-f72133167ed0"
      unitRef="usd">2634000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfNy0zLTEtMS0zNzAzOQ_3b9fddbe-c852-411d-a452-30e7bbe183ab"
      unitRef="usd">2602000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfOC0xLTEtMS0zNzAzOQ_4b0def5b-b3b1-4263-9661-3b3564d42232"
      unitRef="usd">-2634000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfOC0zLTEtMS0zNzAzOQ_8a756789-fcbf-418e-9296-d07d266c29f7"
      unitRef="usd">-2602000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncome
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfOS0xLTEtMS0zNzAzOQ_6e1fa1fa-5096-4e13-bb2d-e188e1dbba5b"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfOS0zLTEtMS0zNzAzOQ_94cf671c-a8aa-4d1e-a801-52b3f295f1af"
      unitRef="usd">61000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTAtMS0xLTEtMzcwMzk_81159514-70c9-40d7-945b-89bc1d053380"
      unitRef="usd">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTAtMy0xLTEtMzcwMzk_054cf793-7735-45b0-a0af-270b142d8c6f"
      unitRef="usd">-89000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTEtMS0xLTEtMzcwMzk_a59f9320-c37c-4b6c-843f-34baef98d176"
      unitRef="usd">-1000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTEtMy0xLTEtMzcwMzk_1c2049ad-f756-4885-b9e6-a9ad54058f81"
      unitRef="usd">-8000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTItMS0xLTEtMzcwMzk_e372335f-e309-4b56-b3b1-71a9b20ce2ca"
      unitRef="usd">-2635000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTItMy0xLTEtMzcwMzk_86a594e9-4542-4cd6-99f5-d3ba59b24252"
      unitRef="usd">-2638000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTQtMS0xLTEtMzcwMzk_385a004d-c1b3-47da-9c1d-dfe390c29a51"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTQtMy0xLTEtMzcwMzk_a22a5c0b-5817-4757-b0a3-681f2ab661d9"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTUtMS0xLTEtMzcwMzk_14845f91-55ff-468e-b5c1-6dee6a531dde"
      unitRef="usd">-2639000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTUtMy0xLTEtMzcwMzk_5c9670e6-ff85-42bc-9fed-508071027017"
      unitRef="usd">-2638000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTctMS0xLTEtMzcwMzk_fbb3fcab-144b-4271-aaa9-20ee981c7998"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTctMS0xLTEtMzcwMzk_fe0a152e-6c5c-4650-9a59-30d31c596efe"
      unitRef="usdPerShare">-0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTctMy0xLTEtMzcwMzk_56b56faf-3c85-439d-933a-4684cf14dd13"
      unitRef="usdPerShare">-0.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTctMy0xLTEtMzcwMzk_8d74278f-f2b7-4f2c-964f-62ce0953a198"
      unitRef="usdPerShare">-0.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTgtMS0xLTEtMzcwMzk_3b4dc841-fdee-4acb-b0a0-5c9ed94b7e5c"
      unitRef="shares">6812836</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTgtMS0xLTEtMzcwMzk_c04045a5-e576-4e02-9597-bd568fdd766f"
      unitRef="shares">6812836</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTgtMy0xLTEtMzcwMzk_ab12bf51-bfca-448b-9649-38992968d2a3"
      unitRef="shares">5710270</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yMi9mcmFnOjIxMWViMmFmMzY0MTRlMDU5NTY0ZjM1YjYwZDY4ZGNjL3RhYmxlOjkwNGJkODkwMWI3YzQ3NWY4ZmMxYzQ3MGJmNmYxMDlmL3RhYmxlcmFuZ2U6OTA0YmQ4OTAxYjdjNDc1ZjhmYzFjNDcwYmY2ZjEwOWZfMTgtMy0xLTEtMzcwMzk_e1b45de4-5426-4572-a83e-7f1cf2d88943"
      unitRef="shares">5710270</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie7614adf727b407d9dcfe9c7866dadec_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfMi0xLTEtMS0zNzAzOQ_9ef5bd30-8097-42ac-a43a-e1788dce59cb"
      unitRef="shares">4506216</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9cf4793645e7478396bfebc5d1280046_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfMi01LTEtMS0zNzAzOQ_930785d0-c19b-46e7-871f-948c43c80435"
      unitRef="usd">11145000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8b89c603f01d4777a2dedbf1801d5be1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfMi05LTEtMS0zNzAzOQ_d4a9cd14-5974-4395-b8d9-2e3216bb8928"
      unitRef="usd">-12599000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idb04f7e476724b32ac14d93d1aecd6cd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfMi0xMS0xLTEtMzcwMzk_60a2ce87-4f8b-44f8-b28a-22807b2a5baf"
      unitRef="usd">-1454000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i6ed8cb8b770442c18891f8011fdd7380_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfMy0xLTEtMS0zNzAzOQ_a5794912-8c55-408e-a73b-16c8c7c61354"
      unitRef="shares">54906</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i112cbf6fe6d94f7e95aa68e4b3b82566_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfMy01LTEtMS0zNzAzOQ_650900c5-f5a3-48e3-9735-2a6c83ff3050"
      unitRef="usd">439000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfMy0xMS0xLTEtMzcwMzk_e23f87d3-df6e-4186-861c-f7003bfb4863"
      unitRef="usd">439000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i6ed8cb8b770442c18891f8011fdd7380_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfNC0xLTEtMS0zNzAzOQ_38d05a1b-b14f-4b8e-8e0f-5b93c7e78477"
      unitRef="shares">2250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i112cbf6fe6d94f7e95aa68e4b3b82566_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfNC01LTEtMS0zNzAzOQ_a6672868-bc5e-46ea-8ee8-a04d070448b8"
      unitRef="usd">15104000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfNC0xMS0xLTEtMzcwMzk_ebad6994-f565-484e-b4eb-8c95a78f5979"
      unitRef="usd">15104000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i6ed8cb8b770442c18891f8011fdd7380_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfNS0xLTEtMS0zNzAzOQ_36d6542a-7d85-4449-8b37-0afc42fba1a0"
      unitRef="shares">1714</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i112cbf6fe6d94f7e95aa68e4b3b82566_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfNS01LTEtMS0zNzAzOQ_5552b994-0a86-4f86-8172-f8ee8b868c8e"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfNS0xMS0xLTEtMzcwMzk_983afa15-cfae-4f14-abb8-2381f772ff39"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i112cbf6fe6d94f7e95aa68e4b3b82566_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfNi01LTEtMS0zNzAzOQ_cbbdc4f5-e4f8-454d-8079-ad7eba73e96f"
      unitRef="usd">399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfNi0xMS0xLTEtMzcwMzk_b2f56369-43ee-4636-b36b-ac9f62da3d3c"
      unitRef="usd">399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i112cbf6fe6d94f7e95aa68e4b3b82566_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfNy01LTEtMS0zNzAzOQ_bde875d6-9788-47c4-a469-7f1d57e0f8e1"
      unitRef="usd">168000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfNy0xMS0xLTEtMzcwMzk_4fb093ee-830f-4baa-93d3-ea85d34abe0e"
      unitRef="usd">168000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i696ce2800db940be9f493ce1a41cc843_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfOC05LTEtMS0zNzAzOQ_b2f3abc2-4e50-4c56-b044-669b16aff62b"
      unitRef="usd">-2638000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfOC0xMS0xLTEtMzcwMzk_25fa4fd8-f99a-4c89-abce-8c4ade0d7088"
      unitRef="usd">-2638000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3fb11e86e5bf43d385426e1375734dd6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfOS0xLTEtMS0zNzAzOQ_ce841e37-83f9-446a-a12f-cdc44388994e"
      unitRef="shares">6812836</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i52bc59ea9a964dd2878f917948cf15f6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfOS01LTEtMS0zNzAzOQ_396bf65c-7acc-4deb-89de-8909e9c52eb9"
      unitRef="usd">27264000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6c36969402654f268647e2010c59c641_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfOS05LTEtMS0zNzAzOQ_5d57f48f-1162-4a6b-8b6e-c43c2ed4ad9e"
      unitRef="usd">-15237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibca337c014ca4895aaf539d38c0f5424_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOmNlYzQ4ZTEwMDEzMzRkMTdhODRmMzExMTQ1YjgyZTYyL3RhYmxlcmFuZ2U6Y2VjNDhlMTAwMTMzNGQxN2E4NGYzMTExNDViODJlNjJfOS0xMS0xLTEtMzcwMzk_b4b1f3e0-6e3e-406e-8194-3ddf0697dfe1"
      unitRef="usd">12027000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8c71d40ad8c8445783218c6cc8c9fd95_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfMi0xLTEtMS0zOTAzNg_e7cd55c6-9dcf-4062-b4e9-53d90c79e828"
      unitRef="shares">6812836</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7e72d21b8d324c0ca3c1f71d2e152b0e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfMi01LTEtMS0zOTA0Mw_8060fd6f-4e40-43ec-a0e0-621212232e10"
      unitRef="usd">27722000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i47d3c892e0334a90bfe742b8fc3fb929_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfMi03LTEtMS0zOTA1Nw_d7c384cd-da9d-47fd-8680-ea96bd660f35"
      unitRef="usd">-2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2d5ea48dd69c4c3fb4e49bd12780ad99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfMi05LTEtMS00MDAxNQ_2c29072a-1e08-4547-9ac5-91f699d92d18"
      unitRef="usd">-21902000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfMi0xMS0xLTEtNDAwMjY_491f7357-abdc-4f87-b03d-fcbf470514c5"
      unitRef="usd">5818000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iff52b3f4d3964f18b58baec76585133c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfMy01LTEtMS0zOTQxNA_a9ed3cab-d450-4328-bfe5-42544f47800e"
      unitRef="usd">181000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfMy0xMS0xLTEtNDAwMjY_daab2020-d7dc-4393-b97e-eda6dea465c4"
      unitRef="usd">181000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfNC03LTEtMS0zOTQyMA_8f50dcaa-b61d-4e82-91ca-19c2a1393fe0"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfNC0xMS0xLTEtNDAwMjY_adfec78b-d1f9-4ff2-b277-1102a35c569d"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i470300e9f67349a4a8f5ed6f67792df9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfNS05LTEtMS0zOTQyNg_bf108d2b-fa5c-4e0c-929e-1895ed5aee6a"
      unitRef="usd">-2635000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfNS0xMS0xLTEtNDAwMjY_dfe27fbe-c5b0-4f17-85a8-766026fb4164"
      unitRef="usd">-2635000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id0cec8f00f4844c59bf6b4e46fa04203_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfNi0xLTEtMS0zOTQzMw_3de0f940-a071-4225-a02c-61afa049c9af"
      unitRef="shares">6812836</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if4e4d371903843b8a67b3c95775d3069_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfNi01LTEtMS00MDAwMA_c09955a6-07e7-4cce-bc9b-21dd16523182"
      unitRef="usd">27903000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8e4a9d93e6d448e682d05b667992ba82_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfNi03LTEtMS00MDAxMQ_1615af1c-0727-4d0a-a54b-a6868f8008ea"
      unitRef="usd">-6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaec88160062a4e4ebb51935d4831bccf_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfNi05LTEtMS00MDAyMA_f5a76080-a589-4900-912e-a51c3cf20d46"
      unitRef="usd">-24537000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yNS9mcmFnOjY1ZGI3NjI3YjhhYzQ3M2M4YzY2ZjU3MWE4NGZkZjU3L3RhYmxlOjJlNzRmZDc4MTAyMzQwN2NhYjcyMmQ0ZWRhNDBlNjIxL3RhYmxlcmFuZ2U6MmU3NGZkNzgxMDIzNDA3Y2FiNzIyZDRlZGE0MGU2MjFfNi0xMS0xLTEtNDAwMjY_34b125ad-1e2f-40e3-9387-0fa1a6b4ba8f"
      unitRef="usd">3360000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMy0xLTEtMS0zNzAzOQ_983da759-e77a-47ba-b840-ccaa5c594967"
      unitRef="usd">-2635000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMy0zLTEtMS0zNzAzOQ_82a726fe-1304-4abc-baba-d672b3162c30"
      unitRef="usd">-2638000</us-gaap:NetIncomeLoss>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfNS0xLTEtMS0zNzAzOQ_9dc31d12-4ae0-4c25-95f8-9cae34fda310"
      unitRef="usd">19000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfNS0zLTEtMS0zNzAzOQ_ffe088c5-1988-4c16-8476-e652726dd997"
      unitRef="usd">18000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfNi0xLTEtMS0zNzAzOQ_88083021-626a-4d48-a077-aebe76d7e582"
      unitRef="usd">-16000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfNi0zLTEtMS0zNzAzOQ_057ef1e8-d372-4992-af65-d31f964e75f0"
      unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfNy0xLTEtMS0zNzAzOQ_05643f2a-8621-4bab-93c2-0bfd2dc54432"
      unitRef="usd">181000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfNy0zLTEtMS0zNzAzOQ_2a03cbba-a3b3-452b-a141-a6c627d778dd"
      unitRef="usd">168000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfOC0xLTEtMS0zNzAzOQ_3ae9bebc-2455-4d7c-b024-c36f33a6e586"
      unitRef="usd">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfOC0zLTEtMS0zNzAzOQ_684594a9-7c1d-44ee-8bb1-c305789dd1cc"
      unitRef="usd">-89000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <ck0001824293:ForgivenessOfDebtInstrument
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfOS0xLTEtMS0zNzAzOQ_b8d5badf-5051-4abb-b9a6-c4fb41e41d46"
      unitRef="usd">0</ck0001824293:ForgivenessOfDebtInstrument>
    <ck0001824293:ForgivenessOfDebtInstrument
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfOS0zLTEtMS0zNzAzOQ_46c002c1-02a8-4155-b783-a06e8395445a"
      unitRef="usd">61000</ck0001824293:ForgivenessOfDebtInstrument>
    <us-gaap:OtherNoncashExpense
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMTAtMS0xLTEtMzcwMzk_6be9606e-0c82-40bc-8513-e2303a97ec5b"
      unitRef="usd">0</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMTAtMy0xLTEtMzcwMzk_8594630d-2601-4b50-bb3b-34a65281eda9"
      unitRef="usd">10000</us-gaap:OtherNoncashExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMTItMS0xLTEtMzcwMzk_ebfbb5b5-f741-4bd7-9b45-05a4367f53a3"
      unitRef="usd">-39000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMTItMy0xLTEtMzcwMzk_9101f616-5ac9-4d30-b451-a5bdcb378b15"
      unitRef="usd">793000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMTMtMS0xLTEtMzcwMzk_324d0978-8288-483d-8f95-161dbd2d8a20"
      unitRef="usd">315000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMTMtMy0xLTEtMzcwMzk_2be259d0-3c6a-4cef-8f83-14bdef3dfe5a"
      unitRef="usd">121000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMTQtMS0xLTEtMzcwMzk_ea223740-771c-4b08-a7f0-af8674b4b988"
      unitRef="usd">-225000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMTQtMy0xLTEtMzcwMzk_e33560cc-8781-4710-b34c-eeafe1403664"
      unitRef="usd">138000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMTUtMS0xLTEtMzcwMzk_56369353-1035-442c-80ee-4ed3a1bd937d"
      unitRef="usd">-2290000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMTUtMy0xLTEtMzcwMzk_e88bd98b-cdfe-4460-bc38-095d4c259da4"
      unitRef="usd">-2948000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMTgtMS0xLTEtMzcwMzk_84154619-9d2d-4748-934f-fc757b503c46"
      unitRef="usd">1154000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMTgtMy0xLTEtMzcwMzk_48a83cf7-7c6e-4050-83ab-564802769774"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMjAtMS0xLTEtMzcwMzk_fcfa8f2e-9548-4424-b750-44f63aafdb57"
      unitRef="usd">1154000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMjAtMy0xLTEtMzcwMzk_266e0f97-0379-485c-98c5-6be0076e5649"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMjQtMS0xLTEtMzcwMzk_c7a7cb41-3046-47b9-b893-a94b07f91847"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMjQtMy0xLTEtMzcwMzk_e303b6e7-922d-4669-90b3-fe922e452da4"
      unitRef="usd">15503000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMjUtMS0xLTEtMzcwMzk_7b9c5c7b-28ce-4fd9-b0d8-9b1e63af319b"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMjUtMy0xLTEtMzcwMzk_be4c37d8-7bcc-492b-97e6-8a6f113db7cc"
      unitRef="usd">350000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMjYtMS0xLTEtMzcwMzk_583372e3-0168-4aea-8188-0815c5eda7d9"
      unitRef="usd">23000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMjYtMy0xLTEtMzcwMzk_d60df4a0-9a87-4807-992d-b4d9f75e0890"
      unitRef="usd">34000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMjctMS0xLTEtMzcwMzk_e3d32a2a-b49c-4bb0-8d7f-75a4e9b12cff"
      unitRef="usd">-23000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMjctMy0xLTEtMzcwMzk_08612644-85e0-4ef7-8d06-2250ff38d6a6"
      unitRef="usd">15819000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMjktMS0xLTEtMzcwMzk_c54a8188-4588-4954-8bfd-d9b79f5919fe"
      unitRef="usd">-1159000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMjktMy0xLTEtMzcwMzk_69f43bcf-389b-4fd7-a7d2-41d1530fcb8e"
      unitRef="usd">12871000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMzAtMS0xLTEtMzcwMzk_73b6599e-c45f-42b8-b660-dc469064b5a2"
      unitRef="usd">3702000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idb04f7e476724b32ac14d93d1aecd6cd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMzAtMy0xLTEtMzcwMzk_e72ccbca-248a-40a3-86b7-1eb44b0705e7"
      unitRef="usd">109000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMzEtMS0xLTEtMzcwMzk_bfbef8bc-33c0-46c5-a7a2-f7d93825f374"
      unitRef="usd">2543000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibca337c014ca4895aaf539d38c0f5424_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMzEtMy0xLTEtMzcwMzk_33bd7a79-2740-4113-871c-b0549481c678"
      unitRef="usd">12980000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMzQtMS0xLTEtMzcwMzk_59618747-de3c-47b7-a04e-f93da508e0d0"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8yOC9mcmFnOmY2ZjEzMzAxZWQzMDQ4NjY4NmZlNzhjOTFhZWVmZjRlL3RhYmxlOjVjYTNmYjQ0NTEyNDQ2NGJiNmU1MTI3N2RhZjJlZjIzL3RhYmxlcmFuZ2U6NWNhM2ZiNDQ1MTI0NDY0YmI2ZTUxMjc3ZGFmMmVmMjNfMzQtMy0xLTEtMzcwMzk_3bcfdecf-1679-46da-bb20-858736293210"
      unitRef="usd">350000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:NatureOfOperations
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8zNC9mcmFnOjE5OTU4ZDdiN2UwYzQzYjJhNzAxMWRkNDgyNWM1ODY1L3RleHRyZWdpb246MTk5NThkN2I3ZTBjNDNiMmE3MDExZGQ0ODI1YzU4NjVfMjI0Ng_48e50f13-e904-4b96-a703-9bb93f460f65">ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vallon Pharmaceuticals, Inc. (Vallon or the Company), based in Philadelphia, PA was incorporated in Delaware on January 11, 2018, which is the date of inception.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. The Company&#x2019;s lead investigational product candidate, ADAIR, is a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine (the main active ingredient in Adderall&#xae;) for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. In March 2022, the Company announced that its SEAL study for ADAIR did not reach its primary endpoint, and there is no assurance that ADAIR will receive approval by the U.S. Food and Drug Administration (the FDA). In addition to ADAIR, the Company completed formulation development work and selected the final formulation of its second product candidate, ADMIR, an abuse deterrent formulation of methylphenidate (Ritalin&#xae;), for the treatment of ADHD.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Developments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The SEAL study (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;S&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tudy to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;E&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;valuate the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;buse &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;L&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation), was the Company&#x2019;s pivotal intranasal human abuse liability study assessing the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability of snorting professional laboratory-manipulated ADAIR 30 mg when compared to crushed d-amphetamine sulfate and placebo in recreational drug users. ADAIR was prepared for snorting by a pharmacist using a multi-step technique that had been developed by a professional laboratory and agreed upon by the FDA. The SEAL study enrolled 55 subjects, of whom 53 completed the study and 52 were included in the final analysis. The study involved a four-way crossover design to evaluate professionally manipulated, intranasal ADAIR 30 mg, crushed intranasal dextroamphetamine, ADAIR 30 mg taken orally, and placebo. All subjects were non-dependent recreational stimulant users with an additional history of recreational intranasal drug use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The SEAL study did not meet its primary endpoint, which was E&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline"&gt;max&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Drug Liking. ADAIR scored similarly to what was observed in an earlier proof-of-concept study, however, reference dextroamphetamine did not score as high as expected and as seen in the previous study, thus driving the lack of statistical significance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is continuing to assess the best path forward for the ADAIR and ADMIR development programs. In addition, the Company has engaged Ladenburg Thalmann &amp;amp; Co. Inc. (Ladenburg) to evaluate its strategic alternatives with the goal of maximizing stockholder value. Ladenburg has been engaged to advise the Company on the strategic review process, which could include, without limitation, exploring the potential for a possible merger, business combination, investment into the Company, or a purchase, license or other acquisition of assets. In the meantime, and in conjunction with the exploration of strategic alternatives, the Company is streamlining its operations in order to preserve its capital and cash resources.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <ck0001824293:ClinicalResearchStudyNumberOfParticipantsEnrolled
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8zNC9mcmFnOjE5OTU4ZDdiN2UwYzQzYjJhNzAxMWRkNDgyNWM1ODY1L3RleHRyZWdpb246MTk5NThkN2I3ZTBjNDNiMmE3MDExZGQ0ODI1YzU4NjVfMTY0OTI2NzQ0ODI1OA_ccdabd40-c4d9-4533-940a-14967e8c3daf"
      unitRef="participant">55</ck0001824293:ClinicalResearchStudyNumberOfParticipantsEnrolled>
    <ck0001824293:ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8zNC9mcmFnOjE5OTU4ZDdiN2UwYzQzYjJhNzAxMWRkNDgyNWM1ODY1L3RleHRyZWdpb246MTk5NThkN2I3ZTBjNDNiMmE3MDExZGQ0ODI1YzU4NjVfMTY0OTI2NzQ0ODI2Mg_36fd3d70-c564-4d5c-a477-73e9735a91c3"
      unitRef="participant">53</ck0001824293:ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy>
    <ck0001824293:ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8zNC9mcmFnOjE5OTU4ZDdiN2UwYzQzYjJhNzAxMWRkNDgyNWM1ODY1L3RleHRyZWdpb246MTk5NThkN2I3ZTBjNDNiMmE3MDExZGQ0ODI1YzU4NjVfMTY0OTI2NzQ0ODI2Ng_5e1f5b82-aba3-4dfc-aec8-fd58ef3d82a6"
      unitRef="participant">52</ck0001824293:ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8zNy9mcmFnOmU2ZWMzNTU2ZGZkYTRjNmE4MjYwOGFiNGY2NWE5NDg2L3RleHRyZWdpb246ZTZlYzM1NTZkZmRhNGM2YTgyNjA4YWI0ZjY1YTk0ODZfMjA2Mg_ac31e79b-9503-4569-a2e2-3b5f03f5e02b">LIQUIDITY&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception and has incurred $24,537 in accumulated deficit through March&#160;31, 2022. The Company has financed its working capital requirements to date through the issuance of common stock, convertible notes, short-term promissory notes, and a Paycheck Protection Program (PPP) promissory note.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In January 2021, the Company completed a $350 convertible note financing and in February 2021, the Company completed the inital public offering (IPO) of the Company&#x2019;s common stock, raising net proceeds of $15,500. As of March&#160;31, 2022, the Company had cash, cash equivalents and marketable securities of approximately $5,177.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expects to incur ongoing expenses as it evaluates its plans for the ADAIR and ADMIR programs and strategic alternatives after it announced in March 2022 that the SEAL study of ADAIR for the treatment of ADHD failed to meet statistical &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;significance for its primary endpoint. The Company is currently assessing the best path forward for the ADAIR and ADMIR programs and has no other product candidates undergoing clinical trials. The Company&#x2019;s future capital requirements are difficult to forecast and will depend on many factors, including but not limited to the terms and timing of any strategic alternatives including a merger or business combination, asset acquisitions or sales, collaborations or licensing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company raises additional funds by issuing equity securities, its stockholders may experience dilution. Any future debt financing may impose upon it covenants that restrict our operations, including limitations on its ability to incur liens or additional debt, pay dividends, repurchase its common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any equity or debt financing may contain terms that are not favorable to the Company or its stockholders. If the Company is unable to raise additional funds when needed, it may be required to delay, reduce or terminate some or all of its development programs and clinical trials. The Company may also be required to sell or license to other parties&#x2019; rights to develop or commercialize its drug candidates that it would prefer to retain. Therefore, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern. The Company expects to continue to incur expenses and operating losses at least for the foreseeable future as it evaluates future plans for the ADAIR and ADMIR programs as well as its strategic alternatives.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8zNy9mcmFnOmU2ZWMzNTU2ZGZkYTRjNmE4MjYwOGFiNGY2NWE5NDg2L3RleHRyZWdpb246ZTZlYzM1NTZkZmRhNGM2YTgyNjA4YWI0ZjY1YTk0ODZfMzg0ODI5MDY5OTI4OQ_af5139ce-ae02-4415-80a3-acb6035fe160"
      unitRef="usd">-24537000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="iac76cfecf8b945eda2c37283b0d1bafa_D20210101-20210131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8zNy9mcmFnOmU2ZWMzNTU2ZGZkYTRjNmE4MjYwOGFiNGY2NWE5NDg2L3RleHRyZWdpb246ZTZlYzM1NTZkZmRhNGM2YTgyNjA4YWI0ZjY1YTk0ODZfNzQ3_046f0ac4-652c-4cf2-9902-a07fb00b8eb9"
      unitRef="usd">350000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i459e0d6af0f74d42a0f684f536cfd55c_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8zNy9mcmFnOmU2ZWMzNTU2ZGZkYTRjNmE4MjYwOGFiNGY2NWE5NDg2L3RleHRyZWdpb246ZTZlYzM1NTZkZmRhNGM2YTgyNjA4YWI0ZjY1YTk0ODZfODQz_18a8ae15-9fd9-41b8-bbcd-4d6a500f06a4"
      unitRef="usd">15500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF8zNy9mcmFnOmU2ZWMzNTU2ZGZkYTRjNmE4MjYwOGFiNGY2NWE5NDg2L3RleHRyZWdpb246ZTZlYzM1NTZkZmRhNGM2YTgyNjA4YWI0ZjY1YTk0ODZfMzg0ODI5MDY5OTI5NA_77dfc247-8d3b-4089-9985-b71c735e1877"
      unitRef="usd">5177000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80MC9mcmFnOjhiZDE1MTdhZWUyMDRmMjY5NjljOTM0ZDVhNWZjMGNiL3RleHRyZWdpb246OGJkMTUxN2FlZTIwNGYyNjk2OWM5MzRkNWE1ZmMwY2JfNjQ4Mw_9c1c0531-67f9-4673-9456-29a602ca58aa">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission. References in this Quarterly Report on Form 10-Q to &#x201c;authoritative guidance&#x201d; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2021 balance sheet was derived from audited financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the unaudited interim financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#x2019;s financial position as of March&#160;31, 2022, and the results of operations and stockholders&#x2019; equity (deficit) for the three months ended March&#160;31, 2022 and 2021 and cash flows for the three months ended March&#160;31, 2022 and 2021. Results of operations for the three months ended March&#160;31, 2022, are not necessarily indicative of the operating results that may be expected for the year ending December&#160;31, 2022. The unaudited interim financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December&#160;31, 2021, included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on February&#160;14, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recapitalization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately prior to the closing of the  IPO (Note 7), the Company effected a one-for-40 reverse stock split of its common stock. All share and per share amounts, excluding the number of authorized shares and par value, contained in these financial statements and accompanying notes, and this Quarterly Report on Form 10-Q give retroactive effect to the reverse split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the unaudited interim financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#x2019;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#x2019;s results of operations could either benefit from, or be adversely affected by, any such change in estimate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist of debt securities that are designated as available-for-sale. Marketable debt securities are recorded at fair value and unrealized holding gains or losses are reported as a component of accumulated other comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains or losses resulting from the sale of these securities are determined based on the specific identification of the securities sold. An impairment charge is recognized when the decline in the fair value of a debt security below the amortized cost basis is determined to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the duration and severity of any decline in fair value below the amortized cost basis, any adverse changes in the financial condition of the issuers and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amounts are recorded as a cumulative adjustment in the period the estimates are revised. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considered the applicability and impact of all ASUs issued during the quarter ended March 31, 2022 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80MC9mcmFnOjhiZDE1MTdhZWUyMDRmMjY5NjljOTM0ZDVhNWZjMGNiL3RleHRyZWdpb246OGJkMTUxN2FlZTIwNGYyNjk2OWM5MzRkNWE1ZmMwY2JfNjQ4NA_ffafc73d-8969-4f31-a5af-1ef202fd6c01">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission. References in this Quarterly Report on Form 10-Q to &#x201c;authoritative guidance&#x201d; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2021 balance sheet was derived from audited financial statements. In the opinion of management, the unaudited interim financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#x2019;s financial position as of March&#160;31, 2022, and the results of operations and stockholders&#x2019; equity (deficit) for the three months ended March&#160;31, 2022 and 2021 and cash flows for the three months ended March&#160;31, 2022 and 2021. Results of operations for the three months ended March&#160;31, 2022, are not necessarily indicative of the operating results that may be expected for the year ending December&#160;31, 2022. The unaudited interim financial statements, presented herein, do not contain the required disclosures under GAAP for annual financial statements. The accompanying unaudited interim financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December&#160;31, 2021, included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on February&#160;14, 2022.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80MC9mcmFnOjhiZDE1MTdhZWUyMDRmMjY5NjljOTM0ZDVhNWZjMGNiL3RleHRyZWdpb246OGJkMTUxN2FlZTIwNGYyNjk2OWM5MzRkNWE1ZmMwY2JfNjQ3OQ_0ce7d069-b866-4327-86d7-76a2a76fa158">Use of EstimatesThe preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the unaudited interim financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, the embedded derivative of convertible notes, warrant issuance, valuation allowances relating to deferred tax assets, revenue recognition, accrued expenses and estimation of the incremental borrowing rate for the finance lease. If actual results differ from the Company&#x2019;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#x2019;s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</us-gaap:UseOfEstimates>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80MC9mcmFnOjhiZDE1MTdhZWUyMDRmMjY5NjljOTM0ZDVhNWZjMGNiL3RleHRyZWdpb246OGJkMTUxN2FlZTIwNGYyNjk2OWM5MzRkNWE1ZmMwY2JfNjQ4MA_c3d7a53f-90a2-4eae-b0ba-d6b01a2139cb">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities consist of debt securities that are designated as available-for-sale. Marketable debt securities are recorded at fair value and unrealized holding gains or losses are reported as a component of accumulated other comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;Realized gains or losses resulting from the sale of these securities are determined based on the specific identification of the securities sold. An impairment charge is recognized when the decline in the fair value of a debt security below the amortized cost basis is determined to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the duration and severity of any decline in fair value below the amortized cost basis, any adverse changes in the financial condition of the issuers and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in market value.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80MC9mcmFnOjhiZDE1MTdhZWUyMDRmMjY5NjljOTM0ZDVhNWZjMGNiL3RleHRyZWdpb246OGJkMTUxN2FlZTIwNGYyNjk2OWM5MzRkNWE1ZmMwY2JfNjQ4MQ_6c5f3917-2005-4c46-89f3-c9b938760b27">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. In considering the fair value of the underlying stock when the Company granted options, the Company considered several factors including the fair values established by market transactions. Stock option-based compensation includes estimates and judgments of when stock options might be exercised and stock price volatility. The timing of option exercises is out of the Company's control and depends upon a number of factors including the Company's market value and the financial objectives of the option holders. These estimates can have a material impact on the stock compensation expense but will have no impact on the cash flows. The estimation of share-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amounts are recorded as a cumulative adjustment in the period the estimates are revised. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the expected term, rather than the contractual term, for both employee and consultant options issued.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80MC9mcmFnOjhiZDE1MTdhZWUyMDRmMjY5NjljOTM0ZDVhNWZjMGNiL3RleHRyZWdpb246OGJkMTUxN2FlZTIwNGYyNjk2OWM5MzRkNWE1ZmMwY2JfNjQ4Mg_f99bf0d0-6c55-4b09-9990-51c651e1f270">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considered the applicability and impact of all ASUs issued during the quarter ended March 31, 2022 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RleHRyZWdpb246NTYwZDAyNWIzMDI4NGFmNWJiNWQ2NzVmMWVhNzA1YzdfMjU0Mg_7a7d256e-3cdd-4c58-9732-21cf904dbfe0">MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s available for sale securities as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjusted Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjusted Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, all of the Company&#x2019;s marketable securities were classified as Level 2 assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. The carrying amounts reported in the balance sheets for cash and cash equivalents, marketable securities, prepaid expenses and other current assets, accounts payable, accrued expenses, and note payable approximate their fair value based on the short-term maturity of these instruments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the embedded derivative liability identified in the 2021 Convertible Notes (Note 6)  was a Level 3 fair value measurement. As of February&#160;12, 2021, the embedded derivative was remeasured based upon the conversion price of $8.00 per share upon closing of the IPO. As such, an expense of $89 was recorded during the three months ended March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of our investments in marketable debt securities with state contractual maturity dates, accounted for as available-for-sale securities and classified by the contractual maturity date of the securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.611%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in 1-5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in 5-10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after 10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RleHRyZWdpb246NTYwZDAyNWIzMDI4NGFmNWJiNWQ2NzVmMWVhNzA1YzdfMjU0Mw_1f06d583-a036-453f-ac75-677c22aaa6c7">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s available for sale securities as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjusted Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjusted Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if636725079b740db9f7e05e222c86d29_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjE5MzMyMjg0Y2Q1ODQ3OTM5Mjc5OWY2ZDEwNGJmMDI3L3RhYmxlcmFuZ2U6MTkzMzIyODRjZDU4NDc5MzkyNzk5ZjZkMTA0YmYwMjdfNC0xLTEtMS0zNzAzOQ_b68346c0-3cd4-487a-94da-25763ebf588d"
      unitRef="usd">349000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if636725079b740db9f7e05e222c86d29_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjE5MzMyMjg0Y2Q1ODQ3OTM5Mjc5OWY2ZDEwNGJmMDI3L3RhYmxlcmFuZ2U6MTkzMzIyODRjZDU4NDc5MzkyNzk5ZjZkMTA0YmYwMjdfNC0zLTEtMS0zNzAzOQ_0ed4c103-0970-44ba-a4c7-805c694e3437"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if636725079b740db9f7e05e222c86d29_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjE5MzMyMjg0Y2Q1ODQ3OTM5Mjc5OWY2ZDEwNGJmMDI3L3RhYmxlcmFuZ2U6MTkzMzIyODRjZDU4NDc5MzkyNzk5ZjZkMTA0YmYwMjdfNC01LTEtMS0zNzAzOQ_ccc74de7-fde0-4796-8a3e-ad57dc20d144"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if636725079b740db9f7e05e222c86d29_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjE5MzMyMjg0Y2Q1ODQ3OTM5Mjc5OWY2ZDEwNGJmMDI3L3RhYmxlcmFuZ2U6MTkzMzIyODRjZDU4NDc5MzkyNzk5ZjZkMTA0YmYwMjdfNC03LTEtMS0zNzAzOQ_b270feec-bad3-417d-a187-cff1582c0113"
      unitRef="usd">349000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5006cf101226413bb3ec2ab87613cd4e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjE5MzMyMjg0Y2Q1ODQ3OTM5Mjc5OWY2ZDEwNGJmMDI3L3RhYmxlcmFuZ2U6MTkzMzIyODRjZDU4NDc5MzkyNzk5ZjZkMTA0YmYwMjdfNS0xLTEtMS0zNzAzOQ_52054cd6-b633-4c65-93ea-e72b38a37293"
      unitRef="usd">2291000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5006cf101226413bb3ec2ab87613cd4e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjE5MzMyMjg0Y2Q1ODQ3OTM5Mjc5OWY2ZDEwNGJmMDI3L3RhYmxlcmFuZ2U6MTkzMzIyODRjZDU4NDc5MzkyNzk5ZjZkMTA0YmYwMjdfNS0zLTEtMS0zNzAzOQ_f372463f-9aec-47b9-ac8d-e4e8ca27b9fc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5006cf101226413bb3ec2ab87613cd4e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjE5MzMyMjg0Y2Q1ODQ3OTM5Mjc5OWY2ZDEwNGJmMDI3L3RhYmxlcmFuZ2U6MTkzMzIyODRjZDU4NDc5MzkyNzk5ZjZkMTA0YmYwMjdfNS01LTEtMS0zNzAzOQ_24581bd7-c0ae-469a-977f-e08e5c7d85e5"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5006cf101226413bb3ec2ab87613cd4e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjE5MzMyMjg0Y2Q1ODQ3OTM5Mjc5OWY2ZDEwNGJmMDI3L3RhYmxlcmFuZ2U6MTkzMzIyODRjZDU4NDc5MzkyNzk5ZjZkMTA0YmYwMjdfNS03LTEtMS0zNzAzOQ_1ec7fd6c-ef23-42ef-9aa1-665cc2f3bea9"
      unitRef="usd">2285000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjE5MzMyMjg0Y2Q1ODQ3OTM5Mjc5OWY2ZDEwNGJmMDI3L3RhYmxlcmFuZ2U6MTkzMzIyODRjZDU4NDc5MzkyNzk5ZjZkMTA0YmYwMjdfNi0xLTEtMS0zNzAzOQ_ba534344-c3e0-46f4-b93d-9e948af9e879"
      unitRef="usd">2640000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjE5MzMyMjg0Y2Q1ODQ3OTM5Mjc5OWY2ZDEwNGJmMDI3L3RhYmxlcmFuZ2U6MTkzMzIyODRjZDU4NDc5MzkyNzk5ZjZkMTA0YmYwMjdfNi0zLTEtMS0zNzAzOQ_c25b496d-79b2-4558-80a2-fd3f21181d66"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjE5MzMyMjg0Y2Q1ODQ3OTM5Mjc5OWY2ZDEwNGJmMDI3L3RhYmxlcmFuZ2U6MTkzMzIyODRjZDU4NDc5MzkyNzk5ZjZkMTA0YmYwMjdfNi01LTEtMS0zNzAzOQ_41a56a66-9b20-4e9d-93ac-b740ff5177bd"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjE5MzMyMjg0Y2Q1ODQ3OTM5Mjc5OWY2ZDEwNGJmMDI3L3RhYmxlcmFuZ2U6MTkzMzIyODRjZDU4NDc5MzkyNzk5ZjZkMTA0YmYwMjdfNi03LTEtMS0zNzAzOQ_22dc81d2-1c66-4f05-834e-5dafec332d7b"
      unitRef="usd">2634000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic295d867cba3424dbf9d11196a15a2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOmQ4ZWZiODIwOTIyOTQ3YzRhOTk3ODc5OGZhMTAzM2NiL3RhYmxlcmFuZ2U6ZDhlZmI4MjA5MjI5NDdjNGE5OTc4Nzk4ZmExMDMzY2JfNC0xLTEtMS00NDEwNA_9d04487c-f8f7-49b6-8350-a6da603b6796"
      unitRef="usd">1153000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic295d867cba3424dbf9d11196a15a2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOmQ4ZWZiODIwOTIyOTQ3YzRhOTk3ODc5OGZhMTAzM2NiL3RhYmxlcmFuZ2U6ZDhlZmI4MjA5MjI5NDdjNGE5OTc4Nzk4ZmExMDMzY2JfNC0zLTEtMS00NDQzMA_7e2603e3-fb7b-46b5-a1f8-fd5b5fe4dfef"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic295d867cba3424dbf9d11196a15a2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOmQ4ZWZiODIwOTIyOTQ3YzRhOTk3ODc5OGZhMTAzM2NiL3RhYmxlcmFuZ2U6ZDhlZmI4MjA5MjI5NDdjNGE5OTc4Nzk4ZmExMDMzY2JfNC01LTEtMS00NDExNA_4cf63af3-f102-47c9-8256-39141be40bf7"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic295d867cba3424dbf9d11196a15a2b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOmQ4ZWZiODIwOTIyOTQ3YzRhOTk3ODc5OGZhMTAzM2NiL3RhYmxlcmFuZ2U6ZDhlZmI4MjA5MjI5NDdjNGE5OTc4Nzk4ZmExMDMzY2JfNC03LTEtMS00NDQzNQ_f2fe36a4-ab6b-40ac-a3bf-1459b1fbe773"
      unitRef="usd">1152000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6895b671b37a41a2983fb05af80a2952_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOmQ4ZWZiODIwOTIyOTQ3YzRhOTk3ODc5OGZhMTAzM2NiL3RhYmxlcmFuZ2U6ZDhlZmI4MjA5MjI5NDdjNGE5OTc4Nzk4ZmExMDMzY2JfNS0xLTEtMS00NDEwNA_181198ef-156c-4541-8004-4c37da7b576b"
      unitRef="usd">2657000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6895b671b37a41a2983fb05af80a2952_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOmQ4ZWZiODIwOTIyOTQ3YzRhOTk3ODc5OGZhMTAzM2NiL3RhYmxlcmFuZ2U6ZDhlZmI4MjA5MjI5NDdjNGE5OTc4Nzk4ZmExMDMzY2JfNS0zLTEtMS00NDQzMA_d4d46b86-4474-4f13-8eb1-852eabae14fc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6895b671b37a41a2983fb05af80a2952_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOmQ4ZWZiODIwOTIyOTQ3YzRhOTk3ODc5OGZhMTAzM2NiL3RhYmxlcmFuZ2U6ZDhlZmI4MjA5MjI5NDdjNGE5OTc4Nzk4ZmExMDMzY2JfNS01LTEtMS00NDExNA_771efd4f-f28e-4eb4-97d2-998e4dc976c1"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6895b671b37a41a2983fb05af80a2952_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOmQ4ZWZiODIwOTIyOTQ3YzRhOTk3ODc5OGZhMTAzM2NiL3RhYmxlcmFuZ2U6ZDhlZmI4MjA5MjI5NDdjNGE5OTc4Nzk4ZmExMDMzY2JfNS03LTEtMS00NDQzNQ_e0d9138d-8e09-47a9-8de3-8554df09073f"
      unitRef="usd">2656000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOmQ4ZWZiODIwOTIyOTQ3YzRhOTk3ODc5OGZhMTAzM2NiL3RhYmxlcmFuZ2U6ZDhlZmI4MjA5MjI5NDdjNGE5OTc4Nzk4ZmExMDMzY2JfNi0xLTEtMS00NDQyNw_5679570d-b67b-461b-8d8a-4c7b645622dd"
      unitRef="usd">3810000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOmQ4ZWZiODIwOTIyOTQ3YzRhOTk3ODc5OGZhMTAzM2NiL3RhYmxlcmFuZ2U6ZDhlZmI4MjA5MjI5NDdjNGE5OTc4Nzk4ZmExMDMzY2JfNi0zLTEtMS00NDQzMA_2a2db0a4-d673-4474-a8fc-9764067a2bde"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOmQ4ZWZiODIwOTIyOTQ3YzRhOTk3ODc5OGZhMTAzM2NiL3RhYmxlcmFuZ2U6ZDhlZmI4MjA5MjI5NDdjNGE5OTc4Nzk4ZmExMDMzY2JfNi01LTEtMS00NDQzMg_2cb68465-1177-4e41-9845-6cd3e1cf45c2"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOmQ4ZWZiODIwOTIyOTQ3YzRhOTk3ODc5OGZhMTAzM2NiL3RhYmxlcmFuZ2U6ZDhlZmI4MjA5MjI5NDdjNGE5OTc4Nzk4ZmExMDMzY2JfNi03LTEtMS00NDQzNQ_31c7c65e-3ab8-4a49-bbee-4b0897b9c024"
      unitRef="usd">3808000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i1c4b8521c9f140c7a9592f7f41d732a6_I20210212"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RleHRyZWdpb246NTYwZDAyNWIzMDI4NGFmNWJiNWQ2NzVmMWVhNzA1YzdfMjAyNQ_62747a35-ac5d-4c25-a182-1973759ce818"
      unitRef="usdPerShare">8.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RleHRyZWdpb246NTYwZDAyNWIzMDI4NGFmNWJiNWQ2NzVmMWVhNzA1YzdfMjA4Ng_f9352d60-5f11-4e2c-8956-ecf260804437"
      unitRef="usd">-89000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RleHRyZWdpb246NTYwZDAyNWIzMDI4NGFmNWJiNWQ2NzVmMWVhNzA1YzdfMjU0NQ_509d17df-456a-442c-b6b2-2ff51872415f">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of our investments in marketable debt securities with state contractual maturity dates, accounted for as available-for-sale securities and classified by the contractual maturity date of the securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.611%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.281%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in 1-5 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due in 5-10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after 10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjNhYWMzNzQ2MzAxMTRhMGQ5NmFiODA1NTI4YmQ2NDdiL3RhYmxlcmFuZ2U6M2FhYzM3NDYzMDExNGEwZDk2YWI4MDU1MjhiZDY0N2JfMS0yLTEtMS0zNzAzOQ_e9fa0371-56b8-41a2-afdd-ac3fb1076632"
      unitRef="usd">2634000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjNhYWMzNzQ2MzAxMTRhMGQ5NmFiODA1NTI4YmQ2NDdiL3RhYmxlcmFuZ2U6M2FhYzM3NDYzMDExNGEwZDk2YWI4MDU1MjhiZDY0N2JfMi0yLTEtMS0zNzAzOQ_7a356c0c-0674-4c2f-abac-4e912914cf2d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjNhYWMzNzQ2MzAxMTRhMGQ5NmFiODA1NTI4YmQ2NDdiL3RhYmxlcmFuZ2U6M2FhYzM3NDYzMDExNGEwZDk2YWI4MDU1MjhiZDY0N2JfMy0yLTEtMS0zNzAzOQ_27b391c7-00a8-4e46-9dfb-8b1c8f716c32"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjNhYWMzNzQ2MzAxMTRhMGQ5NmFiODA1NTI4YmQ2NDdiL3RhYmxlcmFuZ2U6M2FhYzM3NDYzMDExNGEwZDk2YWI4MDU1MjhiZDY0N2JfNC0yLTEtMS0zNzAzOQ_cdb28471-7fc0-4ba2-87e6-9013810d6e29"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80Ni9mcmFnOjU2MGQwMjViMzAyODRhZjViYjVkNjc1ZjFlYTcwNWM3L3RhYmxlOjNhYWMzNzQ2MzAxMTRhMGQ5NmFiODA1NTI4YmQ2NDdiL3RhYmxlcmFuZ2U6M2FhYzM3NDYzMDExNGEwZDk2YWI4MDU1MjhiZDY0N2JfNS0yLTEtMS0zNzAzOQ_7c155f84-7682-4ea5-8908-cb1de8d6e74c"
      unitRef="usd">2634000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80OS9mcmFnOjgwMThmNzVlZDkzNTQ1Y2I4MDlhYzcwYjUyZWFiNzI1L3RleHRyZWdpb246ODAxOGY3NWVkOTM1NDVjYjgwOWFjNzBiNTJlYWI3MjVfNjg_31df70a6-1ed1-49a1-a7ef-e310e85ccf86">ACCRUED EXPENSES&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;894&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80OS9mcmFnOjgwMThmNzVlZDkzNTQ1Y2I4MDlhYzcwYjUyZWFiNzI1L3RleHRyZWdpb246ODAxOGY3NWVkOTM1NDVjYjgwOWFjNzBiNTJlYWI3MjVfNjk_99ba5e5a-00ee-4d75-9d88-c6666f3785d5">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;894&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licensing related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <ck0001824293:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80OS9mcmFnOjgwMThmNzVlZDkzNTQ1Y2I4MDlhYzcwYjUyZWFiNzI1L3RhYmxlOmU0YWMxNjljOTAwZTQ2MGViYTJkNDcyNmUxNzA4NjMyL3RhYmxlcmFuZ2U6ZTRhYzE2OWM5MDBlNDYwZWJhMmQ0NzI2ZTE3MDg2MzJfMS0xLTEtMS0zNzAzOQ_fd020485-15f7-4cad-96cb-158c84e55887"
      unitRef="usd">640000</ck0001824293:AccruedResearchAndDevelopmentCostsCurrent>
    <ck0001824293:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80OS9mcmFnOjgwMThmNzVlZDkzNTQ1Y2I4MDlhYzcwYjUyZWFiNzI1L3RhYmxlOmU0YWMxNjljOTAwZTQ2MGViYTJkNDcyNmUxNzA4NjMyL3RhYmxlcmFuZ2U6ZTRhYzE2OWM5MDBlNDYwZWJhMmQ0NzI2ZTE3MDg2MzJfMS0zLTEtMS0zNzAzOQ_000eba7d-4c0c-45aa-8729-ce04e8d5f195"
      unitRef="usd">894000</ck0001824293:AccruedResearchAndDevelopmentCostsCurrent>
    <ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80OS9mcmFnOjgwMThmNzVlZDkzNTQ1Y2I4MDlhYzcwYjUyZWFiNzI1L3RhYmxlOmU0YWMxNjljOTAwZTQ2MGViYTJkNDcyNmUxNzA4NjMyL3RhYmxlcmFuZ2U6ZTRhYzE2OWM5MDBlNDYwZWJhMmQ0NzI2ZTE3MDg2MzJfMi0xLTEtMS0zNzAzOQ_f83dab67-410e-4bbc-8d94-8679f8643c8d"
      unitRef="usd">102000</ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent>
    <ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80OS9mcmFnOjgwMThmNzVlZDkzNTQ1Y2I4MDlhYzcwYjUyZWFiNzI1L3RhYmxlOmU0YWMxNjljOTAwZTQ2MGViYTJkNDcyNmUxNzA4NjMyL3RhYmxlcmFuZ2U6ZTRhYzE2OWM5MDBlNDYwZWJhMmQ0NzI2ZTE3MDg2MzJfMi0zLTEtMS0zNzAzOQ_87e54944-2b50-49d4-8f50-b71becbb0954"
      unitRef="usd">183000</ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80OS9mcmFnOjgwMThmNzVlZDkzNTQ1Y2I4MDlhYzcwYjUyZWFiNzI1L3RhYmxlOmU0YWMxNjljOTAwZTQ2MGViYTJkNDcyNmUxNzA4NjMyL3RhYmxlcmFuZ2U6ZTRhYzE2OWM5MDBlNDYwZWJhMmQ0NzI2ZTE3MDg2MzJfMy0xLTEtMS0zNzAzOQ_21a199aa-059f-45ec-a89e-2637d672f9a9"
      unitRef="usd">406000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80OS9mcmFnOjgwMThmNzVlZDkzNTQ1Y2I4MDlhYzcwYjUyZWFiNzI1L3RhYmxlOmU0YWMxNjljOTAwZTQ2MGViYTJkNDcyNmUxNzA4NjMyL3RhYmxlcmFuZ2U6ZTRhYzE2OWM5MDBlNDYwZWJhMmQ0NzI2ZTE3MDg2MzJfMy0zLTEtMS0zNzAzOQ_00694c53-3b51-44e3-a148-125ac659063b"
      unitRef="usd">291000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <ck0001824293:AccruedLicensingFeesCurrent
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80OS9mcmFnOjgwMThmNzVlZDkzNTQ1Y2I4MDlhYzcwYjUyZWFiNzI1L3RhYmxlOmU0YWMxNjljOTAwZTQ2MGViYTJkNDcyNmUxNzA4NjMyL3RhYmxlcmFuZ2U6ZTRhYzE2OWM5MDBlNDYwZWJhMmQ0NzI2ZTE3MDg2MzJfNC0xLTEtMS0zNzAzOQ_9a629396-15cd-41a0-ba99-9d99a96b4f94"
      unitRef="usd">57000</ck0001824293:AccruedLicensingFeesCurrent>
    <ck0001824293:AccruedLicensingFeesCurrent
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80OS9mcmFnOjgwMThmNzVlZDkzNTQ1Y2I4MDlhYzcwYjUyZWFiNzI1L3RhYmxlOmU0YWMxNjljOTAwZTQ2MGViYTJkNDcyNmUxNzA4NjMyL3RhYmxlcmFuZ2U6ZTRhYzE2OWM5MDBlNDYwZWJhMmQ0NzI2ZTE3MDg2MzJfNC0zLTEtMS0zNzAzOQ_7254d291-5c4b-4ca7-8dd7-625e188af622"
      unitRef="usd">62000</ck0001824293:AccruedLicensingFeesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80OS9mcmFnOjgwMThmNzVlZDkzNTQ1Y2I4MDlhYzcwYjUyZWFiNzI1L3RhYmxlOmU0YWMxNjljOTAwZTQ2MGViYTJkNDcyNmUxNzA4NjMyL3RhYmxlcmFuZ2U6ZTRhYzE2OWM5MDBlNDYwZWJhMmQ0NzI2ZTE3MDg2MzJfNi0xLTEtMS0zNzAzOQ_e7f0a55f-7e76-435e-bf90-f81a5a90bcbe"
      unitRef="usd">1205000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF80OS9mcmFnOjgwMThmNzVlZDkzNTQ1Y2I4MDlhYzcwYjUyZWFiNzI1L3RhYmxlOmU0YWMxNjljOTAwZTQ2MGViYTJkNDcyNmUxNzA4NjMyL3RhYmxlcmFuZ2U6ZTRhYzE2OWM5MDBlNDYwZWJhMmQ0NzI2ZTE3MDg2MzJfNi0zLTEtMS0zNzAzOQ_d814254a-4bb3-45d4-adaa-2686644e1728"
      unitRef="usd">1430000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81Mi9mcmFnOjFiNjgzY2ZlZDk4YzRmNDU5MTc4YzM2MTMwNzMzMDRmL3RleHRyZWdpb246MWI2ODNjZmVkOThjNGY0NTkxNzhjMzYxMzA3MzMwNGZfMTcwOA_2c1bf00d-4ca8-4fb9-b354-80ea5ba2f830">PPP NOTE AND CONVERTIBLE NOTES&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, the Company issued a promissory note under the PPP (the PPP Note) totaling $61. The PPP Note had a stated interest rate of 1% and had a two-year maturity. Payments were required to be made over a 1.5-year period beginning November 1, 2020, unless forgiven. In January 2021, the Company was notified that the loan along with accumulated interest had been forgiven. As a result, the Company recorded income from the extinguishment of its obligation in accordance with ASC 405-20-40-1, disclosed in the amount of $61 included in other income on the accompanying statements of operations and comprehensive loss. The Small Business Administration (SBA) reserves the right to audit any PPP loan, regardless of size. These audits may occur after forgiveness has been granted. In accordance with the CARES Act, all borrowers are required to maintain the PPP loan documentation for six years after the PPP loan was forgiven or repaid in full and to provide that documentation to the SBA upon request.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#x2019;s Chief Executive Officer, pursuant to which the Company issued convertible promissory notes (the 2021 Convertible Notes), for cash proceeds of $350. The 2021 Convertible Notes bore an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September&#160;30, 2021. The 2021 Convertible Notes converted into 54,906 shares of the Company&#x2019;s common stock upon completion of the IPO. The Company identified the mandatory conversion into shares of the Company&#x2019;s common stock as a redemption feature, which requires bifurcation from the 2021 Convertible Notes and treated it as a derivative liability under ASC 815 as the redemption feature was not clearly and closely related to the debt. The Company evaluated the fair value of the derivative liability. Upon the conversion of the 2021 Convertible Notes to common stock at the closing of the IPO, the embedded derivative liability was remeasured and removed from the balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i908364284b2449eaa88060f3a0a6fa84_I20200531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81Mi9mcmFnOjFiNjgzY2ZlZDk4YzRmNDU5MTc4YzM2MTMwNzMzMDRmL3RleHRyZWdpb246MWI2ODNjZmVkOThjNGY0NTkxNzhjMzYxMzA3MzMwNGZfMTIx_ebf783ca-ef02-4c31-acd5-b99f4d3cc4d0"
      unitRef="usd">61000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i908364284b2449eaa88060f3a0a6fa84_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81Mi9mcmFnOjFiNjgzY2ZlZDk4YzRmNDU5MTc4YzM2MTMwNzMzMDRmL3RleHRyZWdpb246MWI2ODNjZmVkOThjNGY0NTkxNzhjMzYxMzA3MzMwNGZfMTY4_2252ea94-302a-4c7a-a7ea-6ca0df63bc45"
      unitRef="number">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm
      contextRef="ieace1ee3e7294bcc9238b92ee0af49d2_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81Mi9mcmFnOjFiNjgzY2ZlZDk4YzRmNDU5MTc4YzM2MTMwNzMzMDRmL3RleHRyZWdpb246MWI2ODNjZmVkOThjNGY0NTkxNzhjMzYxMzA3MzMwNGZfMTcwOQ_20b8ce54-7002-4988-8eed-f7f3baa4e50d">P2Y</us-gaap:DebtInstrumentTerm>
    <ck0001824293:DebtInstrumentPaymentTerm
      contextRef="ieace1ee3e7294bcc9238b92ee0af49d2_D20200501-20200531"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81Mi9mcmFnOjFiNjgzY2ZlZDk4YzRmNDU5MTc4YzM2MTMwNzMzMDRmL3RleHRyZWdpb246MWI2ODNjZmVkOThjNGY0NTkxNzhjMzYxMzA3MzMwNGZfMjQw_5b3ae355-62c2-44bd-ba8a-d0c2850ee907">P1Y6M</ck0001824293:DebtInstrumentPaymentTerm>
    <ck0001824293:ForgivenessOfDebtInstrument
      contextRef="iac76cfecf8b945eda2c37283b0d1bafa_D20210101-20210131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81Mi9mcmFnOjFiNjgzY2ZlZDk4YzRmNDU5MTc4YzM2MTMwNzMzMDRmL3RleHRyZWdpb246MWI2ODNjZmVkOThjNGY0NTkxNzhjMzYxMzA3MzMwNGZfNTQy_118261fc-6924-40e7-950a-676015f8b0b3"
      unitRef="usd">61000</ck0001824293:ForgivenessOfDebtInstrument>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i6f0dc3494c1646ab80c715e4bcf2f8e2_D20210101-20210131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81Mi9mcmFnOjFiNjgzY2ZlZDk4YzRmNDU5MTc4YzM2MTMwNzMzMDRmL3RleHRyZWdpb246MWI2ODNjZmVkOThjNGY0NTkxNzhjMzYxMzA3MzMwNGZfOTIz_0acfaa84-d1b3-44c2-b6cf-928c6daec3e8"
      unitRef="usd">350000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7820e87649a24600869cfef32d0d6f5b_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81Mi9mcmFnOjFiNjgzY2ZlZDk4YzRmNDU5MTc4YzM2MTMwNzMzMDRmL3RleHRyZWdpb246MWI2ODNjZmVkOThjNGY0NTkxNzhjMzYxMzA3MzMwNGZfOTc3_7817e33e-05b8-44a8-ba32-7265d77edd37"
      unitRef="number">0.070</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i0ae8348a777d4256870275ec7f5b29c4_D20211101-20211101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81Mi9mcmFnOjFiNjgzY2ZlZDk4YzRmNDU5MTc4YzM2MTMwNzMzMDRmL3RleHRyZWdpb246MWI2ODNjZmVkOThjNGY0NTkxNzhjMzYxMzA3MzMwNGZfMTA5NQ_4bdb71e6-0ec9-4266-9727-4689b150beb6"
      unitRef="shares">54906</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RleHRyZWdpb246ZDRlYWYxNGE0MDBlNDQ3Yzg1NDQyM2Y1YzkzMTgyMjhfMTI1MA_38b7980b-d670-4c18-8674-1e62720ef6fc">STOCKHOLDERS&#x2019; EQUITY &lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the Company completed the IPO of 2,250,000 shares of common stock at a public offering price of $8.00 per share. The gross proceeds from the IPO, before deducting underwriting discounts, commissions and other offering expenses payable by the Company, were $18,000. Underwriting discounts and expenses totaled $1,600 and the Company incurred approximately $905 of additional expenses related to completing the IPO for aggregate net proceeds of approximately $15,500. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the IPO, the Company granted the underwriters warrants (the Underwriters' Warrants) to purchase an aggregate of 112,500 shares of common stock at an exercise price of $10.00 per share. The Underwriters&#x2019; Warrants have a five-year term and were not exercisable prior to August 12, 2021. All of the Underwriters&#x2019; Warrants were outstanding as of March&#160;31, 2022. The warrants were classified as equity and the fair value of $399 is reflected as additional paid-in capital. The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.155&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i459e0d6af0f74d42a0f684f536cfd55c_D20210201-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RleHRyZWdpb246ZDRlYWYxNGE0MDBlNDQ3Yzg1NDQyM2Y1YzkzMTgyMjhfOTI_19133a7e-98d4-408c-a55a-1769541f6948"
      unitRef="shares">2250000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i4ab34f687d26476ca4c37cdeaec3802c_I20210228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RleHRyZWdpb246ZDRlYWYxNGE0MDBlNDQ3Yzg1NDQyM2Y1YzkzMTgyMjhfMTQ4_f82d4a12-d31b-4271-941d-0f9de0c2c1c8"
      unitRef="usdPerShare">8.00</us-gaap:SaleOfStockPricePerShare>
    <ck0001824293:ProceedsFromIssuanceInitialPublicOfferingGross
      contextRef="i459e0d6af0f74d42a0f684f536cfd55c_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RleHRyZWdpb246ZDRlYWYxNGE0MDBlNDQ3Yzg1NDQyM2Y1YzkzMTgyMjhfMzA1_a63a38f4-7a91-4d50-b718-1043a3d695a1"
      unitRef="usd">18000000</ck0001824293:ProceedsFromIssuanceInitialPublicOfferingGross>
    <ck0001824293:StockIssuanceCostsDiscountsAndCommissions
      contextRef="i459e0d6af0f74d42a0f684f536cfd55c_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RleHRyZWdpb246ZDRlYWYxNGE0MDBlNDQ3Yzg1NDQyM2Y1YzkzMTgyMjhfMzUz_a4a6f415-f8d2-4e81-90d9-64e2d526483b"
      unitRef="usd">1600000</ck0001824293:StockIssuanceCostsDiscountsAndCommissions>
    <ck0001824293:StockIssuanceCostsOfferingExpenses
      contextRef="i63431f71e5c74bdbb2b0f31ac2cafe55_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RleHRyZWdpb246ZDRlYWYxNGE0MDBlNDQ3Yzg1NDQyM2Y1YzkzMTgyMjhfMzk1_fd588b08-80f5-4c0b-bda5-30a3f51b65fb"
      unitRef="usd">905000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i459e0d6af0f74d42a0f684f536cfd55c_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RleHRyZWdpb246ZDRlYWYxNGE0MDBlNDQ3Yzg1NDQyM2Y1YzkzMTgyMjhfNjIy_56745675-647f-4bae-9e7d-125ed3f7aeb9"
      unitRef="usd">15500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="icfbaf3deac01401e89ec75e6ea05ae13_I20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RleHRyZWdpb246ZDRlYWYxNGE0MDBlNDQ3Yzg1NDQyM2Y1YzkzMTgyMjhfNzgw_358d185d-540e-468c-a5fc-65a959b001e2"
      unitRef="shares">112500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="icfbaf3deac01401e89ec75e6ea05ae13_I20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RleHRyZWdpb246ZDRlYWYxNGE0MDBlNDQ3Yzg1NDQyM2Y1YzkzMTgyMjhfODMw_7aa83075-687b-41e9-87d7-eaa431af51f2"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="icfbaf3deac01401e89ec75e6ea05ae13_I20210228"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RleHRyZWdpb246ZDRlYWYxNGE0MDBlNDQ3Yzg1NDQyM2Y1YzkzMTgyMjhfMTY0OTI2NzQ0Mjk1NA_f494057e-a26f-4057-bfbd-883a8cd20ca6">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i6d2639da3a56431abd41a0af1356176b_D20210201-20210228"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RleHRyZWdpb246ZDRlYWYxNGE0MDBlNDQ3Yzg1NDQyM2Y1YzkzMTgyMjhfMTA2Mw_4b033e42-e2ca-4b31-9fa0-3e6955cf1808"
      unitRef="usd">399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RleHRyZWdpb246ZDRlYWYxNGE0MDBlNDQ3Yzg1NDQyM2Y1YzkzMTgyMjhfMTI1MQ_264ad72c-5ea0-44cf-98f9-f9b5b5f3697c">The Black-Scholes option-pricing model was used to estimate the fair value of the warrants with the following weighted-average assumptions:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.155&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i1911bf6daa244c328b316073998944ff_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RhYmxlOjUyNGRhYmNhNzRkZjQwNjVhYTM1OTA5OTM1ZmFjYjM0L3RhYmxlcmFuZ2U6NTI0ZGFiY2E3NGRmNDA2NWFhMzU5MDk5MzVmYWNiMzRfMC0xLTEtMS0zNzAzOQ_fd79f01e-321e-4bc5-962b-001f6ea41334"
      unitRef="number">0.850</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i3c74df4f8925487f845fee1c71e9e072_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RhYmxlOjUyNGRhYmNhNzRkZjQwNjVhYTM1OTA5OTM1ZmFjYjM0L3RhYmxlcmFuZ2U6NTI0ZGFiY2E3NGRmNDA2NWFhMzU5MDk5MzVmYWNiMzRfMS0xLTEtMS0zNzAzOQ_ad44aacf-9287-4f2e-a005-f06a197b43c4"
      unitRef="number">2.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i4fc7bd8d7fea4e7eba01520925d56116_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RhYmxlOjUyNGRhYmNhNzRkZjQwNjVhYTM1OTA5OTM1ZmFjYjM0L3RhYmxlcmFuZ2U6NTI0ZGFiY2E3NGRmNDA2NWFhMzU5MDk5MzVmYWNiMzRfMi0xLTEtMS0zNzAzOQ_27c21fe3-137e-4551-bf1b-e655b9bf03d7"
      unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="id978ce266ef042feb765030a9e74ad19_I20220331"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81NS9mcmFnOmQ0ZWFmMTRhNDAwZTQ0N2M4NTQ0MjNmNWM5MzE4MjI4L3RhYmxlOjUyNGRhYmNhNzRkZjQwNjVhYTM1OTA5OTM1ZmFjYjM0L3RhYmxlcmFuZ2U6NTI0ZGFiY2E3NGRmNDA2NWFhMzU5MDk5MzVmYWNiMzRfMy0xLTEtMS0zNzAzOQ_b9be663b-17f0-4485-9e68-848dfa7b854d"
      unitRef="number">0.00155</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RleHRyZWdpb246NGFkY2MzMmU0Nzg2NDdmMWI1YzJiZmE3ZDVlY2M2NTJfMTk2Ng_80bba8b0-20fd-456f-b9bb-5142bad4591e">STOCK-BASED COMPENSATION&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation related to stock options issued under the Company&#x2019;s 2018 Equity Incentive Plan (2018 Plan) in the following expense categories of its accompanying statements of operations for the three months ended March&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has granted stock options to purchase its common stock to employees and consultants under the 2018 Plan, under which the Company may issue stock options, restricted stock and other equity-based awards. The Company has also granted certain stock options outside of the 2018  Plan. Stock options granted by the Company generally have a contractual life of up to 10 years. As of March&#160;31, 2022, all equity awards granted from the 2018 Plan were in the form of stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures equity-based awards granted to employees, and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for equity awards is the date of grant, and equity-based compensation costs are recognized as expense over the requisite service period, which is the vesting period or for certain performance-based awards. The Company records the expense for these awards if it concludes that it is probable that the performance condition will be achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below represents the activity of stock options granted to employees and non-employees for the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term&#160;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;708,490&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.64&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890,490&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.70&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,388&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.89&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.66&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of option on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;As of March&#160;31, 2022, the unrecognized compensation cost related to unvested stock options expected to vest was $1,486. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of 3.17 years.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RleHRyZWdpb246NGFkY2MzMmU0Nzg2NDdmMWI1YzJiZmE3ZDVlY2M2NTJfMTk2Nw_426e06fb-cd2a-4d7c-95a9-d6518a3f5502">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation related to stock options issued under the Company&#x2019;s 2018 Equity Incentive Plan (2018 Plan) in the following expense categories of its accompanying statements of operations for the three months ended March&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic0c5dc3daa51452a98594f5d3f6b538f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjE3MzA2YWQxMGVmMjQzODQ5NzFiMzNlMzljN2I3ZTBiL3RhYmxlcmFuZ2U6MTczMDZhZDEwZWYyNDM4NDk3MWIzM2UzOWM3YjdlMGJfMi0xLTEtMS0zNzAzOQ_5e37710a-d85b-40a6-bc46-8d06cb4b08f1"
      unitRef="usd">18000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i009ef9a9802043c7a795e51fb1ac96b0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjE3MzA2YWQxMGVmMjQzODQ5NzFiMzNlMzljN2I3ZTBiL3RhYmxlcmFuZ2U6MTczMDZhZDEwZWYyNDM4NDk3MWIzM2UzOWM3YjdlMGJfMi0zLTEtMS0zNzAzOQ_a95957b2-1522-45fb-ba42-76706868d46c"
      unitRef="usd">20000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0e848c92cf53437f8da4012e0c9545b1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjE3MzA2YWQxMGVmMjQzODQ5NzFiMzNlMzljN2I3ZTBiL3RhYmxlcmFuZ2U6MTczMDZhZDEwZWYyNDM4NDk3MWIzM2UzOWM3YjdlMGJfMy0xLTEtMS0zNzAzOQ_c1325ccb-f6bf-4519-8356-289587ce8684"
      unitRef="usd">163000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib390bd62760a4ca8915004678a850b79_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjE3MzA2YWQxMGVmMjQzODQ5NzFiMzNlMzljN2I3ZTBiL3RhYmxlcmFuZ2U6MTczMDZhZDEwZWYyNDM4NDk3MWIzM2UzOWM3YjdlMGJfMy0zLTEtMS0zNzAzOQ_8d7ce951-12ad-4fe7-af07-9c88eb22b8a0"
      unitRef="usd">148000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjE3MzA2YWQxMGVmMjQzODQ5NzFiMzNlMzljN2I3ZTBiL3RhYmxlcmFuZ2U6MTczMDZhZDEwZWYyNDM4NDk3MWIzM2UzOWM3YjdlMGJfNC0xLTEtMS0zNzAzOQ_1c199218-454a-46d0-8f49-7ebb00dbd350"
      unitRef="usd">181000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjE3MzA2YWQxMGVmMjQzODQ5NzFiMzNlMzljN2I3ZTBiL3RhYmxlcmFuZ2U6MTczMDZhZDEwZWYyNDM4NDk3MWIzM2UzOWM3YjdlMGJfNC0zLTEtMS0zNzAzOQ_515734cc-2742-41cf-a021-92a3a93f8ae4"
      unitRef="usd">168000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RleHRyZWdpb246NGFkY2MzMmU0Nzg2NDdmMWI1YzJiZmE3ZDVlY2M2NTJfNjcz_63a9ac55-e4a8-4ac9-8624-c925d5fdec56">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RleHRyZWdpb246NGFkY2MzMmU0Nzg2NDdmMWI1YzJiZmE3ZDVlY2M2NTJfMTk2NA_350326b9-49d5-40b4-b5d4-ffd658703af8">&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below represents the activity of stock options granted to employees and non-employees for the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term&#160;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;708,490&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.64&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890,490&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.70&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,388&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.89&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjAxZDhkNGY2Zjk0ZDRjZjRhM2RlZmY5NzZhNzg4N2U3L3RhYmxlcmFuZ2U6MDFkOGQ0ZjZmOTRkNGNmNGEzZGVmZjk3NmE3ODg3ZTdfMS0xLTEtMS0zNzAzOQ_d1621c63-92b6-43be-8f38-0dc8deec1b26"
      unitRef="shares">708490</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i55dd8e26998945bf948e411d61ec483e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjAxZDhkNGY2Zjk0ZDRjZjRhM2RlZmY5NzZhNzg4N2U3L3RhYmxlcmFuZ2U6MDFkOGQ0ZjZmOTRkNGNmNGEzZGVmZjk3NmE3ODg3ZTdfMS0zLTEtMS0zNzAzOQ_98d3b68c-0dc5-4227-ad74-b0bde31bfdbd"
      unitRef="usdPerShare">3.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i4ff57a73247a47f5aa2e3b501764627b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjAxZDhkNGY2Zjk0ZDRjZjRhM2RlZmY5NzZhNzg4N2U3L3RhYmxlcmFuZ2U6MDFkOGQ0ZjZmOTRkNGNmNGEzZGVmZjk3NmE3ODg3ZTdfMS01LTEtMS0zNzAzOQ_d7d9e0ba-c67d-47e8-a2e3-a6abc25668a3">P8Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjAxZDhkNGY2Zjk0ZDRjZjRhM2RlZmY5NzZhNzg4N2U3L3RhYmxlcmFuZ2U6MDFkOGQ0ZjZmOTRkNGNmNGEzZGVmZjk3NmE3ODg3ZTdfMi0xLTEtMS0zNzAzOQ_b43ba746-715f-4e0f-b933-ada949462508"
      unitRef="shares">182000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjAxZDhkNGY2Zjk0ZDRjZjRhM2RlZmY5NzZhNzg4N2U3L3RhYmxlcmFuZ2U6MDFkOGQ0ZjZmOTRkNGNmNGEzZGVmZjk3NmE3ODg3ZTdfMi0zLTEtMS0zNzAzOQ_82abdeed-9ed5-4e6b-9233-71cf985904da"
      unitRef="usdPerShare">5.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjAxZDhkNGY2Zjk0ZDRjZjRhM2RlZmY5NzZhNzg4N2U3L3RhYmxlcmFuZ2U6MDFkOGQ0ZjZmOTRkNGNmNGEzZGVmZjk3NmE3ODg3ZTdfNS0xLTEtMS0zNzAzOQ_f699e8e5-19ed-46f4-9616-c34f7b9eed99"
      unitRef="shares">890490</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjAxZDhkNGY2Zjk0ZDRjZjRhM2RlZmY5NzZhNzg4N2U3L3RhYmxlcmFuZ2U6MDFkOGQ0ZjZmOTRkNGNmNGEzZGVmZjk3NmE3ODg3ZTdfNS0zLTEtMS0zNzAzOQ_fe5be9a6-45bb-4618-becc-a89fb3636dee"
      unitRef="usdPerShare">4.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjAxZDhkNGY2Zjk0ZDRjZjRhM2RlZmY5NzZhNzg4N2U3L3RhYmxlcmFuZ2U6MDFkOGQ0ZjZmOTRkNGNmNGEzZGVmZjk3NmE3ODg3ZTdfNS01LTEtMS0zNzAzOQ_e74252b5-9951-4b81-815f-ae65e343027c">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjAxZDhkNGY2Zjk0ZDRjZjRhM2RlZmY5NzZhNzg4N2U3L3RhYmxlcmFuZ2U6MDFkOGQ0ZjZmOTRkNGNmNGEzZGVmZjk3NmE3ODg3ZTdfNi0xLTEtMS0zNzAzOQ_c54b4a68-5fe2-45b5-91f8-536e2c598d78"
      unitRef="shares">253388</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjAxZDhkNGY2Zjk0ZDRjZjRhM2RlZmY5NzZhNzg4N2U3L3RhYmxlcmFuZ2U6MDFkOGQ0ZjZmOTRkNGNmNGEzZGVmZjk3NmE3ODg3ZTdfNi0zLTEtMS0zNzAzOQ_209be1bb-1197-47d7-84a8-7597d44c2d21"
      unitRef="usdPerShare">3.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOjAxZDhkNGY2Zjk0ZDRjZjRhM2RlZmY5NzZhNzg4N2U3L3RhYmxlcmFuZ2U6MDFkOGQ0ZjZmOTRkNGNmNGEzZGVmZjk3NmE3ODg3ZTdfNi01LTEtMS0zNzAzOQ_39e30e2b-cbac-45cd-b7bb-1cef554b0e9c">P7Y10M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RleHRyZWdpb246NGFkY2MzMmU0Nzg2NDdmMWI1YzJiZmE3ZDVlY2M2NTJfMTk2NQ_87bc3913-4db9-4ee3-abcb-db001f376c3f">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:75.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.66&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of option on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.92&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOmM4YzU5NTBkMjExYjRhOWY4MzkwOTZlMjc2NjEwNTJmL3RhYmxlcmFuZ2U6YzhjNTk1MGQyMTFiNGE5ZjgzOTA5NmUyNzY2MTA1MmZfMi0xLTEtMS0zNzAzOQ_eb78279b-560c-4827-a831-b15adaa929e7"
      unitRef="number">0.8865</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOmM4YzU5NTBkMjExYjRhOWY4MzkwOTZlMjc2NjEwNTJmL3RhYmxlcmFuZ2U6YzhjNTk1MGQyMTFiNGE5ZjgzOTA5NmUyNzY2MTA1MmZfMi0zLTEtMS0zNzAzOQ_d7d36158-6bad-493e-a32a-d102883c9a3b"
      unitRef="number">0.8000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOmM4YzU5NTBkMjExYjRhOWY4MzkwOTZlMjc2NjEwNTJmL3RhYmxlcmFuZ2U6YzhjNTk1MGQyMTFiNGE5ZjgzOTA5NmUyNzY2MTA1MmZfMy0xLTEtMS0zNzAzOQ_6caa50ae-aad6-4226-9d6c-bdfce59ef62e">P6Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOmM4YzU5NTBkMjExYjRhOWY4MzkwOTZlMjc2NjEwNTJmL3RhYmxlcmFuZ2U6YzhjNTk1MGQyMTFiNGE5ZjgzOTA5NmUyNzY2MTA1MmZfMy0zLTEtMS0zNzAzOQ_422088f4-88ef-4833-929e-9b37a5141b4a">P5Y7M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOmM4YzU5NTBkMjExYjRhOWY4MzkwOTZlMjc2NjEwNTJmL3RhYmxlcmFuZ2U6YzhjNTk1MGQyMTFiNGE5ZjgzOTA5NmUyNzY2MTA1MmZfNC0xLTEtMS0zNzAzOQ_dcc200f4-4f83-41d5-a9ab-0d75369bdd72"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOmM4YzU5NTBkMjExYjRhOWY4MzkwOTZlMjc2NjEwNTJmL3RhYmxlcmFuZ2U6YzhjNTk1MGQyMTFiNGE5ZjgzOTA5NmUyNzY2MTA1MmZfNC0zLTEtMS0zNzAzOQ_346c7046-efcd-44e4-89c4-9e5102a06c84"
      unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOmM4YzU5NTBkMjExYjRhOWY4MzkwOTZlMjc2NjEwNTJmL3RhYmxlcmFuZ2U6YzhjNTk1MGQyMTFiNGE5ZjgzOTA5NmUyNzY2MTA1MmZfNS0xLTEtMS0zNzAzOQ_3b445ef4-9fab-4daa-9ef8-0f542eedd657"
      unitRef="number">0.0195</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="idbb8f5ee17ea4bf9865a05ec7d3eae69_D20210101-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOmM4YzU5NTBkMjExYjRhOWY4MzkwOTZlMjc2NjEwNTJmL3RhYmxlcmFuZ2U6YzhjNTk1MGQyMTFiNGE5ZjgzOTA5NmUyNzY2MTA1MmZfNS0zLTEtMS0zNzAzOQ_e97927ea-9a08-441e-ac3b-381733a0a940"
      unitRef="number">0.0069</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharePrice
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOmM4YzU5NTBkMjExYjRhOWY4MzkwOTZlMjc2NjEwNTJmL3RhYmxlcmFuZ2U6YzhjNTk1MGQyMTFiNGE5ZjgzOTA5NmUyNzY2MTA1MmZfNi0xLTEtMS0zNzAzOQ_be455e2b-6c03-41bb-a54e-94fe75d4e959"
      unitRef="usdPerShare">4.29</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="ibca337c014ca4895aaf539d38c0f5424_I20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RhYmxlOmM4YzU5NTBkMjExYjRhOWY4MzkwOTZlMjc2NjEwNTJmL3RhYmxlcmFuZ2U6YzhjNTk1MGQyMTFiNGE5ZjgzOTA5NmUyNzY2MTA1MmZfNi0zLTEtMS0zNzAzOQ_4569b6e8-5657-4018-adc4-f87640d5c01e"
      unitRef="usdPerShare">4.92</us-gaap:SharePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="if3397d410ba3402b845134ba54257a68_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RleHRyZWdpb246NGFkY2MzMmU0Nzg2NDdmMWI1YzJiZmE3ZDVlY2M2NTJfMzg0ODI5MDY5OTIyNA_cbc13c00-1aee-4ede-8299-aa98fe781871"
      unitRef="usd">1486000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF81OC9mcmFnOjRhZGNjMzJlNDc4NjQ3ZjFiNWMyYmZhN2Q1ZWNjNjUyL3RleHRyZWdpb246NGFkY2MzMmU0Nzg2NDdmMWI1YzJiZmE3ZDVlY2M2NTJfMzg0ODI5MDY5OTIyOA_a4192795-99c6-4a92-88bf-6e81958b1256">P3Y2M1D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF82MS9mcmFnOjJkMWFiNTE0ODMwYTRkODZiMTVmYzRhNzRkOTFkNmJkL3RleHRyZWdpb246MmQxYWI1MTQ4MzBhNGQ4NmIxNWZjNGE3NGQ5MWQ2YmRfMTQ2Ng_feaaffed-606b-43c8-8cdd-c9226c849632">RELATED PARTY TRANSACTIONS&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the Company entered into a license agreement with Medice which grants Medice an exclusive license, with the right to grant sublicenses, to develop, use, manufacture, market and sell ADAIR throughout Europe. Medice is responsible for obtaining regulatory approval of ADAIR in the licensed territory. Under the license agreement, Medice paid Vallon a $100 upfront payment and is required to pay milestone payments upon first obtaining regulatory approval to market and sell ADAIR in any country, territory or region in the licensed territory and upon achieving certain annual net sales thresholds. Medice will also pay tiered royalties on annual net sales of ADAIR at rates in the low double-digits. The initial term of the license agreement will expire five years after the date on which Medice first obtains regulatory approval in any country, territory or region in the licensed territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company entered into a Convertible Promissory Note Purchase Agreement with certain existing stockholders, including Salmon Pharma, an affiliate of Medice, and David Baker, the Company&#x2019;s Chief Executive Officer, pursuant to which the Company issued the 2021 Convertible Notes for cash proceeds of $350. The 2021 Convertible Notes bore an interest rate of 7.0% per annum, non-compounding, and had a maturity date of September 30, 2021. The 2021 Convertible Notes converted into 54,906 shares of the Company&#x2019;s common stock upon completion of the IPO.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <ck0001824293:RelatedPartyTransactionLicenseAgreementUpfrontPayment
      contextRef="idb6ea0f24b104095965bec61b8cda0e6_D20200101-20200131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF82MS9mcmFnOjJkMWFiNTE0ODMwYTRkODZiMTVmYzRhNzRkOTFkNmJkL3RleHRyZWdpb246MmQxYWI1MTQ4MzBhNGQ4NmIxNWZjNGE3NGQ5MWQ2YmRfMzkx_06fe118a-cdd4-44f8-b3b3-00344b9dce8f"
      unitRef="usd">100000</ck0001824293:RelatedPartyTransactionLicenseAgreementUpfrontPayment>
    <ck0001824293:RelatedPartyTransactionLicenseAgreementTerm
      contextRef="idb6ea0f24b104095965bec61b8cda0e6_D20200101-20200131"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF82MS9mcmFnOjJkMWFiNTE0ODMwYTRkODZiMTVmYzRhNzRkOTFkNmJkL3RleHRyZWdpb246MmQxYWI1MTQ4MzBhNGQ4NmIxNWZjNGE3NGQ5MWQ2YmRfNzky_60d85445-03fb-4b59-90db-8cbb2d871bad">P5Y</ck0001824293:RelatedPartyTransactionLicenseAgreementTerm>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i6f0dc3494c1646ab80c715e4bcf2f8e2_D20210101-20210131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF82MS9mcmFnOjJkMWFiNTE0ODMwYTRkODZiMTVmYzRhNzRkOTFkNmJkL3RleHRyZWdpb246MmQxYWI1MTQ4MzBhNGQ4NmIxNWZjNGE3NGQ5MWQ2YmRfMTIyOA_61edd20b-8200-45cd-aa1f-8c6cdb4f6113"
      unitRef="usd">350000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7820e87649a24600869cfef32d0d6f5b_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF82MS9mcmFnOjJkMWFiNTE0ODMwYTRkODZiMTVmYzRhNzRkOTFkNmJkL3RleHRyZWdpb246MmQxYWI1MTQ4MzBhNGQ4NmIxNWZjNGE3NGQ5MWQ2YmRfMTI4Mg_afac81db-d0dc-4030-956a-4084e52a1585"
      unitRef="number">0.070</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i6f0dc3494c1646ab80c715e4bcf2f8e2_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF82MS9mcmFnOjJkMWFiNTE0ODMwYTRkODZiMTVmYzRhNzRkOTFkNmJkL3RleHRyZWdpb246MmQxYWI1MTQ4MzBhNGQ4NmIxNWZjNGE3NGQ5MWQ2YmRfMTQwMA_8a50b591-72c7-4783-b46e-2e955d789610"
      unitRef="shares">54906</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5ODQzMjg3YjhkZTRkNjdiOGU1NmMwODIyMDdlNWNkL3NlYzo1OTg0MzI4N2I4ZGU0ZDY3YjhlNTZjMDgyMjA3ZTVjZF82Ny9mcmFnOmVmNjhkNTc3OGIzMDRlNWViNzU1YjdhZDJkMTY3ZGY0L3RleHRyZWdpb246ZWY2OGQ1Nzc4YjMwNGU1ZWI3NTViN2FkMmQxNjdkZjRfMTg2Mg_c6178a44-2018-4d85-9a14-4ea973ba58e3">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employment Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;COVID-19 Impact&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The global COVID-19 pandemic continues to present uncertainty and unforeseeable new risks to the Company&#x2019;s operations and business plan. The Company has closely monitored recent COVID-19 developments, including the lifting of COVID-19 safety measures, the drop in vaccination rates, the implementation of, and reaction to, vaccine mandates, the spread of various coronavirus strains such as the Delta variant, and supply chain and labor shortages. In light of these developments, the full impact of the COVID-19 pandemic on the Company&#x2019;s business, operations and clinical development plans remains uncertain and will vary depending on the pandemic&#x2019;s future impact on the Company&#x2019;s clinical trial enrollment, clinical trial sites, CROs, third-party manufacturers, and other third parties with whom we do business, as well as any legal or regulatory consequences resulting therefrom. To the extent possible, the Company is conducting business as usual, with necessary or advisable modifications to employee travel and with most of its employees and consultants working remotely. The Company will continue to actively monitor the COVID-19 pandemic and may take further actions that alter its operations, including those that may be required by federal, state or local authorities, or that the Company determines are in the best interests of its employees and other third parties with whom the Company does business.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>49
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MI08>KRU\1ZR1*?H-C5.GQRGE'#0]?[NK7$F8<?\@DL-:<EA*#D](W@J_@.]
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M"=LM.P.MKX;1DLMH_9 D[1K(UBO(!:^@+W8K[6]?HQL5$C  DIP##@0EHP[
MK4F0N$FXQ7)5R]SUFV6S"4S*('K?'@+H QZ23G'';HNT+D+B+F)/55<YRY1E
M^1KZ4#U9S78;'.O5[H'].,"FL;#GG& G DX#B__<J@-AF$PG'69(6K,A[S";
M$-8;1 U:LRT7PHX$S"MP(B[S8!]\5TDF0W+>A< !:-@U#JWSD/@9*-X!9G=,
M4>C^\8:D(V\2!<Y)9#;M6K6MN9%I5'YA.^Q@AV9\5(9;3R(7/,FIEJX/,)Z&
MN3/VB38'*9IYQW]/T_P07],&)[=+)5-;=^FFD=LK5I<VS=?F8N_>76>=?7_
MM\OJ>JXM4]T6?J5P!!(:I&\#)8<?)S!BJKJ JUZ,W+L[K+4T1I;N<<<HG.ML
M /R^D<!*_6(;:*Y!%_\#4$L#!!0    ( 'V!J50O#(>KP0<  #D1   8
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MY[M'AY,$@.$ENI:O=9F+N"3R8XU;N?*T =]+AQFI?Z$#QGO^Z;]02P,$%
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MR1?J6ZO#D]A'&P)'A8AV$A.63BE11Y)51+);&EDD9XA^%-(OQ1P-VO\."50
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M\9N$K0C@/#-@J5V(@^VOG+._ 5!+ P04    " !]@:E4"K3\O#0$  !'"0
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M 1-"A9%C!$%_#WB.2C$0T?B^QQQT(=FQ_]RB?_*Y4RY;8?%<JV\R=MG)8#&
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MKP7WF-'G&6H6H/VE4G;[P@Z:#[[3OP!02P,$%     @ ?8&I5$6K>":!!
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M]K(!ZZ6#!/U '.Q>CB=_ 5!+ P04    " !]@:E4GW\.%BD%  #$"P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6RM5MMN&S<0_15"!?JD6+;L-&EJ
M&_"MK1[L!+&;/A1]H):S6L)<<L/A2M;?]PSW8MFP#13MB[2[Y-S.G#GD\2;$
M>ZZ(DGJHG>>32952\VDVXZ*B6O->:,ACI0RQU@FO<37C)I(VV:AVL_G^_D^S
M6EL_.3W.W[[$T^/0)F<]?8F*V[K6<7M.+FQ.)@>3X<-7NZJ2?)B='C=Z1;>4
M_FB^1+S-1B_&UN39!J\BE2>3LX-/YT>R/V_X9FG#.\]**EF&<"\O"W,RV9>$
MR%&1Q(/&WYHNR#EQA#2^]SXG8T@QW'T>O/^::T<M2\UT$=R?UJ3J9/)QH@R5
MNG7I:]C\3GT][\5?$1SG7[7I]KZ?3U31<@IU;XP,:NN[?_W0X[!C\''_%8-Y
M;S#/>7>!<I:7.NG3XQ@V*LIN>).'7&JV1G+62U-N4\2JA5TZO?A\?;VXN[ZZ
MN;M59S>7ZN+SS=WBYK>KFXO%U>WQ+"&$;)P5O;OSSMW\%7>'ZCKX5+&Z\H;,
M4_L94AOSFP_YG<_?='BMXYXZ/)BJ^?Y\_H:_P['>P^SO\+5Z0UW;!%8E5MH;
M=8%TK5^1+RRQNK1<N,!M)/77V9)3!&G^?B/JT1CU*$<]^K]0_@_NU%7=N+"5
M$M79*A)UQ=Y5A&+K1ONMJC0K?*1(1EF?@J)'DP* 2-D,(J9*63R$LK0%15:I
MTDDU,:RM(05!4$QKBMH7E+$L,I:MSN,62K4D3Z4XL!ZFI+ 9 ;" R*#RN&\G
M^G*;=PZ)2@I0$E7HEDDA8+_>65"7Q"H$ WW0'/R>6F#0C;'B>OHOXI;!09Y
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M\).T1^+ER5",C\?C/?)>MAYZR?)>?D?>)$E,K7VNEZ(Q4_QG,G?> E'_W7/
MJ_: 5WS J^^%0+K<";,0VY/ZW+A?R'VF@/#$E)74&]*UUK).<Z]2D6NO;%Z*
M1:ZE3G)9".>E5\@L[T0F5TK,E=(".5U)R^M9DDVQ6@&./N/[Z(/*YA!2%?#"
M4FEE95%LZ+VJPEG"0Y,'S2?/Z)Q@6@D5$BD./DXFMR\$R*1'K0KW)G5"ZE14
MM76UU%YXPQ)M701)=#-326US3Y&@M5>/22;U4HFI*<O<$5\<B3NU4%;! A>4
M@HO_J*7%F=#W3E7&>@%6H-06)\>'?]!!O_YR.AX?OY>USPSD2R(,L:QS]@2_
M/'DO(*A443-+A] %F26D@V&U;KW000X\H5-I8=S4I/D"KF!..IC,IB_8AMZU
M#U7*#L2RAQ>-\1]:?_7NN33X(PX^3&:7+XX$P>(WE:ARKNROOYR\.7X?,^,$
M7%9P@ /WKZ%\"O^O$+:%-:5HT-.'FB-Q'2PT5:[)#JA62@T2I]=#?O6#^%O4
M5N=0(149P@7' 5U%G0+,12$T\6[!_K$4<DNFRO0+:#'L3@RJ ]3&=@TKG4-=
MH7  RPX+Q$+F%&[29QI2@Z)X\O:]Z\+.N#Q4" 88^"/)=GPU'K(*#$/E0/>\
M#G71<A0#",'4R=?,%-#&Q4.$^E;G?B,.4"7 &S[@GL3XS"HERD!\BHBO[UB6
MR[&BBT2Z3"Q01-W/BJ&DZ%/_KXF#,ZQ":'SK\APNSG7*H$;"1)S& Q"QQFD^
MDQXXV8!OA'JL4)<)7_'PC9*6#J4-O8@=!S3_&*Z&#01:8 U%:EAK8,;+F*&6
M(D3H27.7%,;5V(03$,.0T:2<U+J&[/X\^%G:=9FIBY0<09T4$0;4^E+KT*HP
MYY)^\>Q]N1BSHY"T /81)W* Z?E3YV))/QL,F[QKR>MIODR"*L^9\^]0J\"^
M5NG9U93?J[D%X6["02>O8A#W%,S7;<%\O;?6/3@&V97S>4G\V%<M_YH$"F.H
M?X&7\:[7UR%.U I37K/%C).((]=A0:*A4GX%TIM#."+2H?VM0MYQ/LC% HD0
MT4B^A2ME2;P>HNB<BD$N<CG/"RY[6T+: I=6$[:!0CJ^?Z.0X2BJ*TVB_B!D
MMQ3X7$O*9NT@/JV9H[?KN&7@NGZT=?<S3Q"CH+$H Y>4$OR?ZX!J"D?L 5:R
MJ-OXN(PVF2 @E!S"=4H0YD+6DA&<LE+09%ZHD"!#5#MKJ82C6:BI" X[LE%X
MS%IRXQ 4('L,=?K*$E5X^1B=.\2"E=(UV9J8I>8J,B0^L#46MDXA:R,*HO*D
M+1+.LFOAYKFQR 'F2@I,D[8A#DH4"G,'BNZ"AAC*PH91T4I0 \(%NR]I6^P-
MA;&-&]6C9WQF(,@N.N'.4%L#"2QJ3ZB*3=FP5WY_.4R8VQ2R [K-T20N<L\Z
MLA9S.@8!P62VB>C'@?,-87J#X3#)1&SGH$2CWC[:>-/2QIN]28]:]E5Y23#8
M-I!]W+%7#$W)[UPE$W4^X!IC5VK0+UMTGKKM4VY:G">GI6KNNZ\"(\#KJ7+Y
M4C.G@\WE2N8%B3D$,@Z=+ "&CNRG4D@ (=)2+LC0!3' %4.QUJ@Y1?XGE4;T
M*X2Z)0JBH^" 2EPKH<ESW LJ<483;HB4DJ0NZU!R#$>97EN5T;"^8FB;4HD#
MDH8F=$_LWK:Q>[LW=C/JK@YI_$X9A#B(P=87OI^3Q*4\XKO)YS_ABIC%G).J
MK JS4<&-VNC#]H'K2$VZ4GN&*?3\XAZ=<R+>GIP.15#H\KE"-!S0$G@P7FWK
M# .%<P5C*#8D(?/FJAG58F=5.VZ9.Q"(2I8*,TX:&I@FR=(N4MHN+DC&U .^
M!XL2;,Q*!8):T=:6X8<BR#:A@_B^L+B B]"2B%BEH:+AE$0628164)Y67A82
M/IHEP"M-@2SF$ 4CH06E255QM!._Z(30VN+? F3$O9VD&DZ3A$IYB&D&B.:@
MYSIS-UAP;\=!%FN@O$N&C06[M:AYV9E0'(J%I4X2T3+6Q8[K^<E,VTCL,!;-
MJ1Y2JN]$^BC IG%%+_"XGW-/^H\O=;H,]1SVL2FN(P@-#'W%"@VZLDE.8MOI
MADHT0+PR5!713VR"TR&>C. :P$<W6QDUIO:-*Z-/_L84Z*T)DUVJH#0&U[JB
MXBMT3=TI=V"]?MH*B6[9$MNV9%+K8N9?%'_R<[OP$W%(8^5W*F B=?@>(@4]
ML"0EQVF);Q ;W+#CYX8?YK!SG6-H90G:/-FYG=YV<J[;S,0HRC7/\9SA+! 5
MEA5$N:1\VY) $\O8#>Y4]R>- E$!?TQ(._9VNP=C\R5<5W1;!N:7ILO;+2I<
M$D(-(,+?SN3-^! 8(6BTTV*@92)4[>9K[9C3.F,AW(]V 1U%QE0CHQ<)-]&T
ML((2?(X:M,O-E'6PFUJ\+8$Y-&7[^HC3MA:=[JT@=YB@(+C[7= :C>LD=,I]
M->G_D[CCJPZC\(A8504F;V[P-X%$(_ 6_ UE,GMHC.]VY]_"M[#NF"]V/A@H
MB2?AJQ!Y&AHSQ(@90F-'LW1S.)H0*H]M\$S( NS*RZ=)Y%3_+-T7F5'GPW:I
M[)(_WW.#J7WXQMT^;7\AF(0/X]OEX><%F+BD)J=0"VP]/GJ+"=&&3_;AQIN*
M/Y,#3=Z4?)EA-E>6%N#]PF!VB#=T0/N[R<7_ %!+ P04    " !]@:E4QMS\
M4\\#  "*"0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6S-5MMNXS80
M_96!NB@V0!)9\B5>KVU B9UMT'@1V$[Z4/2!EL86&XGTDE2\Z==W2%UB-XF1
MQ[[8Y' N9V9X-!SNI'K4*:*!GWDF],A+C=D.?%_'*>9,G\LM"CI92Y4S0UNU
M\?56(4N<49[Y8:O5\W/&A3<>.MF=&@]E83(N\$Z!+O*<J>=+S.1NY 5>+9CS
M36JLP!\/MVR#"S3WVSM%.[_QDO <A>92@,+UR(N"P677ZCN%!XX[O;<&F\E*
MRD>[N4E&7LL"P@QC8STP^GO"*\PRZXA@_*A\>DU(:[B_KKU?N]PIEQ73>"6S
M/WABTI'7]R#!-2LR,Y>[W[#*QP&,9:;=+^PJW98'<:&-S"MC0I!S4?ZSGU4=
M/F(05@:APUT&<B@GS+#Q4,D=**M-WNS"I>JL"1P7MBD+H^B4DYT9SZ+Y[]-E
M='D[A<7TZGY^L[R9+B#Z/H'KZ&8.#]'M_11FTVAQ/Y_.IM^7"_B\9*L,]<G0
M-Q3?>O'C*M9E&2M\)U8;9E*85,-4))@<VON$NP$?UN OPZ,.9TR=0SLXA; 5
MAD?\M9MBM)V_]CO^KAE7\,"R F'"=9Q)72C4\&>TTD;1_?GK2(Q.$Z/C8G3>
MB;$H;S_(-9@4X4KF6R:>?_VE'P877S5$3XQGML! A(,%H\4"XT)QPU&_5?*C
MT2RE!WK+8AQYQ%F-Z@F]\3*UWC/B(Q<;X!I8S<GW4+$#5-JBT@TJ8+JV2YBA
M/1<)CVF5#"!R1]2G.&T:!5'R-UUL3"B,-O!-2:WA7M G)>/_D/0;?4KT:_$M
M[<GY7H_([2,:!^NE1@.8X,KLP1M0&+65B@#!2HI$PR=H=[[0KTLO_'JPLB>S
M0O"8;UE6Z8>GX9>@T?G<.[&2?A>6TI#.)]KU.JT#+U;'R=N=J@03C#%?H:JK
M$/P/JA"<!MWV(>[@I)*';U2AU[UXJ4)PXB2]I@KMTW[PGRJ$)Z6\U8<CS.DV
MS.E^E#E3;7AN;]A^(4A^(YY0&YH91L-5QK3F:TY*JV?*7C@*%X1UQHRMRC/0
M%Q/?XM11'!_A5-F.DE34-NW(@0WHM07]5(.6A2+*O #G@C[P34^3PS[2># I
M:&/[&._EE-<Y.0J>TK2+92%<,&(LVZ/P&0G.7E%8)! ?%,PB?C= S??]^_4F
MU2>4(N43P#,RU5"BEIYUG5PW=Z8ZZ)[137I]PM:&"/3J:(^&Y/NMB^;OS<<<
MU<:] C2X"I6CLI$V#XVHG*\OZN4KA?+;6&)FN";3UOD%W1553OYR8^363=N5
M-#2[W3*EQQ(JJT#G:RE-O;$!FN?7^%]02P,$%     @ ?8&I5+NF:RN/ @
M6@4  !D   !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL?53;;AHQ$/V5T2H/
MK11EKQ""  D(O4A-A2!I*U5],+NS%\5K;VT#R=]W[(4MK0(O:\]XYLR961^/
M]E(]ZQ+1P$O-A1Y[I3'-T/=U6F+-](UL4-!)+E7-#)FJ\'6CD&4NJ>9^% 1]
MOV:5\"8CYUNJR4AN#:\$+A7H;5TS]3I#+O=C+_2.CE55E,8Z_,FH806NT3PU
M2T66WZ%D58U"5U* PGSL3</A++'Q+N!;A7M]L@?;R4;*9VM\SL9>8 DAQ]18
M!$;+#N?(N04B&K\/F%Y7TB:>[H_H'USOU,N&:9Q+_KW*3#GV!AYDF+,M-RNY
M_X2'?GH6+Y5<NR_LV]@X]B#=:B/K0S(QJ"O1KNSE,(>3A$%P)B$Z)$2.=UO(
ML;QGADU&2NY!V6A"LQO7JLLF<I6P/V5M%)U6E&<FT_E\];2XA\6/Y>+K>K&&
M=X]LPU&_'_F&X&V0GQZ@9BU4= 8JA@<I3*EA(3+,_LWWB5;'+3IRFT47 1^8
MNH$XO(8HB*(+>''7:^SPXC-X2_;J>@,F,IBFJ=HRKN'G=*.-HMOQZT*)I"N1
MN!+)F1)K$DVVY0@R;RM@!HL74I!&_=9$+Z)900YUPU(<>Z0XC6J'WN0(BP=8
M2"5)1!M;TI0(N>2DM$H40Z !IF4W0;C'%.L-JJ,GA!6!NA@[D0QWI-&&%&?@
M"OI)0-_!70(?4:!BW,6PC.Y@9>=EQ01A$$$XB($FJZBL"U'(F2%^2="'Z"Z$
M+U5J-2R*[J1W"_T('J6QH/]W<P7A=13TW)K$ ;SU4_R3^UZC*IRJ[2"VPK17
MO_-V#\>TU<O?\/;5H1$5E=# ,:?4X.:VYX%JE=P:1C9./1MI2(MN6]+CA\H&
MT'DNI3D:MD#WG$[^ %!+ P04    " !]@:E4:R=-Q*0"  !7!0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970R,"YX;6Q]5&%OVC 0_2NG3)TV:9 08$4=()66
MJ=56M0/::9KVP20'L7#LU'9(^^]W=B!C4N%+XCO?>_?.OO.P4GIC,D0++[F0
M9A1DUA8786B2#'-FVJI 23LKI7-FR=3KT!0:6>I!N0CC*/H<YHS+8#STO@<]
M'JK2"B[Q08,I\YSIUPD*58V"3K!WS/@ZL\X1CH<%6^,<[6/QH,D*&Y:4YR@-
M5Q(TKD;!9>=BTG/Q/N")8V4.UN J62JU<<9M.@HB)P@%)M8Q,/IM\0J%<$0D
MXWG'&30I'?!PO6?_ZFNG6I;,X)42/WEJLU$P""#%%2N%G:GJ!G?U]!U?HH3Q
M7ZCJV'X_@*0T5N4[,"G(N:S_[&5W#@> 070$$.\ L===)_(JKYEEXZ%6%6@7
M36QNX4OU:!+'I;N4N=6TRPEGQ_/%_=6WF_OOU]/9_/V[0=PY_P+3'X^WBU_P
M8<&6 LW'86@ID0L/DQWII":-CY!VX4Y)FQF8RA33__$A"6Q4QGN5D_@DX1W3
M;>AV/D$<Q?$)OFY3==?S=8_P39]+;E_A]^726$V-\><$9Z_A['G.WA'.KXQK
M>&*B1+A#9DJ-U+L6;F516@-,IGZ3^5Y<8)))_ERB>>MP3^=99 @3P9)-:YYD
MBBX(5.%(6X7F"9=KR%6*U$;,0&DP!:L C>74P B6L"NG<^MUJI7W5$QK)DED
MQ6U6QRA!T^K(*M_6F+;8%C5-*3!#\^L3F@MX4H(*$NXL!_UV!&<P?2EHWEQ:
MU#EP":_(M(&XW8=KON4ITCEH)R7RX3-N-JV51J100I#0_6ZGWX>SMZXE/&CV
M'/7:C[2!1)72UGW?>)M7X[(>EG_A]9-#;;7FTH# %4&C]CD-J:['N#:L*OSH
M+)6E0?3+C%X^U"Z ]E=*V;WA$C1OZ?@O4$L#!!0    ( 'V!J502P#(<D 0
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M +"^XEP]3+);</G5,_P-4$L#!!0    ( 'V!J52I$TX EP(  *D%   9
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;'U4WV_:,!#^5TY1'UJI(Q"@ZRI
M"I!JU4I5\:-[F/9@DH-83>S,=J#;7[^S QGM@)?$/M_WW7<^W_6V4KWJ%-'
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M1+/]2M'QVSVO33&SO+"E7=K2-MKRF(8HUB)2*.0?,(ACKJBY*(.?O9+9>]^
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MQ/:)M)THOLQOZ%.NZ+Z?#Q?TK$2A-]#W&2=G%Q-]Z2\?JOW_ %!+ P04
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M-9=4[*.R$^C]7$JSZ=@%JK\/X^]02P,$%     @ ?8&I5 1C^D:R @  +@@
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M<VAE970S-2YX;6R55F%OVC 0_2NG:)5::9 0"H4)D(!2K9K:HM)V'Z9],.0
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M^[^3ZM"_Z\;MA^7SYN0;'W"V<.:[_P502P,$%     @ ?8&I5.N(NN65 0
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M2P$"% ,4    " !]@:E4<P^PZ^\    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !]@:E4F5R<(Q &  "<)P
M$P              @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( 'V!J51\(-BR904  )T6   8              " @0X(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !]@:E4-LC#.6H$   2$0
M&               @(&I#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ ?8&I5 !DVSQT @  NP8  !@              ("!21(  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( 'V!J51J?YBX400
M (</   8              " @?,4  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    " !]@:E4D10N&,\$   9%   &               @(%Z
M&0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ ?8&I5&$K
MK0AC!0  $A4  !@              ("!?QX  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( 'V!J50O#(>KP0<  #D1   8
M  " @1@D  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !]
M@:E4AZ?Q<=L&  #S#P  &               @($/+   >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ ?8&I5$Z#([2H"@  D!L  !@
M         ("!(#,  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( 'V!J50S9]FIS@8  *,0   9              " @?X]  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ ?8&I5"'V*!!] @  5@4
M !D              ("! T4  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    " !]@:E4RM$OU*H%  #Q#   &0              @(&W1P
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( 'V!J50*M/R\
M- 0  $<)   9              " @9A-  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ ?8&I5-AQ0:7!!0  _ T  !D
M ("! U(  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !]
M@:E41:MX)H$$  !%"@  &0              @('[5P  >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( 'V!J52??PX6*04  ,0+   9
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M970R,"YX;6Q02P$"% ,4    " !]@:E4$L R') $  "G"@  &0
M    @(&$=0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M 'V!J53[<7@J80(  %<%   9              " @4MZ  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ ?8&I5)@1$3,0 P  -@D  !D
M             ("!XWP  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    " !]@:E4+NF:D P"  #H P  &0              @($J@   >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( 'V!J53%7LA/B@,
M  $-   9              " @6V"  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ ?8&I5*D33@"7 @  J04  !D              ("!
M+H8  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !]@:E4
M%W+AB9X"  "G!@  &0              @('\B   >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( 'V!J52Q8.= G0(  .8&   9
M      " @=&+  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ ?8&I5,PPWQP0!   M X  !D              ("!I8X  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !]@:E4!4DZH,,#  !*#
M&0              @('LD@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( 'V!J50$8_I&L@(  "X(   9              " @>:6  !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ ?8&I5.2"'P#D
M @  D@@  !D              ("!SYD  'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    " !]@:E4(97]O94"  #M!0  &0
M@('JG   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( 'V!
MJ50X>^ZKC@,  /L,   9              " @;:?  !X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ ?8&I5/#U);L. P  CP@  !D
M         ("!>Z,  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M    " !]@:E4=^/C/5T#  #/"@  &0              @(' I@  >&PO=V]R
M:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( 'V!J53J7X3@,P,  -@3
M   -              "  52J  !X;"]S='EL97,N>&UL4$L! A0#%     @
M?8&I5)>*NQS     $P(   L              ( !LJT  %]R96QS+RYR96QS
M4$L! A0#%     @ ?8&I5*[:9J^? P  =1@   \              ( !FZX
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( 'V!J536^OFQ> $   ,6   :
M              "  6>R  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( 'V!J53KB+KEE0$  ((6   3              "  1>T  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     L "P ZPL  -VU      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>53</ContextCount>
  <ElementCount>170</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>18</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Statements of Changes in Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit</Role>
      <ShortName>Statements of Changes in Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/StatementsofCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LIQUIDITY</Role>
      <ShortName>LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2108104 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS</Role>
      <ShortName>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113105 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSES</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2116106 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES</Role>
      <ShortName>PPP NOTE AND CONVERTIBLE NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2118107 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2122108 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2128109 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2130110 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2206201 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2314302 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ACCRUEDEXPENSES</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2319303 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2323304 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - LIQUIDITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LIQUIDITYDetails</Role>
      <ShortName>LIQUIDITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/LIQUIDITY</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of the Company???s Available for Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails</Role>
      <ShortName>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of the Company???s Available for Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails</Role>
      <ShortName>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Investments Classified by Contractual Maturity Date (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails</Role>
      <ShortName>MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Investments Classified by Contractual Maturity Date (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails</Role>
      <ShortName>ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails</Role>
      <ShortName>PPP NOTE AND CONVERTIBLE NOTES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2420409 - Disclosure - STOCKHOLDERS??? EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - STOCKHOLDERS??? EQUITY - Estimate of the Fair Value of the Warrants and Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Estimate of the Fair Value of the Warrants and Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - STOCK-BASED COMPENSATION - Activity of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Activity of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ck0001824293-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS</ParentRole>
      <Position>36</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ck0001824293-20220331.htm">ck0001824293-20220331.htm</File>
    <File>ck0001824293-20220331.xsd</File>
    <File>ck0001824293-20220331_cal.xml</File>
    <File>ck0001824293-20220331_def.xml</File>
    <File>ck0001824293-20220331_lab.xml</File>
    <File>ck0001824293-20220331_pre.xml</File>
    <File>ex311_ceo302cert33122.htm</File>
    <File>ex312_cfo302cert33122.htm</File>
    <File>ex321_ceosection906cert331.htm</File>
    <File>ex322_cfosection906cert331.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ck0001824293-20220331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="267">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="33">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>55
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ck0001824293-20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 8,
   "contextCount": 53,
   "dts": {
    "calculationLink": {
     "local": [
      "ck0001824293-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ck0001824293-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ck0001824293-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ck0001824293-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ck0001824293-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ck0001824293-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 244,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 1,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 6
   },
   "keyCustom": 13,
   "keyStandard": 157,
   "memberCustom": 4,
   "memberStandard": 14,
   "nsprefix": "ck0001824293",
   "nsuri": "http://www.vallon-pharma.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "dei:DocumentType",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.vallon-pharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "dei:DocumentType",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108104 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS",
     "role": "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS",
     "shortName": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113105 - Disclosure - ACCRUED EXPENSES",
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116106 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES",
     "role": "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES",
     "shortName": "PPP NOTE AND CONVERTIBLE NOTES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118107 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122108 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128109 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130110 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2206201 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309301 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables",
     "shortName": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314302 - Disclosure - ACCRUED EXPENSES (Tables)",
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "if3397d410ba3402b845134ba54257a68_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Balance Sheets",
     "role": "http://www.vallon-pharma.com/role/BalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "if3397d410ba3402b845134ba54257a68_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319303 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323304 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "if3397d410ba3402b845134ba54257a68_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:ClinicalResearchStudyNumberOfParticipantsEnrolled",
      "reportCount": 1,
      "unique": true,
      "unitRef": "participant",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)",
     "role": "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
     "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "if3397d410ba3402b845134ba54257a68_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:ClinicalResearchStudyNumberOfParticipantsEnrolled",
      "reportCount": 1,
      "unique": true,
      "unitRef": "participant",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "if3397d410ba3402b845134ba54257a68_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404402 - Disclosure - LIQUIDITY (Details)",
     "role": "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
     "shortName": "LIQUIDITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "if3397d410ba3402b845134ba54257a68_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "if3397d410ba3402b845134ba54257a68_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of the Company\u2019s Available for Sale Securities (Details)",
     "role": "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails",
     "shortName": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of the Company\u2019s Available for Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "if3397d410ba3402b845134ba54257a68_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i1c4b8521c9f140c7a9592f7f41d732a6_I20210212",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Narrative (Details)",
     "role": "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails",
     "shortName": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i1c4b8521c9f140c7a9592f7f41d732a6_I20210212",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "if3397d410ba3402b845134ba54257a68_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Investments Classified by Contractual Maturity Date (Details)",
     "role": "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails",
     "shortName": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Investments Classified by Contractual Maturity Date (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "if3397d410ba3402b845134ba54257a68_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "if3397d410ba3402b845134ba54257a68_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:AccruedResearchAndDevelopmentCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - ACCRUED EXPENSES (Details)",
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails",
     "shortName": "ACCRUED EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "if3397d410ba3402b845134ba54257a68_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:AccruedResearchAndDevelopmentCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "iac76cfecf8b945eda2c37283b0d1bafa_D20210101-20210131",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:ForgivenessOfDebtInstrument",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - PPP NOTE AND CONVERTIBLE NOTES (Details)",
     "role": "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
     "shortName": "PPP NOTE AND CONVERTIBLE NOTES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i908364284b2449eaa88060f3a0a6fa84_I20200531",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "if3397d410ba3402b845134ba54257a68_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Balance Sheets (Parenthetical)",
     "role": "http://www.vallon-pharma.com/role/BalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "if3397d410ba3402b845134ba54257a68_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i63431f71e5c74bdbb2b0f31ac2cafe55_D20210201-20210228",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:StockIssuanceCostsOfferingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420409 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDetails",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i63431f71e5c74bdbb2b0f31ac2cafe55_D20210201-20210228",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ck0001824293:StockIssuanceCostsOfferingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i1911bf6daa244c328b316073998944ff_I20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Estimate of the Fair Value of the Warrants and Assumptions (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Estimate of the Fair Value of the Warrants and Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i1911bf6daa244c328b316073998944ff_I20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i55dd8e26998945bf948e411d61ec483e_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - STOCK-BASED COMPENSATION - Activity of Stock Options (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Activity of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)",
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "iac76cfecf8b945eda2c37283b0d1bafa_D20210101-20210131",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "role": "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "idb6ea0f24b104095965bec61b8cda0e6_D20200101-20200131",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ck0001824293:RelatedPartyTransactionLicenseAgreementUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Statements of Operations and Comprehensive Loss",
     "role": "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss",
     "shortName": "Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "ie7614adf727b407d9dcfe9c7866dadec_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Statements of Changes in Stockholders' Equity (Deficit)",
     "role": "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit",
     "shortName": "Statements of Changes in Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "ie7614adf727b407d9dcfe9c7866dadec_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Statements of Cash Flows",
     "role": "http://www.vallon-pharma.com/role/StatementsofCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "role": "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS",
     "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - LIQUIDITY",
     "role": "http://www.vallon-pharma.com/role/LIQUIDITY",
     "shortName": "LIQUIDITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ck0001824293-20220331.htm",
      "contextRef": "i48a983a1b57c4df09e6611d23c69c984_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 18,
   "tag": {
    "ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued General and Administrative Expenses, Current",
        "label": "Accrued General and Administrative Expenses, Current",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "AccruedGeneralAndAdministrativeExpensesCurrent",
     "nsuri": "http://www.vallon-pharma.com/20220331",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_AccruedLicensingFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Licensing Fees, Current",
        "label": "Accrued Licensing Fees, Current",
        "terseLabel": "Licensing related"
       }
      }
     },
     "localname": "AccruedLicensingFeesCurrent",
     "nsuri": "http://www.vallon-pharma.com/20220331",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_AccruedResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research and Development Costs, Current",
        "label": "Accrued Research and Development Costs, Current",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://www.vallon-pharma.com/20220331",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_AffiliateOfMediceAndDavidBakerCEOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliate of Medice and David Baker, CEO",
        "label": "Affiliate of Medice and David Baker, CEO [Member]",
        "terseLabel": "Salmon Pharma, Affiliate of Medice and David Baker, CEO"
       }
      }
     },
     "localname": "AffiliateOfMediceAndDavidBakerCEOMember",
     "nsuri": "http://www.vallon-pharma.com/20220331",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Research Study, Number of Participants, Completed the Study",
        "label": "Clinical Research Study, Number of Participants, Completed the Study",
        "terseLabel": "Number of subjects that completed the SEAL study"
       }
      }
     },
     "localname": "ClinicalResearchStudyNumberOfParticipantsCompletedTheStudy",
     "nsuri": "http://www.vallon-pharma.com/20220331",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ck0001824293_ClinicalResearchStudyNumberOfParticipantsEnrolled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Research Study, Number of Participants Enrolled",
        "label": "Clinical Research Study, Number of Participants Enrolled",
        "terseLabel": "Number of subjects enrolled in the SEAL study"
       }
      }
     },
     "localname": "ClinicalResearchStudyNumberOfParticipantsEnrolled",
     "nsuri": "http://www.vallon-pharma.com/20220331",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ck0001824293_ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Research Study, Number of Participants, Included in Final Study Analysis",
        "label": "Clinical Research Study, Number of Participants, Included in Final Study Analysis",
        "terseLabel": "Number of subjects included in the final SEAL study analysis"
       }
      }
     },
     "localname": "ClinicalResearchStudyNumberOfParticipantsIncludedInFinalStudyAnalysis",
     "nsuri": "http://www.vallon-pharma.com/20220331",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ck0001824293_ConvertiblePromissoryNotePurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Promissory Note Purchase Agreement",
        "label": "Convertible Promissory Note Purchase Agreement [Member]",
        "terseLabel": "Convertible Promissory Note Purchase Agreement"
       }
      }
     },
     "localname": "ConvertiblePromissoryNotePurchaseAgreementMember",
     "nsuri": "http://www.vallon-pharma.com/20220331",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_DebtInstrumentPaymentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Payment Term",
        "label": "Debt Instrument, Payment Term",
        "terseLabel": "Debt instrument, payment term"
       }
      }
     },
     "localname": "DebtInstrumentPaymentTerm",
     "nsuri": "http://www.vallon-pharma.com/20220331",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ck0001824293_ForgivenessOfDebtInstrument": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forgiveness Of Debt Instrument",
        "label": "Forgiveness Of Debt Instrument",
        "negatedLabel": "Forgiveness of PPP note",
        "terseLabel": "Forgiveness of PPP note"
       }
      }
     },
     "localname": "ForgivenessOfDebtInstrument",
     "nsuri": "http://www.vallon-pharma.com/20220331",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_MediceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medice",
        "label": "Medice [Member]",
        "terseLabel": "Medice"
       }
      }
     },
     "localname": "MediceMember",
     "nsuri": "http://www.vallon-pharma.com/20220331",
     "presentation": [
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_PaycheckProtectionProgramCARESActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck Protection Program, CARES Act",
        "label": "Paycheck Protection Program, CARES Act [Member]",
        "terseLabel": "Paycheck Protection Program, CARES Act"
       }
      }
     },
     "localname": "PaycheckProtectionProgramCARESActMember",
     "nsuri": "http://www.vallon-pharma.com/20220331",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ck0001824293_ProceedsFromIssuanceInitialPublicOfferingGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance Initial Public Offering, Gross",
        "label": "Proceeds from Issuance Initial Public Offering, Gross",
        "terseLabel": "Gross proceeds from stock offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOfferingGross",
     "nsuri": "http://www.vallon-pharma.com/20220331",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_RelatedPartyTransactionLicenseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, License Agreement, Term",
        "label": "Related Party Transaction, License Agreement, Term",
        "terseLabel": "License agreement, term"
       }
      }
     },
     "localname": "RelatedPartyTransactionLicenseAgreementTerm",
     "nsuri": "http://www.vallon-pharma.com/20220331",
     "presentation": [
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ck0001824293_RelatedPartyTransactionLicenseAgreementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, License Agreement, Upfront Payment",
        "label": "Related Party Transaction, License Agreement, Upfront Payment",
        "terseLabel": "Upfront payment received under license agreement"
       }
      }
     },
     "localname": "RelatedPartyTransactionLicenseAgreementUpfrontPayment",
     "nsuri": "http://www.vallon-pharma.com/20220331",
     "presentation": [
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_StockIssuanceCostsDiscountsAndCommissions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Costs, Discounts And Commissions",
        "label": "Stock Issuance Costs, Discounts And Commissions",
        "terseLabel": "Stock issuance costs, discounts and commissions"
       }
      }
     },
     "localname": "StockIssuanceCostsDiscountsAndCommissions",
     "nsuri": "http://www.vallon-pharma.com/20220331",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ck0001824293_StockIssuanceCostsOfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Costs, Offering Expenses",
        "label": "Stock Issuance Costs, Offering Expenses",
        "verboseLabel": "Additional offering expense"
       }
      }
     },
     "localname": "StockIssuanceCostsOfferingExpenses",
     "nsuri": "http://www.vallon-pharma.com/20220331",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r23",
      "r310"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of marketable securities premiums"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails",
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r15",
      "r38",
      "r39",
      "r40",
      "r372",
      "r383",
      "r384"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r37",
      "r40",
      "r46",
      "r47",
      "r48",
      "r74",
      "r75",
      "r76",
      "r272",
      "r379",
      "r380",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r258",
      "r259",
      "r260",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional\u00a0Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r240",
      "r241",
      "r264",
      "r265"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r173",
      "r227",
      "r234"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of Underwriters Warrants",
        "verboseLabel": "Warrant issued reflected in additional paid-in capital"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r241",
      "r255",
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r71",
      "r110",
      "r113",
      "r119",
      "r143",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r270",
      "r273",
      "r284",
      "r308",
      "r310",
      "r355",
      "r371"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r35",
      "r71",
      "r143",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r270",
      "r273",
      "r284",
      "r308",
      "r310"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r128",
      "r150"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Adjusted Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r132",
      "r135",
      "r367"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due in 5-10 years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r132",
      "r134",
      "r366"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due in 1-5 years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "auth_ref": [
      "r132",
      "r136",
      "r368"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "Due after 10 years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r132",
      "r133",
      "r365"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in 1 year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r125",
      "r129",
      "r150",
      "r359"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofInvestmentsClassifiedbyContractualMaturityDateDetails",
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r127",
      "r150"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities, available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Accounting"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r21",
      "r63"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r21"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents, and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r59",
      "r63",
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, at end of period",
        "periodStartLabel": "Cash and cash equivalents, at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r59",
      "r285"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant exercise price (in usd per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants granted (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r31",
      "r160",
      "r360",
      "r375"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 10)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r161",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r74",
      "r75",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common Stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r12",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending Balance, shares (in shares)",
        "periodStartLabel": "Beginning Balance, shares (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheetsParenthetical",
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r42",
      "r44",
      "r45",
      "r50",
      "r362",
      "r377"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r64",
      "r65"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Conversion of convertible notes to common stock"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r64",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Convertible notes, converted, shares issued (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r67",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r191",
      "r198",
      "r199",
      "r201",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "PPP NOTE AND CONVERTIBLE NOTES"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r70",
      "r72",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r181",
      "r187",
      "r188",
      "r189",
      "r190",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r203",
      "r204",
      "r205",
      "r206",
      "r293",
      "r356",
      "r357",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r176",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in usd per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r174",
      "r203",
      "r204",
      "r292",
      "r293",
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r28",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Convertible notes interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r29",
      "r70",
      "r72",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r181",
      "r187",
      "r188",
      "r189",
      "r190",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r203",
      "r204",
      "r205",
      "r206",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, maturity"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Summary of the Company\u2019s Available for Sale Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r242",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Activity of Stock Options Granted"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r51",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r87",
      "r89",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r279",
      "r280",
      "r363",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share of common stock, basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r51",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r89",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r279",
      "r280",
      "r363",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share of common stock, diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": {
     "auth_ref": [
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.",
        "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net",
        "negatedTerseLabel": "Expense recognized on embedded derivative"
       }
      }
     },
     "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation, weighted average amortization period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r46",
      "r47",
      "r48",
      "r74",
      "r75",
      "r76",
      "r78",
      "r84",
      "r86",
      "r96",
      "r144",
      "r227",
      "r234",
      "r258",
      "r259",
      "r260",
      "r268",
      "r269",
      "r278",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r379",
      "r380",
      "r381",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "MARKETABLE SECURITIES AND FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r296",
      "r298"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Payment of finance lease liability"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r295",
      "r297",
      "r299"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of finance lease right-of-use asset"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r137",
      "r138",
      "r140",
      "r141",
      "r142",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r151",
      "r152",
      "r153",
      "r154",
      "r200",
      "r225",
      "r277",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r275"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "negatedTerseLabel": "Revaluation of derivative liability",
        "terseLabel": "Revaluation of derivative liability"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows",
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r155",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Summary of Estimated Fair Value of Investments Classified by Contractual Maturity Date"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r25",
      "r71",
      "r114",
      "r143",
      "r162",
      "r163",
      "r164",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r271",
      "r273",
      "r274",
      "r284",
      "r308",
      "r309"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r18",
      "r71",
      "r143",
      "r284",
      "r310",
      "r358",
      "r374"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r27",
      "r71",
      "r143",
      "r162",
      "r163",
      "r164",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r271",
      "r273",
      "r274",
      "r284",
      "r308",
      "r309",
      "r310"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Dividend rate"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected term in years"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r99",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r59",
      "r60",
      "r62"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r41",
      "r43",
      "r48",
      "r49",
      "r62",
      "r71",
      "r77",
      "r79",
      "r80",
      "r81",
      "r82",
      "r85",
      "r86",
      "r90",
      "r110",
      "r112",
      "r115",
      "r118",
      "r120",
      "r143",
      "r162",
      "r163",
      "r164",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r280",
      "r284",
      "r361",
      "r376"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows",
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Noncash financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r110",
      "r112",
      "r115",
      "r118",
      "r120"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r36",
      "r38"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on investments",
        "verboseLabel": "Unrealizes loss on marketable securities, available-for-sale"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r26",
      "r310"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.",
        "label": "Other Noncash Expense",
        "terseLabel": "Non-cash interest, depreciation and other expense"
       }
      }
     },
     "localname": "OtherNoncashExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Underwriters' Allotment"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r19",
      "r20"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from convertible notes"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails",
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from common stock, net of offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r55",
      "r56",
      "r126"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r239",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r239",
      "r302",
      "r303",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r239",
      "r302",
      "r305",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r300",
      "r301",
      "r303",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r267",
      "r341",
      "r387"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r14",
      "r234",
      "r261",
      "r310",
      "r373",
      "r382",
      "r384"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r74",
      "r75",
      "r76",
      "r78",
      "r84",
      "r86",
      "r144",
      "r258",
      "r259",
      "r260",
      "r268",
      "r269",
      "r278",
      "r379",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r108",
      "r109",
      "r111",
      "r116",
      "r117",
      "r121",
      "r122",
      "r123",
      "r237",
      "r238",
      "r342"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "License revenue-related party"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in usd per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r241",
      "r254",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r241",
      "r254",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Investments [Line Items]",
        "terseLabel": "Schedule of Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.",
        "label": "Schedule of Investments [Table]",
        "terseLabel": "Schedule of Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r304",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r32",
      "r68",
      "r97",
      "r98",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r220",
      "r225",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted average remaining contractual term\u00a0(years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Exercisable, Ending Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Exercisable, Ending Balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r246",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, Ending Balance (in shares)",
        "periodStartLabel": "Outstanding, Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, Ending Balance (in usd per share)",
        "periodStartLabel": "Outstanding, Beginning Balance (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r242",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Fair value of option on grant date (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Stock awards, contractual life (up to)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r250",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, Balance Ending (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, Beginning Balance (years)",
        "verboseLabel": "Outstanding, Ending Balance (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r34",
      "r46",
      "r47",
      "r48",
      "r74",
      "r75",
      "r76",
      "r78",
      "r84",
      "r86",
      "r96",
      "r144",
      "r227",
      "r234",
      "r258",
      "r259",
      "r260",
      "r268",
      "r269",
      "r278",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r379",
      "r380",
      "r381",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r96",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r33",
      "r192",
      "r227",
      "r228",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock for convertible notes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock for services (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r11",
      "r12",
      "r227",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock for IPO, net of issuance expenses (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r34",
      "r227",
      "r234"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock for convertible notes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of common stock for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r11",
      "r12",
      "r227",
      "r234"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock for IPO, net of issuance expenses"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r12",
      "r16",
      "r17",
      "r71",
      "r124",
      "r143",
      "r284",
      "r310"
     ],
     "calculation": {
      "http://www.vallon-pharma.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets",
      "http://www.vallon-pharma.com/role/StatementsofChangesinStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r69",
      "r212",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r234",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.",
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "terseLabel": "LIQUIDITY"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r137",
      "r138",
      "r140",
      "r141",
      "r142",
      "r200",
      "r225",
      "r277",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/MARKETABLESECURITIESANDFAIRVALUEMEASUREMENTSSummaryoftheCompanysAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrants outstanding, measurement input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants outstanding, term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/PPPNOTEANDCONVERTIBLENOTESDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r88",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r87",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.vallon-pharma.com/role/StatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=51888271"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "15",
   "Topic": "815",
   "URI": "http://asc.fasb.org/subtopic&trid=2229187"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r388": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r389": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r390": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r391": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r392": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r393": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r394": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r395": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r396": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r397": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r398": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r399": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r400": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r401": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>56
<FILENAME>0001824293-22-000034-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001824293-22-000034-xbrl.zip
M4$L#!!0    ( 'V!J536AV* 2@<! !%+"0 9    8VLP,# Q.#(T,CDS+3(P
M,C(P,S,Q+FAT;>Q]ZU<;N;+O]_-7]&6?>\[,6HCHV2V1&>YB@&0S)S8)D.3
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MYO+0C8,V[YVYI<$FM:FWJ32*@Q6CJ64)E<Q@1XQ.]>BZ!YF)0-(OK"R0*=F
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M4Q\$O--NM7SC5M5=:H "+#H],#PNGZJ(]I1$T];V\J& R%4,#=0QV%XE$I\
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MYLO:RR4)5EMN_8H &Z6DS<6"\UPHG/K.F'DL!7=<<H<2HD#AQ%8C38U$/C%
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M\BZD!PG*',4ZWJKD3]TLJ23_*25_U$IA1J7.&8^L%!2%O4_@6< GAGUBC"<
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MZ;492]0>H GZ/S]>HNS5ZX-PB+7OH[=HO4 5_OTO_7K5\C^IF*[N8_*/[G3
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MN&43:D!Y08!R[SO_-P>4&CAN!QR+OE9N/"R$)W&*M<]2JTF>,TJDD%F2,I7
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M__/QXNBS/<L93YL'7T3KH/T%G@?W?7/:VFH5S>YVTMS:_G;T_@.%,<:'EY^
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MGO+M_W[*MY^4=MN8<,7^%[@&* Z0Q7WMW>@B&(X#,+*#ZM)@J\&F!^JP-;4
MEC3F",'^N.-1M'8FY"'Z6)&'=S-+ 78 B>5H!;,Y*[[V,?\"3"X85SV$']OC
M[M3P3$O252 &1M@-AQA?Q)M55*UO+\ ?@U>)?MO;@F>=+;PA_/I_X=?#V6N.
M%EYSV.L/0M,EL(4>'Q (5D?GR(+[@PL"(RK.\&W II:6/Z%1]P38K^N5%'&
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MS KNA4O-<AQZ[2C.3 CF@E_/84.]N3+1,D0TAH%:AZW<N8^F.[?E6?SR$ Q
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MPA"P\04P@K(J?^B%AI]V^M@TN-.'!X1V -J8<7?<N6HU$$]R[,PV>U0#&_S
MA^/.Z.ICIKTUBI[I=UW9H#CT+/@&].MD7 S;H0\@&*$".W_FX,U4G*P76@T,
M;&BS%D:#_6 Y%2".A%,"+U0U!IZU(BJ[M=VVDXLV66J\,Q[DGPMG-3,)^(-)
M3FV<:Z\7.[G$-]IH>E?-#BS*KK^J)"^6T[0./EP<QS!#:>P-217CL)(N(TI0
ML&992F,!BT#S9"6G02'JC$MIJMKD56)5M7M"@0ERAQH2R$X)D]@+ S0H"-9P
MVH=ZX-JX!8C=K?K#JD7Q?A?[,;X9#PM<MV@^:Q6>\=O^F\;O*.=N\+7JO1&\
M<41>/;8%]K.\"*0+%6D#KCS1 QO4$H: S#X\9>C*J['#XT74!QT;5$7R_$QF
M0,V&I9J=##3VVP@*O:@20=<:'[?WHX89E<TD\_Y@T#_'#HIZP3AT->BPKE1E
M,LK(]DT0RO(50V?6XEM9JZ\:U97+$3@FP\3^BE4+0VSE/:[R*N%1X'=\+6S5
MI_SJ$ZJ&H#"597LF'"' RHWZNCZIJW4]F(:CU25$@B!<Z86V-W/  A'?&P],
M&SNC-TX&KNR!&A;2P!=P:=PW$+=2?/OF2[O? 7]MN%%)/OY^7W>Z,&M[;0VV
M-?2OTMX7G:*B\DUG"^/*7I!;&M8@>J._N,&5\4X;C+YM%\Y'V]^<&8=F:KMP
M)X,7GXT'PW'5O;5L\+O"NS1SK[G@9PY+UW)U9[C?-V;M,N%[!BC0\+:0G7IJ
M3<(5-W'*4YU+:K)8.. QGGGIV(TA>\)?]ZJ!O(,7F1LQXO:+1>O=@YW+8ZJ-
M!Q>/$["%"1 78"\Y6$NBF#2IU<XD3KYZG8CEN&F)J-=T!P24<BB\=_1%,\FH
MDUG*E8:7HU2F"BRY3YBE-O4BKQKSQ;4O>B_R8)+C3,:92Q)'J,!F"UQ+(+()
M(QE+A<TR9RWV6LLVE^7AOT-C/MV#A=P E.@1-,(8.0=8VYCS5)<:0NV[LU$@
MNU7W-5IU7_N>?%7@- 'E:Z4J] D<+D@5U4XF7.HLRRQG(I4991FV]@.)8LJ4
M\> XGJ +_G #\9JU>'P[&=Q,XD+7R>%.0-;X9EM!3]P9\@F\Z(9H?3@&URG/
M8I<2ZHPBG*4I41G+"$^ERF-!<Y>GKUX+OJ%6)+N7?2&'UW7<!HE$XQIL;]4\
M$J[HN" S\_TCY[M7SW5$Q<^!:H#@HB6<ZSX:A/ 6S]:E0V5=]ZRD90Z5 NQZ
M:8TK5@<P6G@@%!5UF_A6UZA$H&8#5SISH_(1*UN\ED%B]+9D+/"Z0'27!C/Q
M(2/3 ;+8N:AZO8$_UKF8Y 5/V!XVF[LZ:Z[L+5]-VG(7VE4CVXP^K>CL6GWA
MFK>& 5R=V=+376X*>GV/V=G,+'2;+0\1=<$5M[/9O](9_";]LB=4]D6VQ(X7
M)FCNSUML2(KIAF3=1_OY]]%>MTWE[*DVE??G?,!M0/S1!6+:^FTSMR9)(=T/
M].CSNR[6P6UMA00/VF)-WH*_FZ>M;@N3-RZW>?-TAR\R@:.MCYW#SX=8!Y>6
M"1X?DL/+DQC^OFBRP_CP\LME\P"?V\:ML;C9.$YDGBE)<P("1PFX@A*/D7,"
MY(!EX!?XU)O%;6:J?&:<M\SIC+/<JMS&)M.4J<1X89:VF?</=M_^[__L_KVU
M_7&_,M71]H=/.P>'T4_L,?_PZ4\B_.&.?Q2X^6MNH YO2W,:A'/M@S:3?O(K
MHC85M:L8"#" [[J?*QT%+I0#1U-[ZC,.KH*F/I7<BP0\9"N$J<(0;!*&8$S^
MP%' @MJ[/LQM*SB\\(\YUV"G=S" "2D']SS<A,<&A]V#G>-8Q4FB,T>4M!AB
MEH9H(32)LU0)'OM4<8G5L9F@&W15"_D955\DCSHZ&^>@*/"9=Z%?^!DH_X^[
MQ^^Y05C(10G2><)!:#++4IZE1G.39,8Z#*Q(RDP5P%@0'/8=L=G#X<R>]D*E
MH'GP@1][R2S7,2,VB7-P%;.8*!Y;0KVRCAIF8@-B(#=720#&*H(4E&[+R: _
M',["E5.V'QR'W'D,9X';,#8A>!L8TCF6P8=_X"Y5J*2]$82I& ZGVQ#E)L94
MDJ9E<\_*FMN3=MD58FV4^[VWB9/>$:"NV=J:#Y8B+J&_LP.#*'1G+RC';O5&
M[W'6GD5BZ^,+Z&4C/M9IHA/I.<FTB@FW9<T.26+*X0,+8*5C+-RQ$J3 &UXI
M9D&RIJ(4DKK QCV]U 1TFHA+J+>V-1ERHV??SE2C%IC5 O/I\EASG7H>"^*E
MQ;8/$A"-6D52[I@58$(DGE&/-])5D!8"0/.!JY[!U',;Z3, MF\PNR,,W=QJ
M'R;A2>RS&'R\# -S.<NI3V(-V*J]$^*^)&4"*)/"02]8"K[$QZ"$4N84W!WJ
M!5;9RTENM2 )U8D7<9X*#U*@5IP#0IJ"">;X#]V9H<1<N&X2\01(F?!BW*[3
M)R>XG3UR4<^-KNS;_;STW!O.K*!!;['RO*TV_3\ZXXJOSN[>GCZ_- %KG>Y<
M' MPH^$_ ;B2>6PT!DS:919+83B;^$R[7 ',B VQTBX]N5=X!X\V^JP'F' Q
M?/*7^)%K"ZK4<Z6.37-!IG'L"<97R2/A=U-6BLDAY]5KECOUG^8^^K_3*?@]
MI'),,A8PU6 * K=VE8W/M4_ L3$TYC1V4CF3"9<Z385V<;+:T5GA(;_M:,RH
MJL:X._B(LS+UE:?=I][J#M">-Q>3=ZDNO"&Y>&GN4NORY/PX$=+&4E@B.-9F
M3(/7C'E:0BNA<K#/CF'(GJU4^^_YS)C7X@:F&+J[><L/*T3;U1B#!SW]<"HY
M\8N5CMVMYOEQIK5,*-H$F8$S'3M%9&8SXK0&#JB!=WB4#GH3;WH>;B91U<ET
M1VW]U?T@=_DV<G!UX2=/ 8^C7-7=\6@XTB$)8<VSUA\_A')(=P]V6.L2[_LE
M;C6./5><BLP1S5+@!? CR7UNB92)EL8R:G3ZZK4'JK4ZA1W6NQO<D!#(P+WC
M"A=TF416 -$$D],8GXR'HPB IDKT:'0ZDYW:[XI.N&U_MJ*X>8U)<5CONTH>
MJ?JNE')X?N6+!D&AW,B'[[FPX3)UFJ[N4-_*1[(L3935B18I:DINL;:0]G$B
MTCA+\UNSW(8]A>D)J:T'_<:4S>_IPN[TWNHSY#W5E)11XQ=+9IL'#0;0Q7.:
M)(XSXL M!3J;@-?L-26)2Q6X&3Z6%'/8E%J1<HR^D>\ SRJE8LYYPKQ74@ /
M*V=\\[N(=0^[@=/VRHWAT 4$FSM$WJQR$G;1UP&O'H0?+FCU>X/)/]_H83'\
M)R1=P/@/G&GW"LR\7:?.:T^SD_CAF*5<VXP9(L""8)*C)TIZ1;S*12Y\DJIL
M:2<Q4=*R6'.P? FG"?QM91XSI2QVUK-V<2<1\>9-1YLO9-^T^QUD2B&=AB C
M0JSJ_O_MO7MWTTC6/OI5M#@]9\%9EMN2)5_@=U@K$& R0Q*:I+L/_-.K))42
M@2QY)#LA?/JS+U52R983)Y#$"9[UOC/!EDMUV;7O^]EY)%-*,9F7;(K+<D9F
M]8H4F9I[:?6_ZJ]FL?$@(QN$:2%.0* ")^#\G?+YY9'+RTR=UJCFE3OQ@'JX
MC88W;K9V:5LTF)#C_HRV:(\"A?FO'%.:,*5J"[Y\:7ZS,W:<(!Y$0KC E?KN
M"&37H#?L$PJ)%\?MB$U+&L-E6J^2')SV/)W/-B>_^8;"0+5F_O/BX!W^?7!Z
M\/WCU\]?_C@_^/+7Z:?C?9C#CH\M.3]/WG[Y]&6_MX@U<G"\U_O\[FWRR7W3
MAS$F\$[WX.^WI_O?__3W=[_"N_Z:?/K[(-G__C'>7\:1C*/A. :CQ.Z[#K8X
M"'U[/' #&^SG&"P4S^GWO2<O1WY+BC3KJ/^Z#A[>0[KVZ+TG18KL %"=J,KH
M&BT0:9']QWG5^^$0%$,O'HU=!)^(1YX?2^F$0["T96_HME_UI4R &UWU!^K0
MN-N;OMS4342>)P07PPQM+W;!,.[U?#ON#80S'@9>/X2;[G:7XS"_7-^%W03K
M 3%?&O39K="_E!-X<3@,HE$TC$%:R*$,1,_QW1[PA<@'HW&P%?KWS0J6P1G=
M8>@ZL>S;3G\(0M_W'3N(G<"6 ]\/QD'<ZT?#)R][OY[,_YB47^VXD+)9ZG=-
MH?](;WHT1I I=S"0<<]S8QD,!WZOWQ-C.?1$Y(S;;[J_O>EW=M.7.ZW ;9:#
M03^PG6&,OJ(1J/=R,+)'WBB*Q3 8^5Z$-]WQ5\&PMMSU"JQOJ4#HLL*A-:MC
M1AL+US>Z-[B^JH;B,,90N<Q*E2A">3"4<T0!R%>BE)'&V]D4+^GA:UUY^?'T
M\[N#+_O?_Y,>[(;>P9<_^I^Q&O/O_8M/D\^G!^X?SN>_#[X<P&U9])(>O'O[
M]9.[_WU_\F?OX/N)>[ ;3?;_WG,^??]/\GGRIO]Y]Z\4OG</CO\3[Q]_=0].
M_AGU@D",@A[L:AR!C!O$-ER&P/8=SPU %_;'CESTDD8]SPL%Z,'#8.!Y" 4H
MP@#32'KCGC?P16N]A?UJY^@-HOKM?WAS<+1SO'=X<(-BBZM?O8! &+KAT =V
M[/BQ-_3D2 RD(_S1P D'@3/T*N9^:^4^X:F,YIC!I'O]',GB+ EE38DFK>ZD
M0(KTUV'\48;Y208W#R/G2<X$_$N3Z_D_GCN0O4$<V&&$J&G1,+3'OAC;T<!W
M1I@HY_?<1?+;N#P?LV2V E.BQ H[0(*@=#U-$68:'R=?<(BAU) =-?SC8O4Q
M4.;(XAHS:R_#FE"L?/V0PHJ?TG?XYS.-LU3'&50&H06$*$_R(N$$$,2V60^,
M!U,+<<39*:J($]B/T](".Q$FVQ*UI6@L!DF?KQ^R>#"AAZ'?'?;\VP@]>.[P
M1L->_EW?OY7)]IS^SXB37-E89[R..<7%T7=C88RN4IF(K-ZJ"W-,%V:?+\R;
M^L)8<%=N8DNNTX!H7=#JS=Y!9"3K>*"N7.TOM67.+^>R_"A+23<*A4XDSV2:
M3U&$W1 )_G$VD:@.W[WZ\-?;"._ZH/<;Y>A93@ +>Z$?A?U("+"4?!?L!'_L
MQ7[4CP>!WQ_%K:;!I0E@K/G+J-TP4$4R&Y/U=4/]7SEZWO3WO^^XG_[^X]O^
MN[\F^U_^^ YS]0^^OTWVOQ^D^]_3+S '>->K9-'1LW\<?M_?_7SZ>??-^>>_
M/UT<[.Y[![M?^V W?-]W__Q^^/<^S#E*]]^UMJKW97\X='K"CD9^8'L],;"#
MT!O8HZ@W" ,OZ(UB*LZ[DXZZ6R:S93*7,IE>;RRQR?.HY_:\?C@4P[$O?2<.
M'!&.!T%O$1%QRV3NA<DL-J;!R@I_&+BVX[NN[?EQ ':]Y]K#P; W& U&D3<(
M4?_ZH0CR0]*ZWLE,%H*!9(4!OWOVZX6,6BZY''FC<.R&F&G9'\:C2'@]QY6]
M<.Q[?N!L-8D-N.3+(:/0Z;M^& 8V*'PQ7')G;(_Z_L!V1V-_- PEW',/-(E!
M_R:JQ#6LT<=^/8+^N!=$ W<XZ EL/31V_%[/&PQ'8N3W@N%X*P,WXGHLRL!1
M!'=@[#NVXXK(]F(YM$7<&]KC<#22@>L&(]&#Z^%=H6G_S,;!F&2XT6*2.@=O
M&P7?I@GQ0]OT^ R,&P4XM\SU3IGKP7(VNA,ZX['KC$#MP/:7@ZAGCV)O; ]E
M$/1Z41#U?62NH^5V&_?HQMARJ"V'NCZ'BH)@%/M2.D,IO" >CP:^Z"%L>]27
M0@ZVZM]F<*A%]<]W_&'?"T/;'7JN[3EA; LX'GOLBKX8]^.1D&0=K:/^7=[T
M=I.3.[#=CP9K:>9NF!@LF%C10-? *E&5+*0[&V78AHOJ0NMTCRJ%HZ,^7.[J
M@KV(*$VD^7KL8E3.8/OJB=7(A5PCKS)1Q+DHHK*)\HZK@LN55TO3?6Z:2\22
M?6P75$&YPVQINET%RJ,?U,,T@1&M$W8:I1<:/ +Y E+)7*16FL0T\GQJU9T@
M;BV'"SE%L)2JA?FY)Y0 \^JB?D3E%>[@Q@$S23@IAC.X-K5[WETG<QU\";__
M,P!&($+?MR7V&_%$.+9' ]>S0ZJ)B(&'^P/$'ED"G* ",^I/UPX#P2VS--0#
M$7!%8T8_!75Y&":BRH$J)M36RR30#>]B95Y-U<6@;+O$-6R4P5ZX1PLV;JDY
M#O^(>S(D1:-&G7=)]W"9$88JMI3BI@DJ7;%LYJ_I;#+."LL1=(KG0_TLN0T%
MS+9,8-"2<R-U:\2<FB32G<E"J5;#W^FN&4EI, H<[$QRKRT]1*Q>46*9(N:_
MT=N9HTWJ/'I>%,ZQ23A)V5@R+9<WK;'%C16'F*BI.K7I%$Y"'U$[<>7"C<6U
M+:G@7EN*ZR[O4!O3YCS#4O5I-$]$UB>28)8?LD]JR5=RIS?X)"&4W("2[JJ^
MDL9[\2<,H6&=)]BN#MOVG2;R3$;;9AE7-,MP%S;(^.]MWXN'W_>BO2W]55GI
M"UGLB(PU"GTPZ&/7\\-P'/:#4(AH!!.50]>]]2QVL[1B1>)ZK0V52AUZM:@.
M_=*YZSO_]/U>WQT$8]L;1[[M]0+/#OS(L^,X&OBC8:\/A_P@<M<Y^SJ0:7Z.
MK4*Q=RI:)MRM%1@UBL]%):I5^VA1/JZ7._X84\;]8=?MKY<N?:TL;*<[<@8/
M)67\04VVWQVXZPW[\_*V'U2J,2.Y<I4(<8/;"X%O_%[\K4"\+ WBU411O;.=
MN=1Y?I>*\I7;YK9N&YAM8/V@663ZA1"$AD7$4W(3/%O0R7Z5//=#$R]S9NW*
MD)JM6DIP.C\2![I>*.+AYJ*T0E[[?A2-I#L@L"X_B,?>2'J@30\<&7JCOF24
M6L>]LCGQE6KT*BWZD%FH<<('"H;@(8!@_U@\8^?;Y]W3KP?O/KF?OWR%]WS\
M\AG&V7<_II\GG_R#[_"[[R<PCS_[2_&,W;=?#]_]T?O\Y?/D$-?T[F!R\.[-
M]\_O_IK 6/T#T-D/=T]@GE$;*E#D#%PPSOKVV T&MM</I#V*^R.[%X5@)<K0
M"=S!DY?#WJCCC:_(Z]PFCV^3QV\E<KH"7WT3.9:6YCLLS!L@[5M6=3U6M1AZ
M'8^B?H X_\";?-MSW:$MHJ%G![T@DGTGB*,@>O(2;):[X5-;S:+=*1?'_E ,
M^ZXW%-XP]H5P93_P>\YPX W<8;"0U\#7\R>%):^\CQ^U;OVZ5JT12-]]9 ',
MN[ZJSJ)6,8S&LA<(.QP,(]L;RI&-9&"+@0A"UQ\,1J*/@#H#;R54RF.K%&$O
MX2]7%M+>B?;'LC-O0833\91[*IWA&IT@M[)\#0:Q7*X:@*4AAM[ 'CI^;'NR
MA^A,?6 0D1A[8Q 4/C8Y<$9N:S/)'_ EM5RRQV,J_!IZ_SUPCY61OU;VL34"
M?A[C6"J_<05H^S*RQQ)CC7(0V&,7&,?0"6.$*NAYD7CRTN^.?BK76/?17\$#
MJ\EY'5WF<0$C$_Z8^^*^C<GMWOWXWEWGUCZDR_DV+V*9/&)#8WTZ>NREQK>Z
M$[^<5%N(*U;H=-:Z &R_ENMO34,_[O?'P\AS>H'H>STW&'F^T_<"X7NN/Q2#
M43MD^#:H^)"4](/EH&(\&(_E2/JV UJZ[0UBSQX/G($=]KUX&(Q!?1^/G[P<
MC7L;$U1\G/Z :ZF0C\]1L(G<9^L;^'EL9]$W$$L_D&,QL#T_"(#M.",[D&%H
MB]$X#OJ#_B"2\LE+K]N[HL71UJ;["6' >ZQ.W(8![^E"+H8!Y1 XK1OX]A@!
M<[Q@Y-@C]/<+.?!EW^OWW&&(8<#A4BWD8PT#OC$ZB-_(S%@72V'QJX?,8!Z:
ML6$<\M;8^,E,9CF4&/I>X,'QVGXL$902V8T3PS_[ ^F&_G@4#4=/7KI^O],?
MW0C^=AM*W%H(=\@RMA;"S^,5BQ:"VQL'T@'CP''&0]L;1D-[A" -0Q_)P O=
MR'4PA1!E\1;<\H'I^ZOOT"I]W]GJ^S]TO1;U_?Y8]GO2#>P0#%T0Q6%D!T.\
M;:&,?1#3/3D&?7_8'8VOUO>O!$?B._#R_P3%[PL%ZG?5^*R=HQ,&D"+)OT3*
MY?$[93F?\&=48?]+5XS_\<]H&(3]L=.WO0C+QB6FA@9A8$<!]IWO#P=A/VZK
M&+^_TO!7J0B_VG#V>8I=P^@H;2QLQ(#1)(]D:IV+TIJ7JA*\G(&R,),&E SC
ML!B8,[$E!5A_9C6Y1IUA(!(8HL9F@:'Q5<V&9N>*S]FZ>%#4=/882\B'_HW;
M@UW1R.NFS<PN_\X;>S]]LN/N:+C>J-NF8]NF8]NF8P^[Z1A;!N,-]RC\E2.0
M59K,+FZ_H+'5Q[*QQM*:O=5_,*?9^VG^B+>@H*#6*@V-%:%C$5&S/N6/H,ML
M3F_V'[*6)OO>I^]_^@?'K[[N?WGS[1.,<?CW)V__^]?SP^//Z?Z7T#WX\N8<
ME-?)HK7TZ?OIEX/CK\[^NS\N]H_A/>_>^)^_G'S'GNX'DS\O#KZ#VGN\X^Q/
M/K?50,A@.'*'X\#V!SVPED98SSCJ.W;@^"(28NR.Y?#)R]&H.UC5F_UVFOLY
M#\/=]Z];C=ENV=5E[.H'P:NW[.H!L*M%WVD$ASMP_)$]"+#QR;@O;=%WA1TY
M/7<TZH=CT0^ 7:%MMV575[&K:VN',?WG86J'^D(2B!$B$A."T8W8=]LV]+?^
M\Q_SGU_&1!^OF_RN..ERA[5!*(3?$\ _131 ((N!/8X&H1U$<2C]L8P'KGSR
M<M#M#2YUD]_PSMPH3>W1WKL;:3+;>_<@[MVB!@,WK3<:Q9X]&LD8#*X^HEZ-
MI3T.^D/L=NT$'M6.#BZ_=[^49V<W.4LBB2CXH$/_K)3S1VD3/0@7CC[.K45T
M77[2TJTL"D.WUP-^XL6CONTYD6^+L0CL7C3T^X-Q$$5#]\G+GV@0/7BSYQZ\
M-(^>[SP(7\R6[_P WUG48_K>(!SVO($MXS"R/4^"1C,./7LL?:?GBMX@Q [-
M6[[SB[I;/B;E5SO&V'>"45)9SFZNO+7LPZ-DHANMO.&!OH7SW%/'N66BUV:B
MRS7*_<#S?(F5R3&H;%XD!/#/>&3W8M]SI8RB@3]\\M+ICG\X^'8)+WE03/1G
M^YNV?&?#E;<MW_D)?&=1>9/CX=B%T[;'HC<"Y<V1M@C[@=T?.<-^7_3$V.NA
M\C88;_G.+^AO>]M($%99P55B<-2BQVVA+5:?>O]AT/N=5:ZURXM'5%IV5WR]
M!=%6>KZ/M2^#L(?.P""PX3"D/?9B.?0C3X[],8)/N,M\?0MXL^4*/X<K!*'H
M]X=AS_%"X8W&OA"QWQ]'_5%(9HW'+3&V7.'6N,)2R-$?C(.!'-D^F).VUW-&
MMHA"SXY'PX'7BWPX*H*D&5]1<+I&2=RE'8@WHL5F>\_8JWO 7M(0'>L\YIG1
MC7JI7[5%39:Y*FN>8<=I&5G-#IZRRD_*J24U57+]=MGU^RG"V.XOWKLWJEOH
M$3?-;C?F#G*U"K+;RN-\)E+S^]>PZ(-\]DG"Y/2VF#6)ZX%1]!_F?;]Y8>+W
MDQ[,V=_?_>0?'N]='.S\$P:ATP][/=L14MJ>C*0]<L=C6XCQ"&3ZR!D-G2<O
MG8XW&BQ=7NQ1GI27D&;2)+N@T5*=^JB+ENJ^20[BZ3N/4/>!O^6\LENC2D9+
M?YL7ZB-\[K'EO/PT@CS<^4=XSM@=CA%.*1S8GAB[]F@4Q#;(%V?LCP+']0>(
M7N ,%X4#9UQVEV6$M5PD2KM\9:OP@?-DG<K2VQ4S[1TUQUV6$LO_?<L7Y2-+
MF@^BF%T<@[U>,C,HZR;C&U+V[>X?:6+^S]?]OX%XC]\ L>V??X+W'.Y^3O:/
M_YI\^O[Q]. [_/OX[=>#R7^^+A+S_N2/;Y^ >/>/_P!-ZM7IP;L_O(/)WK>#
MOS]_ 2VI#__V]__^P_TT^1C#,^[!R3^Q!(4T!H8VZ T"V^N'(WL41J"KCUT7
M@Y;C0=]=;!$?#GO1.'+"X2AT/:#&H#^,HP@(?M"3CN='BV7B']^\WSE^LVM]
MV/EX_,DZ_KAS<+3S^GCO\.!H95+7ZG[V5[Y\\Y2LO<SZCX!%%!>H(O5814).
M++(+B\HF0< D&<@<8:7 SK,2Y,I)(<D[;)TGLU-K7T;PA75^FH2G['@J]6>P
M'ODM3.=E<B;USSO\*WP/&5$HS]A=5<X#]4S9P4\C>2;3?-K!,OF.!4N=QPC&
M4= _BJ]R1GW32YFFUL[NSMY';):>ST].\_G,>C,O\JGLZHF _"QD.87;E6#M
M.G97SX.9:IQ;R),Y7,4<]D!,IT5^)E*4DSQFDM%4U<0H*;U(\-FN]6<6R<+\
MMMZ9CG[Q5"21]9=(4Z 1<2TM,0)#0/1 R0V<GM<;^^.!'\APX 1P!T1/#HC#
M]#2'@3]6J8OA5R A9^1Z[KB_BNF\YP7LZ/G_.8T+F(QR^6^*FG?WC.C[UV__
M] :Q=)R1L('W>+;GQ2,[Z =]N]?K>UXPCD(YBD&Q:TF?L.:\C4 %M(]$KT2*
M_YLG!:MR\)4%]QJ4H3R3^D%0!8%6K3@IP+RXG%!AB/;+ (2+=SC,Y]FLN.C4
MA&L!\<-(Q+56$3<-1G,0X6DBSZB_M"QP(O!5ABVF,WAE*1#> JZ=+$_S-"JK
M^W:>P#R #GE]LX382)%?B!3^+M%#O31*=>,$)R"4U>SR<X5-:$?)23(K45O&
M; 70 %6K:_QQZSWDB8#J#-M]J>)[H]MV\_N%^=JMJNMY#NJPS'ZQ>W;P_>O%
M/X->-/(]S[=[_1C$?>"/[7$O"D#F!X$;@?44")"@,8H251&TH+6*>*;X,8&G
M )&Q3%(T:=ZFLO4N_="5Z:X/H'+_@MZY5-"_1NL,3$<4E1^*?)*4)6X"&&3P
M[WD1GH(Y9^TTM0#-'>2WI)PANR"G"7(%68 X3S)0 ZA=PI%()["/'\ NG(@.
MJ@B@Y"5I0D<6J\/J$ /:%6<@/5^)K[)HS)=Z60Q?E-9KX$VQ]>:;#.<SI(M#
M&"G$AZ?SHIRC3@'K82(PEPOKF>/1P4>X%XWUXB)+4A!"49Y:0!FAE!&QI^M(
M[T'<B\*^-_9"9^ -1##JA4/'EUX0QFX\DNYBI'ZE]-;6P@<UD;=P'L9\=V7P
M"XMG-G0'CHPBMP>< A@SXX@)X<3 . 9A%'@Q&&9],'3]90'-DF0%#01Y01IL
M(RW.<*"LF;,QA%E)]-^.!2ROUQN!@1C+N.]&O6@0^X%RLCM7@D;B4>]E)=@M
M>.O,+(NC&<D<62#0B3C9G*R+^Z (;__D'P&&PL@!V0%['-I>K]^SQ_Y P%\C
M3_JN</R1C\ARRQ3Q+W24D7(RZ5CPA8UN.(P0 >MBIG0J(F"1(+?GP/<OE*B)
MK2,YG4D\?JO?(W>S<REQA?R)YKG7@R[^0>:R@K9XDB5YW]3D:G(C-UZY1XS3
M>1  Q??AM3C?W_EG)/P>Z"Z./71#! T=]>W &TC;E6/?CX:C\<#I/7GI>YUQ
M;]D1;/%Y:WUV4=X!,:+LY'@$J>=(GJGDM _^S=Z'PP55I#W4LZ;C;KBQCCNG
M=U^>.SB623(C0VTGBU[3UI[(+ 339O.<=P<7ZAI,_IH<P/@'QV'_\-W>]_W=
MCS#F7\G!]S^=3U^BT\^[<$V./_4_O_O46[P&G__^Y!Z^^\,Y^!YZG[[LGQ_
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MDMR>XY)?G'YS^.H(O^@HC!MTBD\$H]*MF '1ZGQ*7E ,JEY(@1X93/8J<XO
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MER06B&F115#[9I4?^7^<"4$U&84N1JN]]?1SNJ8Z\0/+V^A*(3LIFCE %RS
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MK%9!''\!6(ZE1#OH'/X,T[KUU5=%$90Q8<+;:. :5(?FF(BU ,#5)BZJBL&
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M;@C*58!)).<5*KB&KJ&;I1.Q52FEVNWZG.J<&_*6Y02.:4#>%#(L4$VHGVN
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M=N@THRM/PW?['\IG'//6]!6>$B6V9')QXD%%N#J?;VL>WCGA$&B-C%66!@J
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MQ\NT,YE!#\/BCHLHB4\8<0TY:PS"CJ-RI6",^)#LO&_OJ W*Y3;C[2Y$J^3
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MF]$V.!>HUIV<LD8Y\2"L)K?[69EQCS!A=?7U:LE^;<2@)6DUEE,TC@BE0P,
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M?T.<>>IT;U.46401%:AR<'0X"1A"<"DG5^XV9=R'=: D:,4)5RQ#$-H(5R>
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MEM>,!E\.+W0.1-(R$.8- 0GHEXK@P=6AU8K MX%HZ]1=A2N/#\+?_P+]V![
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M7=0ZY2C638TGHCWK9L8B<E\#(T8G]K_U.G[8[K2'7Z^]T>0X."U)%DH0:=%
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M"'<61\'+945@@D06HA-!9@=U<CT> ;7Y<X.-,>9NLE!#FJN1)/8PM.MB[7.
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M^#\K 4*8>ZU;%L0/S)Z%=5#!\IXNAC?5HJ!TF6RQ8!(2.I-(2P^EC#\LA4S
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M3S<@7D8%ZR&'S)PGES11K!2ZU[S,C_*#E=DBA:!0QWG[_II2-\R)121?J\7
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M/X5RX7/U.<A]I_U)&4W^-WP'&+P#=TPJRFD\RW[3BVX/$$M3E+LN/@ 24@@
MHBFK:DHIYC7Q#N&>=YHF:DC*=I^S>4X@U4$='?V#,:72K/N2UUF=SXGG6_,Z
MBV;N2Z[R<JW<#RT^2G9&5!R3:T]20X^L!=*FW(@U_AW]D(JB[0*L-IF>EZ!B
MIEND^'7^.T2_0K%!$%L8Z<(_ZRA QS8U7?B'R_7WM.,UMUYZ/K(K.,N_8-BG
M11%I6",D3X]+OK7N/"+T79G+L)]X=C_:[H%@?I5TT^^4@'WEJ>R;W++N,^#,
M=:8RX!/2P0.#.H=\[],!0Z3V6%WZO$ 7=T.'ZT]-CJL_F+N7^5)Z#3IC)\,$
MFJ TX[/8?HV0+*WSD[[[<?7']TEUA'H2*ZMLQ\CG6>Z=-H=-"O 7:@C4'>IU
M?Q=Y$4VOU*413;)U&D*%H=Y^1MA3AP=)<^PCV1<'>P3+$_>>)T\9#?1^R+.7
M0@8@UR./&$B__4 62<M*^B:/"K>F<^H\F.ZR[M_KQMV==4ARW=Z77F;0F5&2
M/$//5)BO.KYG0Q"%MZ/8$6_T(\?@]'BG^>D"7[/JJ\.=9WNL%"^^M:_^3"S1
M:LB.C[K\4@2RX4ZF_]MSK1>#JCTG=SZ!LF!&'_W.A\%T"YV.-_B>_QX1C[F,
M[GJR_,(,$\ZK+'9I@>J%Y#Y<,?U#=+; U;Z-))-9,M)K=7A=UCQA#HG9WUUZ
M/]Z*FM2?]VI'LIEOS-W .V,@/(Z5#XI<?//Q[X?("V=A-8:Z-B\-KU^_L\@]
MM<Y_*RVTO%/*@V#A)'#3F+W%Q84MYO)G#Q,3@&KK:A_WR5;VI<\6@\*DQ-4%
M")''ALP"&ZT3763E\A,EI8T]E"5HUJ7HC/DYN9YWX'GUY<?@.NY;0 @M_ ]F
ME<G&\O5G\D5\?&M-4E3='9\\)_[@HX)<1R.%MMGEI>U;;2/Y;@-B47IR'+IB
M<;I%PU#\M54B6UD'K!3=!N'SL\/>4U*_AG^ZP*SE[_1X[W,78MY'(C8KP?ZV
MNM.SWG>]<A6/)J_?]H'*Y!T5"J0'A+#KT]I[%)ZB<Q'+53:+<E<39I_D^=5:
M=$K^P&OB0MN@ /GB.OP:UKH^U]N^-5FJV?>6AOZW%GGI&5M/0UF^1R:?/]VA
MB5A9*WIO8&A9:OH 8^@P"QET(;)3 #++ RQJVX*4A#U>])AR"22+W3<<ZS#O
M#-+!"7RCI4F5+CR/*R9O#\Q>-=.ZA2(S_.V)1/!_>PC)TI1616?>#_ K[9D]
M./&$XKA;]RXWQARQ&3^XT?B)_>(\_*4!Z'AIGB=&CE[%T],MTFUM+?FNFOP\
M/H+?:!^KB,5_H#,GUX!YA)QB;=T%*T^3DCHWR)[/BXY<P"VG)N)F-7_9;Q=/
MAR\3+NK7KNP_&>]D$EBA>=[P;/0DB=VNI-NQ0^!#FNB;&=3R\NPM1?44F=8Z
M2R'^C:--DB>4UT\:1*LX\B 8W1S2![,VK12 V0/-(A"=Q-]70&J;%KLU=].=
MZ?5V3%AOT"TS%J<C!)E^%C0N]=]:HQ&L_:0::P:IJK7*('BD3C_G:E^N(QVU
M).I\Q#7EB.MY,SNO2TZM&PS!P :["/7K)+ R8M+(E_'A& O&FRAV\YDI!ZRE
M5=OJG9^,X?=@#K:=+,:?N"!)OH5W^.A:6NV?ACA<?FXO$YYEE^%\?-,!@\4;
M;V155J%W5%WPEV6(7!1@7HG(:3]_?(1J97:U,*L+3[N/W0YX6F%E%@/UXM&:
MV&]*Z/YG/>XM:S>D9)<H)(>5.8K%?W6>=^%Y11;!F[KF0)/L<ASW6URS:K\!
M<?T?SYO%O7VJ5D>=9/0!\=TE$IQEH@F. BRHYRWL\CM-I877Z17TVM>/R*S(
M]LD)!TD$FYQGB#B3^R$7 %@<&P:8&_%F?Y:++JV<%G <6,%]3X1O/=C+^XZI
MG^LXIF5:=V?H$I"*[4Q/^+QL)OP1<M\3H0S#WAO *YL^)46DZ>%M</#-QSBZ
M9A-)Y^P-9:?(77H9@)9:1B$#>6(KVPD=7:+B(X<3&1<+!!:\@CQ0[-Y>QB5C
MY=*.4S=[& DJB4Z^U58:8F&;+5=H!"/P@NA+K7:'/E<+A <RP5YK5OB(DT^?
M7?B5R^@[A5\9$7N/_OF_+>H0$@IJIP>9=CE2Q@=AFPE=IK@G\5**<MTIB4.'
M-Z3S)SH)\3]>:VG=%E4;+S8P-\JYZFYR(?/1YBCGY1P)WC)H&(H;;_$8JQ3A
M*<W[I#RYQ61P)ZNDOO+S"SV?#+<XK9;1ISKJ"V6;![YD%A]2Y/B1W=_GB0\7
MI67'.['H=D:CPE9C*GY']H28TQL=ANU78MS[QJU;]D-0?CVXV+;GZ6'(*=.3
M0YA$.M8[XEK"4R/_,Z@[*,Q4VK0$F<^)S*"=L<8?O#"-=UEHA6"CK.D%I9S>
M]35T/T)$]@OK'/UV))[DF?/\]IF/?C-@.+SSLFQ$_F1H96J!9UJ,(_.LMJ'J
M]6?G;H5E0C[&2+*JJ1W%59U XT>N'WZ_&I&Q-K"]$8%#XR5VMTWM"<[P]C16
MN(2Y0G52&_\]0W0+XQL+BZ5>T\=! <<2NEQO98%;FQ-Y6-7RY4=OOATX@%QQ
M5U1<[$<E2/?*+O\EO]J>T7Q?@DWXQ%*!HB4],L,QX7G5=A>(&_3X\,4\WTS/
M?_SKUE6I6!MN9$^15WCT->.='@80C100]]!8:\0TA'R^A4R?O5A@V+UECH]O
M9T<T7TE?,!(,]*VPB[LGPL$OZ:KV#P5XK\#'=Q;U694$"7 C243%D3>(Z'5\
MVLW4%^K\DJ/D $TNT[7L_M1P@CB\OZ9JVX7PP!LR7QC^VY.5SQ'KD/&XMJ&'
M4]'N6\PFUYTET4%FA"V"25WP%<CUX *OA#FPI RS-6N^X7^&R@F>Z[1U-_)=
MBS"YDM@6,O/?)T;S5_%YBT4Q4UD-FU"&9C^9],0F(U]5L2I#%EE^928=%BW-
M8<]MPB0L'E?Y?+O$B5DHIZAM]U@2+C%F6PV_KSZX*]-YN9#NZ!]2%E&" /%C
M&">+>B^LG XTD_G#Q>N3A[HMNHS5PCFH!!TMDCSYE$WZS3[00Y"P"AA1^,S3
M-Z_5&8C7IC_U\)0L,L:$*M,\G:[*%OEZFFH: _>5Z<)]01][6[V>Z_*;1(>U
M&V82M6V.6:IW(R'ET ]P:@=9F/=B.YD=Z__M-D^*^>CV%IOM!Y6$\3@=P$N,
M"M:]NRT$>JJ5E -U6*V)M,17+$A#'E2_!OL5;\\DS2I-\HISL\[FMNCO6UU%
M"8?1+_=;5;/:CM(]W?U]/59T"Z^).]A]13YY^4*/<^.A_QO>#QOUKMR&>_<I
M0&35AH^)^YK,?#NY!O&59$9\#&9P -06&LPK_'"U_2'$N%JE^56R_\JO[/,4
M(/'375Q,9A[3?DRH\,U%&%YU^L@46WYM3!(GV1J5G\OY\(]H]#?VN)9MN>;K
MJH*?W/^P]R'D#TQ+] .*V?'+$OMZ!Z1'*O8)<UTR*.+ 6@_Y(HZ4 EW3P<^#
M*>DO ]Y?81)/36;)('WVLW/F2HY)7]RE+_\Z*YPW/Q:;T<(^,&GMV@E@]6D\
M5*A/DC,JTVB6"YZZRVB3';YVJ+9*;Q]#)ERVUL&)NDE*0SE)YOG"0BD 3QU?
MX8;I*['0AT[HD@U95J>GK>ZXV+3X&'R15]'\3L,8*1"%J:< Y;Q;TCD3DQT+
M3L@P8?JJ9MWY 8[^8X,?/C#\<;5*\AENG<?Y-@+A-ZJXYVWP/*Z6$[K[/GK:
MQ]MX&:-:UE3-VB?1=>,GD%%/[GT(D=."S-""K2(S>&+)>F#90RLF+40KBOO;
MM/#N9#X>=@^HLPE/E[K-D<TGPE:P-SZ<@$W 'EX>\<C-YI,>OK5F'+78Q^O!
M9:#YXK'I/!A<X"U$$5M_=^!8O]\EAV:/[V3]RYT^_A+G*$#G6!()-.='67\?
M:M9NCSB(3P.3;INNG?;?]Z>14^0_*%ODB0(T!'9TU0%QJLT-]^U TT*>PD/_
M+-T<6#Y-#08O7LD>#$:HH+!>2<0?24V0HX=2B(/UW/$#.UB_"U%HF0)<$<=J
MD^+U("15QXK#;V"%%Q4G\_@\'2"4'6HO.W,9P(HA(IX4H&R7F(2BI@ 3\!8*
M<%^T:-O8HV@A[U\\]3E)@R!XD)G$P8-)UB:H,3@3<+CO?UX*X=[;)7+9D!GV
ML5YD^LSY 7R!@H^"/H]5R\HZF7>HLB_'*J8?\ZGXGCZN4\MG2C#JR83?K?O#
MQCF:W?H9E[)TFM6&WVF/F*Q0 "'4:YE@:!ES:1>.<T$F2(W?E@*8\A3D:3C+
MS]@O1:?XX@:ZF1$JD"HEHF \00,^;EKU'A%RZ((W5F?]:JXPK*:DPCN4246N
M(09(7C\)><Z6PQR87>!'7^#DU2 V6JC K+6W^;BA[E//K;[> JEAE8W>7MT7
M_KI]_NUT 4X/W5_\S%RJ0,#1G@,L#3XTV[JPOG42G.Z0"D='9GE!^D1D]G)U
M<5X$:5*\A8[-\Q_X=X>Q82)"15*NF2P_9$MHSMQ1X=NK+<+?+#MRK/H=IX!U
M:9\<4[Q:>BGZ)^TGZN.0[=N"PG4?_$&WR9O6ZP?*KA7Y=)U6G(J][;G9>BN_
M 8;57Q=MAF'?A6ZU+.BMA.QKX:OF\2-G+J'^; LKKIX_P_C;(J;N%^8]SGH>
MBR2SG"/%-MR8]4\=7B G95BY?CDD"!1<T4*LY^/RH?$X= 7B\H'Q&,:/IH'^
M/E2> BB<QJ@L>^+$*$"1$<$12]=:Q.)GAAUMJ)B'L;UJN#2X,Z+&>VIR8)HX
M?(6/UC;ZJQG;'1KAD,H\?!Y>DG#7>_/(!??Z_?$'/]@"E,ZQL[-]56=$O-SA
M[O<FVXG;L7*C@MPJ(H'T1:,HO,0X42A\4>:,]03>]RCPSP(N)O+S1WR*5I6>
ME?F$/>WJAQ=\C9#]WGN-9^!NKC"Y+V\?78UP;T&]JGU-WDY#[]V24O>\_][8
ML@@+A;\JY#UR(_VLHR-8$"6'B4[8U=8IEX@ZI1S6V5ESE5E.#*=@23$K5U[L
MER43SP$14T^8P.5N#M>X,BO6Y[H*?[-5I[U/U>+ND$Z/H&O.RY?*)M0Y$D._
MT_!6<R"53J]MI@!XA2 *$)&YZ$6,1?(B)GCV*<"]6P@NSX,Z:,NFG-$;O[K*
M==\YLE/)R@I?Z.AO_^DYDG-%'7+;G<SK%0AF^!LLBLS\#"2)N>U)./OFFI5T
M[JRD\#JHC^=-YYCS"N=MXS36N!1U3TUQ2M;1!!&B<_R1,RD7+H@_$4_DQB+"
MI10<HFRD_K2HJN7%S&<R_?!BTO0]5&9,9#$H\'+FO48!3FZT")[NZ;: 1/0#
MPG[$^%W5C;EI;?EKI1JRH=I&"9ZB(D%K3ON99(9!L"*S^4%)'PHK9&CPP@+0
M, 3W=E.$K^9G"F"W)NM! ?02'IG?H0!JHA=0=8.XM. FC--";JZ\:"\%*""(
MSA28<V4.&$Q",M[_S'/*<!BVMIZQF)RR2(][NOI)6_"^:J)-(_7(>!=:"(6I
MA94BMPZ]Q M+<*$MIQ4'KSN=ZVX)3@V?M69(JM 5-62%W&1Q.OE%*D5@LB#\
M*!<KN%Y1.%QUM"(:VN_@?/!*8*OF85+O_;#MS&:[.U-"+3JW^=ZIC0>/HY]5
MLR@V7/M9GTEV(2+/5K[?=30@4( >,CWI(CZ/S#)*^E)W*Y>4.G '7U^D4>4U
ME>]Q4S[L6VR4O@_G:A1IQDVE_S8"="AF&S(9VCK56%$_"+_F_8[C-\$Z/7U*
M362'^GQ5;<)^H/Y,.]=Q([2OGGL3D:/B(EV_:T$!&DLZ2!5A]0<$Y*;+D3=8
M_J;@/6GEVP<\UGQXU'RML^'"':9WJJLI&3.Z%];"KB7>N'"KKG12S7.AX6=5
M=<S.G,J+6+$(39:84+>:U#MTU>H51*CI"+I8G\@CMYA-Y!PV+8ML%I;Z/>HG
MSA1ACZTLW?;*ZOVP5Y(G-+:$7 C^M,HW<U:RO0,KGK$<E(.X@DBF #)?IT,'
MKFV;0Q7(VH?UFG[18-=5 BK6[J< OF?@+VH.\M7)+9(NT28]Q19L-:U6"5(K
MU'TYL\ \XT+UU$TIXXTER1U&%=8RFFXP5"#\%"QD&YZBROMW9FFY#,P2_]WV
MW/^?A1L+)0K^74FY/8;"I*!+$U-8 Y>JJO#A./X59R6MF@2PJ[1KXI"TG+LJ
M+*Q#[#2AHM7HS=>@G4+[F8: M?4V I,&945@,M%GKOFQ+D[SJ#]UBA8UJ3IQ
MD=?+R'KBC=089XI.<&T2/'/3;>KSE87G:O?K.$<1L"2K*%?V;SD5#R</H$@4
M)S[;"(<*VZV(=C)H&#UT-O3Z7==07^T;F?+;<L=!++;+_J587*^NV"C_\0#^
M<AJ1,VV!E\AIM-@ZQXCKRQUP\N!?O#<N;=#04CA]ANXK.]1S7$27_20V;",_
M9@3Q#(F7.&[5QU_NZ!! T!"APVHK45)3A7EO&2;6$ELQ?3>/=KC//NUL#@I"
MSMI$M9!@FU?U)J>.UUTVLSOQ"!NC*5_%^IT.&<)5>+>P&JE"7=$!QDH6>N6^
MV7!QE-XY<D_#GF'1OW4/DJAL)"HUV_VK1S:'G K&>QP,JXV@1C1)DP7DILK5
M+^(3"BVD5(_#K65_:LZBML:Z?2)FKENK'P1SIV0$;X,7I$*QCV1"$%@]Y(>A
M5\)<,7)>4G=W6ZW%45-)YOEAOQW$X+'-:3?,FJ8^Q/?PO"0F@/$&DHJF-B\(
M[X^Q!E8BU>C/,FQR>:(JR%<+8*^3,6O82>5EZ0:L@Q83JB6,[ "]V;YRONX(
M-7I=+S%N]G@?D4%.^F/0,M38,C4V!AN+) Y4HYQ9\2HI1_ZD./7+UMXW]4-;
MTS@J"BZ]K!K)PF[<?2V59?D&N<W1F:%-@SFY,\+66"P2<0S#7SHF<M?.@_W_
M:K.IJ?"YAIJA.KVLZ*FD$$_$->E'@W(!5W/+I(KCHU0YHSXTG=\N6G*L@7Y$
M\=898"$+EY(6!LYNUB2%$'4S^J])53#21QG=7ISQ-/J3TUTLQG;G8KTCD378
M&W[?T-%_KN^D<"[%YUOY?G?#T+Y>4@DIFCQ" 4I=0*(TK3U/2P$"R&+>;CVM
MYK38F1S9[>1N2[:R)I&3C 2WMQMWFD26.%CW86"P(\"IX_->)-,G%'8M/!0O
MJK/#ANRY"A76712&?^Z?T)%)T&(/O_#D,<T;'6HGMH33:3#)+4'&_X&H0/ W
M!ZDS*UQ,-]M;?Y%!(LDE:-G,._L5GZ\?3JAIZ8NL&Y6MV!MCD@!.*40>S8]_
M1] >DR=(6^B.BOA:]$AV\OCZ_OK&[;VD1?O4C..<2""S7R+K]0[;+TE:N</Y
MU@-]T%&_ ?-*X1#%-'GK>H@+; \:EGQ*(-.;@"JXXY&@\E!\8/3/%ID0LN!Z
MV=:8GXDG_77M*$[:4MRJ)1M\[<38;4O],;J6%X9U1FX%>2XFCE& >8NY]@+7
MH_ALB3"9L=9OJRY)*TN7$!^N/U8&6"2W(2%I3'XWL?:-R?;!1(D,AU0A[$[T
MN:J28;![#)R;I%,V?@QTB<6/Q.EVB8W_6;%TIS=<;M+,42^M3 U7\MK$I\(A
MHHY>^:.UU[*_PUL1Q8@6&,@XFGH0M$3%/YG#K_%QY%.;%?0FY^)9WZ\E23;]
M0+.(LHE)8Q'(<0.K$4UOR! PC&\0)16C7X^E7L>7^;NL.,P)1+C$]2K-IAZ.
M7[I\,L,9&G_>DJF&".8);3[HB:B#M,D(:9MY1&.]AOYX@]B5N!X3' -M=0FV
M)2I/S,K0MT+EO$K,)</S<F>"3HYPV=&>R+ YR1&%73;'I-.QBKQ'XTI)XV7E
MQ[R&2N*S$W&MI_&6*A#&T?:!S2^$O?K7QTDI6RA>?(I-F;*!=3L(=""O"/0=
M:$?C)9';$KC=!:'5< 5D%)JMG!"9PZAMG[&9I&H2G!S_*=9BNN9B0&,_HR!S
M;T<RZ0QX&131U&=^W%+OI(_W)>@X>J5>P,[VG)/R<[AF-R+_4XW*-^#K_&'2
M5]X\GP_+",'+177MMMY2FI#G5QVN)>HJK),L?L\;=#S)5O>4V-] O!$6Q E'
MXV2:CI)_)OAD;R:S5+PNL["<[JSBJ2K6^<V4+UL8E3W#YH1+(S."T'UV6&/!
M(,_/D/3-H[QJI'C\/2K@&95-K4J/7O;>&:BA\ZD2L:RIU1GK0N3@)#.&+J+P
ME[3#G_]1H/):9/UH.ER>1!;V@?IGRWVK:(N\<49%KD=+/TE"9:JC%S),M]5#
MT/>&'#7A5;*\]^=7ZIT6(,P;75]6(Y>]Q0#>$&.HO-O/V[;/SIVR.>U;:O%"
M/KWP+Y#P;JCGWQI'K,NM.XRE([-[I F>UDZGA] H(=/[?[<II AL.OW=IF#.
M&.FS^'>;POU2U6_<ST#>>X=[##Z +AN/H@".+A&GL$ _ZGF21FO#I3&Q21=[
MQZ\B"*Z8CN48!<&R$H;,.$V$,06HH !$=ILC5U*UW_LY2=QX"]ZBC=-F6[4R
MP4<QQ=T_F$&- H@GO'R6^\_-G&=<P.V%VK2)6C)]#]:=3'\R/]T'G8<%O29"
MK^4@JS8X=([-@[$T"4^OB4LM4XE]I!%1N7!';'S09+%;O?E@'>4P.9T M9@E
M]2SYE'1F#^SJNI$ENBD 5ML%K[39A,#J1UHI=5BK$EBC&VZ<#RH8A,D]Q X+
MWY_,HZHQ^#-S??;#W7--SNA_A-5QY%!L4=/[M#"B7I[#*4M0QG3%+#G=7[7)
MQ8$CJJRVA.KV<:'243&IL %";D6=/605\M/&T18&_3-!#*_;J6[X$OCDG"AA
MJ'M"V62+7AF()?: R64.Q51 V5"8[#FY)'T;I8]D'H?Q,P\E6ZX_K.V7_%[%
M&Z.<;!-WFQ ;>";PSKN3;RP6T?TXEHJGZM:EOC)B*,V,C?>>.*[KQB<7*]90
M3^#%^$PRRRPI]0 :/NR@J,Z-3RCP?B> E""\G^J>D__^WF>P2:KK6C]&6;L#
M&]3FOXG-7N1MUL=?D=D:4$R?)VSS+K"VH'G-=6W\G:7L$D9#Q*JJ@QN]EX1&
M/SQO$HI&\!\>2! YD\@,IC@!,GTZKA#"[7V)L,W_<+$]^3BTT!;Z?-QY'"H6
M]#WN\LLK5Z,[]7%7;%U^]2I?0I:N-%;^K 7;^JZ3+9\O?AM^1X7E_C60!X@F
M1R@FT/K2WR1VJII3PR.$TQ>004KQ;_;?OFS UBKJQWL&[-]5%2.I,."="R16
MA1#/T,7H;?3?Q8EP@DI56)V$0F&6O8_+D0P;WNOQO;A%O;A[%[8+7ZC)7I^A
M?O8C,NYF !XL0K0@V ;YR2#L)@_U(]$T'K4%>O-U,6\4TEBF\_H\YU_O#=]3
M<9#:'\_32'4_+Y7T"2<UJ_]K17U;,\-%KV%@8*"H<!_98RI3U;(IC%Y>@NN-
MK_,2!6;!^[KA[+<\"5K>]O/7JCQ=\_TD\<'Y35FD"%.I*=KMWD#EG0(*4!,M
M6I0<%$)3+1#:=])F9Z>8[<M<7R<[8VFIVL%ED&X?V]5H0AVGJPQX%J%A>!$T
M46 2TG1%'A$-$98WB6\?V^M S*<Q60IUS1\9U=RL3:!C]OPFJ^5VH?&%6J^/
M=0?GBV*/8L,0&6OG)(L#IV$4\49'XG#!U6[CFC>G9J2(C A)G,;V_]-795A!
M(,4LNDPTDL<AV(=I'([\SLDS^,QYL$%H-OWYB?7+G^8?UO>NTZM4RBI;^@TP
M^:N.[Z%A,[3;GU43OHT=LVLKU#>?7XX>=^O\\2Q'J(GN?-$B!2 S1!,$^@AG
MR;-0-G6!?+=KR)_HE'IFM.N^QV1'BO/^#?&(]F;%U]_J7&!9;Z\]]QZ@E:BJ
MJU=$9)Z4K>SWJN>6'B#2]TE<!K!TB#I\#=&4CJA4FI:7"4L[4Z'7VV,G@GOS
M(:[;[ O:EC=61.UJ'J//F2(CJ8*8GRAG2?S^W\>7\'%#> NT2K^E*/RA?,GZ
M^VN_BC>O!J-\LQ\Q*=W.#;1@U^G/"]K/$+1E(#=+%3T?R9^OKHI3*=AAT^4*
MFT[4%+T0L'-.I0^NT>Z#*.[P?;5M %LI![5+LXI?4%ESN[68W9,N#JIW\7V3
M)G>/WUL\*I,\@#Y;9[)8Q-;K? "E6U=2;=O_)=5\_J+#^<M\XF&6 )78)^!2
M[@TWOY(9@=):*!4*LY4V+48T)16!E3Y4KV9?'A'"[UT[$GM^V]D0]^1NOBKD
MVL2=H!&^'X*F2]OO(.5T[04V1TC\XL(NQ#M0*_XI+J3(/6_VI99G]$IL6H_A
MS-;MNY>W<@&,*016;Z?,'=2LP5(C[>^%",=ZU^Q4.!COGG@P)'9W.S\Z$O#U
MMJNNKO:,N9QY=T T_D,NG5C<6V#3P'0.C7VCO?4$73% Y(ILJ?F9;G^$9"!*
M&RP4/*AYJ91ZZ4RWZ(#16\,';&[%.C<L;$I<F^=7PU('34'0WG_/>3<RS\#(
M2G_M)IG>G2"L0:"'-R-8X8(^CC6%7[,9ZQV:9E<VE&CZW-QGGVC;PH[8M1U/
MST1(8OE'LY[\R!WP443GJ>^Q&T1$O=.&$.X0>8<0KW8#X->Q+-6UY4B^5\?F
MMP:I5^ZE7HJJ.97=F6%]056TJ+2PVDR"89!M, YOI58V1F?WYN2L_E@$6_](
M*KVY1/MML3=&@;<[VQ"O38CC(.B.P$IAQ,MI^,N:14@IYWNJ,FU]TIX<C<3L
MQQ73M$,!TTL$^8_'#BES#=,!)7,#G%)2E<DUAS"LS+'P-1^-Y+C<&K@^6(>2
M-+W05& 3A@B'5;#4DE*PNXVIDKBLH>J8.S\<XF:UW^AK2$74BD*V51[?<MI%
M3(Z3F1^1?C1(6TS/>3>O-J&87F=)](8:CJBC?UU<#;Q8P<K>N<HL&XNFBR Q
M\B8_OX[J^)6Y[ \'B17UZMJ\DPG^(OIPAMB=@8*K<X)&I$)8/&K/@112!=^T
MZ.RVJ8+8DE8=OQ_%="#L-:7_2 Z_6.&;% +%C,$F;]X>6JRJ&?)S+>@-RWWC
MXJ=]4>\"-6U8L,V#*J-@:HD/=-SSHXL/*ED&W9(R*,!-H<$N5QE?F;032[+=
MJZ+UE'88UHEN*W/!F<'"@AFLE4*_/_DE50I?\+D419!N[N$C/FE@)_V&8H:A
M81#Z<M]M!"8[\B(>^?P-$VJ"_YND3?Y56D%-$?6'+?82-'==/U +USSW;I$N
MNJ8MP4M:MCO.R]J_5*@?'EBC>PKY=&""9L>[&V#A]3Y9CF.\R=8YV;UCQT^\
MWLKS\OR?M]-FP1XG.Z[M]:,PVAUIO/!>%/<!0L!;P+(!NQM>SM=ZE)0X$$+C
MJ24DK"@H>_UJMXY($&SD+^G8)#-\_P?19 !].3(V\G0=#L6BDQP6"G@N+8R]
MI+-KO1V'MD]QXI)0OKJF>R6>^&5\!.P5D=/=^V3Z;8*GMUZ[C)>8.O?(BA5O
M&]O2B;M#64VX8-3>BV?Q,G5F:X_@]N&E.C;%.V]A=1$U_D14S\#*>Y\W"H,Y
MW61>U$G:.#=7CV_8SO9B,A^'6=;CM34OR9PE-M\@_:)V_9+_^#K$O_LZ1,-E
M$,(7$4W&T@C,5U3IHEZFKK,K[F9[A@4KD[D*\]$+8+_HAS6NF>\MZUQL[/LW
MHIF,P3EA>?Q<"<L2MO:&/QR:^GU%V\&R5H/&6O= )J#Z-7@8MG"CQ13?XL/&
M._Z:YJB!/;Q=0Z=>>/US8*PP&]O.=0,QLGL= D=GB2]8?*C7"K\T6L'L:STF
MX92R???T7>K"AL;H]XDX?9=GP+J)G_Z"LT9[JMB(0K3UT:;A:(735QD7EVNV
ML@\]U:*L=8604KVM<?IB<8[1\/&XI7+94\M/8_H^GHBE6ID1?-U+1>_P.0N/
M.YK<T@F?I[YO*1YA>UQ=WVX*&F@%IVI+4!FSZ(IAJ,;JXZ,B(DB\I$C0CDG(
ME.C1CZ'7%2A.BW4$O9_*^TAY-^]0]PVW]D:V'CM(?VA:[<U[,Q[K:95^C&"/
MX8EGZ=&.]GN(RVR;2DVO6HU_,%BP];Q?_U[LBC(U]:[;'35[ZE6<I4'BGR2Q
M7*L3D(5Q9R^\YRJM>S ZXKR9CH=HPA?]0#<'J5Y0+'N(I0"+KR-E\WR>6%_X
M<^>IP+<WU8&/C3WHV*J**N .Y%D85@<1 Q)K_;-.J#!A=A\UA95SB[A+R L-
M0U;A#.E9@+QX."#5(W!CC=DE8('I[#7+SX[7WO2ODV\2HS;M\!'W]V.^'ZO;
M@=$SJ3S@00J 8C*@'"C,MS2^ J(5^,^?>,]_SG6LD>Z1<YB: ?8%<:M\@MN?
MGO])916#;.B1Z0= -L:+Y25RY6&XJZ+]>-\Z%TEW3V^:B[=&N,CK?;/M$!$R
M*+ZO [#4836N4@"(PBX,^X@5?YGN[]2F4(#R'22.NGE?]U9RZ933E)[ZA;&#
MHV=V ;5G&V>01);<MUK&Q"KVM]MJGDI/XBI,RG:7*(#VJ?!/JR_='W]+8,G:
M1]R:KA0 4+_I;7^4@K\QCX)XWWR,-,:B(_)M4"75!D$EH9<W1VVUNDM331("
MEDR?PY#WKTFWF\O[!SKD92;A038I9M.&/J*MHP"#K+ V(813F@!J*<J[EMQ8
ME79Z81.?631833U?1 '>4(#MCOY5M,WJ*2U(/S(@JO >^"0$ZWKK.!2%^8*@
M:Q FRN"HXA>*PM4$[)T6F>%GA>%!RYI'#@8,V*1XM0<GU#?:YS\PK?7@Q^4'
MW.5T1>7C=-J^?EG^DOHCS=R9>]7NMQ43E^"KHO!*-%C5J3Q4;YS/39AR7^,R
M_9-6@B)RM"QV;*]7+LY7M6Q;& ^J#4@?]I16JAJRZ;RV?& B=M5XQZRGF+Q[
ML6$1"R7RL^,&3(?\MGT7))I)/.MADBXNXMOK!LA%EPO ZR.KEKE,[N_/W@XM
M%9A(3'L=2R;H45MGU%W<@C\P@/V""B PP\@IZ/Q<PJW=8$]D: -4Y\5<Y;OW
M495*0\4;N57L/Z!W7_(="%$ -755\H"Z"ND+T=]U'A$FS#VN)EIDONJ9FNWX
MIZQ09^XCL?1"!\O'G*V'#D%]U[\47#_D2GN#>K<TUCR61=0I=RTWT'Q/IS)(
MO(BO77#Y@.(X@/%Y*YG_K2=U-]VJDN'I+PEV59_@43\X\O,92LLDS_P((IF
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M!1MO/Z=STYUY1(U;['A_@.[QBD4FQ,XSHOVL:BCZ!%5_1!,R?X;_'L,<0-V
MU5XG017@CB?!$FDG.+M;9+N[ 8R9.E;R9#O8]BYAT A)VK$>3216_3U-V!Y]
M-)",/VMJ,]O,2^D"W+(W6:/]NGWS$2AB?''!NX@,?C1\==W_4K=^L!_Y/J;\
MZM-]KB[G_); ()'X^04<63R$*GP$PJ*GO&N\6Q&AO];$A,G0T^E62-T5Q3KS
M\H\;X6E18\&W[ZIKOC_HR=[U)"S/_@PDA#0FF01K*G[_XZ %^86/'6PQ*7FG
MPYQO>)GWX6OZB]B[!@#X:]%*D[W?>'__B]-6>FE]O1])*U"FL<_ /"4\.Y7*
MY!1VL$/J ,XK!\5,>[L'OZ$Z%]TJ#]4>*3_5^FOUGI5)#NQSU,WXM$H]Y+S&
M8Q:W'VWZ)SZ$_:8!&& F \>,0?A?)R&";#0'J<;N69&CGTZJ.V_AS=4X1G9^
M&!6E, 7)F@CVH7T)R""CB2JMNR0O"C#]Q.TOL6LT;"[9\0C$XN@T=;D*F#\$
MZ=5O">\G_U. DD9(AW!N4BY/7PI832"CAL1E4![EY_N%X=N#N"(<609&Y2F=
MW:*>39AY,<5.G/S2H5(KN!OY\O=#F$."0$<B#U=W,F@%;2[JPZ:W#>!I9C9@
M>"_J/\!?%ZI':E.*YM .PKW!A=^R\KZSY[J=LT]1Y4M!:V)EO^"S#P'YT[EN
M4>ZW*H34H,'N5M[6H^O[J8I?GBZS156LTED"!W1X27I1OEL;IA0WU"W:&[KJ
M'_+Z[%3QA=0<J_@HTL];EOWFE7_9K?[JQ8A=ZRB]V'+1#!2]5DEG;:.@D.9T
M-E/*)4<H5YTJT^/RUNCL=:$[@Y=*5E4'@I0;6_UG0_3,SO%%_2-Y41(,B/&M
M7]@ZTX*QU22[KR,9N4Y7,@LR,_/EK^[?KV76G]=A3AQ[?^RF9"P(NW:;?H8,
M;.XUN9;..D3AM7;4TDP2H%K,NSPF!^\;!>UGO2\XH:3GW,MJ_OG4OH9B-[L+
M<P "\78^0HO_3WMI29Z? MX3EXU)>##5N?9HV0T&7NCW)710>?1(&()YNQK]
MG".$!0U9;;@<X.'-D>F2T2;<HBYYT/G-V4+98.J'L+1ZGU_06?.E<MF?OGV5
M:YO^DL\S"-\ A*<<\'_6N04G"(C1)N9/+9T[-<B&A8S_;A%<1P"@$2$2&:#_
MR_7:@V(_BR=[$R+T%_X'M3:?52A*-MX4*_3/)!.\.^4*<GZVL&S*)G7^AKB_
M2A:;8,$+3]KPVBF)UZ].Q+P0NV>>^7$^!<Q_^M;8#7^Q:((Z\2&OT_WLZ9T5
M#/^NV70K+J0&VPQ]3S]'2*E%D(P]6H3B?\;E:'^=,F[E+KN?Y3<[$#+[.)[2
M^^)[8876F:ROG\WW5 #%WD#_F2:, $N\<P1BG9A^<D"7(#M-$]X[/8O^V>/Z
MWN6%^L)FA8.VZV:LKQ#= KY+H9^QH!4+SYC@5_T)T_>J'I=!PL=]RB*MU*P-
M?VF.=*@W3@I61V<9&0AT=D"5VL8P(V[<R6@9OYXA["RV<T\Y6:^T,&[<$O.!
M)F&JPTL>(QV#Q6,(GOOXR",0&X)TZ1>=U['2QJR<:&5Z!IG3*_BZYYJ!W<+K
M:?6*)SP[,C%/=Z)_&](?8F9F%"=X<<Y0\L6$R,)+FPU#L[CC:H1/D97G#2U+
MV4-$8KPG55I.@NPT&ZJZ#EVY>^BEGW7ODY]M01]5SF,[=SR<]4I;RBH_I2Z3
M(6<!): H$=,831Z$V2E\V(TA1I.'"F)%YO,*N@RYZ95*U]<!U/!0W&LOI05[
MV<X7R1X=XT4WSX71T4>@IXIC=X] I+^TX@8(]7+Q#B_*]$<'[T97\H2%[NG*
M^Q%,W3=C+_>?>*/6AWD^)4A8C ZL4\]>%;(K,_-U37 1_9I99U1^+DSEU/N,
M(C80TW@#4U0IA^6]I@X?)QK?M-_H@M^!F-BV9ZHQ_Q[-U891RR2Q>JL.1_I$
M"Z?ST_\4DUVAH5-G!NOL$+,:2\.O)_QO7M$^VR<8&?[M_(O[!=WZ@JQL^MVY
M8FDZUM=CWU5_VZ"D&5[,NZ+8E')J "V"=!W5)9"B,U>NWPC;J"@>*I HKZB$
M_1-UF5>OB#=7A_=,99Z J<Y9$/ Y=@"0,Q8=3)/\;FHHCFD3ZH YY>@V3FYI
M2I<D&DYTE*U?ARNW2[NQ]*G4GCV(@KZ"N8M?93K88Q#[<H)42!MD##9G'KRG
M/^*B:D.HR,[^F]:OU ,7%WO'>5,=\'4+G#[8.1+.; ;U>FW6_I8K-=)J8/?
M(E4^Q?3>CQ^*Y?_B#,[(D+U1X&Y<R$1IO 3P3S-9:>Y+>%9] P*LESEU9QXL
MU197_S%_:A'?U8]:<-/QOP)+A1&<5?XF0 CZ".;O$;T5A^V%'P*I[*0Q8<@7
M'O+HBCR:.>E^Y"472_<Q0P/_#<K?2\DYS28_8#'_E[( ?>N Y4A8PDC[]-B?
M3R9H(S#%/DCHKJD.^A?JJ3DIB"*)Z<JE*A^!BA\ 0PZJY9'K_VW(8[G.GV"Z
ME[#BSW&[C@[+9;3F0COY"YCO %R/Q0?3;8#B.@*]& 0\W-VD HSN(^H2L)@I
MV'8L[ 1F[&KQ$6@H*P]FT8395H;-VL<G'X%JH0_19@P!/[;- OLWA6IT69S]
M]($BFN4(5$0+H7_4@XWGK,(2B?M$AT-H'\0XALJSIZUSUGQYN4[/TU,TLBS.
M6-*MA2TA5N_IC["3!I($D,C"Z+8JX)9\:76*F)FTU$IH>)W+\A;A][N^=/+S
M<W?_E'5*NK//O+EM:'2G,2+X8]1-7AHGI@F%<PS%V6V1I:);)^^V(Z3-B3=^
M("V;W@5? Z.F[N1_]ZAVZ=U4^GGO]3JL6Q0=V5CM6T:,M:3*[6"RYU";/N_1
M>-ZU(]!-0"-V;9>-KE^+])F[\7S49 BO@-AC/XB=&A^?NO )'FH=D"XN(Y7X
M^0WH1"PP\27@N+AP,^^T^&F!=3P9U%ODT,PQ^+00=I9?8Y/W94BS]BA-IVH1
M16 %JRU+Q9]ZDD!F881 W^#IZO0AH>EV+)=%9GL@H4BJ(BRV\+[_<SM)??4F
MBJ:Z,U=+/SO31^Q* $YE_M(V>FCMK&@LN>!W0\JGZ<T5_PLF;Y\T3,%M4I<8
M>96^_J!'$&XD_"[QTUN?[VLD/M^LA)SF?X4,\W\]:6\Y'17!5O*AZ<33WVLR
M3 <#C%P!P+$$<=+;*ODA @W<?WY.LWO*Q=3\C/G>.<57]>&]6<0>1;B83=D@
MLO-)O-W$P0/8A%XK+O@0T@X)J1D-0AEE3<#%($3>CS7H-#NWVHSJ !W9%;TJ
MZ0^=FE%P,@7PMF_1G371&Q<ISY$[LZYIDI7LL_XZL<UKVCLV?SK3K2RB0:X.
M-LH3NDR;3&K8$;7;FBFR7UK,O9.]_"UW=F"YV]4-S/=C\XP92>. 6A)K9-(;
M?A%-QK?(5_-(E)IBHG<HSMX?C?\^M/4MKA7-NR,<[A,'<:YXDCS[*[_[VU.!
M;,G%O'U+7 3N3RHIO(X6"X5C0C#<EY:JPNF<--\1^L*M8S[XVT'5[^SIOC<'
MV_V3M\$JM 3'PW?7R]_QFPU>&ME7RB_6SY9=:3D7_?R4RH&BD-U:L))YP& Z
MK@]Q"'VPKNQ\^ZN87AU&(42#6$O7[PC';;#['('2Q7!AU^FC6JJ8+@&B-^TM
M KI[>Y2H9U,)8F1@X:=I58O]#1W]NXP"SG^T7LOM4>BGF($=LI;0LJ[ZJ\Y[
MM_>I+!$DHY?(B!:/D]$45(8MWEPBD&3=B#<Y<(E(G9PQ. ".]T0C+5J81*35
MH,6H5V*>*,3E3],R+)+./G\ZA!_(KM((^2LO\E+E^4VPN*<D$\T?&.R3&)B
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M=6Z%+D?(*O;_1@[7KC;J@]XKC>E0R?^!M(.FL9P+T#[!+7?(*+.4P32YHS2
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M_;OB6IK@OP^_^=LS ROKP@2EF'G0-VBF!U; @6RP=(IB-@#*+[75> 0B08J
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M:/;(VVWCL&CJQ:SU)/F]ANR,=;[BJ3'KB09RX;,/MR5R-]EB]$;*\A:GR>+
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M_FR"1UW%^!CXC5#N;:V+'H%:T)UDR!ED_&PQ9.QSR.9#]-;'6E^CG4HO=!.
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ML:N^M/C'GORP^.\C-]:FCN,X0<Q,'81@.A$]#I]_,GVZ3LE'G QN]$:<&9)
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M8$GPKF8JH,ZM&4]W])FF\!$J[Z<HO#BVQN\<\TW6OH@=$0]Z:?+VYR%1M>,
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M&"21\P@O>0Z@[()V9_MLD;KN@0[#AY#L)$EHMQ76A!@N3A8![N/;700.KG.
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M=9LL00A<M\X!_,YH"6*P!-F6'D:K/N0%\LO0DQ7Y!H,BX?^!9&/.7#P'L&V
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M#_=ZNCE>N6I=?2[/3#2Q(KN ,Y^4%N>_O@*^N)$'=8G!UY1N:K')X'S),F.
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M8V/4[5\>8P+IAS#5S3I6P6V#>%,P*H[1G43C4CE=B6A=1?[EX^1 T:/#$3)
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MH M-Y-TW* :%@J]#5&AQ( ,S)?#BS\O.!Q9_J0>W.:ZT=E56P#G\(GNYY>Z
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M_DB^RLWAH]H&=>8T_>/N.T^\D_R%[S2S 7KOR*. 5?.81_03!L/'4&+Z#DG
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M"1[Z[K[>NQ)D#(X\!V9U?M)-7K_](O"I)ET5EXC<J>^"ED9_^JM$<O\O+[3
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MKON4@V&*H0#%4VD;)IH.GGA-1;'XD#R0^YE"@4I6".H!F4;<UBEQ#HA$^N'
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MLXQYV'4M'!G[[4P[X5D#R_KI<8Z?F\)L>A[,WTUB=S]XN"D\L#)76DCJ5'^
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M%?:!6U?^*AU1>U-\]4F<MD?EJ9M,R!Q%+':+L7?O0F2@Z#)]BTJ?T/W8(HY
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MXO58FRI\B^(  !K9D(@0DJ' >"UDST5 :E2 *D4,\C?.FA?DG20Z*9G8VU3
MG^@.7\;6O<#-<=$0K#S_LXR'_GM_JWF0_%H?AMX,MMCJ5C[OY'U7\]V@28^5
M,$M$_TOK'>/0\9#]Q3ZVUIBO%1^)#Q=Z6%[EZ>K&^PK-WGH(/V/-9R5XY0+>
M2+/G 9!P)TPO_'?OV/VGR#(;XSJZ ^#=ACE#Q+T\%#SF@[Q!E4YI>STL/; H
M'(D*,6^,N80($Q8?4<:U07!J"G)74W4"K5=MZ0J?>06=G*V-%[AO72_O3K.O
MNI?T.JLEW=?UEW\SWG$&ET,:/??CB150:+9QN6Y>:&5V[C.3P'Z9E(R_&%5X
M<Z-2STEJ=7YFJ1HS,4\6:D >\I>B&C:'DJ-X+2A+A<X>%]^E.].ZLB7OY[WP
MJ*N;\4!> 5O@%-UM6!2\[&$FZE("J8UYD13B,>VR-8%R<>:/?/\6<\XSJ.5=
MIF?=@WEDYYZF9*6'YR^<;;]W9\;NVN.[OS#7EF]9SM")HH6E9YCO'U^X:[J9
MG)R0&Y5 )GZG/U8,%M:UF,99WPI=R?@(NBU3=.G3- @R V7\I2#+(%C70"X$
MPM(6P<G[1W[B=FU>>@)3*2MKT_VB?>VL+YL,#X< [>)ARPF1+-?([R[5VI?2
MDXF6FU)%]GJ2Z \O.BC]LOHA@OL/V0G-]^"5/IEH"4P?_;\9[']A*6 FC9+U
MKD7&L*M-W7B@BRG;$YV$RM+N<$5Q5Q:VW7YS3*8OG(4,KS:T^FG.>O]E.+%E
M=!K?,-E>OHY0(X'LO@_OK?*B?E"=.ER9FZFCK[HA#W43'?)OK ^8NRP>(9AZ
MN239N(28!)]K++A":\6ED]2V80RA\]GOOWJNK#KYV5-=_-1Q 1BAUT7 XHW=
M%#5F<F]O7VFBG]VS)4")2-'!;NH!]0@&%QZ,^X'L-+]53AE-<3K7)HA](/;Z
MR><WLD58A_ J>XPH]0E9[/Y9YX3B28Q"104NS[LF =W"NX]"I)T6O(UR(OPX
M[3(XPE=:P-@)C0D&7/F/_!'_)'5H'W.)C\J>)X?W77I7?B"=+3/,]N5L*RZ3
M=/J8E?2# W5=TY.&UK21BS58=$MHHZ\2K6"7SVFTD8N+RT+7X'RYY^9OR%RD
M(=IP$SP,](TL@TE+>5O*N<]&Q;H6LJWN?BD.T6(40"UG<0H\J?(A1@@==+@;
M:5:#E3_L^N-'<5S-0M6B6ZC,/LHT[33?;234=!FYP:&,?)?:.JO1TY3H!(A)
M<\T=D:[('I@;U,AC'QRU&FF4"IR2$;[OY<9Y;.UBNI:__WWR9GK%6J=>WGEJ
M$+@?XC![U^@1WP8+TLCXESF*K]?VI63'-?"U(DHN4(QTRY\=,Q9>R B#P="4
M5>2'T9.4K)RQ /2\7F_)R#6='OFD!TTIBU5#PU?Z.7A%7[2[:]8=G=_Z50 ?
M1RP0*!NT\*[Q4FI?(/,B^2MI]]7!^%>>;7N!Z:28BLNI9N&LA!#FO6;2J5R1
M9/42BTZCKLVUA#%&&?IN*MWA59-A[S?C ;VE?!]F90O5+A:1C R$4V[!H['%
M62E'$UZA97S2C;M(;/>*OJ:@%N^R_Z'K)JC[RT\VG):$H"O+T#Z4%H>KJ)G\
M8:OV2" S[DHI[RGV/=$]7''=8VPS'/HL96HV\R OS9'ZH+O+AFYL]<OZX:AV
M2H%M\"TCHY[X#)@?V\M4V+@PU]\R#?]T_K:IH>SV_.ACSVW8F_F90K& .N7R
M10_E2Q,;;F\55YVM6=,1UX*^XG@J3M[KQ-"G414MUU;*R4I,023M/1WKZ.$:
M0+6Q+BS[.EQU(<G%52']EC&75+73L69WGL71J6J U%*O&(8HW6CTS6>J?*2G
MMXQ*U7BYY*1;*4JU;5XCG+]_@AJU<H;]J ^.B K!4JX3!K"DX+D134HOX78%
M<KP75>"U&W$[XTTCL!R^95.'WOT+%*6CN64:*D_'_3%KD2LHJG"Y4]7&YXHP
MFT/D'G;QP*]Y/H5O[]P9CQDSLYGKOE/K+(1:UC%$\'C*V[XM]K>)M>-_BVUK
M;POXSL1#!@N1Y+K*,O2AVB*J98M+A.&]%4&]?*:<PRD_W?=B.VH=T4O[[L%,
M?O(S(Q_]R6G0JS;F+G=^9O6ELK+6$R'"-R4]C@GOS]TY>R"V/S&<&8H@WVA0
MP2U25Z?*.AZUM)U.K:K-QV9.;(ISR:4ON+M/VMDO;M7B8V=BJ'BFH VXKT9I
M<9%R[N=J@\$NYE6*5>RX'M^9**^3MKR7?K^G<+E::*MQV(IQ/(036B*JC^?2
M.1K[!D]79!$?;=4FG=?T?N#+?DV])"BW\LP>W;43^,];*_!!!QHW78=QQP;'
ME(?O=KH\.?%( G/S9F\Y]>2Q%^6'!!(>22R]D^N+Y$=Z?4-+&TNEKXL]%IL9
MG2,>1M7$%3G5N'HY!AC'D$'V$%?3>1^GD^:E*;3XLII20^_BKC0Z!\3=]]<P
MKC/%*=673P=3;1IC9LO&Y,_:O_9BWQ^]*V]8,C*7@TT3QM-#0S /(<']ZE07
M&B1I U]8S4!D)N"S3X1Q3PG7C.OGAV?KG&4TQ>H:S\H>=W_3RNXJN=>ML:^[
M#T%QRUX85V^H'/+I%7"(.>+B:T83?8/]GK@.#.# ?0(4..TF'9/MTU OSE\=
MVG1$]XW5G*5UT_"*YI0VM?9@VR2S=2'[I(],=Q^^4<RC_G8U]W.?QW+FSEJ9
MBHZ[NQ-_5]@SEGH&QB>J91K?/[:3C:<J9>_%P9TN)=KQE98-J/-FYOU761BH
M=$!<<TZ.\JE*%5L ;V6AZ4!=Q<X2UNN=PTG=B+<7-SB8)YY;LM@O0%R?PYB2
M9V%QT.G7YC-* TK<L^S"_HKU;[@>94)C$_;!_*XO(&'T%AYQJ2W/)MY[">U7
M7[UWY;%#$P/MU]0\7#:2[;>J,1(&R31F!HOS?[-H=N-K>?228/3M3MWAN_%]
M3[YL"/2\: JPX3<^Y+*BIS]D_T-5C)ZK,1@Y,SK<EK>5!V\3^">=Z.?]7UM=
M1J,.7BUL.J)SY(#LQT5S\7K\U7',P;Z#I!Q2#Z]CVVF754^D=CXE?5S9.#!5
MS]ZKIKQDRJ)<4:$4OWIV#?*2#P/Z_W0N?[6 -IQ;7BD0G:[TP</1Q4/Z;*6N
M>9+XAQ.U>4%?X^];A;=4HKM&G/LFB3\)*QI 6)'BHC]_W>J*<\IB0'4!_CQ%
MZ)_W_,FF9(<NR,OPU3DX'HCX/1YL'DK>8YLW;G32BG:GL!U;7&+FBG9-VG&(
MC91:318F<"L;@:@>671=[%PN=X=4^03FX]^5L#+PS\<>;3JUB[7;VS]_/M.N
MK2D>\FD;5B^3"?PZOW-*[^DV;#]+]*7/IOOBY5]/U;-+G)BV91!#JI);\C<6
M<O<C2.G;]PVL(!=6[6G@2EG+3L61?U"GGQ9=3Q2^O!=RDA2&GCL1;$)\(:M/
M3QXZNC[L]1BEJ%B2G.DR.MSIUM=)JZ7I=$]^1>3>/747A=9M5AIDYL@-V=B/
MU->:0!,+DN]U,O[\V[ ]>W]9FCS$-" .7J#?L+B\=C!DM8]^MU(S2-ZA\.=$
MVZ"[/C;O4TZ'IYH%\G6T'(?2OI:'>)G?V3WJ(K<7>. B6B3JV5M!(XAYG8%\
M$V83NI=(,49%P NUJZ3PT?Z*WCR)PO*71V)+?\9[);.5N9_)B-70@83B0E^2
M_P5Z!1D7I''"SJ9>0[)/[7RN]%FO3**>RRGV9,&K^\1;@I ]S6G90W.]YZU'
M-+E[2NN%)\/->,7"?8Z_I6BN75P%FHATB8V%<6H6V2#*E.06G#W2VO1]2\X@
MHVR\.[[\OC9$GOA2?7'#1;@C)[LS%SPCU;>4N"ZP'*3Q:]DS:,/W/C:W!-0+
M+)$)1?%=]K&837]"\S:,':A[BG<BL#=- O6-=O=&;N:VY,S0+'>+:Z#.M_/Q
M-ZO<4U%S3/Q-560*$6@IU#VA,;Q1)3\DIQ444E\^F#I3)_P]YJMX!4S\<M^L
M(9$IFL=0'AZN#G,9-_!RB!%[/B"+-6PUGC)$4J#_#3$NS'B++I7P\KO(56G8
M3=5<SA''5IQ-1JODRS0/<TXN:J1#;-4^;=.^L258N49G@.5IO+6)(+R;)NLT
M8X>$R"V+\HN\4=4!9 *_IJKB%O</9LBO+RIV97/7KTQS!/_TL%]E"$/C?$CC
M KJW>'!.:,N&J49YVRC84SKO'>UDVLME+QG7+?@_=J-%3FY_81U[W>%X]O\,
M:3>39Q^4Y]NCO>">T\*P7]:JT[XPWGXKE#?ER[N[E:_CUL;Y93X6;I5?G5*1
MZEJ2JVNKM/?*W^@X]X6-'\[ZK=]^]O6N]9OV[=N4][8J^LI'^1O=_SC_?GC_
MC?,#<Z8<]V6?65,?Z7];MKU"]"MO8+OO.X9;#<]SLIC6QPAYRZ==+=E=6^R]
M<].>-NMN[Q.S.!\53ITJ(9JJ?*')-6+1?NECR1LE5GTZ\DCMJ:7UMKOWO][>
M^*M.GMN;WS-@H:C$6B&O$_^*@>7=_ \^\X7^'8R76/].Y\OON\X/IVTLN/2B
M:I>RI^PFPQ-;=M25^<R\Q2U_3X/'\L[J!Z#8SI27^W=63JTV^8"=[G4;[7H#
MIK0-NS(>[V*V#HOX]V25N1#S:@8_=]._?A7S#_W*[]UC7[[DM55MW]JE]X\E
M[MR\IS&]Z2%_:$E":/M&T4_R1^[_4%C^YOI'Y:AI_^PYL^*D9SW\<U+8]6I:
MDU MBU^L0+72BL>OXW>EV.DGIC='V/SJGKUUSJ2@H/A[W=EQOY?]4O[D\_BP
MCTMA?-3)5RNR2V87%OYGX)E457;K]&I[I5+_'SK_&=Y:KXGPS#4_NC91>49N
M,FOK%"'^Q4L4I[_B,/V]&]@9_?)C:N7'ZF_2/P(?Z;K]>AQR92L_3T3W[=.=
M/)MC8]R%CNOT/9ET[I*RF,J329X''^UA!AUIDF_^YOKBV)_3I<R[MJ8\_AY>
M]6;5_)_<R75[5[\^WQS/;F/^V[[&Z%*-]$-9\]_JAZM$?'E[Y]]2W?%)8+>E
M]-.TLI\S^\\<^1RO?'R.]^&??6)S9>;SOWDJ&;N5XZ!IVK[3N\NWO?CE)WAB
M\QS>RBMG7O_VV)JR\ZG:W/\,>];TS>K26'_Z_#[XN.(H'L6C>!2/XB&'[?_?
M! !02P,$%     @ ?8&I5+]UI5C#;0  @J$$ !T   !C:S P,#$X,C0R.3,M
M,C R,C S,S%?;&%B+GAM;.R]:7/<.)8V^GU^!6YWQ$Q5A-!%$.""GN4-69;[
M58S+TEBN[NFHN)&!U>94*E.3S'19\^LO0#+W#6""%#UQ)Z9=MD0"SWE '!P
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MGJ?T06'VI_#AQ]I>0!G+XLMT;-XHZ[Q]'Z9S5?WT\7E<S&_L&<JLM$E"K<9
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M)PB+;V@*Z%K,BZ^5)X(&5<WVI5,6^(N1:GZB!DLOH^EHS;S>&'5M!JTM(#M
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MR JF($(9)5HJ@C7U*FV+YNK8%O=;YT ESF>7^3V6^!$GMAOGCV.Z(K\(JA'
M:@C@<)C@8)PN$'QXW6:LH!KLX18!' QX G9? C?F@ 5&T:<E;'E2/'>'+6Z*
M#GNC-"J^Q7ZOG"-=,E*1\]3D"F+)"22*(\@(XQ"S#)%<BC1US>VZ']?_OW0=
MV7;4/,@@\F/YWAU'1MUJ)&Z+D8%ZB[QW4Y'NW42"MQ&I>.7#6^J94:QYDB<$
M*HUR2 J[W>>B4+!@C&DC4)$*Z;T@;)@9VV*N2D3?O/KEX1)ATVJHQ[*N":W'
MDNPBP 9<3NV62?LWU@3<V.]^)69]!KM^RZ)6:,(O:9JFAE^.M [WZ%*B_>J>
MT4.EYNXV_/&.S]7U8I,4N#E+9;K0)*,Y-,P4D&@DH6 H@6F29QD7B&NNO Z"
M3ED;&V7LG:VKJ)S+T&X#-TY[QOE.XMPQ?A<*O<C\L?<3O,$LPAEU)U#"!M!.
M6APV,-9E\(V 5Z</]>_!,5VHM[KXZRN^6KW,%U_JXTJJM4HRP>W" UM:<6U[
M!$H83 I$L4JH79EXG2]WLCHV>JG2U-S)X]OF&_X=-LXCWHU@@N,8F6AV$!YI
MK>'R &NOZ[!.V(X:G5$*WDSCO.7!^VAT!N-8"XWN'_87U_^T6#M%.:7LEZZ\
M6Y:6Y7Z:?[M:*CV3"!FN-8'8Z,3N@JB$3$D#C= X$X(56G<JJSIM9FR<4WL*
M-JY.0.TLL-X"YVYWC?T3R)ZFFG!X1>:6OE!Y2>V?1Z*7V/Z)VPXFMW]^:(>"
M^QVN#E5IV>S:.M-(:Y%8RM4LDY#D!89%8G<]&.N\2'/+$$4GR6H?HV.CALLZ
M6G>"N=LB)#1XD7FBI6SR2)_FF-62[1!%KI,\8OB=*R3;H3A?&WGBLSVK!/A\
MX1(%;A<?]<HN<%S.[_6B7*\J5>[R1J_O5GK-?YMQRJG)-(5()"DD2&;0"59!
M(45.!;6[([^H;%?#8Z.A>VU7@<]U:'9I@-HYOSN=\6S=W'D&I* YT:F$BDC[
M$DAD @M"&51%SDU*52Z*O$<&7-")&#[)[?WFH]O;(L;W//(;P[F\*7X%%M6]
MW^# \0FPKMM59^5\P(H.3[C"%G5T-3YL78<G)(W2#M_/7Z1J^ -W!S'KV]7]
M_,O7]<VSB]G=FGV^VA5_?'3E;YOKRLV%Y0PGJ<Y80B$64D."40$%1AQB)262
MU.@\\6MY>YD_8WOO;/T#7]Q?=N'V)_N0EN[$Y42)>I2)ZABJ&P[^V$&\K?SB
MQD?[5(#*24N!U7@J:<;=B$ ]))?.M9NS[2="MLT-@V\,9<?>/KV'!N2E +:H
M15Y\VWXD['*#]]Q^8[_5&Z7D@J5I3H2".4^0.RC53G*.0IZFA<E(0I1?0_$V
M0V.CS2H%?^^H?63MQ3V%J%O![<:((2"+3'4]T?(FKW-0!&6E5F.#TLVY(;_E
MD;/7^Y\V;-CG!2?B8;Y^U+,\H9G04D&DF LKIAPRS TT&<)4%JHH=*?LB6,W
M'QL15$ZY-S5._B3^O'U?=]P;'D7O_#G")9A$?M)]X? Z-6@;=Z^S@L;-!CLA
M:!O&X;E ZS47=DMY< 4_,YEAD5%L8%%I*W*405&P#'+,A$(IT8GQJXUY=?NQ
M/:+[!BH_5_YYOI[?8-?MI=P?D<@/:'<P^C>/>37F..UB:A/OTR#FU?!:6\*\
MOJJOYMBO4RF7SPNGY'.W6B[L/V5U]_)N^3B7+_6?^Q[.1E"$#9>0B8S8!YO9
MY;BQ#S8J<($D)32AN9_BF)\#8WOT[[6LDGAW8P"O!^$K/>8Y'=VX(B;(D=G$
MNMX.KLL=<(Z#GS=_1^FPW1>]P'ICGDX,K#;6#Z*FUEC/^_145EU_U:LC)4:Y
M($;)',$L2W)(4BF@2+B !<%&&%$D&'LE9[?8&1N756Y>7K/5AFHWK@J 561*
MJF&*6\-U!H6PJJLMMH957CT]X(;ZZIG+>P8AYZ5\7+K>6;?FL!+D7E<R!5?+
M<ETV:DI]54 O,S*BY^!,,5,4]<\PX(6-TEWFTK"QO"#P-2)^8>YZ<;7UC+*T
M4)@PF.020R>O!#GE=L92F4A*I5*2]"RS]GI7#U9?':*NVK^@>D0<%"4),':N
MW[NE]'7(W+L\0<\%%Z^6O^A5Q_=BX_H1?;TJOX*^R%I'VRO$_/I.@\67CP[@
M,+A\_(*>D67Y5:OG1_MN:>:05B&P?32$:BRHP@HF3F&#Y)C HD &4EH84J@B
M,\BKHT]WTV/;RFT]=P<EVX3I3[WRSSW@[QBXC@)J[+7N$3P/_-Z$NN/$G_P!
M"QL1[VY^V&BY-RR-2+K_'4+JA1SLE<J-5M&'MUI%M[4\T?=5JLWUXDZOYDOU
M@W89-UI-+<GR+_K3;WHEYZ6^6\VEGC%-E.2)@DS1U$D-&<BYHG9)G'#&69Y1
MP2X7(8GB^]A(]/N#A,7G4H%O=BU0)2YZYBT..?T=.7B<DSI@P*)-S*X\HV9W
MNY6OJQ%P!4DU!A.P10%L8 !;'$ %1&PMEZBS-X! 3!S_1Z Z$W5BNDG9Q'4A
M:+NK[^8+OI#'VRS)1&6H0 P:+3 D)#%0&"4@(ZE$:9(QE7E5D_J[,+97U,[5
MX.VN3LU#UU/GF.A&/W<^V>YJC_O[M+OJ .(0[:Y.N3&&=E<=8.K8[JK+G?KQ
MX-\U=Z%SQ\/7BV_/ZP=[F^EO\W*&4JDQ5QDL\EQ!DB6NUU6.(<YTD6N,B/&K
M*VHS-#9.._ 35(X"YZE]NJROGIEUK=AV8[ 0B$7FJ7Y@>=/0.22"DDVKL4$I
MY=R0WQ+'V>O[)M8NY;^_+A_M)THGY;-^F9E,<R$3!O,B9:ZCB(%,&@5SI'*4
MR$R+ OL<<S5-C/.TJSSP\P^_9PFF?ZG4O7P+I8] *D6J9$8UQ*(H(.%<0$%%
M!CDQN:0Z*PJ2S+Y52^+/:[Y:#P'L6W/QX/V@O\P7"[>:^<#M+T[L5;OCR7&1
M8@$S3A)(1%6@D6?08)P4*D4YD6:#YZ>%&@[-K;%X6%H+(8'L&,^Y")K889<#
MY_X(:O? =+U>S<7SN@J;KY?@CH=-H&I')'"Z>,/,P"GC;<-LIHVW7AEFW5K%
M!/ZY?.3K2KMBH[^*%:-:"0.IT,02 ;5$8'(*,Y/(5.0I,2*Y9!%[U.K85K1[
M_RY;OAZ'N-]:]F+@AE[83NHP*MC['$'SU@NEJ(O>XY;?=05\$HQSR^'3'^Y'
M08>=//2ZG"X.3_ V#JC;Q;TK=5NYO?M"W2P7J^V/'W@Y+_^Y%>%YT/+K8OZ?
MY\:QMEWZ86Z$@@(9;??ADMGE-LN@9HG.$ZFH2;TH;!"OQT:!!UV &D]V62G-
M[H8$]F/RH\MAO@[=Z'9TDQR9KOO-;]2\B4&G(.B[8!C/!WV7##H9;]]%PQJ_
M(,YS79;/6GU\=E;K [CJK*ZL_]^U4=2K7^Q[M)QQSO+$Y A*S1 D"B$H=(+L
M+CLM.".)LOMLOP)K'_-C>[LX!]UVVZ5GR>73DR69*E@$S'(%RHW3_86G/.?&
M8\\>!?$A]O.@]A#4KN]R(&KO)]O?.OBW(PB\M_=&+OR^O[L+P\<$O.$Y&B_P
MOTM/";[JF:U,'AJ8%9(BY 3UJ"4T2 J=P@+G&B:R8 3)7*69\9+6.VYG;'1V
M=4!ADPUE@7G]2/57SVO!N!M;!4 N,BUM0/M<@_::B *JUYW&(:PJ78NM8=7F
M3@^XH2)WYO)^_+ 5F[,+LUIM[M;N*M:\"K6_#33,[-<C31%)8&$TA83@''*6
M,;M(TJ3@Q!ANL ]I^!@?&Y/LA1SW/D_ T\$.;>[<]F,2K]GH1B^Q,([,.3MX
MW0:W=AS<'B+=V N'8Z(^D 6E)R\'!N6L/M"\);)>]^B9"<G75>WL[3>]JK:8
M=GMG\IPFN8))3CDDB!++88Q!F:5**<:$*?QD=AHFQL94M_??3V^N?YH^7-_>
M@.G-1_#QT^>K^^N[ZN?;[\"'?WR^OOGT^;-G<F,3VFZ$=!E@D6FG=LYM=O?N
M@9_CB-^TXA VO[!I9MC\P=9A-O(#VZ_LVR?T7\_ENDK-?EC>:^?P_%'?:$LM
M<OFDG0#ZP_)82N+&@Z,9NCK5)LU4 864EC\DTG8UA.T?*N%:(\D4]M+?B^'D
MV!CH8(PN(V&U'258Z#5XM"-T_UNU%'RNTX#!<CNX_MG746:_&\6]]YQ&)LDW
MT[D;H&O_ .HA;GM%V%^?R/7>#3=VKG?,"0G<IS6"HP.W=XT'=;,K;$1;%\?;
MJG.1@[7MS.Z5><YQ!A7)"21&8\@2EL*49T+2@J0X\VMGT6YK;&^ P[A;[^!:
M U#O -LE, T:9*L<G1SN>*,$VMKPB!5L:]A[KX!;V\!/!-U:/Q(FR<]I2,BZ
M0=;3)OVL, 8+I'*(4IY#PM,4B@))BS,26.>)78FB2S+\FB;'1AM;#X$U]N36
MA2^:KSQS5SH W8U'PL(7F4Z.)/GMP'0.#Y#AUXY/U/2^(V;?-;>O'89SB7TG
M/MES0_P+GS^ZU IWOL@?];[WC&LM\7>W_ZY^^F&^_CI?W"[TC_9QVZ5XS+!1
MK-!"0TJPW?H2BJ!(D8!2:R$*DZ69]@J=7>;.V+CJX[-V#(4KCO+<JEXV+QTW
MI8.A'9G:JHXT>^\G8#<R:)8KZ,8V ?NLN0G8C.W%7OE8T9CE0'>L\-F^Q>VN
M=?MK\-'^9@+<L($=?L#=9Q#DP^XS+W-IV!UE$/@:>\<P=^W?D^MJN?C%TM)\
MN:C_M78;TVUSG^F3D^K&LY2E*29V_K!*)20LD9 G.89&,(WR#'&=>[78[6IX
M;.2Z][E.1*O\GKL$U\5RK>OX8>\M9N?9Z$:T,3 >@E+W/D_ SNM7K;]JQ\/V
M_/)!*G@/L$[&!^\)Y@/)L1YA7I_O1V ; >([OEJ_/*SXHG1A^N6BW L6[]/Z
M&:&$%QA#ECMM&4HIY-@26:*IRI'FM&!>82\/VV.CL?M/?YL^?/H([J;W#S^"
MA_OIS>?IE3N']3Q\]8&_&VE% C4R;VV\!I7;X-!OL'<\TOEM#\2"\I>/_4$I
MK <P;UFLSRU"B4#LSOJ,-#)!.(4&910225)84*J@-FE!E<2"<Z]>)>VFQD93
MK^O*:R$(S]/7$[AV(Z0P:$7F'X\"_"CGFN=!BER3_SYGC.>'?;Y&/]!YWXWU
MF)=?K^TZJUS7!4X[0:OKM7[:IPXPKA7%>0)UBADD:<%@P5 &TT02)3C1=BWD
ME7C6U?+8V&7C.# !%/8ZH]^-=*)@&IF#MG#NG*YB6WL9O<KO. IZOFB%36SK
M;'W8?#=?4!II<-XW:&.NPYG^F_W77W^W_1_[A]/@_>OO_@=02P,$%     @
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M93PJD\QFR,8[*ZL(ZT78:\KR;8++^Y:O/3"\,JO90]N IQ]:TV[6;!-P#Z#
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M7/8NMY5&1D)V02!C^&_1064<O0M<2R ,U4($:>X/_UT3:&N3,&S1<26,U5%
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M"T&T5YTU ,SO%G?++&AVI4X(@L?P/:*SBUP1+S+(<DRB7<,5]^[UP*U7332
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M25F.O\!=I@373$D5B4JE87_ -1HX!P*)*F.!1<;KU->O1=ZP^;)Z<.M?-PT
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M9@NP;+U:/G<NV<>EGR^;6#._=A>J#U>IC<M1-<IRYEQ #U;[4GX!0$*B0&@
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MUEL^QEL(RQ$+)N'BR212AWY$QB^60B9@%,B<A$ZF3GKU&:*&W6VK0*UO532
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MH"D$V3/JC;6B]4$U"H6KD4H_I'C[ I9,$FX,8T\D@I&$(@+'0P[ZV44. <C
MNQIY'?['\GE^^MA?.0?U[4G+T\#>*;S^T5Q]IM1.2$= 5095(@>D83^+G7'
M&4"C2- /;<Z4T3O,N*Y*LSG7UI?V6G-^__,LP!4=B;M-V,!I-(2)FCU0VE9P
M%E4I3 &$0?%8=FE?0\[7>0+X #=98XI4LO&F[#M*Z7O6_W0@<T<*&*,,$6>6
MY  S]@*Z %?9)3Z>3J28,,Q^*1T7]^BJX$669$+.&(Q.8^G(D*Y %Z#V(J5!
M=2L EK^XA7[%WH.V7<L_85N_RAU)8V32KBVFT!&T_KE9G[+UV[CESUC-5\[
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M?Y]G]PK%P_U!\3J$=V:J-23OSG$[ QH.P5@PQ"DU*J5(YM0 QK&41/!2S69
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MM>2-;]Q_^/LS^?OPUE_[@ZO7G/YRW>LU5\+M;4%?\[\N=;]S/?\_4$L#!!0
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M,C(P,S,Q7V-A;"YX;6Q02P$"% ,4    " !]@:E40%\<QG\;  !$$P$ '0
M            @ '#(P$ 8VLP,# Q.#(T,CDS+3(P,C(P,S,Q7V1E9BYX;6Q0
M2P$"% ,4    " !]@:E4*64,\R5- 0 P=@$ '               @ %]/P$
M8VLP,# Q.#(T,CDS+3(P,C(P,S,Q7V<Q+FIP9U!+ 0(4 Q0    ( 'V!J52_
M=:58PVT  (*A!  =              "  =R, @!C:S P,#$X,C0R.3,M,C R
M,C S,S%?;&%B+GAM;%!+ 0(4 Q0    ( 'V!J52;X# I:T0  +W^ @ =
M          "  =KZ @!C:S P,#$X,C0R.3,M,C R,C S,S%?<')E+GAM;%!+
M 0(4 Q0    ( 'V!J52K<;RC=@@  $0K   9              "  8 _ P!E
M>#,Q,5]C96\S,#)C97)T,S,Q,C(N:'1M4$L! A0#%     @ ?8&I5*I)C<UO
M"   0BL  !D              ( !+4@# &5X,S$R7V-F;S,P,F-E<G0S,S$R
M,BYH=&U02P$"% ,4    " !]@:E4UO,K/^X$   A%@  '@
M@ '34 , 97@S,C%?8V5O<V5C=&EO;CDP-F-E<G0S,S$N:'1M4$L! A0#%
M  @ ?8&I5+PGMI7H!   $A8  !X              ( !_54# &5X,S(R7V-F
L;W-E8W1I;VXY,#9C97)T,S,Q+FAT;5!+!08     "P + "H#   A6P,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
